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RIASSUNTO  
Mutazioni epigenetiche ricorrenti nelle malattie mieloidi 
 
Negli ultimi 40 anni, tramite studi di citogenetica sono state identificate diverse alterazioni 
somatiche ricorrenti nei pazienti con neoplasie ematologiche mieloidi, tra cui le malattie 
mieloproliferative (MPN), le sindromi mielodisplastiche (MDS) e le leucemie mieloidi acute 
(AML). Studi genetici e funzionali di queste anomalie hanno consentito di classificarle in 
un modello definito “two hit” della trasformazione delle cellule emopoietiche 
(leucemogenesi), che comprende: le mutazioni di classe I, che conferiscono un vantaggio 
proliferativo attraverso l`attivazione di diverse cascate del segnale (tali mutazioni 
includono quelle di geni che codificano per membri stessi della trasduzione del segnale o 
attivatori a valle della trascrizione); e mutazioni di classe II, che determinano il 
differenziamento mieloide delle cellule staminali attraverso la regolazione dell`espressione 
genica di target trascrizionali specifici della linea mieloide.  
Piu` recentemente, sono state identificate nuove mutazioni in aggiunta a quelle 
precedentemente descritte, che pur verificandosi di frequente nei pazienti con malattie 
ematologiche neoplastiche, non possono essere classificate come di prima o seconda 
classe. Queste mutazioni, recentemente identificate,  sono a carico di geni che codificano 
per proteine che regolano la metilazione del DNA (DNMT3a, TET2, IDH1/2 ecc) o le 
modificazioni post-traslazionali degli istoni (L3MBTL1, PRMT5, ASXL1, MLL, EZH2 ecc). 
E` di grosso interesse scientifico comprendere il ruolo funzionale di queste alterazioni 
epigenetiche nella patogenesi delle malattie ematologiche, per poter identificare nuovi 
target (target epigenetici) terapeutici.  
In questa dissertazione saranno discussi gli studi che abbiamo condotto per 
elucidare il ruolo di una delle alterazioni somatiche epigenetiche ricorrenti nelle malattie 
mieloidi (la delezione della proteina Polycomb L3MBTL1). Questi lavori hanno consentito 
di dimostrare che questi eventi ricorrenti contribuiscono alla leucemogenesi mieloide.  
Inoltre, abbiamo dimostrato che diverse mutazioni di classe I e II (per esempio 
JAK2V617F o AML1/ETO) alterano l`epigenoma delle cellule maligne, in aggiunta ai ruoli 
classici nel promuovere la proliferazione e il differenziamento delle cellule emopoietiche. 
Questi dati sottolineano l`importanza delle anormalita` epigenetiche nella patofisiologia 
delle malattie mieloidi. 
 
 
L3MBTL1 
 
L3MBTL1 rappresenta l`omologo umano del gene oncosoppressore della drosofila, 
l(3)mbt [lethal(3)malignant brain tumor], la cui inattivazione determina aumentata 
proliferazione dei neuroblasti ottici della mosca adulta e delle cellule gangliari del cervello 
della larva. Dopo aver cristallizato i tre domini in tandem (di circa 100 aminoacidi) MBT fu 
dimostrato che L3MBTL1 umano compatta la cromatina attraverso il legame con residui 
lisinici mono- e di-metilati sugli istoni H1 (H1K26) e H4 (H4K20) attraverso il secondo dei 
suoi tre domini MBT. Subito dopo l`identificazione molecolare di l(3)mbt, Bornemann et al. 
riportarono che un altro gene della Drosphila, Sex comb on midleg (Scm), codificava per 
una proteina che conteneva due domini MBT in tandem in posizione N-terminale. Scm fu 
originariamente identificata come un gene richiesto per l`accurate mantenimento della 
distribuzione dei geni omeotici durante lo sviluppo e fu pertanto classificato come un 
repressore Polycomb group (PcG). Infatti, gli embrioni mutant Scm presentano un classico 
fenotipo PcG di sviluppo in cui i segmenti anteriori del corpo assumono l`identita` di quelli 
posteriori (per esempio il torace nell`addome), dovuto alla mancanza di repressione dei 
geni nel locus bithorax.  
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Il gene umano L3MBTL1, e` localizzato sul braccio lungo del cromosoma 20, in posizione 
20q12, nell`ambito della regione comunemente deleta nei pazienti con sindromi 
mielodisplastiche, malattie mieloproliferative o leucemia mieloide acuta, associate alla 
delezione del cromosoma 20.  
La delezione del cromosoma 20 (20q-) rappresenta la seconda anormalita` cromosomica 
piu` comune nelle neoplasie ematologiche, dopo il cromosoma Philadelphia. L`anormalita` 
20q- viene osservata nel 10% dei pazienti con malattie mieloproliferative, di cui la piu` 
comune e` la Policitemia Vera, nel 4% dei pazienti con malattie mielodisplastiche, e nell`1-
2% dei pazienti con Leucemia mieloide acuta. L`inattivazione (o aploinsufficienza) di geni 
oncosoppressori su 20q potrebbe spiegare la patogenesi di questi disordini.  
L`espressione di L3MBTL1 nel compartimento ematopoietico (nelle cellule CD34+ che 
rappresentano le cellule staminali/progenitrici ematopoietiche) e l`assenza di mutazioni a 
carico dell`allele non deleto, hanno fatto a lungo ipotizzare che l`aploinsufficienza di 
L3MBTL1 possa contribuire alla patogenesi delle neoplasie ematologiche mieloidi 
associate alla delezione del cromosoma 20.  
1) Per definire il suo ruolo in ematopoiesi e la possibilita` che la sua ridotta 
espressione nella malattie mieloidi associate a delezione del cromosoma 20 contribuisca 
alla patogenesi di questi disordini, abbiamo silenziato l`espressione di L3MBTL1 nelle 
cellule staminali/progenitrici (CD34+) isolate da sangue cordonale (usando short hairpin 
RNAs). Abbiamo osservato che le cellule staminali emopoietiche deplete per L3MBTL1 
dimostrano un aumentato differenziamento verso la linea eritroide. In maniera consistente 
la overespressione di L3MBTL1 nelle cellule staminali/progenitrici CD34+ come nelle linee 
cellulari 20q- riduceva il differenziamento eritroide. Inoltre, i livelli endogeni di espressione 
di L3MBTL1 si riducevano durante il differenziamento eritroide indotto da emina o 
dall`esposizione a eritropoietina, suggerendo un ruolo specifico per la ridotta espressione 
di L3MBTL1 nell`indurre le decisioni di differenziamento delle cellule emopoietiche verso 
la linea eritroide. Il silenziamento di L3MBTL1 aumentava anche la sensibilita` delle cellule 
staminali progenitrici all`eritropoietina (Epo), con aumentata fosforilazione (indotta da Epo) 
di STAT5, AKT, and MAPK ed evidente fosforilazione anche in assenza di Epo. Questi 
dati suggerirono che l`aploinsufficienza di L3MBTL1 contribuisce ad alcune neoplasie 
mieloproliferative (20q), specialmente la Policitemia Vera, attraverso la promozione del 
differenziamento eritroide.  
La Policitemia Vera infatti è una malattia clonale della cellula staminale emopoietica, 
caratterizzata da una proliferazione persistente ed incontrollata della linea eritropoietica 
indipendentemente dai meccanismi che fisiologicamente regolano l’eritropoiesi. Nella 
policitemia vera, la proliferazione eritroide è predominante e determina un aumento 
numerico dei globuli rossi nel sangue periferico. 
2)  Per investigare il ruolo di L3MBTL1 come oncosoppressore, abbiamo continuato 
ad utilizzare un approccio “loss-of-function”, attraverso l`utilizzo di vettori lentivirali che 
consentono l`espressione di shRNA  diretti contro L3MBTL1. Abbiamo trovato che la 
deplezione di L3MBTL1 nelle cellule umane causa stress replicativo, rottura del DNA, 
attivazione della risposta al danno del DNA e instabilita` genomica. L3MBTL1 interagisce 
infatti con Cdc45, MCM2-7 and PCNA, componenti dell`apparato replicativo, necessari per 
la progressione della replicazione. Questi dati suggeriscono che la delezione di L3MBTL1 
causa danno del DNA, tramite la perturbazione della replicazione del DNA. Un`attivata 
risposta al danno del DNA e l`instabilita` genomica sono aspetti comuni nella tumorigenesi 
e rappresentano una conseguenza dell`overespressione di molti oncogeni. Questi studi ci 
hanno consentito di proporre un modello in cui la delezione di L3MBTL1 contribuisce allo 
sviluppo delle neoplasie ematologiche associate alla delezione del braccio lungo del 
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cromosoma 20 attraverso l`induzione di stress replicativo, danno al DNA e instabilita` 
genomica.  
3) Per definire come L3MBTL1, una proteina del gruppo Polycomb con attivita` 
trascrizionali di repressione, regola gli eventi iniziali del differenziamento, abbiamo creato 
delle linee cellulari embrionali che constitutivamente eprimono shRNA diretti contro 
L3MBTL1. Il silenziamento di L3MBTL1 nelle cellule umane embrionali consentiva una 
normale morfologia, proliferazione, cinetica di ciclo cellulare, normali marcatori di 
superficie e cariotipo dopo 40 passaggi. Pero`, sotto condizioni che promuovevano il 
differenziamento spontaneo, le cellule embrionali senza L3MBTL1 si differenziavano in 
una popolazione relativamente omogenea di cellule larghe, piatte, tipo trofoblasti, a 
differenza del differenziamento multilineare delle cellule di controllo. Le cellule senza 
L3MBTL1 esprimevano numerosi marcatori della linea trofoblastica e secernevano ormoni 
placentari. Nonostante le cellule senza L3MBTL1 potevano essere indotte a differenziare 
in varie linee embrionali, esse adottavano un destino esclusivamente trofoblastico durante 
il differenziamento spontaneo. Questi dati dimostrano che la deplezione di L3MBTL1 non 
disturba il self-renewal delle cellule embrionali, ma piuttosto aumenta il differenziamento 
verso tessuti trofoblastici extraembrionali. 
Questo fenotipo risultava molto simile a quello delle cellule embrionali trattate con BMP4 e 
infatti il trattamento con BMP4 riduceva il livello di esperssione endogena di L3MBTL1. 
Questi dati suggerivano che la deplezione di L3MBTL1 potrebbe essere responsabile 
dell`attivazione della cascata del segnale di BMP4. 
           4) Infine, piu` recentemente abbiamo dimostrato che L3MBTL1 regola 
l`espressione di un fattore di trascrizione specifico per la linea eritroide EKLF. L3MBTL1, 
che generalmente funziona come repressore trascrizionale, regola la trascrizione di 
smad5 e controlla pertanto la cascata del segnale BMP4/smad5 e i suoi effettori a valle, 
incluso EKLF. Data la rilevanza clinica di regolare l`espressione dei geni globinici da parte 
di EKLF nelle emoglobinopatie, abbiamo utilizzato un modello umano di beta-
emoglobinopatia, cioe` le cellule staminali pluripotenti indotte da pazienti. Queste cellule 
sono state infettate con vettori lentivirali per esprimere shRNA contro L3MBTL1 e si sono 
mostrate capaci di generare una progenie eritroide che esprime alti livelli di espressione 
dei geni globinici e di fattori della trascizione a valle di BMP4, incluso EKLF. Pertanto, 
pensiamo che L3MBTL1 possa modulare l`induzione dell`espressione di EKLF, attraverso 
la modulazione del pathway BMP4/smad5, regolando infine l`espressione dei geni 
globinici e servendo pertanto come potenziale approccio terapeutico per le 
emoglobinopatie. 
 
 
PRMT5 
 
PRMT5 e` un`arginina metiltransferasi di tipo II che fu inizialmente identificata come una 
proteina che lega JAK (JAK-binding protein 1 - JBP1) nei lieviti. PRMT5 media la 
dimetilazione simmetrica dei residui argininici sugli istoni H2A, H3, e H4, e metila altre 
proteine cellulari come p53, SPT5, e MBD2. Insieme a MEP50, che contiene il dominio 
WD40 e con pICln, PRMT5 forma un grosso complesso proteico 20S con funzione di 
metiltransferasi, chiamato il  “metilosoma”. Questo complesso funziona nel processamento 
dell`RNA attraverso la metilazione di proteine Sm e ha un ruolo anche nella biogenesi 
delle snRNP. PRMT5 e` stata anche ritrovata nei complessi che rimodellano la struttura 
della cromatina hSWI/SNF e NURD, dove puo` esercitare controllo trascrizionale sulla 
espressione dei geni bersaglio. Per studiare le malattie mieloproliferative indotte dalla 
mutazione  JAK2V617F, abbiamo ricercato l`interazione in vivo tra PRMT5 e le chinasi 
oncogeniche mutanti JAK2 (JAK2V617F e JAK2K539L), e abbiamo determinato come 
questa interazione contribuisce al fenotipo mieloproliferativo che inducono.  
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La mutazione JAK2V617F constitutivamente attiva la tirosina chinasi JAK2 ed e`espressa 
nella maggior parte dei pazienti con malattie mieloproliferative. Abbiamo trovato che la 
proteina mutata JAK2V617F (e JAK2K539L) si lega a PRMT5 in maniera piu` forte della 
proteina JAK2 wild-type. Queste chinasi oncogeniche (mutazioni di classe I) acquisiscono 
anche la capacita` di fosforilare PRMT5, riducendo la sua capacita` di metilare i suoi 
substrati istonici, e rappresentando una specifica acquisizione di funzione che consente 
loro di regolare le modificazioni cromatiniche. Abbiamo documentato la fosforilazione di 
PRMT5 nei campioni di pazienti positivi per JAK2V617F e quando abbiamo silenziato 
l`espressione di PRMT5 nelle cellule umane CD34+ usando shRNA, abbiamo osservato 
un’aumentata formazione di colonie e differenziamento eritroide. Questi risultati indicano 
che la fosforilazione di PRMT5 (con funzione epigenetica) contribuisce al fenotipo delle 
malattie mieloproliferative indotte dalla mutazione classica di JAK2.  
 
 
CONCLUSIONI 
 
La nostra conoscenza dei meccanismi che promuovono la trasformazione mieloide si e` 
molto evoluta negli ultimi anni grazie all`approfondimento degli eventi genetici che sono 
stati identificati nei pazienti con questi disordini. Inoltre l`identificazione di mutazioni nei 
geni coinvolti nella regolazione epigenetica ha rivelato nuovi meccanismi di 
trasformazione. Regolatori della metilazione del DNA (come TET2, IDH1, IDH2 e 
DNMT3A) e delle modificazioni degli istoni (come L3MBTL1, PRMT5, MLL, ASXL1 e 
EZH2) rappresentano il bersaglio di alterazioni somatiche in una percentuale significativa 
di pazienti con malattie mieloidi. Questo suggerisce un ruolo cruciale per i modificatori 
epigenetici nella regolazione della emopoiesi normale e illustra come la perdita della 
funzionalita` epigenetica normale puo` contribuire alla leucemogenesi. Pertanto, elucidare 
l`impatto delle mutazioni epigenetiche sulla leucemogenesi e la risposta terapeutica sara` 
essenziale per l`avanzare delle nostre conoscenze e il trattamento delle malattie mieloidi.  
La nostra comprensione delle conseguenze biologiche di questi cambiamenti epigenetici 
e` ancora a uno stadio iniziale. Nonostante possiamo capire l`attivita` specifica di un 
singolo gene e derivare modelli generali di come le modificazioni epigenetiche influenzano 
la trascrizione, non conosciamo ancora i componenti cruciali che sono alterati da queste 
modificazioni epigenetiche e come queste influenzano l`andamento epigenetico, 
l`espressione genica e le alterazioni fenotipiche delle cellule emopoietiche. Per 
definizione, le mutazioni in questa classe di geni influenzano globalmente la mappa 
cromatinica e molti geni e pathway ne risultano alterati; per cui, e` improbabile che una 
spiegazione semplice e lineare possa spiegare come queste mutazioni contribuiscono allo 
sviluppo della leucemia. L`espressione genica e l`analisi epigenomica hanno identificato 
un gruppo di geni bersaglio dei modificatori epigenetici, come il cluster genico HOX, che 
sono essenziali per la trasformazione maligna da parte di specifiche mutazioni 
epigenetiche. Quel che abbiamo imparato e` che queste mutazioni nei modificatori 
epigenetici non ricadono nella classificazione precedentemente stabilita di mutazioni di 
classe I o II della leucemogenesi. Clinicamente, le mutazioni epigenetiche si verificano in 
combinazione con una delle mutazioni di classe I o II o con entrambe. I dati attuali genetici 
e funzionali suggeriscono che le mutazioni nei modificatori epigenetici ricadono in almeno 
due nuove classi: quella delle mutazioni che influenzano la idrossimetilazione del DNA 
(TET2, IDH1 and IDH2), e quella delle mutazioni che direttamente regolano la metilazione 
del DNA e/o degli istoni (L3MBTL1, PRMT5, MLL, ASXL1 e DNMT3A). Queste due nuove 
classi di mutazioni epigenetiche probabilmente contribuiscono alla trasformazione 
leucemica influenzando la regolazione epigenetica, pertanto generando un panorama 
dello stato della cromatina che puo` mantenere e cooperare con l`effetto delle mutazioni di 
classe I o II. Studi ulteriori sono necessari per chiarire queste possibilita` e capire come 
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diverse combinazioni di genotipi di alleli associate alla leucemia risultano in fenotipi di 
leucemia mieloide distinti in termini biologici, terapeutici e prognostici.  
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SUMMARY 
 
Recurrent epigenetic modifications in myeloid malignancies 
In the past four decades, cytogenetic and candidate-gene studies have identified recurrent 
somatic alterations in patients with myeloid malignancies, including myeloproliferative 
neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia 
(AML). Genetic and functional studies have suggested that there are at least two classes 
of myeloid leukaemia disease alleles that contribute to haematopoietic transformation: 
class I alleles, which confer a growth advantage by activating downstream effectors of 
various signalling pathways including members of the signal transducer and activator of 
transcription (STAT), PI3K and RAS–MAPK pathways; and class II alleles, which alter the 
expression of key transcriptional targets in myelopoiesis. However, several lines of 
evidence suggest that there are leukaemia disease alleles that cannot be classified into 
this widely accepted two-hit model of myeloid leukaemogenesis. Emerging genetic data 
suggest that there are additional classes of mutations that commonly occur in patients with 
myeloid malignancies. The most prominent examples are from recent genome-wide and 
candidate-gene studies that have identified somatic alterations in genes that encode 
proteins regulating DNA methylation and post-translational histone modifications. These 
data suggest that somatic alterations in epigenetic regulators are a common genetic event 
in myeloid malignancies and contribute to haematopoietic transformation. These data 
suggest that the classical two-hit model of myeloid malignancy pathogenesis must be 
modified to account for novel classes of mutant disease alleles, most notably mutations in 
epigenetic modifiers. These include mutations in tet methylcytosine dioxygenase 2 (TET2), 
isocitrate dehydrogenase 1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer 
of zeste homologue 2 (EZH2) and DNA methyltransferase 3A (DNMT3A), L3MBTL1 and 
PRMT5, which have recently been shown to have biological, clinical and potential 
therapeutic relevance in myeloid malignancies. These data underscore the importance of 
aberrant epigenetic programming in the biology of myeloid malignancies. Here, we discuss 
how a specific somatic alteration in epigenetic regulators (deletion of the Polycomb protein 
L3MBTL1) leads to repatterning of the epigenome and contribute to myeloid 
leukaemogenesis. Moreover, we have found that several class I and class II alterations 
(such as JAK2V617F or AML1-ETO) that are central to the pathogenesis of myeloid 
malignancies have direct epigenetic functions in addition to their canonical roles in 
promoting haematopoietic cell proliferation. 
 
L3MBTL1 
L3MBTL1 is the human homolog of the Drosophila tumor suppressor gene, l(3)mbt 
[lethal(3)malignant brain tumor], whose inactivation results in overgrowth of adult optic 
neuroblasts and ganglion mother cells of the larval brain. After cristallyzing the structure of 
human L3MBTL1, we showed that it compacts chromatin by binding mono- and di-
methylated lysines on histones H1 (H1K26) and H4 (H4K20), through the second of its 
three tandem MBT domains. Shortly after the molecular identification of l(3)mbt, 
Bornemann et al. reported that another Drosophila gene, Sex comb on midleg (Scm), 
encoded a protein containing two tandem MBT repeats at the N-terminus. Scm was 
originally identified as a gene required for the proper maintenance of expression patterns 
of homeotic genes during development, and was therefore classified as a Polycomb group 
(PcG) repressor. Scm mutant embryos have a classic PcG developmental phenotype, in 
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which anterior segments of the body plan assume the identity of more posterior ones (e.g. 
thorax into abdomen), due to the loss of repression of genes in the bithorax locus. 
L3MBTL1 is located on chromosome 20q12, within the common deleted region identified 
in patients with 20q deletion-associated polycythemia vera, myelodysplastic syndrome, 
and acute myeloid leukemia. Deletion of the long arm of chromosome 20 (20q-) represents 
the second most common primary chromosomal abnormality in the hematological 
malignancies, after the Philadelphia chromosome. The 20q- abnormality is observed in 
10% of patients with myeloproliferative neoplasms (MPN), most commonly polycythemia 
vera (PV), in 4% of patients with MDS, and in 1-2% of patients with AML. Inactivation (or 
haploinsufficiency) of putative tumor suppressors on 20q has been proposed to explain the 
pathogenesis of these disorders. 
The fact that L3MBTL1 is expressed within the hematopoietic CD34+ cells (which 
represent the hematopoietic stem/progenitor cells) and that no mutations were found 
within the non-deleted alleles, suggests that haploinsufficiency of L3MBTL1 may 
contribute to the pathogenesis of these disorders.  
     1) To define its role in hematopoiesis, we knocked down L3MBTL1 expression in 
primary hematopoietic stem/progenitor (ie, CD34+) cells isolated from human cord blood 
(using short hairpin RNAs) and observed an enhanced commitment to and acceleration of 
erythroid differentiation. Consistent with this effect, overexpression of L3MBTL1 in primary 
hematopoietic CD34+ cells as well as in 20q- cell lines restricted erythroid differentiation. 
Furthermore, L3MBTL1 levels decrease during hemin-induced erythroid differentiation or 
erythropoietin exposure, suggesting a specific role for L3MBTL1 down-regulation in 
enforcing cell fate decisions toward the erythroid lineage. Indeed, L3MBTL1 knockdown 
also enhanced the sensitivity of hematopoietic stem/progenitor cells to erythropoietin 
(Epo), with increased Epo-induced phosphorylation of STAT5, AKT, and MAPK as well as 
detectable phosphorylation in the absence of Epo. Our data suggest that 
haploinsufficiency of L3MBTL1 contributes to some (20q-) myeloproliferative neoplasms, 
especially polycythemia vera, by promoting erythroid differentiation. 
Polycythemia vera is a myeloproliferative blood disorder in which the bone marrow 
produces too many red blood cells.  
2) We used the loss-of-function approach to explore the possible tumor suppressive 
mechanism of L3MBTL1 and found that depletion of L3MBTL1 from human cells causes 
replicative stress, DNA breaks, activation of the DNA damage response, and genomic 
instability. L3MBTL1 interacts with Cdc45, MCM2-7 and PCNA, components of the DNA 
replication machinery, and is required for normal replication fork progression, suggesting 
that L3MBTL1 causes DNA damage, at least in part, by perturbing DNA replication. An 
activated DNA damage response and genomic instability are common features in 
tumorigenesis and a consequence of overexpression of many oncogenes. We propose 
that the loss of L3MBTL1 contributes to the development of 20q(-) hematopoietic 
malignancies by inducing replicative stress, DNA damage, and genomic instability. 
       3) To define how L3MBTL1, a chromatin-associated polycomb group protein with 
transcriptional repressive activities, regulates early events in differentiation, we created 
hESC lines that constitutively express shRNAs directed against L3MBTL1. Although the 
L3MBTL1 KD cells could be induced to differentiate into embryonic neuroectoderm, they 
adopted an exclusive trophoblast fate during spontaneous differentiation. The data 
suggest that L3MBTL1 depletion does not affect hESC self-renewal but impacts 
pluripotency; depletion of L3MBTL1 directs hESC differentiation 
toward extra-embryonic tissues, rather than embryoderived tissues. 
To further examine the differentiation of L3MBTL1 KD cells into trophoblasts, we directed 
control cells toward trophoblasts using BMP4. We compared the gene expression pattern 
of the BMP4-treated control (LUC shRNA) cells with the spontaneously differentiated 
L3MBTL1 KD cells and found similar but higher trophoblast marker expression (CG-β and 
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HAND1) in the BMP4-treated control cells. Of note, L3MBTL1 expression decreased at 
least 4-fold in the control cells treated with BMP4 compared with untreated LUC shRNA 
control, which is also consistent with the notion that downregulation of L3MBTL1 allows 
trophoblast formation to proceed in hESCs. To further investigate the role of BMP 
signaling, we measured the level of phosphorylated SMAD proteins (SMAD 1/5/8) during 
the spontaneous differentiation of the LUC shRNA and L3MBTL1 KD cells. We found an 
increased level of phospho-SMAD 1/5/8 in differentiated L3MBTL1 KD cells compared with 
the control cells. We also measured the secretion of the placental hormones CG-β and 
progesterone into the medium from spontaneously differentiated L3MBTL1 KD cells and 
also the untreated and BMP4-treated controls. L3MBTL1 KD and BMP4-treated control 
cells show a continuous increase in the concentration of both hormones, with the hormone 
secretion by the knockdown cells being nearly as high as from the BMP-treated control. 
These results show that L3MBTL1 KD cells differentiate into functional trophoblast cells, 
which indicates the role of L3MBTL1 in regulating the spontaneous differentiation of 
embryonic derivatives. 
4) Finally, we more recently found that L3MBTL1 also regulates erythropoiesis and 
globin gene expression by regulating the expression of the erythroid-specific transcription 
factor EKLF. We found that L3MBTL1, which generally functions as a transcriptional 
repressor, regulates the transcription of smad5, thereby controlling the BMP4/smad5 
signaling pathway and its downstream targets, such as EKLF. Given the clinical relevance 
of regulating globin gene expression in beta-hemoglobinopathies, we then utilized a 
human model of beta thalassemia, i.e. patient-specific induced pluripotent stem (iPS) cells, 
which we lentivirally infected to express shRNAs against L3MBTL1. The L3MBTL1-KD iPS 
cells generated high-fetal globin gene expressing erythroid progeny, which manifested a 
strong BMP4 transcriptional signature including increased EKLF expression. Thus, we 
propose a model, where L3MBTL1 fine-tunes the induction of EKLF expression, by 
modulating the BMP4/smad5 signaling pathway, ultimately regulating fetal globin gene 
expression and serving as a potential approach to treating the hemoglobinopathies.  
 
 
PRMT5 
 
The type II arginine methyltransferase PRMT5 was first identified as JAK-binding protein 1 
(JBP1) in a yeast two-hybrid assay. It mediates the symmetrical dimethylation of arginine 
residues within histones H2A, H3, and H4, and methylates other cellular proteins as well, 
such as p53, SPT5, and MBD2. Together with the WD40-repeat containing MEP50 protein 
and with pICln, PRMT5 forms a large 20S protein arginine methyltransferase complex, 
termed the “methylosome.” This complex functions in RNA processing by methylating Sm 
proteins and affecting snRNP biogenesis. PRMT5 has been also found in the hSWI/SNF 
and NURD chromatin-remodeling complexes, where it can exert transcriptional control on 
target gene expression. To gain insight into JAK2V617F-induced MPN, we investigated 
the in vivo interaction between PRMT5 and the oncogenic mutant JAK2 kinases 
(JAK2V617F and JAK2K539L), and determined how this interaction contributes to the 
myeloproliferative phenotype that they induce. 
The JAK2V617F constitutively activated tyrosine kinase is found in most patients with 
myeloproliferative neoplasms. While examining the interaction between JAK2 and PRMT5, 
an arginine methyltransferase originally identified as JAK-binding protein 1, we found that 
JAK2V617F (and JAK2K539L) bound PRMT5 more strongly than did wild-type JAK2. 
These oncogenic kinases also acquired the ability to phosphorylate PRMT5, greatly 
impairing its ability to methylate its histone substrates, and representing a specific gain-of-
function that allows them to regulate chromatin modifications. We readily detected PRMT5 
phosphorylation in JAK2V617F-positive patient samples, and when we knocked down 
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PRMT5 in human CD34+ cells using shRNA, we observed increased colony formation and 
erythroid differentiation. These results indicate that phosphorylation of PRMT5 contributes 
to the mutant JAK2-induced myeloproliferative phenotype. 
 
 
CONCLUSIONS 
 
Our knowledge of the mechanisms that promote malignant myeloid transformation has 
evolved as a result of an improved understanding of the range of genetic events that are 
found in patients with these disorders. The recent identification of mutations in genes 
involved in epigenetic regulation has elucidated novel mechanisms of transformation. 
Regulators of DNA methylation (such as TET2, IDH1, IDH2 and DNMT3A) and of histone 
modifications (such as L3MBTL1, PRMT5, MLL translocations, ASXL1 and EZH2) are 
targeted by somatic alterations in a significant subset of patients with myeloid 
malignancies. This suggests a crucial role for epigenetic modifiers in the regulation of 
normal haematopoiesis and illustrates how the loss of normal epigenetic functionality can 
contribute to leukaemogenesis. As such, elucidating the impact of epigenetic mutations on 
leukaemogenesis and therapeutic response will be essential for advancing our 
understanding and treatment of myeloid malignancies. 
Our comprehension of the biological consequences of these epigenetic changes is 
still at a nascent stage. Although we may understand the specific activity of an individual 
gene and/or have derived general models of how epigenetic modifications affect 
transcription, we do not yet have a grasp of the crucial components that are altered by 
these epigenetic mutations and how this affects epigenetic patterning, gene expression 
and phenotypic alterations in haematopoietic cells. By definition, mutations in this class of 
genes affect global chromatin landscapes and many genes and pathways are altered; 
thus, simple linear explanations are unlikely to precisely show how these mutations 
contribute to leukaemia development. Gene expression and epigenomic analyses have 
identified a subset of downstream targets of epigenetic modifiers, such as the HOX gene 
clusters, that are essential for malignant transformation by specific epigenetic mutations. 
Greater efforts in this regard, coupled with advances in epigenomic platforms, will help to 
gain greater insight into the role of these mutations in MDS, MPN and AML. However, 
what we have learned is that mutations in epigenetic modifiers do not fit neatly into the 
established framework of class I and class II mutations in leukaemogenesis. Clinically, 
epigenetic mutations occur in combination with both class I and class II genes and also 
occasionally with each other. Current genetic and functional data suggest that mutations in 
epigenetic modifiers fall into at least two novel classes: one set of mutations that affect 
DNA hydroxymethylation (including TET2, IDH1 and IDH2), and a second set that directly 
regulate DNA methylation and/or the histone state (including L3MBTL1, PRMT5, MLL, 
ASXL1 and DNMT3A). These two novel classes of epigenetic mutations probably 
contribute to leukaemic transformation by affecting epigenetic regulation, thus generating 
a chromatin landscape that can sustain, and cooperate with, the effect of class I and class 
II mutations. Further study will be needed to clarify these possibilities and to understand 
how different genotypic combinations of leukaemia-associated disease alleles result in 
biologically, therapeutically and prognostically distinct myeloid leukaemia phenotypes. 
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1. INTRODUCTION 
 
1.1 L3MBTL1 
L3MBTL1 is the human homolog of the Drosophila tumor suppressor gene, 
lethal(3)malignant brain tumor1, whose inactivation results in overgrowth of adult optic 
neuroblasts and ganglion mother cells of the larval brain2.  
The L3MBTL1 protein contains three MBT repeats, which assume a three-bladed 
propeller-like architecture, as well as a Zn finger and an SPM dimerization domain3,4. We 
previously demonstrated that human L3MBTL1 functions as a HDAC-independent 
transcriptional repressor transcriptional repressor5 and after crystallizing the MBT repeat 
domain3  determined  that L3MBTL1 compacts chromatin by binding mono- and di-
methylated lysine residues in histones H1 (H1K26) and H4 (H4K20)6,7 via the second of its 
three MBT repeats.  
L3MBTL1 is located on the long arm of chromosome 20, within the common deleted 
region identified in patients with myeloid malignancies. Deletion of the long arm of 
chromosome 20 (20q-) represents the second most common primary chromosomal 
abnormality in the hematological malignancies, after the Philadelphia chromosome8. The 
20q- abnormality is observed in 10% of patients with myeloproliferative neoplasms (MPN), 
most commonly polycythemia vera (PV)9, in 4% of patients with MDS10, and in 1-2% of 
patients with AML11. Inactivation (or haploinsufficiency) of putative tumor suppressors on 
20q has been proposed to explain the pathogenesis of these disorders. Two mutational 
analyses of small numbers of 20q- patient samples found no mutation in the non-deleted 
allele of L3MBTL112,13, suggesting that haploinsufficiency of L3MBTL1 would have to 
contribute to these disorders. Somatic, focal deletions of other human L3MBTL family 
members, the l3mbtl2 and l3mbtl3 genes, have recently been found in human 
medulloblastoma14. These findings suggest that L3MBTL1 is a candidate tumor 
suppressor gene in myeloid malignancies associated with 20q12 deletions. 
Despite the known role of L3MBTL1 in affecting chromatin structure, the function of 
L3MBTL1 in human hematopoiesis has remained largely unknown.  
1) To define the role of L3MBTL1 in normal human hematopoiesis, and its potential role in 
the 20q- myeloid disorders, we utilized RNA interference to reduce L3MBTL1 expression 
in human cord blood (CB) CD34+ hematopoietic stem/progenitor cells (HSPCs).  
2) L3MBTL1 binds to chromatin most prominently during the S phase of the cell cycle, 
concomitant with the appearance of the monomethylated H4K20 (H4K20me1) mark6, 
suggesting that the biological function of L3MBTL1 may be related to DNA replication. The 
accurate duplication of DNA during replication is essential for maintaining genomic 
stability, as uncorrected errors made during this process can lead to DNA breaks, which 
generate mutations and/or chromosomal translocations that can promote tumorigenesis15. 
DNA breaks resulting from replicative stress trigger an ATM/ATR-dependent DNA damage 
response (DDR), which prevents the proliferation of cells with damaged DNA by inducing 
either cell cycle arrest or apoptosis. An activated DDR is present in precancerous lesions 
from tissues of different origins, and many overexpressed oncogenes cause replicative 
stress and activation of the DDR. When coupled with mutations in checkpoint and/or DNA 
repair genes, these abnormalities can lead to cancer16-18. We examined the function of 
L3MBTL1 in mammalian cells and found that L3MBTL1 interacts with several components 
of the DNA replication machinery.  
3) In order to further investigate the role of L3MBTL1, we utilized human embryonic stem 
cells. Human embryonic stem cells (hESCs) can be used to study the early events in 
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human development and, hopefully, to understand how to differentiate human pluripotent 
cells for clinical use. To define how L3MBTL1, a chromatin-associated polycomb group 
protein with transcriptional repressive activities, regulates early events in embryonic cell 
differentiation, we created hESC lines that constitutively express shRNAs directed against 
L3MBTL1. Human embryonic stem cells (hESCs) are derived from the inner cell mass of 
early preimplantation blastocysts; they self-renew and are pluripotent. They can be 
maintained in an undifferentiated state, but can also be induced to differentiate into cell 
types characteristic of all 3 germ layers and of extra-embryonic tissues, offering the 
potential to model aspects of mammalian development and disease. Indeed, progress 
made over the past decade has determined that directing hESCs toward specific cell fates 
requires similar kinetics and signaling pathways as those required during development19. 
The trophoblast is an essential extra-embryonic tissue that arises from pluripotent 
trophectoderm (TE) during mammalian development. Interplay between transcriptional, 
epigenetic, and physiological factors governs TE cell fate. Several transcription factors 
including Cdx2, Tead4, Eomes, Gata3, Elf5, Ets2, and Tcfap2c are involved in TE lineage 
specification and its further expansion 20-24. Differential epigenetic modifications including 
DNA methylation and the distribution of histone modifications and their modifying 
enzymatic complexes25-28 contribute to lineage identity in the early embryo by regulating 
the appropriate gene expression profiles. Because in vitro cell fate decisions are similar to 
those made during development in vivo, hESCs can be exploited to reveal critical aspects 
of human development.  
We hypothesized that as a chromatin-associated protein with repressor properties, 
changes in the level of L3MBTL1 activity could alter the chromatin structure and influence 
the ability of hESCs to either self-renew or commit to differentiation. To test this 
hypothesis, we generated and characterized 2 independent and stable clones of 
L3MBTL1-depleted hESCs, using a lentiviral vector system to express short hairpin RNAs 
(shRNAs) directed against L3MBTL1 mRNA. 
4) By utilizing embryoid bodies (EB) as a model of hematopoietic development, it was 
shown that the level of erythroid-specific transcription factor EKLF expression resulted 
proportional to the amount of BMP4 added29,30; however, the effect of BMP4 on EKLF has 
never been proven to be directly conveyed by smad proteins, although ten conserved 
smad binding motifs were identified within three main regulatory regions of EKLF gene. In 
addition to its role in affecting erythroid differentiation of HSPCs, we found that L3MBTL1 
regulates the expression of EKLF in a smad-dependent manner. EKLF functions as a 
critical regulator of beta-like globin genes31,32. Its expression, restricted to the 
hematopoietic organs, has been shown also in pre-erythroid differentiation stages, where it 
is suggested to be mediated by the BMP/Smad signaling pathway.  
BMP4 interacts with the BMP receptor, enabling the interaction between its two subunits 
(BMPR-IA or IB and II), which then leads to phosphorylation of Smad1, Smad5 and/or 
Smad8 prior to their association with Smad4 and translocation to the nucleus33. Extensive 
literature indicates that the BMP4 signaling pathway is required throughout development 
for the establishment of hematopoietic fate from mesoderm 30,34,35. Indeed, exogenous 
BMP4 can augment the hematopoietic differentiation of hESCs, as well as substantially 
increase the proportion of committed hematopoietic cells generated from iPSCs36. The 
addition of EKLF to the growing list of BMP4-regulated genes hints that the BMP4 
signaling pathway and Smad activity are required throughout hematopoiesis and 
specifically in erythropoiesis, as opposed to being necessary only for the initial 
establishment of hematopoietic fate. Indeed, knock-down of Smad5 impairs maintenance 
of the erythroid program 37-39 and stress conditions trigger BMP4 pathway to promote 
erythropoiesis 40 and to cooperate with lineage regulators enhancing transcription of cell-
type-specific target genes during hematopoietic regeneration 41.  
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In this study we determined that the regulation of EKLF by the BMP4 signaling pathway 
exists in definitive hematopoietic / erythroid cells and that it is directly mediated by smad 
proteins. 
Our previous studies identifyied the role of the Polycomb protein L3MBTL1 in regulating 
erythroid lineage differentiation of HSPCs 42, functioning as a transcriptional repressor43 
and yet regulating differentiation of human embryonic stem cells in a BMP4-like manner44.  
We have subsequently investigated whether L3MBTL1 functions in erythropoiesis via the 
BMP4 signaling pathway regulating EKLF. We found that L3MBTL1 represses SMAD5-
mediated targets, including EKLF. Moreover we found that knock-down of L3MBTL1 can 
efficiently increase expression of fetal globin gene in primary hematopoietic cells as well 
as in patient-specific beta-thalassemic induced pluripotent stem (iPS) cells. Thus, we 
propose a model of EKLF regulation, which involves a crosstalk between a chromatin-
related protein (L3MBTL1) and a cytoplasmic signaling pathway (BMP4) and mediates 
globin gene expression in a clinically relevant setting, i.e. human models of beta-
thalassemia. 
 
 
1.2 Epigenetic roles for class I and class II genes 
In addition to the discovery in patients with myeloid malignancies of mutations in genes 
that primarily function in regulating DNA methylation or post-translational histone 
modifications, various previously characterized class I and class II alleles have recently 
been found to affect the epigenome as part of their transforming activity. This includes the 
discovery of the direct histone modifying activity of janus kinase 2 (JAK2), as well as 
identification of interactions between the fusion oncoproteins that are characteristic of APL 
and PcG proteins. The first JAK2 mutation (JAK2-V617F) was identified in patients with 
MPN and was found to be an activating mutation within the JH2 pseudokinase domain45. 
JAK2 mutations are known to activate canonical cytokine signalling pathways through the 
phosphorylation of STAT proteins. However, recent studies have demonstrated a novel 
role for JAK2 in epigenetic regulation. Dawson et al. showed that JAK2 localizes to the 
nucleus and phosphorylates Y41 of histone H346. This phosphorylation results in reduced 
binding of heterochromatin protein 1α (HP1α), a chromatin-binding protein that leads to 
transcriptional silencing.  
 
1.3 PRMT5 
The myeloproliferative neoplasms (MPNs) are stem cell disorders whose proliferation is 
thought to be driven by activating tyrosine kinase gene mutations, such as the BCR-ABL 
fusion gene in chronic myelogenous leukemia (CML)47. The JAK2 kinase V617F mutation 
is found in most patients with non-CML MPN 48-51. It is a constitutively active kinase that 
can phosphorylate STAT5 in the absence of upstream signals, confer cytokine-
independent growth to Ba/F3 cells, and induce a myeloproliferative disease in mouse 
models49,52-55. 
Upon activation, the receptor-bound JAK2 phosphorylates specific tyrosine residues of its 
downstream targets, activating cell survival/proliferation-promoting signaling pathways56. 
Several kinase cascades are activated by JAK2V617F, including the STAT5/BCL-XL, 
PI3K/AKT, and ERK/MAPK pathways49,57; however, they may not completely account for 
the MPN phenotype. 
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The type II arginine methyltransferase PRMT5 was first identified as JAK-binding protein 1 
(JBP1) in a yeast two-hybrid assay58. It mediates the symmetrical dimethylation of arginine 
residues within histones H2A, H3, and H459-61 and methylates other cellular proteins as 
well, such as p53, SPT5, and MBD262,63. Together with the WD40-repeat containing 
MEP50 protein and with pICln, PRMT5 forms a large 20S protein arginine 
methyltransferase complex, termed the “methylosome.” This complex functions in RNA 
processing by methylating Sm proteins and affecting snRNP biogenesis64-67. PRMT5 has 
been also found in the hSWI/SNF and NURD chromatin-remodeling complexes 61,68,where 
it can exert transcriptional control on target gene expression. 
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2. MATERIALS AND METHODS 
 
2.1 Purification and in vitro primary culture of human cord blood CD34+ cells 
Mononuclear cells were isolated from CB by Ficoll-Hypaque Plus density centrifugation. 
CD34+ HSPCs were purified by positive selection using the Midi MACS (magnetic-
activated cell sorting) LS+ separation columns and isolation Kit (Miltenyi). CD34+ cells 
were cultured in Iscove`s modified Dulbecco`s medium (IMDM, Cellgro) containing 20% 
BIT 9500 medium (Stem Cell Technologies) supplemented with SCF (100 ng/ml), FLT-3 
(10 ng/ml), IL-6 (20 ng/ml) and TPO (100 ng/ml) (these cytokines were purchased from 
Peprotech, NJ).  
 
2.2. Generation of lentiviruses and infection of primary hematopoietic CD34+ cells  
Lentiviral vectors were produced by transfection of 293T cells, according to standard 
protocols69. After 24 hours of growth, cells were infected with high-titer lentiviral 
concentrated suspensions, in the presence of 8 µg/ml polybrene (Aldrich). Lentiviral 
shRNA constructs were purchased from the TRC shRNA library at Thermo Scientific Open 
Biosystems and modified by subcloning the GFP gene instead of the puromycin gene into 
the pLKO.1 vector as a marker of viral integration. Sequences targeted by short hairpin 
RNAs (shRNAs) were: GGAAAGACGATGACGGAAA (shLUC), 
GTAGTGAGTTGTAGATAAA (sh1), GGTCAGTCATAGTGGAGAA (sh2), and 
GCCTGCACTTTGATGGGTATT (sh3). shRNAs were cloned into the H1p HygroEGFP70 
(shLUC, sh1 and sh2) or LKO vectors (empty vector and sh3). The luciferase-directed 
shRNA, cloned into the H1 vector, was used as control71. RNA sequences were selected 
using the Dharmacon SMARTselection design software. Forward and reverse 
oligonucleotides were resuspended at a concentration of 5 mM, heated to 95_C for 5 min, 
and allowed to cool to RT overnight. After annealing, the duplexes were cloned into 
SmaI/XbaI sites of an H1P shRNA cassette. 
shRNA targeting PRMT5 or a scrambled shRNA was cloned into the pLKO.1-GFP 
lentiviral vector. HA-PRMT5 WT or M6 cDNAs were cloned into the lentiviral vector pBGJR 
(modified by replacing the CMV promoter with the EF1α promoter). Viruses were produced 
by transfecting pLKO.1-GFP or pBGJR vector with helper plasmids into 293T cells, 
according to standard protocols. GFP-positive cells were sorted 2 days after infection. 
 
2.3 Flow cytometry 
Transduced CB CD34+ cells were sorted for green fluorescence (GFP) and CD34 
expression after staining with an APC-conjugated anti-CD34 antibody (BD Pharmigen), 
using a fluorescence-activated cell sorting (FACS) Vantage cell sorter. Transduced K562 
cells, cultured in RPMI medium supplemented with 10% fetal bovine serum, were sorted 
for GFP at 72 hrs after the infection. Cells were harvested for flow cytometry on days +7, 
+9, +11 in cytokine-driven liquid culture. Cells were stained with the following antibodies: 
CD34-APC (BD Pharmigen), CD11b-PE (Immunotech), CD14-PE (Immunotech), CD71-
APC (BD Pharmigen), GlycophorinA-PE (Invitrogen), CD41-PE (Immunotech) and 
analyzed by FACS.  
 
2.4 Isolation of MPN samples 
CD34+ cells were isolated from PV patient phlebotomy samples or ET/MF patient 
peripheral blood samples and cultured in SFEM (serum-free stem cell expansion media) 
supplemented with SCF (100 ng/mL), IL-3 (20 ng/mL), IL-6 (10 ng/mL) and Epo (0.5 
IU/mL) every other day. Cells were harvested at day 7 or day 9 for Western blot assays. 
The cells were >70% CD71/GlyA double-positive at these times of collection. 
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2.5 Cytospin preparations, GIEMSA staining and Benzidine staining 
2 x105 cells were centrifuged into slides for 5 minutes at 500 rpm and air dried. Cells were 
stained with May-Grunwald Giemsa stains and observed under light microscope for 
morphologic analysis. Benzidine staining was performed as described previously72. 
 
2.6 RNA extraction and quantitative Real-Time PCR (qRT-PCR) 
For qRT-PCR, total RNA was isolated from 2 x 105 cells using the RNeasy mini kit 
(QIAGEN, Germany), and then subjected to reverse-transcription with random hexamers 
(SuperScript III kit, Invitrogen). Real-time PCR reactions were performed using an ABI 
7500 sequence detection system.  
 
2.7 Methylcellulose colony and  LTC-IC assays. 
For the CFU assays: 1x104 GFP+ CD34+ transduced cells were plated (in duplicate) in 
methylcellulose with erythropoietin (5 IU/ml), SCF (50 ng/ml), IL-3 (20 ng/ml), IL-6 (20 
ng/ml), G-CSF (20 ng/ml) and GM-CSF (20 ng/ml). BFU-E, CFU-GM and CFU-GEMM 
colonies were scored 14 days after seeding.  
For the LTC-IC assays: 4x105 GFP+ CD34+ cells were grown on MS-5 stromal cells in 
IMDM, supplemented with 12.5% horse serum, 12.5% fetal bovine serum (FBS), 4 mmol/L 
L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin and 1 µM hydrocortisone. 
Medium was half-replenished every week and cobblestone areas were scored at week 
five.  At week five, cells were harvested and plated in methylcellulose medium with 
cytokines, as described for the CFU assay. 
 
2.8 Antibodies 
The following antibodies were used for western blot assays: the affinity purified anti- 
L3MBTL1 antibody, pSTAT5 (Cell Signaling), STAT5 (Cell Signaling), pMAPK1/2 (Cell 
Signaling), MAPK (Cell Signaling), pAKT (Cell Signaling), AKT (Cell Signaling), pFOXO1/3 
(Cell Signaling), JNK (Santa Cruz), JAK2 (Cell Signaling), p16 (Santa Cruz), Raf-1 (Santa 
Cruz), phopho smad1,5,8, smad1, smad5, phospho smad2, smad2, (Cell Signaling), 
HHEX (Chemicon), EKLF (abcam), HA (santa cruz).  
 
2.9 Ras Activation Assay 
Ras-GTP was precipitated from total cell lysates using the Ras activation assay kit, 
purchased from Millipore, according to the manufacturer's instructions.  
 
2.10 Overexpression assays 
Retroviral vectors were produced by transfection of Phoenix A cells with MIGR1 control or 
MIGR1 full length L3MBTL1-HA c-DNA plasmids9, according to standard protocols69. 
CMK, U937, HEL and K562 cells were grown in RPMI medium supplemented with 10% 
FBS and infected with high-titer retroviral suspensions in the presence of 8 µg/ml 
polybrene (Aldrich). 72 hours after infection, the GFP-positive cells were sorted by FACS. 
 
2.11 Chromatin Immunoprecipitation (ChIP) assays 
Approximately 4x106 cells were used per Chip reaction (per antibody) after cross-linking 
with 1% formaldehyde for 10 minutes at room temperature. Chip was performed according 
to the previously reported methodology73. The associated DNA after purification was 
subjected to qRT-PCR to detect specific DNA sequences. Quantitative results are 
represented as percentages to 10% DNA input.  
 
2.12 Gene expression profile (GEP) and Gene set enrichment analysis (GSEA)  
RNA was extracted and hybridized to Affymetrix U133A arrays, scanned, and subjected to 
quality control parameters and normalization as described. GSEA contains gene sets that 
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relate to common biological functions. GSEA first ranks the expression of each gene 
based on its correlation with one of two phenotypes being compared (in this case 
L3MBTL1-KD vs controls). It then identifies this rank position within the independent gene 
set being queried. From this ranking it calculates an enrichment score that reflects the 
degree to which genes within the independent gene set are over represented within those 
genes most highly correlating with one of the two phenotypes. The normalized enrichment 
score (NES) takes into account the number of genes within the independent gene set. 
Permutation on the phenotype class labels is used to obtain the null distribution of NES 
and the nominal P-value. The false discovery rate (FDR) is computed by comparing the 
tails of the observed and null distributions for the NES 
(http://www.broadinstitute.org/gsea)74.  
2.13 Human embryonic stem cell culture and differentiation protocols 
hESC line H9 (WA-09) cells were cultured on a feeder layer of mouse embryonic fibroblast 
(MEFs), purchased from GlobalStem, and plated on gelatin-coated tissue culture plates. 
ES cells were maintained in an undifferentiated state in human ES 
(HES)media(DMEM:F12; Invitrogen) supplemented with 20% knockdown serum 
replacement (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mmol/L 2 
mercaptoethanol (Invitrogen), 1 mmol/L l-glutamine (Invitrogen), and 6 ng/ mL FGF2 (R&D 
Systems). Cells were passaged using Dispase (neural protease; Worthington Bioscience). 
Spontaneous differentiation was induced by plating control and L3MBTL1KD cells in 
feeder-free conditions on Matrigel (BD Bioscience)-coated dishes in HES medium without 
FGF2 for 2 weeks; cells were fed daily. The day on which the cells were seeded was 
defined as day 1. 
Embryoid bodies (EBs) were generated by culturing control and L3MBTL1 KD cells in low-
cell-binding dishes for 14 days with the same medium used in spontaneous differentiation. 
EBs were collected by gravity and fed every other day. 
The directed differentiation to trophoblast was achieved by culturing the cells on Matrigel-
coated dishes in HES medium in the presence of exogenous BMP4 (100 ng/mL). Briefly, 
control and L3MBTL1 KD cells were cocultured on MS-5 stroma cells and fed with KSR 
medium supplemented with SB431542 (10 mM/mL) and dorsomorphin (600 nM/mL) 
during the first 7 days; then cells were fed only with KSR medium until day 14. 
 
2.14 Immunofluorescence 
Cultured cells were washed twice with PBS before being fixed in 4% paraformaldehyde at 
room temperature. Cells were washed 3 times with PBS before permeabilization with wash 
buffer (0.3% Triton X-100 and 1.0% bovine serum albumin in PBS) for at least 5 min. The 
primary antibody (diluted in wash buffer) was added to the cells for 2 h at room 
temperature, and then the cells were washed 3 times in wash buffer before the addition of 
the secondary antibody (diluted in wash buffer) for 1 h at room temperature. The cells 
were washed 3 times with PBS and stored at 4_C. The primary antibodies OCT-3/4 (4 
µg/mL; sc-5279), HAND1 (0.4 mg/mL; Ab11846), and L3MBTL1 (1:50 dilution) were 
detected using the appropriate secondary antibodies conjugated with Alexa Fluor 546 
(Molecular Probes). Negative controls consisted of no primary antibody, no secondary 
antibody, or the appropriate IgG isotype controlas indicated. DAPI counterstaining was 
performed on fixed cells to visualize all cellular nuclei. 
 
2.15 Western blot analysis 
Total cellular protein extracts were prepared using RIPA buffer (SIGMA R0278) 
supplemented with Halt Protease Inhibitor Cocktail (Thermo Scientific 78430) according to 
the manufacturer’s instructions. Nuclear and cytoplasmic extracts were prepared using the 
PIERCE kit (78833) for subcellular fractionation; 40 mg of protein extracts were 
electrophoresed on a 4–12% denaturing gel and electroblotted onto a nitrocellulose 
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membrane. The membrane was incubated with different antibodies at 4_C overnight and 
then incubated with the indicated secondary antibodies at room temperature for 1 h. The 
Pierce Enhanced Chemiluminescence kit was used to detect antibody reactivity, according 
to the manufacturer’s instructions.  
 
2.16 Cell cycle/DNA and flow cytometry analysis 
To analyze DNA content, cells were washed with PBS, and fixed in 70% EtOH at 4_C. The 
cells were washed with PBS, resuspended in propidium iodide solution (5 µg/mL) 
containing 10mg/mL RNase, mixed, and incubated 45min at 37_C. Flow cytometric data 
were acquired on a BD FACSCalibur (BD Biosciences) using CellQuest Proversion 6.0. 
Propidium iodide was excited by the 488 nm laser and fluorescence emission was 
measured in fluorescence parameter 3 (FL3) with the standard 670LP filter. Doublets were 
excluded by gating out high FL3-W (width) cells. Single cells were analyzed for 
percentages of G1/G0, S, and G2/M in MultiCycle AV (Innovative Cell Technologies). 
Detection of trophoblast marker HLA-G in L3MBTL1 KD spontaneously differentiated cells 
was performed by immunostaining with an APC-labeled anti-human HLA-G (eBioscience 
17-9957 clone 87G) using 0.125 µg/sample; 7-AAD (5 µg/mL) staining served to exclude 
dead cells from subsequent analysis. For each sample, 5 · 104 cells were analyzed on a 
FACS Calibur flow cytometer (BD Biosciences) using CELLQuest (BD Biosciences); data 
analysis was performed using the FlowJo software (Tree Stars, Inc.). 
For BrdU/propidium iodide staining, cells were incubated with 1 mM BrdU for 1 h and then 
stained with BrdU-APC antibody and propidium iodide, according to the instructions in the 
BrdU Flow Kit (BD Biosciences). Minimally, 105 cells were analyzed on the BD 
FACSCalibur flow cytometer, and the data were collected using BD Cell Quest Pro 
software and analyzed using FlowJo software (Tree Star). 
 
2.17 Immunoassays 
Media were collected from growing cells and stored at - 20_C until assay. Chorionic 
gonadotropin (CG-β) and progesterone levels were measured using ELISA kits, as 
indicated by the manufacturer (Calbiotech). 
 
2.18 Statistical analysis 
Data were analyzed using PRISM Version 5.04 (GraphPad Software, Inc.). Sample 
comparison was performed using 1- way analysis of variance (ANOVA) followed by a post 
hoc Tukey test or 2-way ANOVA followed by a post-hoc Bonferroni test, with the level of 
significance set at P < 0.05. 
 
2.19 Immunoblotting and Coimmunoprecipitations.  
U2OS cells were lysed in lysis buffer [20 mM Tris-HCl (pH 8), 0.5% Nonidet P40, 0.5% 
Tween 20, 1 mM EDTA, 1 mM DTT, 150 mM NaCl, 1 mM PMSF and protease inhibitor 
mixture (Calbiochem)], and then briefly sonicated and centrifuged. The protein 
concentration was measured using the Bradford assay (Bio-Rad), and equal amounts of 
protein were loaded on NuPage gels (Invitrogen). Protein transfer was conducted onto 
Immobilon-P PVDF membrane (Millipore), and the membranes immunoblotted with 
antibodies to the following proteins: phospho-Ser-317 Chk1, phospho-Ser354 Chk1, 
phospho-Thr68 Chk2, phospho-Tyr15 Cdc2, p53 (all from Cell Signaling), actin, Rad51, 
p21, geminin (all from Santa Cruz), α-tubulin (Sigma Aldrich), γH2A.x (Biolegend), 
H4K20me1, H4K20me3, H3 (all from Millipore). For coimmunoprecipitations, whole-cell 
extracts were prepared from 293T cells overexpressing HA-tagged L3MBTL1 using the 
same lysis buffer as above. The lysates for coimmunoprecipitations were treated with 
1,000 units/mL of benzonase (Sigma Aldrich) overnight at 4 °C to degrade DNA and RNA. 
They were also treated with 50 µg/mL ethidium bromide to disrupt DNA-protein complexes 
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and exclude DNA-mediated protein-protein interactions. The lysates were incubated 
overnight at 4 °C with HA-agarose beads (Roche) or normal rat IgG serum (Santa Cruz) 
followed by protein A agarose beads (Roche). The coimmunoprecipitates were washed 
four times with lysis buffer containing 250 mM NaCl before immunoblotting for the 
following proteins: MCM2-7 (all from Bethyl Laboratories), PCNA (Millipore), Cdc45, Fen-
1, Sld5 (all from Santa Cruz). For reciprocal coimmunoprecipitation, Flag-tagged L3MBTL1 
was overexpressed in 293T cells, and lysates treated as above were immunoprecipitated 
with antibodies against Mcm2, Mcm5, or rabbit IgG, followed by adsorption to protein A 
agarose beads. 
 
2.20 Comet Assay.  
DNA breaks were measured using the Comet Assay Reagent Kit (Trevigen) with minor 
modifications. Briefly, cells embedded in low-melting point agarose on a slide were lysed, 
treated with alkali, and electrophoresed in 1× TBE buffer for 40 min at 1 V/cm, stained with 
propidium iodide, and imaged under the fluorescent microscope. To evaluate the extent of 
DNA damage present in each sample, the average tail moment (a product of percent DNA 
in tail and tail length) of 100 cells was calculated using CometScore software (Tritek). 
 
2.21 Immunocytochemistry.  
Cells were plated on coverslips, then fixed in methanol, permeabilized with 0.25% Triton-
X/PBS, blocked in 2% FBS/PBS, and incubated with primary antibody for 1 h, followed by 
secondary antibody conjugated with a fluorescent probe for 30 min, both at room 
temperature. Cells were stained with DAPI, mounted onto coverslips in mounting medium 
(Vector Labs), and imaged on Leica Upright confocal microscope or Carl Zeiss fluorescent 
microscope using appropriate filters. The primary antibodies used were directed against 
γH2A.x (Millipore), 53BP1 (Novus Biologicals), and phospho-Ser1981 ATM (Cell 
Signaling), and secondary antibodies used were anti-rabbit Alexa488 and anti-mouse 
Alexa568 (both from Invitrogen). Quantitation of the DNA damage foci was determined by 
scoring foci of at least 100 cells per treatment used. 
 
2.22 DNA Fiber Analyses.  
Control and L3MBTL1 knockdown U2OS and MRC5 cells were sequentially labeled with 
50-µM IdU and 250-µM CldU for 1 h each. DNA fiber spreads were prepared as described 
previously with some modifications. Briefly, three aliquots of cells were resuspended in 
PBS at 1 × 106 cells/mL, spotted onto a microscope slide, and lysed with 15 µL of 
spreading buffer [0.5% SDS in 200 mM Tris-HCl (pH 7.4), 50 mM EDTA]. After 6 min, 
slides were tilted 15° to allow lysates to slowly move down the slide, and the resulting DNA 
spreads were air-dried, fixed in 3:1 methanol/acetic acid, and stored at 4 °C overnight. The 
slides were then treated with 2.5 M HCl for 30 min, incubated in blocking buffer (1% 
BSA/0.05% Tween 20/PBS) for 1 h followed by 1 h at room temperature with 1:500 rat 
anti-BrdU antibody (Abcam; to detect CldU) plus 1:100 mouse anti-BrdU (BD Biosciences; 
to detect IdU), diluted in blocking buffer, followed by incubation for 30 min in 1:350 
Alexa488-conjugated goat anti-rat antibody and 1:350 Alexa595-conjugated goat anti-
mouse antibody (Invitrogen). Slides were air-dried and mounted in Prolong Gold antifade 
reagent (Invitrogen). Microscopy was carried out using a Zeiss LSM 5 Live Confocal 
microscope, and the fiber lengths were measured using Volocity software (PerkinElmer). 
 
2.23 Metaphase Spreads.  
Cal51 cells were treated with Karyomax solution (Invitrogen) for 5 h and then lysed with 75 
mM KCl. Cells were fixed with a 3:1 methanol/acetic acid solution, dropped onto slides, 
dried, and stained with DAPI. The metaphase chromosomes were imaged under the Carl 
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Zeiss microscope and evaluated for abnormalities such as chromatid and chromosome 
breaks, gaps, and exchanges. 
 
2.24 Cell Culture, Transfection, and Plasmids 
The human leukemia cell lines TF-1, HEL, and Ba/F3 were grown in RPMI Media 1640 
with 10% FBS (Invitrogen), supplemented with recombinant human IL-3 (2 ng/ml) for TF-1 
and Ba/F3 cells. To inhibit JAK2 activity in HEL and TF-1 cells, cells were treated with 
three distinct JAK2 inhibitors: JAK Inhibitor I (Calbiochem), CEP701 (LC Laboratories), 
and TG101348 at the indicated concentrations (DMSO was used as the diluent control). In 
the time course experiment, HEL cells were treated with 3 µM TG101348 for 0, 1, 2, and 
4 hr. To activate JAK2 in TF-1 cells, the cells were deprived of cytokine for 12–16 hr, and 
then GM-CSF (25 ng/ml) or Epo (20 U/ml) was added to the growth medium for 20 min. 
Transient transfection of 293T cells was performed using the PolyFect Transfection 
Reagent (QIAGEN) per the manufacturer's instructions. To express the mutant or wild-type 
JAK2 proteins in 293T cells, the wild-type JAK2, JAK2V617F, and JAK2K539L cDNAs 
were subcloned into the CMV promoter-driven pCDNA3 vector (Invitrogen) using EcoRV 
and Not1 sites. FLAG-tagged or HA-tagged PRMT5 and HA-tagged STAT5 cDNAs were 
also subcloned into the pCDNA3 vector through appropriate restriction sites. For in vitro 
kinase assays, the full-length PRMT5 open reading frame was subcloned into the bacterial 
expression vector pSBET, which contains a glutathione S-transferase (GST) tag and a 6× 
Histidine tag at the N and C termini of the inserted sequence, respectively. 
 
2.25 In Vitro Kinase Assay 
In vitro kinase assays were performed using commercially available JAK2 kinase 
(Upstate), which contains only the kinase domain (from amino acid 800 to C-terminal end), 
and bacterial-purified GST-PRMT5. For each reaction, 0.5 or 2.5 µg of GST-PRMT5, 0.5 
or 1.25 ng of JAK2, and 5 µCi of [γ-32p] ATP were added to the kinase buffer (8 mM 
MOPS [pH 7.0], 0.2 mM EDTA, 10 mM MgAc, and 0.1 mM cold ATP). Reactions were 
incubated at 30°C for 20 min, and proteins resolved by gel electrophoresis. 
 
2.26 In Vitro Methylation Assay 
HA-PRMT5 was purified from transfected 293T cells by anti- HA immunoprecipitation. The 
immobilized proteins were then incubated with 25 µl of HMT buffer (20 mM Tris [pH 8.8], 
4 mM EDTA, 1 mM PMSF, 0.5 mM DTT) supplemented with 2.5 µg of recombinant histone 
H4 or H2A (New England Biolabs) and 1 µCi 3H-SAM (Amersham) at 30°C for 4 hr. The 
reaction was stopped by adding SDS loading buffer, and the proteins were resolved on 
SDS-PAGE gels. 
 
2.27 Microarray Analysis 
RNA was isolated from HEL cells expressing control shRNA or PRMT5-directed shRNA 
using the RNAeasy Plus Kit (QIAGEN), transcribed into cDNA using random hexamer 
priming and Superscriptase (Invitrogen), and then hybridized to the Affymetrix HG-U133 
GeneChips. The data were analyzed using Partek Genomic Suites, version 6.5, using a 
false discovery rate (FDR) of 1% to filter our data and identify differentially expressed 
genes. Duplicate, independent samples were prepared for each condition. 
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3. RESULTS 
 
3.1. L3MBTL1 and the erythroid lineage differentiation of HSPCs 
 
a) Knock-down of L3MBTL1 accelerates erythroid differentiation of human 
hematopoietic CD34+ progenitor cells 
To investigate the function of L3MBTL1 in human hematopoiesis we knocked down 
L3MBTL1 in CD34+ human CB cells, using lentiviruses expressing shRNAs targeting 
L3MBTL1, and 72 hrs after infection documented the efficient knock-down of L3MBTL1 
mRNA and protein in the sorted GFP+ CD34+ cells by qRT-PCR and Western blot, for 
several different shRNAs constructs (Fig 1A). These cells were then placed in Epo-driven 
liquid culture (6 IU/ml), and the expression of CD71 and Glycophorin A (GlyA) was 
monitored by flow cytometry at different time points. The generation of mature erythroid 
precursor cells (CD71/GlyA-double positive cells) was consistently faster and more 
efficient for the L3MBTL1-KD cells, compared to the control vector infected cells (Fig 1B). 
Furthermore, while CD71/GlyA double-negative cells were prominently found among the 
control cells, there were no CD71/GlyA double-negative cells after L3MBTL1- KD.  These 
observations were consistently seen using several different shRNAs constructs targeting 
L3MBTL1, demonstrating enhanced erythroid differentiation following L3MBTL1 depletion.  
 To evaluate the sensitivity of L3MBTL1-KD cells to Epo, we measured GlyA and 
CD71 expression by FACS analysis in the L3MBTL1-KD HSPCs after plating these cells in 
culture with SCF (100 ng/ml) and different doses of Epo (0.5, 2, 4 and 6 units per ml).  At 
the lowest concentration of Epo (0.5 UI/ml), and at all tested concentrations of Epo, the 
L3MBTL1-KD cells showed accelerated erythroid maturation compared to control cells 
(2.4, 1.8, 1.6 and 1.6 fold, respectively) (Fig 1C).  
Consistent with the immunophenotypic evidence, these cells also showed 
morphologic evidence of erythroid differentiation following L3MBTL1- KD. As erythroid 
differentiation proceeds, erythroblasts display a gradual decrease in cell size, increase in 
chromatin condensation and increase in hemoglobin (Hb) concentration75, and indeed, the 
L3MBTL1-KD cells appeared smaller with more condensed chromatin than the control 
cells (which displayed a larger, more homogeneous, and eccentrically placed nucleus, as 
seen in Fig 1D). Likewise, benzidine staining also revealed 6.6 fold enrichment of Hb-
containing cells compared to controls at day 7 of culture, consistent with the time of 
highest immunophenotypic difference, with a 1.7 fold and 1.3 enrichment at days 9 and 11 
of culture (Figure 1E). These results further indicate a role for L3MBTL1 in regulating the 
erythroid differentiation of human HSPCs.     
    
b) L3MBTL1 expression decreases during normal erythroid differentiation of human 
HSPCs 
To investigate whether changes in L3MBTL1 expression are only seen during erythroid 
differentiation, we cultured normal CB CD34+ cells in various cytokine cocktails that 
preferentially support erythroid, myeloid or megakaryocytic differentiation and evaluated 
L3MBTL1 expression (by qRT-PCR) at different time points. L3MBTL1 is downregulated 
upon differentiation generally, but especially in cells exposed to the erythroid promoting 
cytokines SCF plus Epo (Fig 2A). These cells maintain a low level L3MBTL1 expression 
over time, whereas the cells grown under other culture conditions show a rebound in 
L3MBTL1 expression by day 7.    
Given the increased erythroid differentiation following L3MBTL1- KD, we also 
assessed whether L3MBTL1-KD altered myeloid and megakaryocytic differentiation. 
L3MBTL1-KD and control GFP+ CD34+ cells grown in G-CSF-driven liquid culture showed 
similar expression of myeloid-specific cell surface markers (CD11b, CD14 or CD33) (Fig 
2B and data not shown). Similarly, we observed no effect on the expression of the 
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megakaryocyte marker CD41 in thrombopoietin (TPO)-driven cultures (Fig 2C), 
demonstrating that L3MBTL1 depletion specifically affects erythroid differentiation (Fig 
2D). 
 
c) Knock-down of L3MBTL1 induces leukemia cell differentiation towards the 
erythroid lineage  
To determine if L3MBTL1- KD can also affect the differentiation of leukemia cells, we used 
lentiviral vectors to express shRNA targeting luciferase (shLUC) or L3MBTL1 (sh1 and 
sh2) in K562 cells. We sorted GFP+ cells (by FACS) 72 hours post-infection and as seen 
in CB cells, KD of L3MBTL1 in K562 cells increased GlyA expression, compared to control 
cells (Fig 3A), and led to higher benzidine staining before and after hemin-exposure (Fig 
3B). As hemin is known to trigger the erythroid differentiation of K562 cells72 , and activate 
globin gene expression76, we studied L3MBTL1 expression in K562 erythroleukemia cells 
following hemin exposure. Four days of hemin exposure (at 50µM) markedly decreased 
the level of L3MBTL1 mRNA (Fig 3C) commensurate with an increase in benzidine-
positive cells and increased globin gene expression (data not shown). Thus, L3MBTL1 
loss can induce erythroid differentiation in leukemia cells as well as in normal human 
HSPCs.  
 
d) Loss of L3MBTL1 leads to expansion of erythroid progenitors in long-term 
cultures  
To elucidate the role of L3MBTL1 in the earliest stem/progenitor cells, we performed LTC-
IC assays, culturing 4 x 105 GFP+ CD34+ transduced cells on MS5 stromal cells. We 
observed an impressive expansion of progenitor cells from the L3MBTL1-KD cells at week 
5. The L3MBTL1- KD cells grew mostly on top of the MS5 layer, in sheets of cells rather 
than cobblestones, while the control cells formed normal cobblestones that grew 
underneath the stromal layer (Fig 4A). To define the nature of these cells we used flow 
cytometry to define their lineage-specific cell surface marker profile. The L3MBTL1-KD 
showed strikingly higher GlyA expression compared to control cells, suggesting that these 
cells are erythroid progenitors (Fig 4B). KD of L3MBTL1 led to a reduction in stem cell 
frequency in both limiting dilution and bulk CAFC assays (Fig 4C). Furthermore, when the 
week 5 culture of the LTC-IC assay cells were plated in methylcellulose, we observed a 
greater number of BFU-E among the KD-cells than the control cells (Fig 4D).  
While CD34 expression was initially higher in the KD-cells, by day +11 we found no 
difference in CD34 expression between the KD and the control cells (Fig 5A). Given these 
findings, we evaluated whether the commitment towards the erythroid lineage that follows 
L3MBTL1 down-modulation impairs the proliferative potential of HSPCs. Cell counts at 
each time point (day +7, +9 and +11) revealed slower growth of KD-HSPCs compared to 
control cells in liquid cultures with SCF, IL-3, TPO and FLT-3 (Fig 5B), or Epo-, G-CSF- 
and TPO (data not shown). We also evaluated the clonogenic ability of sorted CD34+ 
L3MBTL1-KD HSPCs in CFU assays and found decreased progenitor frequency 
compared to controls; all types of colonies were less frequent (Fig 5C).  
As the cell`s proliferative potential appears to be slightly decreased following 
L3MBTL1-KD, we tested the sensitivity of HSPCs to TGFβ.  We treated CD34+ cells with 
200pM TGFβ, which induces the expression of p5777; we observed a greater induction of 
p57 mRNA in L3MBTL1-KD cells at two hours compared to control cells (Fig 5D);  no 
change in p57 expression was observed in the KD-cells in the absence of TGFβ.  
 
e) L3MBTL1- KD alters the Epo-dependent and Epo-independent phosphorylation of 
STAT5, AKT, and MAP Kinase  
To investigate the effect of L3MBTL1-KD on intracellular signaling pathways, we prepared 
lysates from CD34+ L3MBTL1-KD cells cultured in Epo for one week and performed 
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Western blot analyses. We found increased signaling downstream of the Epo receptor, 
with consistently greater phosphorylation of AKT, FOXO 1/3 and MAPK and variably 
increased phosphorylation of JAK2 and STAT5 to controls (Fig 6A and 6B). RAS-GTP and 
Raf-1 protein levels were decreased in the L3MBTL1-KD cells, consistent with the 
enhanced erythroid maturation (Fig 6C and 6E). Moreover, this pattern of activation 
mirrors the activation of signaling pathways seen in similarly cultured CD34+ HSPCs 
isolated from JAK2V617F+ MPN patients (Fig 6A).  
To determine if knock-down of L3MBTL1 can contribute to the Epo-independent 
erythroid cell growth found in MPN patients, we placed sorted CD34+ L3MBTL1-KD cells 
in Epo-free culture media supplemented with SCF, IL-6, FLT-3 and TPO for one week and 
found a small GlyA-positive, i.e. erythroid progenitor, cell population in the L3MBTL1-KD 
cells (Fig 6D). Despite the absence of Epo, phosphorylation of STAT5 and AKT was 
clearly seen (Fig 6E). Moreover, L3MBTL1- KD cells also displayed increased p16INK4a 
expression (Fig 6E), protein associated with the induction of erythropoiesis in primary PV 
samples78,79. 
To assess whether decreased L3MBTL1 expression may be implicated in the 
pathogenesis of non 20q- MPN, we evaluated the expression of L3MBTL1 in granulocytes 
obtained from 75 MPN patients (who did not show loss of 20q), and compared it with the 
level of expression in granulocytes obtained from 10 normal donors using the Affymetrix 
HGU133a.2 array. Granulocyte mRNA from 28 patients with Polycythemia Vera and 47 
patients with Essential Thrombocythemia was studied using gene expression array. We 
observed a ≥ 20% decrease in the expression of L3MBTL1 in 43% of the PV samples 
(12/28) and 62% of the ET samples (29/47) compared to the normal controls (p=0.000027 
and p=0.0004 respectively) (data not shown). This suggests that downregulation of 
L3MBTL1 may also play a role in the non 20q- myeloproliferative neoplasms.  
 
f) L3MBTL1 restricts erythroid differentiation  
To address the function of L3MBTL1 in 20q- disorders and to explore the mechanism by 
which L3MBTL1 affects erythroid differentiation, we overexpressed the full length 
L3MBTL1-HA c-DNA in three human 20q- hematopoietic cell lines (i.e. HEL, CMK and 
U937 cells) and in K562 cells. We sorted the GFP positive cells and evaluated 
Glycophorin A expression by FACS analysis: L3MBTL1-HA expressing cells showed 
decreased expression of Glycophorin A (Figure 7A), suggesting that L3MBTL1 restricts 
erythroid differentiation.   The decreased GlyA expression was seen in CMK (58% vs 86%) 
and U937 cells (0.5% vs 9%), as well as in HEL (85% vs 93%) and K562 cells (71% vs 
84%).  
We have also overexpressed L3MBTL1 in primary human CD34+ cells, obtaining an 
almost 200-fold increase in L3MBTL1 expression, as documented by qRT-PCR (Fig 7D). 
We placed the sorted GFP+ CD34+ cells in Epo-induced liquid culture, and consistently 
found a decreased percentage (62% vs 70%) of CD71+/GlyA+ cells after three days of 
culture (Fig 7C). The milder decrease in GlyA expression seen in primary human CD34+ 
cells, compared to the 20q- cells, may reflect the normal genetic background of the 
transduced cells and their intrinsic growth rates.  Overexpression of L3MBTL1 in HEL cells 
decreased the expression of p16INK4 (Figure 7B), further suggesting that L3MBTL1 may 
affect erythropoiesis by regulating (i.e. repressing) p16 expression. Further studies are 
needed to address this issue. 
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3.2. L3MBTL1 and the DNA damage response 
 
a) Depletion of L3MBTL1 Inhibits Cell Proliferation and Causes G2/M Arrest.  
To assess the role of L3MBTL1 in cell cycle regulation, we depleted L3MBTL1 mRNA and 
protein in U2OS cells using lentiviral vectors that expressed several shRNAs directed 
against its ORF. Down-regulation of L3MBTL1 mRNA and protein was achieved efficiently 
with three different shRNAs (≥90% knockdown; Fig 8 A e B). The depleted cells were 
monitored for S phase entry by using BrdU incorporation, and we detected a marked 
decrease of S phase cells and the accumulation of cells in the G2/M phase (Fig 8C). 
These findings indicate that these cell cycle effects are relevant to the myeloid 
compartment. 
 
b) Depletion of L3MBTL1 Generates DNA Breaks.  
Cell cycle alterations triggered by L3MBTL1 depletion suggest that cells may be 
experiencing replicative stress, leading to DNA damage. To verify this hypothesis, we 
examined two DNA damage markers, the production of the phosphorylated histone H2A.x 
(γH2A.x), which localizes to sites of double-stranded DNA breaks (DSBs), and the 
distribution of 53BP1, which is recruited to DNA within minutes following DNA damage by 
binding to H4K20me2 and possibly other modified histone. We observed an increase in 
both γH2A.x and 53BP1 foci following L3MBTL1 depletion with all three shRNAs in U2OS 
(Fig 9 A e B). We also measured the formation of DNA strand breaks in L3MBTL1-
depleted cells using the comet assay, which visualizes damaged DNA on a single-cell 
level (15). Comet tails were detected in depleted U2OS cells (Fig 9C), MRC5 and Cal51 
cells (Fig 9D), indicating DNA strand breakage. We treated MRC5 fibroblasts with varying 
doses of gamma irradiation to establish a range of tail moments (Fig 9D) and determined 
that depletion of L3MBTL1 caused extensive DNA damage, similar to that induced by 5 Gy 
of irradiation. 
 
c) Loss of L3MBTL1 Activates the DDR and Affects H4K20 Methylation Status.  
DNA damage triggers a checkpoint response that prevents cells from progressing into 
mitosis. To explore this pathway, we first examined the phosphorylation of the ATM 
kinase, one hallmark of the DDR pathway, and detected increased phospho-ATM foci that 
overlapped with 53BP1 foci in L3MBTL1-depleted cells (Fig 10 A). We also examined 
whether the downstream components of the ATR/ATM-triggered DDR pathway were 
activated following L3MBTL1 depletion using immunoblotting to monitor changes in 
phosphorylation of the key components of this system, including Chk1 and Chk2. As 
shown in Fig 10 B, increased levels of phospho-Ser317-Chk1, phospho-Ser345-Chk1, and 
phospho-Thr68-Chk2 were detected in cells at 24, 48, and 72 h postinfection, similar to 
that observed in cells irradiated with 10 Gy. 
Depletion of L3MBTL1 altered the activities as well as the levels of a number of 
proteins associated with checkpoint regulation and the DDR pathway (Fig 10 B-D). These 
include: (i) the formation of phospho-Tyr15-Cdc2, a modification that inhibits Cdc2 kinase 
activity, which is required for cell cycle progression into mitosis (Fig 10B); (ii) the up-
regulation of p21 and p53, downstream effectors of the DDR pathway, as well as Rad51, 
which plays a key role in double-strand break repair by homologous recombination, and 
(iii) an increase in the level of γH2A.x (Fig 10D), in keeping with the data shown in Fig. 2. 
We also observed an increase in the amount of H4K20me2 (40- to 90-fold), which plays 
important roles in DNA replication and DNA damage recognition, but detected little effect 
on the levels of H4K20me1. Conversely, overexpression of L3MBTL1 in U937 cells that 
have monoallelic loss of the commonly deleted region of 20q had the opposite effect, 
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namely, a decrease in H4K20me2 and an increase in H4K20me1 (Fig 10E). Collectively, 
these data show that the DDR pathway is strongly activated following depletion of 
L3MBTL1 and suggest that changes in the level of H4K20 dimethylation could contribute 
to these effects. 
 
d) L3MBTL1 Depletion Slows the DNA Replication Forks Movement.  
The presence of DNA damage and activation of the DDR suggest that depletion of 
L3MBTL1 may trigger defects in DNA replication. We examined DNA replication fork 
progression by DNA fiber analyses. For this purpose, control and L3MBTL1-depleted cells 
were sequentially pulsed for 1 h each with IdU and CldU, lysed, and DNA fibers spread on 
slides. The fibers were labeled with antibodies to IdU and CldU and fluorescence-labeled 
secondary antibodies. Fibers containing green IdU fluorescent label flanked on each side 
with the red CldU fluorescent label represent DNA molecules formed by bidirectional 
movement of replication forks. Fig 11A shows DNA fibers isolated from control and 
L3MBTL1-depleted MRC5 fibroblasts. The length of the green IdU-labeled fibers, 
indicating DNA replicated from origins, was shorter in depleted cells than in fibers isolated 
from control cells. Furthermore, the total length of red CldU- and green IdU-labeled fibers 
was shorter in L3MBTL1-depleted cells than in control cells, indicating slower replication 
fork movement. The average length of DNA fibers from L3MBTL1-depleted cells and 
control cells was 16.8 µM and 31.7 µM, respectively (Fig 11B); 78% of the DNA fibers from 
L3MBTL1-depleted cells were <20 µM, whereas 33% of fibers from control cells were this 
length (Fig 11C). Similar data were obtained using U2OS cells, indicating that this effect is 
not cell-type specific (Fig11D and E). The average rate of fork progression in L3MBTL1-
depleted cells was ~40% slower than in control cells, indicating that L3MBTL1 is required 
for the normal progression of DNA replication forks. 
 
e) L3MBTL1 Interacts with Components of DNA Replication Machinery.  
Because L3MBTL1 appears to play a role in replication fork progression, we tested 
whether it interacted with components of the DNA replication machinery. We 
overexpressed HA-tagged L3MBTL1 in 293T cells, and examined its interaction with 
members of the MCM2-7 complex, a critical component of the putative replicative helicase. 
As shown in Fig 12A, HA-tagged L3MBTL1 interacted with the MCM2-7 complex, and 
L3MBTL1 was immunoprecipitated by antibodies against MCM2 and MCM5 (Fig 12B). 
Cdc45 and the GINS complex form a replicative helicase complex with MCM2-7 (CMG 
complex) that travels with the replication fork. These findings prompted us to examine 
whether L3MBTL1 interacted with these components as well as other replication proteins. 
As shown in Fig 12A, the interaction of L3MBTL1 with Cdc45 was detected, whereas an 
interaction with Sld5 (a subunit of the GINS complex) was not observed. Interactions with 
PCNA, the DNA sliding clamp required for processivity of the replicative DNA 
polymerases, were also noted, whereas interaction with Fen-1, an enzyme involved in 
DNA repair and lagging strand processing, was not observed (Fig 12A).  We also 
examined whether the levels of replication proteins were affected by depletion of 
L3MBTL1 in U2OS cells. Thus, L3MBTL1 interacts with a number of proteins that play 
roles in different stages of DNA replication, consistent with the notion that it affects 
replication. The mechanisms contributing to these effects remain to be investigated. 
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3.3. L3MBTL1 and pluripotency of human embryonic stem cells 
 
a) L3MBTL1 knockdown does not affect embryonic stem cell renewal 
We initially screened 10 different shRNAs that target L3MBTL1 using K562 cells (data not 
shown) and used the 4 most efficient shRNAs to transduce H9 hESCs. Ultimately, 2 
shRNAs were used (shRNA1 and shRNA2) (Fig. 13A) that most consistently knocked 
down L3MBTL1 in H9 cells compared with the H9 cells expressing a nontargeting, 
luciferase-specific hairpin (LUC shRNA) and the parental H9 cell line. Overall, 11 
L3MBTL1 KD ES cell clones were generated.  
Although the self-renewal properties of L3MBTL1 knockdown (KD) hESCs were retained, 
we observed striking morphological changes when L3MBTL1 KD hESCs spontaneously 
differentiated and established that they spontaneously differentiate into trophoblast-like 
cells. L3MBTL1 appears to be an important regulator of early cell fate decisions during 
mammalian development. 
The L3MBTL1 KD hESCs showed normal colony morphology (Fig. 13C), normal cell cycle 
kinetics (Fig. 13D), an unchanged pattern of cell surface markers, and a normal karyotype 
in prolonged culture (data not shown) when cultured under normal hESC growth 
conditions. We obtained an *70% reduction in L3MBTL1 mRNA levels (using either 
shRNA1 or shRNA2) and observed a small decrease in the levels of the pluripotency- 
promoting OCT-4, NANOG, and SOX2 transcription factor mRNAs (Fig. 13E). 
Immunofluorescence analysis confirmed the normal expression and localization of OCT-4 
protein in all cell lines (Fig. 13F). Thus, L3MBTL1 depletion does not detectably affect the 
undifferentiated state of hESCs. L3MBTL1 knockdown impairs embryonic cell production 
during spontaneous differentiation 
 
b) L3MBTL1 knockdown impairs embryonic cell production during spontaneous 
differentiation 
To determine whether loss of L3MBTL1 affects differentiation, we withdrew FGF2 from 
HES media and grew the hESCs under either adherent or nonadherent conditions, 
inducing their spontaneous differentiation. hESCs were maintained for 2 weeks under 
adherent culture conditions as colonies, using Matrigel-coated dishes. Depletion of 
L3MBTL1 had clear morphological consequences, as all 11 clones derived from the 
shRNA1- or shRNA2-expressing hESCs generated differentiated colonies composed of 
large, flat mononucleated cells by days 7–14. In contrast, the control luciferase knockdown 
H9 cells and the parental line H9 generated mixed colonies composed of many different 
cell, morphologies (Fig. 14A and data not shown). We also observed morphological 
consequences in the EBs generated from L3MBTL1 KD cells under nonadherent 
conditions; in contrast to the control cells, the L3MBTL1 KD cells failed to give rise to 
typical EB structures containing differentiated cell types. Starting at day 5 of differentiation, 
the L3MBTL1 KD EBs underwent significant cell death that continued until day 14, 
indicating defects in differentiation, whereas control cells developed into characteristic EB 
structures (Fig. 14B). Flow cytometric analysis for Annexin V binding and 7-AAD 
permeability confirmed an increased cell death in the L3MBTL1 KD cells compared with 
the control cells at day 7 of differentiation (Fig. 14C). 
To characterize the differentiation state of the L3MBTL1 KD cells in monolayer cultures, 
we performed reverse transcriptase qPCR analysis to quantify the expression of a variety 
of pluripotent and lineage-specific markers. 
Differentiated control and L3MBTL1 KD cells were evaluated and significant differences 
were seen. As expected, the pluripotency markers OCT-4 and NANOG were reduced in 
both the L3MBTL1 KD and the control KD cells compared with the undifferentiated cells 
(Fig. 14D). Of note, L3MBTL1 levels were upregulated at least 3-fold in the differentiated 
controls compared with the undifferentiated controls, suggesting a potential role for 
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L3MBTL1 in the earliest stages of differentiation. However, the shRNA constructs 
continued to suppress L3MBTL1 mRNA levels despite the increased expression 
that have occurred during normal differentiation (Fig. 14D). Quantification of lineage 
marker expression shows downregulation of the SOX1 (ectoderm) and AFP (endoderm) 
markers in the L3MBTL1 KD cells, compared with their increased levels in the 
differentiated controls. Interestingly, we observed a substantial upregulation in the 
expression of ACTC1 (mesoderm) and the trophoblast marker chorionic gonadotropin 
(CG-β) in the L3MBTL1 KD in contrast to the differentiated control cells (Fig. 14E). We 
also performed reverse transcriptase qPCR analysis to assess the expression of additional 
lineage markers including NEUROD1, SOX2, MAP2 (ectoderm); HNFA4, FOXA2, 
PECAM1 (endoderm); and MIXL1, RUNX1, and RUNX2 (mesoderm). 
 
c)L3MBTL1 knockdown promotes differentiation of hESCs toward trophectoderm 
The flat cell morphology (Fig. 14A) and the greater than 18-fold upregulation of CG-b in 
the differentiated L3MBTL1 KD cells (Fig. 14E) led us to examine the expression of other 
trophoblast markers, including CDX2, HAND1, KRT7, KRT8, and GCM1. CDX2 mRNA 
upregulation parallels the appearance of morphological changes in spontaneously 
differentiated L3MBTL1 KD cells by days 6–7, reaching a peak on day 9; in contrast, 
HAND1, KRT7, KRT8, and GCM1 mRNAs peak at day 14. The expression pattern of 
these markers further indicates that L3MBTL1 KD cells primarily differentiate into 
trophoblast cells (Fig. 15A, B). We have confirmed that HAND1 protein is expressed in 
differentiated L3MBTL1 KD cells by immunofluorescence (Fig. 15C) and that more than 
80% of the cells analyzed at day 14 of differentiation have trophectoderm phenotype, as 
indicated by the expression of HLA-G (Fig. 15D). 
To further examine the differentiation of L3MBTL1 KD cells into trophoblasts, we directed 
control cells toward trophoblasts using BMP4. We compared the gene expression 
pattern of the BMP4-treated control (LUC shRNA) cells with the spontaneously 
differentiated L3MBTL1 KD cells and found similar but higher trophoblast marker 
expression (CG-β and HAND1) in the BMP4-treated control cells (Fig. 16A). Of note, 
L3MBTL1 expression decreased at least 4-fold in the control cells treated with BMP4 
compared with untreated LUC shRNA control, which is also consistent with the notion that 
downregulation of L3MBTL1 allows trophoblast formation to proceed in hESCs (Fig 16A). 
To further investigate the role of BMP signaling, we measured the level of phosphorylated 
SMAD proteins (SMAD 1/5/8) during the spontaneous differentiation of the LUC shRNA 
and L3MBTL1 KD cells. We found an increased level of phospho-SMAD 1/5/8 in 
differentiated L3MBTL1 KD cells compared with the control cells (Fig. 16B). We also 
measured the secretion of the placental hormones CG-b and progesterone into the 
medium from spontaneously differentiatedL3MBTL1 KD cells and also the untreated and 
BMP4-treated controls. L3MBTL1 KD and BMP4-treated control cells show a continuous 
increase in the concentration of both hormones, with the hormone secretion by the 
knockdown cells being nearly as high as from the BMP-treated control (Fig. 16C). 
These results show that L3MBTL1 KD cells differentiate into functional trophoblast cells, 
which indicates the role of L3MBTL1 in regulating the spontaneous differentiation of 
embryonic derivatives. 
 
d) Directed differentiation is not impaired in L3MBTL1 KD cells  
L3MBTL1 KD cells did not express ectoderm markers under conditions that allow 
spontaneous differentiation (Fig.14D). However, to determine whether directed 
differentiation was affected in L3MBTL1 KD cells, we induced neural differentiation by 
coculturing them on MS-5 stromal cells for 2 weeks. We observed neuronal rosette 
formation on day 8 with all clones (Fig. 16D, upper panel), demonstrating that L3MBTL1 
KD cells can differentiate into neuroectoderm if provided with a sufficiently strong signal. 
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Further, reverse transcriptase qPCR analysis found a similar level of induction of the 
neuroectodermal markers SOX1 and PAX6 in the knockdown versus the control cell lines 
(Fig. 16D, lower panel). We also directed the differentiation of L3MBTL1 KD hESC toward 
hematoendothelial cells (CD31+CD34+) and found that the KD cells responded to these 
differentiation signals as well, albeit less efficiently than to the controls (data not shown). 
These results indicate that L3MBTL1 KD does not impair hESC differentiation toward 
embryonic neuroectoderm or hematoendothelial cells when potent differentiation-
promoting signals are provided. 
 
 
3.4. L3MBTL1 and the BMP4/smad5 signaling pathway 
 
a) L3MBTL1 regulates EKLF expression via SMAD5 in hematopoietic and 
embryonic stem cells 
Our previous data implyied that the Polycomb protein L3MBTL1 regulates erythroid 
lineage differentiation of hematopoietic stem/progenitor cells (HSPCs) 42 and titrates 
BMP4-like events in human embryonic stem cells 44. To evaluate whether L3MBTL1 
regulates EKLF expression, we lentivirally expressed shRNAs targeting L3MBTL1 in 
primary cord blood (CB) CD34+ cells and evaluated expression of several master 
erythroid transcription factors by qRT-PCR. Interestingly, EKLF was the most induced 
among the erythroid-specific genes (Fig. 17A). By screening ten potential smad 
binding sites across the entire length of the upstream enhancer, the proximal 
promoter and the intronic enhancer of the EKLF gene, which were previously 
identified in EBs30, we determined the in vivo direct recruitment of Smad5 at most of 
these regions with chromatin immuno-precipitation experiments (ChIP) in K562 
erythroleukemia cells (Fig17B). This finding indicates that smad5 plays a direct 
functional role in the transcriptional control of EKLF expression in definitive 
hematopoietic cells, beyond the EBs. As confirmation, the identification of blocks of 
perfect conservation within each of the three cis-elements of the EKLF gene, that are 
mostly GC-rich in nature, indicate a feature that has been described to serve smad 
binding as well80. Next, we evaluated whether L3MBTL1 affects the binding of smad5 
to these regions. We retrovirally overexpressed L3MBTL1-HA in K562 cells and 
performed ChIP experiments by using smad5 antibody. We found that 
overexpression of L3MBTL1 impairs recruitment of Smad5 on EKLF regulatory 
regions (Fig17B).  
Indeed, activation of BMP4 signaling is required for the enhanced EKLF expression in 
L3MBTL1-KD cells, as the specific BMP signaling inhibitors (Dorsomorphin and 
SB431542) block the rise in EKLF expression seen in L3MBTL1-KD hES cells (Fig. 
17C). Indeed, we previously generated a stable human embryonic stem cell line 
lacking L3MBTL1 and showed that these cells mirror the phenotype of cells treated 
with BMP4: they spontaneously undergo throphoblastic differentiation, and in fact, 
L3MBTL1 expression decreased in response to BMP4 treatment 44. Therefore, in 
order to determine whether regulation of EKLF by L3MBTL1 is due to direct 
regulation of smad5 expression, we performed ChIP experiments in hES cells by 
utilizing smad5 antibody and found recruitment of L3MBTL1 at the smad5 promoter 
(Fig 17D).  
Overall, these data indicate that L3MBTL1 regulates EKLF expression via SMAD5 in 
hematopoietic and embryonic stem cells. 
 
b) Modulation of L3MBTL1 expression affects globin gene expression 
In order to evaluate the significance of regulating EKLF via smad5 in terms of globin 
gene expression, we lentivirally expressed shRNAs targeting L3MBTL1 in primary CB 
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CD34+ cells and found increased expression of fetal globin gene compared to 
controls (Fig. 18A-B). Conversely, we observed downregulation of gamma globin 
gene expression when we overexpressed HA tagged L3MBTL1 (L3MBTL1-HA) in CB 
CD34+ cells or K562 erythroleukemia cells (Fig. 18C-D). To determine whether this 
effect on fetal globin gene expression was restricted to erythroid or even 
hematopoietic cells, we also examined primary hES cells after lentiviral KD of 
L3MBTL1 and found detectable fetal globin gene mRNA in the KD hES cells (Fig. 
18E). These data indicate that L3MBTL1 is a repressor of fetal globin gene 
expression.  
In fact, treating L3MBTL1-overexpressing K562 cells with BMP4 (40 ng/ml) restored 
fetal globin gene expression, overcoming the repression mediated by L3MBTL1 
(Fig.18F). Therefore, to determine whether EKLF is essential for the effects of 
L3MBTL1 on globin genes, we knocked down both L3MBTL1 and EKLF in K562 cells 
and could no longer induce high-level gamma globin gene expression (Fig. 18G).  
 
c) Knock-down of L3MBTL1 activates smad-mediated transcriptional response 
in patient-specific beta-thalassemia iPS cells and allows generation of high-
fetal globin gene expressing erythroid progeny 
Given the relevance of inducing fetal hemoglobin production in patients with β-
hemoglobinopathies to ameliorate the clinical severity, we depleted L3MBTL1 from 
induced-Pluripotent Stem (iPS) cells, that were either derived from patients with b-
thalassemia major81 or from CB CD34+ cells. We infected the iPS cells with H1P-
hygro-EGFP+ lentiviral vectors expressing shRNAs targeting L3MBTL1, or Luciferase 
(the control vector), and obtained efficient KD of L3MBTL1 in GFP+ cells that still 
retained stem cell-related cell surface markers, such as Tra-181 (Fig. 19A). We then 
analyzed L3MBTL1-KD beta-thalassemic iPS cells that had been induced to 
differentiate towards the erythroid lineage, and in fact expressed the CD71 and GlyA 
erythroid cell surface markers; these cells showed high levels of fetal globin gene, 
compared to control cells (Fig. 19B). This represents an important proof of principle, 
implying that the regulatory network involving chromatin modifiers could impact on 
the course of red cell disorders, and represent an innovative strategy for treatment of 
hemoglobin disorders.  
To further investigate the mechanisms mediating the effects of L3MBTL1 in 
regulating globin gene expression, we analyzed the gene expression profile (GEP) of 
the L3MBTL1-KD iPS cells. We found increased expression of several BMP/Smad 
target genes, as well as downregulation of negative modulators of TGFb-superfamily 
ligand signaling (Fig. 19C-D). Upregulated genes included HHEX, ID2, ID3 and 
MAFF, all of which have been implicated in regulating HbF expression82. HHEX is 
known to regulate globin gene expression during ontogeny and its promoter contains 
a 71-nucleotide BMP-responsive element (BRE)83. ID genes are direct targets of 
BMP4 and Id proteins can regulate HSPC fate decisions36. Expression of the 
inhibitory Smad, Smad7, which inhibits TGFb-related signaling84 was downregulated, 
as were Lefty1 and Lefty2, extracellular inhibitors which antagonize Nodal signaling85. 
Overall, we found enrichment of many Smad-related genes (Fig. 19E) and 
hematopoietic transcription factors (data not shown) using Gene Set Enrichment 
Analysis (GSEA).  
To identify which Smad-related signaling pathway is triggered by L3MBTL1 depletion, 
we evaluated the level of phosphorylation of Smad1/5/8 and Smad2/3, which 
primarily function downstream of the BMP receptors, and the TGFb, activin and 
Nodal receptors, respectively. We found enhanced Smad1/5/8 phosphorylation, 
indicating enhanced BMP signaling (Fig. 19F). Finally, EKLF expression was found 
upregulated in both iPS cell lines lacking L3MBTL1 by WB (Fig 19G-H).  
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Overall, these data confirm that L3MBTL1 titrates BMP signaling and indicate that 
activation of this signaling and of its downstream targets correlates with generation of 
high-fetal globin gene expressing erythroid progeny in patient-specific iPS cells (Fig 
19I). 
 
 
3.5 PRMT5 
 
 
a). PRMT5 Interacts with JAK2V617F and JAK2K539L More Strongly than Wild-Type 
JAK2 
First, we examined whether PRMT5 interacts with JAK2 and if the V617F (and K539L) 
activating mutations in JAK2 affect this interaction. We coexpressed FLAG-PRMT5 with 
HA-tagged wild-type JAK2 and JAK2V617F, or HA-PRMT5 with nontagged versions of the 
wild-type JAK2, JAK2V617F, and JAK2K539L proteins in 293T cells, and found that 
whereas the wild-type JAK2 interacts with PRMT5, both the JAK2V617F and JAK2K539L 
mutants bound PRMT5 more strongly than wild-type JAK2 (Fig 20A and B), demonstrating 
that both constitutively activated forms of JAK2 have increased affinity for PRMT5. Next, to 
determine whether the endogenous JAK2V617F and PRMT5 proteins interact in leukemia 
cells, we performed co-immunoprecipitation (Co-IP) assays using two different anti-JAK2 
antibodies and the JAK2V617F-positive HEL cell line. The interaction of JAK2V617F with 
PRMT5 was readily detected using either antibody (Figure 20 C). Because none of the 
commercially available anti-PRMT5 antibodies efficiently immunoprecipitates PRMT5, we 
also utilized a HEL cell line that we engineered to stably express HA-tagged PRMT5. 
Using an anti-HA antibody, we could detect a robust interaction between PRMT5 and the 
mutant JAK2 (Figure 20D). To map the region(s) in JAK2 that interacts with PRMT5, 
we constructed a series of N-terminal deletion mutants of HA-tagged JAK2 with or without 
the V617F substitution, and expressed these proteins with FLAG-tagged PRMT5 in 293T 
cells (Figure 20E). Co-IP experiments showed that deletion of the first 382 amino acids 
(which contain the receptor-binding FERM domain) from JAK2V617F greatly reduced its 
interaction with PRMT5. Given that the C terminus of JAK2 (808-1132) does not bind 
PRMT5, this indicates that the N-terminal portion of JAK2 is responsible for binding 
PRMT5. The JAK2Δ382WT deletion mutant protein also binds weakly to PRMT5, 
suggesting that loss of the FERM domain may expose other epitopes in wild-type JAK2 
that can bind PRMT5. 
 
b) Oncogenic JAK2 Kinases Phosphorylate PRMT5 In Vivo 
To determine if JAK2 kinase can directly phosphorylate PRMT5, we performed an in vitro 
kinase assay using bacterially purified GST-PRMT5 as the substrate (Fig 21A). JAK2-
dependent phosphorylation of GST-PRMT5 was readily detected because a JAK2 inhibitor 
(JAK Inhibitor I) (1 µM) completely abrogated the phosphorylation (lane 8). We next 
determined if JAK2 phosphorylates PRMT5 in vivo, by coexpressing HA-PRMT5 with wild-
type JAK2 or the JAK2 mutants in 293T cells, and using anti-HA immunoprecipitation 
followed by anti-phosphotyrosine immunoblotting. We found that PRMT5 was 
phosphorylated by the mutant JAK2V617F and JAK2K539L kinases, but not the wild-type 
JAK2 kinase (Fig 21B and C). To determine whether wild-type JAK2 can phosphorylate 
PRMT5 when it is activated by signaling through the erythropoietin receptor (EpoR), we 
transfected 293T cells with JAK2 wild-type or V617F mutant with or without the EpoR, and 
added 20 U/ml of Epo to the cells for 20 min (Figure 21D). Wild-type JAK2 was activated 
by the presence of Epo and its receptor (as shown by JAK2 autophosphorylation and 
phosphorylation of HA-STAT5, lane 10). However, unlike JAK2V617F, the activated wild-
type JAK2 kinase did not detectably phosphorylate PRMT5, indicating that PRMT5 
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phosphorylation is indeed an acquired function of the mutant JAK2 kinase. Interestingly, 
phosphorylation of PRMT5 by JAK2V617F was reduced in cells overexpressing the EpoR, 
suggesting that the level of EpoR expression can affect the ability of JAK2V617F to 
phosphorylate PRMT5. 
We next determined whether phosphorylation of endogenous PRMT5 by JAK2V617F 
occurs in JAK2V617F-positive HEL leukemia cells. HEL cells were treated with either 
DMSO or JAK Inhibitor I for 16 hr, and the phosphorylated proteins were 
immunoprecipitated using an anti-phosphotyrosine antibody (Fig 21E). Although PRMT5 
(and STAT5) is phosphorylated in DMSO-treated HEL cells, and the phosphorylation of 
both proteins is greatly reduced by the JAK2 inhibitor, PRMT5 is not phosphorylated in the 
TF-1 hematopoietic cells (which express wild-type JAK2), even when the JAK2 kinase is 
activated by Epo (or GM-CSF), which clearly triggers STAT5 phosphorylation (Figure 
21F). These results identify PRMT5 as a bona fide in vivo substrate of JAK2V617F, but 
not activated wild-type JAK2. 
c). Phosphorylation of PRMT5 by JAK2V617F Greatly Impairs Its Methyltransferase 
Activity 
PRMT5 has been shown to methylate histones H2A, H3, and H4 in vitro and in vivo. To 
determine whether phosphorylation of PRMT5 affects its enzymatic activity, we purified 
HA-tagged PRMT5 protein from 293T cells engineered to express either wild-type or 
mutant JAK2 and HA-PRMT5. After we confirmed the phosphorylation of PRMT5 by 
JAK2V617F, we incubated the purified PRMT5 with [3H] S-adenosylmethionine and 
recombinant histone H4 (Fig 22A) or histone H2A (Fig 22B) in an in vitro methylation 
assay. Although coexpression of wild-type JAK2 had little effect on PRMT5 
methyltransferase activity (Fig 22A lanes 8–10), JAK2V617F significantly impaired 
the ability of PRMT5 to methylate histone H4 (lanes 11–13). As expected, coexpression of 
MEP50 with PRMT5 greatly enhanced its enzymatic activity (lanes 2–4). Similar results 
were seen for JAK2V617F (and JAK2K539L) on histone H2A methylation (Fig 22B).  
We next examined whether JAK2V617F and JAK2K539L expression affects global 
H2A/H4 R3 symmetric dimethylation levels in vivo using 293T cells transiently expressing 
JAK2 wild-type, JAK2V617F, or JAK2K539L. Wild-type JAK2 had no effect on the global 
level of H2A/H4 R3 methylation; however, both oncogenic JAK2 kinases nearly abolished 
H2A/H4 R3 methylation (Fig 22C). We next assessed histone arginine methylation levels 
in HEL cells, in the presence or absence of JAK Inhibitor I, CEP701, which is a JAK2 (and 
FLT3) inhibitor and TG101348, the most specific JAK2 inhibitor tested. Treatment with all 
three JAK2 inhibitors markedly increased H2A R3 symmetric dimethylation in the cell (Fig 
22D and 22E) (H4 R3 symmetric dimethylation is not found in HEL cells in the presence or 
absence of the JAK2 inhibitor). To determine how rapidly JAK2 inhibition affects the level 
of H2A/H4 R3 methylation, we performed a time course experiment using HEL cells 
treated with TG101348 (Fig 22E). An increase in H2A/H4 R3 methylation was seen within 
1 hr, which peaked at the 2-hr time point. At 4 hr, the effect on H2A/H4 R3 methylation 
began to reverse, likely due to instability of the inhibitor because both STAT5 and PRMT5 
phosphorylation began to increase at the 4-hr time point. In contrast, these JAK2 inhibitors 
had minimal effect on H2A/H4 R3 methylation levels in TF-1 cells, even though they 
blocked STAT5 phosphorylation (Fig 22F). Thus, the oncogenic JAK2 proteins gain the 
ability to regulate global H2A/H4 R3 symmetric dimethylation levels, presumably via 
phosphorylation of PRMT5. 
Although JAK2 regulates gene transcription through the canonical JAK2-STAT5 pathway, 
as well as other pathways, our data suggest that the oncogenic JAK2 kinases (like V617F 
and K539L) can also regulate gene expression via repression of PRMT5 activity and 
possibly changes in the methylation of the histone H2A and H4 tails. We performed gene 
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expression profile analysis on DMSO-treated versus CEP701-treated HEL cells and on 
PRMT5-directed shRNA-expressing HEL cells versus control shRNA-expressing cells 
using Affymetrix HG133 GeneChips. We found 881 genes whose mRNA levels changed 
more than 1.5-fold in both duplicate samples of the CEP701-treated cells, and 585 genes 
whose expression reproducibly changed ≥1.5-fold in cells where PRMT5 was knocked 
down. Because inhibition of JAK2 activity derepresses PRMT5 activity, we hypothesize 
that genes that are reciprocally regulated between the inhibitor-treated samples and the 
shPRMT5-treated samples will be regulated by JAK2-induced PRMT5 phosphorylation. 
Indeed, we found 90 such genes (42 upregulated by the inhibitor and downregulated by 
the shRNA, and 48 downregulated by the inhibitor and upregulated by the shRNA), 
including genes involved in ribosomal biogenesis and autophagy (Fig 22G).  
 
d). The Major Phosphorylation Sites in PRMT5 Map to Its N-Terminal Region 
There are six tyrosine residues in this region (at position 280, 283, 286, 297, 304, and 
307), and we mutated the first three (M3), first four (M4), and all six tyrosine residues (M6) 
to phenylalanine, and examined the extent of PRMT5 phosphorylation in transfected 293T 
cells (Fig 23A). Compared to wild-type PRMT5, the M6 form of PRMT5 had markedly 
reduced phosphorylation when coexpressed with JAK2V617F. The residual 
phosphorylation could be due to dimerization with endogenous wild-type PRMT5, or to the 
presence of other phosphorylation sites within the protein. In contrast the M3 form of 
PRMT5 had a similar degree of phosphorylation as wild-type PRMT5, suggesting that the 
last three tyrosines are the major sites of JAK2 phosphorylation in PRMT5. 
To demonstrate that PRMT5 is phosphorylated at these tyrosine residues, we 
generated a phospho-specific anti-PRMT5 antibody (P-PRMT5-747) using a mixture of 
peptides containing all combinations of phosphorylated Y297, Y304, and Y307 tyrosine 
residues. A dot blot assay confirmed that this antibody recognizes the phosphorylated and 
not the unphosphorylated peptides (data not shown). To confirm that endogenous PRMT5 
is phosphorylated by JAK2V617F in HEL cells, we treated the cells with the JAK inhibitor I, 
CEP701 (Fig 23B) and TG101348 (Fig 23C) and performed several immunoblots. These 
JAK2 inhibitors significantly reduced the phosphorylation of PRMT5 and STAT5, 
demonstrating that endogenous PRMT5 is phosphorylated within these three tyrosine 
residues by JAK2V617F.  
 
e). Phosphorylation of PRMT5 by JAK2V617F Disrupts Its Association with MEP50 
Because MEP50 markedly enhances the enzymatic activity of PRMT5 (Fig 24A and B), we 
examined whether JAK2V617F impairs PRMT5 activity by disrupting the PRMT5/MEP50 
complex. Using 293T cells that transiently express HA-PRMT5, and either the wild-type 
JAK2 or the V617F mutant protein, we could readily co-immunoprecipitate endogenous 
MEP50 protein from cells expressing wild-type JAK2 with an anti-HA antibody (Fig 24C). 
However, coexpression of JAK2V617F significantly reduced the interaction between 
PRMT5 and MEP50. The kinase activity of JAK2V617F is required to disrupt the 
PRMT5/MEP50 association because treating the cells with JAK Inhibitor I blocked the 
phosphorylation of PRMT5 and restored the interaction between PRMT5 and MEP50 (Fig 
24D). To determine whether phosphorylation of PRMT5 affects the PRMT5/MEP50 
complex in JAK2V617F-positive HEL cells, we established a stable HEL cell line that 
expresses myc-tagged MEP50 and purified the PRMT5/MEP50 complex using an anti-
myc antibody(Fig 24E). Although the unphosphorylated form of PRMT5 bound to MEP50, 
the phosphorylated form of PRMT5 was exclusively in the flowthrough following the 
immunoprecipitation. Thus, phosphorylation of PRMT5 by JAK2V617F blocks its 
association with MEP50 in hematopoietic cells. 
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f). PRMT5 Negatively Regulates Hematopoietic Stem/Progenitor Cell Expansion and 
Erythroid Differentiation 
We examined whether decreased PRMT5 activity promotes myeloproliferation and/or 
erythroid differentiation, by knocking down PRMT5 expression in human CD34+ CB cells 
using shRNA. We achieved only 60%–70% knockdown of PRMT5 mRNA but still 
observed a 2-fold increase in CFUs(Fig 25A). We then overexpressed HA-tagged wild-
type PRMT5, or the M6 mutant form of PRMT5 (PRMT5M6), in CD34+ CB cells and 
performed CFU assays. Consistent with the knockdown experiments, PRMT5 
overexpression significantly decreased colony formation (Fig 25B), indicating that PRMT5 
negatively regulates progenitor cell proliferation and expansion. 
We also examined whether PRMT5 activity regulates erythroid differentiation, using 
in vitro liquid culture assays. We knocked down PRMT5 or overexpressed wild-type 
PRMT5 or the PRMT5M6 mutant in CD34+ CB cells and cultured the GFP+ cells in 
medium supporting erythroid differentiation for 1 or 2 weeks. Although PRMT5 knockdown 
cells showed a significant increase in CD71/Ter-119-positive cells, overexpression of 
either the wild-type or the M6 mutant form of PRMT5 blocked erythroid differentiation (Fig 
25C and D). To further determine whether downregulation of PRMT5 activity is important 
for JAK2V617F-induced myeloproliferation, we overexpressed the wild-type or mutant 
PRMT5 (PRMT5M6) proteins in JAK2V617F-positive CD34+ cells isolated from 
therapeutic phlebotomy specimens of patients with PV and performed CFU assays using 
1 × 104 GFP+ cells (Fig 25E). The control JAK2V617F-positive CD34+ cells formed 
predominantly BFU-E colonies. However, the cells overexpressing PRMT5M6 showed no 
BFU-E or CFU-GEMM colonies, suggesting that the phosphorylation-defective form of 
PRMT5 can abrogate the erythroid differentiation potential of these cells. 
To determine if PRMT5 is phosphorylated in JAK2V617F-positive patient samples, 
we isolated CD34+ cells from therapeutic phlebotomy specimens taken from patients with 
PV (Fig 25F), using normal CB CD34+ cells as a control. Of the ten patient samples 
tested, all of the JAK2V617F- positive (or exon 12 mutation-positive) samples had higher 
PRMT5 phosphorylation than the CD34+ CB cells or the JAK2V617F-negative CD34+ 
cells. We found less phospho-PRMT5 in two of the three JAK2V617F-negative patient 
samples analyzed, compared to the JAK2V617F+ MPN patient samples (Figure 5F, lane 6 
and 11). The weak positivity in CB CD34+ cells and the high level of phospho-PRMT5 in 
the one JAK2 wild-type patient sample suggest that other tyrosine kinases can also 
phosphorylate PRMT5 in hematopoietic cells.  
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4. Discussion 
 
4.1. L3MBTL1 and erythroid differentiation 
Haploinsufficiency of the polycomb group gene (PcG) L3MBTL1 has been identified 
in patients with 20q- associated myeloid malignancies12,13, but whether this has functional 
relevance for these disorders has not been previously determined. We have demonstrated 
that L3MBTL1 loss induces the erythroid differentiation of human HSPCs and therefore 
could contribute to the most common 20q- associated hematologic disorder, polycythemia 
vera. Further, L3MBTL1-KD CD34+ cells show an enhanced response to erythropoietin, 
resulting in the more rapid development of immunophenotypically and morphologically 
mature erythroblasts with increased hemoglobin content, compared to control cells. We 
have demonstrated the increased sensitivity of L3MBTL1 knock-down hematopoietic 
stem/progenitor cells to erythropoietin at different concentrations of Epo and at very early 
time points. The erythroid commitment that follows L3MBTL1- KD occurs early, based on 
the erythroid progenitor cell expansion seen in the LTC-IC assay.  
L3MBTL1 is classified as a Polycomb group protein and recent evidence suggests 
that PcG proteins regulate stem cell pluripotency by maintaining the repression of lineage-
specifying genes that trigger the differentiation process86,87. L3MBTL1 is downregulated 
upon Epo- or hemin-induced erythroid differentiation. L3MBTL1 is also downregulated, or 
at least is less abundant in MEP cells compared to more immature stem cells or progenitor 
cell populations (such as CMP), which suggests that erythroid differentiation may require 
“silencing” of L3MBTL1 function. As a compactor of euchromatin, L3MBTL1 could serve as 
an epigenetic brake on erythroid commitment. Gene expression profiling of cells treated 
with Epo supports this hypothesis, as L3MBTL1 is one of the genes most strongly 
downregulated upon Epo exposure88. Pr-Set7, an H4K20 specific methyltransferase that 
physically associates with L3MBTL1 and is responsible for the H4K20 methyl mark that 
serves as a docking site for L3MBTL1 binding, is also downregulated in hemin-treated 
K562 cells6,89, which also suggests that the ability of L3MBTL1 to bind chromatin and 
maintain repression of its target genes impairs erythroid differentiation.  
Recently, the ability of reactive oxygen species (ROS) to trigger the precocious 
differentiation of Drosophila stem cells into all three mature blood cell types has been 
linked to downregulation of PcG expression90. This downregulation is associated with JNK 
activation and it triggers differentiation towards lamellocyte but not plasmatocyte or crystal 
cell differentiation, somewhat similar to the effects of L3MBTL1 KD on erythroid but not 
myeloid or megakaryocytic lineages. ROS triggers FOXO activation90 and similarly we 
found increased phosphorylation/activation of the STAT5, AKT/FOXO, and MAPK 
pathways in L3MBTL1- KD HSPCs, even in the absence of Epo. Such Epo-independent 
signaling is a hallmark of the MPNs, especially polycythemia vera. PcG members 
specifically repress the JAK-STAT pathway in the Drosophila eye imaginal disc91 and our 
data suggest that L3MBTL1 acts in a similar fashion to regulate erythroid differentiation.  
We also found increased expression of p16INK4a in L3MBTL1-KD cells. Increased 
expression of p16INK4A is also found in erythroid colony-forming cells isolated from patients 
with PV78. p16 has been linked to erythroid differentiation and apoptosis in 
erythroleukemia cells79 and may play a role in mediating the effects of L3MBTL1 in 
erythropoiesis, since we also observed downregulation of p16 following L3MBTL1 
overexpression. Downregulation of FoxOs by L3MBTL1- KD could also contribute to the 
decreased CAFC frequency seen following L3MBTL1-KD92.  While we previously reported 
that L3MBTL1-KD can increase c-myc levels in some cell types, and cyclin E or A levels in 
others7,93; we did not observe such increases in the human CD34+ cells at the time points 
assayed (data not shown). Such increases are seen in terminally differentiated cells (such 
as 293T cells) and may be needed to observe a strong proliferative response to L3MBTL1-
KD.  
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In future studies we wish to determine whether L3MBTL1 loss can cooperate with 
the constitutively activated mutant JAK2 kinases found in patients with MPNs. There 
appears to be a relationship between del20q and the occurrence of the JAK2 V617F 
mutation. In one study of 29 patients with 20q deletion, 28 were found to be JAK2 
V617F+94. In another study of MPN patient samples, the JAK2V617F/JAK2 burden was 2-
25% of the clonal cells, even though all of the clonal cells had del20q95. While these 
studies suggest that the 20q deletion may represent one of several potential pre-JAK2 
events (others being mutations in TET2, ASXL1, c-CBL or currently unknown 
proteins)96,97, Schaub et al. have reported that del20q may occur after the acquisition of 
JAK2V617F in some clones98. It is likely that during the genesis of the MPNs the 
acquisition of additional genetic mutations (i.e. JAK2V617F) may allow the cells to override 
the anti-proliferative mechanisms elicited by p16 or MAPK activation.  
L3MBTL1 plays a key role in hematopoiesis by regulating the erythroid 
differentiation of HSPCs. Given that L3MBTL1 is located within the common deleted 
region on 20q seen in patients with PV, our data suggests that loss of L3MBTL1 is 
important in the pathogenesis of such disorders.  
 
4.2. L3MBTL1 and the DNA damage 
L3MBTL1 interacts with components of the DNA replication machinery (MCM2-7 proteins, 
Cdc45, and PCNA) and is required for the normal movement of DNA replication forks. 
These findings suggest that L3MBTL1 influences multiple aspects of DNA replication and 
repair. The methylation status of H4K20 is important in DNA replication and DDR 
pathways 99. SUV4-20 methyltransferase catalyzes the di- and trimethylation of H4K20, 
and Suv4-20 knockout mice, which can only form the H4K20me1 derivative, are more 
sensitive to DNA damage than wild-type mice100. Loss of Pr-Set7, a histone 
methyltransferase that monomethylates lysine 20 on histone H4, induces DNA damage in 
human, mouse, and Drosophila cells. Pr-Set7 has also been implicated in DNA replication. 
We previously established that L3MBTL1 binds to mono- and dimethylated H4K20, and 
interacts directly with PR-Set7. The binding of L3MBTL1 to chromatin occurs during S 
phase, coincidental with the appearance of H4K20me1, suggesting that it binds to the 
mark to exert its effects6. Depletion of L3MBTL1 resulted in a marked increase in 
H4K20me2 levels (Fig 10D), possibly by allowing dimethylation of H4K20 by Suv4-20 
histone methyltransferase. The biological effects observed following depletion of L3MBTL1 
closely parallel those resulting from the loss of Pr-Set7, suggesting that the ability of 
L3MBTL1 to recognize and bind to the H4K20me1 mark produced by Pr-Set7 plays an 
important role in maintaining genomic stability.  
At present, it is unclear how L3MBTL1 contributes to genomic stability and 
influences fork progression. Its role in fork progression may relate to its function in 
maintaining genomic stability, as L3MBTL1 depletion triggers the DDR, which leads to 
checkpoint activation and a halt in replication. Recently, Qin et al. found that loss of 
L3MBTL1 in mice does not alter H4K20 methylation or result in tumor formation101. 
Differences between the Qin et al. study and ours may reflect the effects caused by the 
acute loss of L3MBTL1 vs. its chronic absence in the knockout mice, where functional 
compensation by another L3MBTL family member could occur. Furthermore, H4K20 
methylation levels may be controlled differently in ES cells than in the normal, human 
diploid fibroblasts that we have studied. As oncogenesis is a multistep process, it seems 
highly likely that additional molecular events are needed to induce tumorigenesis.  
Interactions between L3MBTL1 and Cdc45 and MCM2-7 suggest that L3MBTL1 may have 
a more direct role in DNA replication; however, further studies will be required to define the 
functional significance of these interactions and to determine whether the position of 
L3MBTL1 is within or external to nucleosomes, because nucleosome deposition occurs 
behind the fork on newly synthesized DNA. L3MBTL1 may also prevent the conversion of 
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the H4K20me1 mark to H4K20me2 by Suv4-20, as we detected an increase in H4K20me2 
in cells depleted of L3MBTL1. Though L3MBTL1 is degraded during mitosis6, depletion of 
L3MBTL1 before the G2/M transition leads to the generation of the H4K20me2, which 
recruits 53BP1, thereby promoting the DDR and hindering normal replication. Normally, 
Suv4-20 acts during the M and G1 phases to convert H4K20me1 to H4K20me2102. This 
methylation step may occur primarily in the absence of chromatin-bound L3MBTL1. 
Consistent with this notion, we found that L3MBTL1 depletion slowed replication fork 
progression and increased the formation of 53BP1 foci. Whether removal of L3MBTL1 
from the H4K20me1 mark is required for the DDR, by triggering the H4K20me2 generation 
and subsequent binding of 53BP1, will require further investigation.  
DNA damage and genomic instability promote oncogenesis103, and tumor samples 
isolated from patients at diagnosis often show constitutive activation of DNA damage 
signaling16,17. Mechanistic studies implicate oncogene-induced DNA replication stress, 
including replication fork collapse and formation of double-stranded breaks, as the 
stimulus that evokes the DDR response18. We have shown that the depletion of L3MBTL1, 
a candidate tumor suppressor gene, leads to the activation of the DDR. Failure to correct 
DNA damage caused by the loss of L3MBTL1 could lead to genomic instability and the 
development of a myeloid malignancy. These observations suggest that the role of 
L3MBTL1 in DNA replication and genome stability may be evolutionary conserved, 
implying that the loss of L3MBTL1 contributes to the development of 20q12 hematopoietic 
malignancies by causing DNA damage and genomic instability.  
 
4.3. L3MBTL1 and the pluripotency of human embryonic stem cells 
Undifferentiated ES cells generally contain more permissive chromatin with higher levels 
of activating marks (lysine acetylation) and lower levels of repressive marks (H3 lysine K9 
and K27 methylation), whereas differentiated ES cells generally display silenced chromatin 
structure104. One of the great challenges in human stem cell biology is to understand the 
mechanisms that selectively silence certain gene-rich regions of the genome, to allow the 
production of the full range of cell types found in the adult. Compacted chromatin is 
generally found during differentiation, but very little is known about the individual proteins 
that differentially silence genes and affect the outcome of differentiation. 
In this study, we found that knocking down the epigenetic ‘‘reader’’ L3MBTL1 strongly 
influences the differentiation potential of hESCs toward trophectoderm under conditions 
wherein spontaneous differentiation occurs, without affecting hESC self-renewal in the 
undifferentiated state. 
L3MBTL1 KD hESCs can be cultured continuously with no noticeable changes in their 
behavior, morphology, or cell cycle status and only minor changes in the RNA levels of the 
pluripotency markers OCT-4, NANOG, or SOX2 (Fig. 13C–E), which suggests that 
L3MBTL1 does not play a critical role in maintaining the undifferentiated status or self-
renewal potential of hESCs. 
Nonetheless, L3MBTL1 KD clearly impaired the developmental potential of hESCs in 
spontaneous differentiation assays. Withdrawal of FGF2 triggered profound changes in 
the differentiated L3MBTL1 KD cells under adherent conditions with loss of ectoderm, 
endoderm, and mesoderm marker expression; this implies that L3MBTL1 KD cells have 
limited pluripotency. The differentiated L3MBTL1 KD cells do express trophectoderm 
markers (Figs. 15B, D), and in fact, the increased expression of CDX2 is consistent with 
the L3MBTL1 KD cells being restricted to a trophoblast fate (Fig. 15A)105. Cdx2 acts early 
in the lineage hierarchy and its overexpression triggers embryonic stem cells to 
differentiate into trophoblast stem cells106. Overall, these changes could explain the failure 
of these cells to form typical EB structures in nonadherent assays. It is also possible that 
genomic instability during EB development could explain the increased cell death seen in 
L3MBTL1 KD cells (Fig. 14B,C). In contrast, the differentiated control cells maintained 
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expression of embryonic lineage markers, and consistent with their upregulation of 
L3MBTL1, the expression of trophoblast markers was absent. 
The production of extra-embryonic trophoblast cells from the L3MBTL1 KD cells 
resembles the effect of BMP4 on hESCs. BMP4 directs hESCs toward trophoblast with 
increased SMAD 1/5/8 phosphorylation, CG-β secretion, and HAND1 expression, which 
occurs concomitantly with a marked decrease in L3MBTL1 expression (Fig. 16A and B). 
Both the BMP4- stimulated hESCs and the L3MBTL1 KD cells secrete placental 
hormones, demonstrating that knockdown of L3MBTL1 drives hESCs to become 
trophoblast-like cells (Fig. 16C). The lack of other embryonic cell types derived from 
L3MBTL1KD cells is not absolute, as L3MBTL1 KD cells can still form neural tissue and 
hematoendothelial cells in response to strong inductive signals. This suggests that 
L3MBTL1 may promote the retention of pluripotency of hESCs, at least in part by blocking 
trophoblast differentiation. 
Thus, L3MBTL1 may play a role in the earliest cell fate decisions involved in human 
development, most likely by repressing genes involved in trophectoderm differentiation. 
Such a phenotype was recently described for Mbd3, a component of the Mi-2/NURD 
repressor complex107. L3MBTL1 may promote chromatin compaction via its recognition of 
mono- and dimethylated states of H4K20 by L3MBTL16 or by recruiting additional 
chromatin remodelers to block the trophectoderm differentiation of hESCs. In Drosophila, 
dl(3)MBT has been shown to bind histone H4 K20 monomethyl in close association with 
the dRPD3 histone deacetylase, resulting in deacetylation of histone H4 K5/K12108. 
Mass spectrometry (MS) studies have revealed that a large percentage of histone H4 is 
dimethylated in undifferentiated hESCs (*65%) with some unmethylated (*20%) and 
some monomethylated (*10%) or trimethylated (*5%) residues. 
Nonetheless, epigenetic disturbance during the early events of differentiation may be a 
consequence of knocking down L3MBTL1, explaining the lineage selectivity of hESCs 
toward the trophectoderm fate. 
In summary, L3MBTL1 KD hESCs proliferate normally in the undifferentiated state, but are 
impaired in their ability to spontaneously differentiate toward embryonic tissues, and 
preferentially differentiate into trophoblast tissue. Further studies are required to establish 
the molecular basis of the lineage selectivity that occurs after L3MBTL1 knockdown. 
 
 
4.4 L3MBTL1 and the BMP4 signaling 
Combinatorial crosstalk among transcription factors is essential to direct the lineage 
specification of hematopoietic stem/progenitor cells. Our study supports a model where 
the erythroid transcriptional network, which is dominated by the transcription factor EKLF, 
is facilitated by the L3MBTL1-mediated regulation of BMP4/Smad5 signaling. In 
agreement with larger maps of combinatorial interactions among transcription factors109, 
our work implies that lineage specification (erythroid in our case) is not completely 
determined by tissue-specific transcription factors (specifiers like EKLF), but can be 
modulated by crosstalk with transcription factors that are broadly-expressed (like smad5). 
A similar effect is seen in the regulation of monocyte differentiation by SMAD3 (generally 
expressed) and FLI1 (whose expression is restricted primarly to macrophage-related 
tissues such as spleen and lymph-nodes) 109.  
BMP4 was previously identified as a critical regulator of hematopoietic lineage 
differentiation from mesoderm during development, while more recent evidence indicates 
that it functions as a dynamic player during hematopoietic regeneration following stress 
40,41. The cell-specific context and the transcriptional status of a gene can alter SMAD1 
binding: in erythroid cells SMAD1 binds the same targets as GATA1, which helps activate 
these genes, while in CD34+ non-erythroid progenitor cells, SMAD1 binds with GATA2 
on progenitors expressed genes being largely absent from erythroid genes41,110,111.  
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We speculated that manipulating the pathways regulating hematopoietic regeneration 
(like the BMP/smad pathway) could therapeutically affect the differentiation of 
hematopoietic stem/progenitor cells. It appears that, human stress erythropoiesis exhibits 
properties similar to fetal erythropoiesis, and fetal erythrocyte antigens as well as the 
expression of fetal hemoglobin (HbF) are observed during the recovery from 
erythropoietic stress 112,113. These characteristics are also observed following bone 
marrow transplantation 114,115, in acute anemia syndromes like childhood transient 
erythroblastopenia 116,117 and in patients with thalassemia and sickle cell anemia 118. 
Analysis of peripheral blood and bone marrow progenitors from sickle cell anemia 
patients identified a population of progenitor cells that express CD34 and glycophorin A 
(GPA) on their surface, and also CD71 and KIT. These cells give rise to a higher 
proportion of HbF+ cells than normal bone marrow progenitors 119,120.  
We have identified a BMP4-dependent erythropoiesis pathway in human definitive 
hematopoiesis, and the downstream target genes of this pathway in erythroid cells, such 
as EKLF. Moreover, we found that manipulation of this regulatory network, through knock-
down of L3MBTL1, enhances the function of EKLF and the expression of fetal globin gene 
even in cells that are not committed to an erythroid fate. This unreveals an additional layer 
to the regulation of the EKLF transcription factor in hematopoiesis, especially in the 
erythroid lineage, as initially suggested in embryoid bodies during the BMP4-mediated 
promotion of the hematopoietic differentiation from mesoderm29,30.  
L3MBTL1 fine-tunes the BMP4 signaling pathway in ES cells, iPS cells and mature 
hematopoietic cells, affecting smad5 binding on EKLF gene and consequently regulating 
its expression and its function on globin gene regulation. The beta-thalassemic iPS cells, 
which we generated lacking L3MBTL1, show activation of the BMP4 signaling and higher 
ability to generate erythroid progeny expressing fetal globin gene. These findings suggest 
that targeting L3MBTL1, or promoting BMP/Smad signaling, could have beneficial effects 
in patients with b-hemoglobinopathies. Characterization of this regulatory network is 
important to identify potential novel therapeutic approaches for treatment of inherited red 
cell disorders like beta-thalassemia, as well as for bone marrow failure syndromes with 
Epo-resistant anemia.  
 
 
4.5 PRMT5 
We have determined that oncogenic mutations within the JAK2 tyrosine kinase (V617F 
and K539L) enhance its interaction with PRMT5, leading to PRMT5 phosphorylation 
in vivo. Although both the wild-type and mutant forms of JAK2 proteins interact with 
PRMT5, phosphorylation of PRMT5 is a “gain-of-function” of the mutant JAK2 kinases, 
which reduces PRMT5 methyltransferase activity and decreases global histone H2A/H4 
R3 methylation. 
The PRMT5-interacting region in the JAK2 protein maps to its N terminus, making it 
unlikely that the mutated residues in the JH2 domain play a critical role in this interaction. 
Furthermore, it appears that the active conformation of the mutant JAK2 proteins, and not 
necessarily their kinase activity, allows them to bind PRMT5 more strongly because the 
increased binding persists in the presence of JAK2 kinase inhibitors (data not shown). 
We find that PRMT5 that is phosphorylated by JAK2V617F no longer binds MEP50, 
even though we can detect an interaction of MEP50 with unphosphorylated PRMT5 in 
HEL cells. It is possible that much of the PRMT5:MEP50 complex that contains 
unphosphorylated PRMT5 is cytoplasmic, rather than nuclear, because we and others 
have shown that both proteins are found in the nucleus and the cytoplasm, and PRMT5 is 
known to complex with MEP50 in both locations. Given the enhanced proliferation seen 
following knockdown of PRMT5 in normal CD34+ cells, it would seem “easier” for the 
JAK2V617F+ mutant cells to simply degrade, or not express PRMT5. However, PRMT5 
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preferentially promotes p53-dependent cell cycle arrest at the expense of p53-dependent 
apoptosis62 and indeed, we find that knocking down PRMT5 in HEL cells triggers cell 
death (data not shown). Thus, JAK2V617F-expressing hematopoietic cells may require 
that some PRMT5 protein be present, to complex with MEP50. Given our confirmation of 
the recent demonstrations that JAK2 can be found in the nucleus46, PRMT5 
phosphorylation may be differentially regulated in the nucleus versus the cytoplasm of the 
cell, and in hematopoietic cells versus other cell types. 
The kinase-dependent regulation of global H2A/H4 R3 symmetric methylation reveals a 
link between an oncogenic tyrosine kinase and this particular chromatin modification. We 
have also shown the dynamic nature of this regulation. To gain insight into how 
JAK2V617F could regulate gene expression through phosphorylation of PRMT5, we 
performed gene expression profiling comparing the JAK2-regulated genes (defined using 
a JAK2 inhibitor) with the PRMT5-regulated genes (defined using shRNA directed against 
PRMT5) and found 90 genes that were reciprocally regulated.  
Forced expression of JAK2V617F induces a PV-like disease in mouse models52-54, and 
our studies suggest that in addition to activating the STAT5 pathway, this mutant JAK2 
kinase can induce myeloproliferation and erythrocytosis by abrogating PRMT5 activity. 
Although knockdown of PRMT5 in many cell lines, such as HEL and K562, led to 
apoptosis and/or growth arrest, its downregulation in normal CB CD34+ cells provides a 
proliferative signal. We too find that PRMT5 regulates globin gene expression in HEL, CB 
CD34+ cells as well as in K562 cells (data not shown). However, the distinct effects of 
PRMT5 knockdown on gene expression in HEL versus CD34+ cells (data not shown) 
demonstrate the importance of cell context on PRMT5 function. 
Although PRMT5 is most highly phosphorylated in JAK2V617F-positive MPN patient 
CD34+ cells (and in granulocytes), it is also phosphorylated to some degree in 
JAK2V617F-negative MPN and normal CB CD34+ cells. Overexpressing PRMT5 (wild-
type and, in particular, the M6 mutant form of PRMT5) in JAK2V617F-positive CD34+ 
patient cells resulted in a block in cell expansion and erythroid differentiation, providing 
further evidence that phosphorylation and abrogation of PRMT5 activity are important 
functions of this oncogenic kinase. Nonetheless, further experiments are needed to assess 
the relative contribution of PRMT5 phosphorylation to the various clinical syndromes 
associated with the JAK2V617F mutation. 
In conclusion, we have identified a “gain of function” for the constitutively activated forms 
of JAK2 kinase (JAK2V617F and JAK2K539L), namely phosphorylation of PRMT5, which 
allows them to control transcription by regulating histone H2A and H4 arginine 
methylation. Given the diverse functions of PRMT5 in the cell, further studies of the 
proteins methylated by PRMT5 and the pathways affected in JAK2V617F-expressing cells 
will shed additional light on the molecular pathogenesis of the MPNs. 
 
4.6 Overall Conclusions 
These studies have identified crucial roles for epigenetic modifiers (L3MBTL1 and PRMT5) 
in the regulation of normal haematopoiesis and illustrates how the loss of normal 
epigenetic functionality can contribute to leukaemogenesis. As such, elucidating the 
impact of epigenetic mutations on leukaemogenesis and therapeutic response will be 
essential for advancing our understanding and treatment of myeloid malignancies. 
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6. FIGURE LEGENDS  
 
Figure 1. Knock-down of L3MBTL1 promotes the erythroid differentiation of human 
hematopoietic CD34+ progenitor cells. (A) Lentiviral constructs expressing shRNAs 
targeting luciferase (control) or L3MBTL1 (sh1 and sh2) lead to efficient knock-down in 
primary cord blood CD34+ cells, as assessed by Western blot and qRT-PCR. ShRNAs of 
a different backbone (empty vector and sh3) also yielded efficient knock-down of 
L3MBTL1. All the presented data were confirmed using both sets of constructs. (B) 
Expression of CD71 and Glycophorin A on human HSPCs, as assayed by flow cytometric 
analysis at days 7, 9 and 11 of Epo-induced culture. (C) Expression of CD71 and 
Glycophorin A on human HSPCs, cultured with different concentrations of Epo, as 
assayed by flow cytometric analysis at 7 days. (D) Cells, from figure 1B, were stained with 
May-Grunwald Giemsa on day 7 of Epo-induced culture and their morphology captured by 
light microscopy. (E) Epo-exposed cells at day 7, 9 and 11 of Epo-induced culture were 
resuspended in benzidine solution and the cells that stain dark blue-green were scored as 
positive. 
 
Figure 2.  L3MBTL1 knock-down specifically promotes erythroid but not myeloid or 
megakaryocytic differentiation of human CD34+ cells. (A) L3MBTL1 expression levels 
were assessed by qRT-PCR in normal CD34+ cord blood cells. The cells were placed in 
different culture conditions stimulating erythroid, myeloid and megakaryocityc 
differentiation for 2, 5 and 7 days. Total RNA was extracted from 2x105 cells. (B) 72 hrs 
after lentiviral infection, GFP+ CD34+ cells, were cultured in myeloid conditions for 7, 9 
and 11 days and the expression of myeloid-specific markers CD11b (CD14 and CD33 not 
shown) were assessed by flow cytometric analysis (n=3). (C) 72 hrs after lentiviral vector 
infection, the GFP+ CD34+ cells, were cultured in megakaryocytic conditions for 7, 9 and 
11 days and expression of the megakaryocytic specific marker CD41 was assessed by 
flow cytometric analysis (n=3). (D) GFP+ CD34+ cells, 72 hrs after lentiviral vector 
infection, were cultured in erythroid conditions for 7, 9 and 11 days and expression of the 
erythroid-specific marker GlyA was assessed by flow cytometric analysis (n=3). 
 
Figure 3. Knock-down of L3MBTL1 induces further erythroid differentiation of K562 
erythroleukemia cells. (A) K562 cells, grown in RPMI medium supplemented with 10% 
fetal bovine serum, without exogenous cytokines or hemin, were infected with lentiviral 
constructs targeting luciferase (shLUC) or L3MBTL1 (sh1 and sh2). GFP+ cells, sorted by 
FACS at 72 hrs post-infection, were analyzed for GlyA expression by flow cytometry. (B) 
GFP+ K562 cells, before and after exposure to hemin (50µM) for 4 days, were stained with 
benzidine to assess their Hb-content. (C) K562 cells were treated with 50µM hemin for 4 
days and the L3MBTL1 mRNA level assessed in the hemin- exposed vs the non-treated 
cells by qRT-PCR (n=3). 
 
Figure 4. L3MBTL1-KD leads to expansion of erythroid progenitors in long-term 
culture. (A) Sorted 4x105 GFP+ CD34+ were plated on MS5 stromal cell layer and 
cultured for five weeks. At week five, the colonies were examined using an inverted optical 
microscope. The red arrows indicate the cobblestone area forming cells in the wt and 
shLUC figures. The red arrows indicate the overgrowth of progenitor cells (predominantly 
erythroid) in the sh1 and sh2 photographs. (B) The expression of GlyA on floating cells 
from 5-week LTC-IC cultures was evaluated by flow cytometry. (C) CAFC colony numbers 
were evaluated at week five of MS-5 stromal cell based culture (n=2) (D) Week 5 LTC-IC 
cells were plated on methylcellulose, and the secondary BFU-E colonies were scored after 
10 days. The ratio of BFU-E is shown, based on BFU-E numbers in the control cells. 
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Figure 5. Proliferation potential of L3MBTL1-KD human hematopoietic progenitor 
cells. (A) The maintenance of CD34 expression was evaluated in L3MBTL1-KD CB cells 
by flow cytometry. GFP+ CD34+ CB cells were cultured with SCF, FLT-3, IL-6  and TPO. 
(* indicates the p value, =0.0046) (B) Cell counts of L3MBTL1-KD CB cells were monitored 
at different time points in liquid culture with SCF, FLT-3, IL-6 and TPO. (C) 72 hrs after 
lentiviral infection sorted GFP+ CD34+ HPC were placed in CFU assays and the number 
of CFUs quantified. (D) p57 mRNA expression was assessed by qRT-PCR in L3MBTL1-
KD HPCs, with and without exposure to 200pM TGFβ1 for 2 hours (n=2). 
 
Figure 6. Primary hematopoietic cells lacking L3MBTL1 show Epo-independent 
phosphorylation of STAT5, AKT, and MAP Kinase. (A) Primary GFP+ CD34+ cells 
were harvested after one week in erythroid culture and lysed, according to standard 
protocols. Cultured CD34+ cells from MPN patients bearing the JAK2V617F mutation were 
harvested after one week of culture in Epo. Phosphorylation of STAT5, AKT and MAPK 
was assessed by Western blot. The protein levels of JAK2, STAT5, AKT, MAPK and 
L3MBTL1 were also assessed. (B) Primary GFP+ CD34+ cells were harvested after one 
week in erythroid culture and FOXO phosphorylation and JNK expression levels were 
assessed by Western Blot assay. Tubulin serves as a loading control for figures 6A, 6B 
and 6E. (C) 2 x 107 GFP+ CD34+ cells, plated in erythroid culture conditions, were tested 
for Ras activation, by detection of GTP-bound Ras. Cells were lysed and incubated with 
(GST)-Raf-RBD fusion protein (Millipore) coupled to glutathione agarose beads. GTP-
bound Ras was detected by Western blotting with an isoform-specific antibody. (D) 
Expression of the erythroid markers CD71 and GlyA was evaluated on L3MBTL1-KD CB 
cells cultured without Erythropoietin, in SCF, FLT-3, IL-6 and TPO. (E) After one week in 
culture without EPO, the GFP+ CD34+ cells were lysed and phosphorylation of STAT5 
and AKT were assessed by Western blot analysis. The protein levels of JAK2, STAT5, 
AKT, MAPK, Raf-1, p16 and L3MBTL1 were also assessed. 
 
Figure 7. L3MBTL1 restricts erythroid differentiation. (A) GlyA expression was 
assessed by FACS in the L3MBTL1-HA expressing CMK, U937, HEL and K562 cells 
compared to the MIGR1 (empty vector) transduced cells. (B) p16 protein expression levels 
were determined by Western blot analysis in L3MBTL1-HA HEL cells vs. the MIGR1 
(empty vector) control HEL cells. JNK and L3MBTL1 levels are also shown. Tubulin serves 
as the loading control. (C) GlyA expression in L3MBTL1-HA expressing CD34+ cells after 
three days of culture with SCF 100ng/ml and Erythropoietin 6IU/ml, compared to the 
MIGR1 (empty vector) transduced cells. (D) L3MBTL1 mRNA expression levels in 
retrovirally infected CD34+ cells, quantified by qPCR (n=3). 
Figure 8. L3MBTL1 depletion inhibits cell proliferation and causes G2/M arrest. 
U2OS cells were infected with control shRNA or one of several different lentiviral shRNAs 
targeting L3MBTL1. Levels of L3MBTL1 mRNA (A) and protein (B) were measured by 
quantitative RT-PCR and immunoblotting 48 h after infection. L3MBTL1 mRNA levels 
detected were adjusted for loading discrepancies using Hprt mRNA as the loading 
standard, and the levels of mRNA detected were plotted as a percent of the L3MBTL1 
observed in U2OS cells infected with control shRNA. To quantitate depletion of L3MBTL1, 
the relative protein levels of L3MBTL1 were adjusted using the α-tubulin loading control 
and quantified relative to the protein level present in the control sample (set as 1). (C) 
U2OS cells were infected with control shRNA or with L3MBTL1 shRNA #3. After 48 h, 
cells were incubated with BrdU, stained with BrdU-APC antibody and propidium iodide 
(PI), and analyzed by flow cytometry. The distribution of BrdU (y axis) and PI (x axis) is 
plotted. 
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Figure 9. Depletion of L3MBTL1 generates DNA breaks. (A) U2OS cells infected with 
one of several shRNAs against L3MBTL1 or with control shRNA were stained with 
antibodies against 53BP1 and γH2A.x. (B) DNA damage foci were quantitated in control 
and L3MBTL1 knockdown cells based on whether they contained more or less than five 
foci per cell. (C) The tail moment was calculated and plotted from three independent 
comet assays of U2OS cells treated with control shRNA or L3MBTL1 shRNA U2OS cells 
at 24 and 48 h after infection. (D) Calculated tail moments from comet assays of control 
and L3MBTL1-depleted MRC5 and Cal51 cells 48 h after infection are plotted. The tail 
moment was calculated from comet assays of control MRC5 cells vs. cells irradiated with 
the indicated dose of gamma irradiation and the data plotted. 
Figure 10. Depletion of L3MBTL1 activates the DDR. (A) Control and L3MBTL1-
depleted U2OS cells were stained with antibodies against 53BP1 and phospho-ATM 
(pATM) 48 h postinfection. (B) U2OS cells infected with control or L3MBTL1 shRNAs were 
harvested 24, 48, and 72 h postinfection and immunoblotted with the indicated antibodies 
to detect activation of the DDR. Unirradiated cells (unirr) and cells harvested 1 h following 
10 Gy of gamma irradiation (γ-irr) were used as negative and positive controls for 
activated DDR proteins. (C) Lysates from control and L3MBTL1-depleted U2OS cells were 
isolated 24 and 48 h postinfection, and the levels of Rad51, p53, p21, and actin 
determined by immunoblotting with the indicated antibodies. (D) Lysates from U2OS cells 
infected with three different shRNAs against L3MBTL1 were harvested at 48 h and 
immunoblotted with antibodies directed against γH2A.x, H4K20me1, H4K20me2, histone 
H3, and tubulin. (E) Histones were extracted from U937 cells that overexpress L3MBTL1 
or that contain empty vector control and immunoblotted for H4K20me1, H4K20me2, and 
histone H3 (loading control). 
Figure 11. Depletion of L3MBTL1 alters the progression of DNA replication forks. 
MRC5 and U2OS cells infected with control or L3MBTL1 shRNA were incubated for 1 h 
with IdU followed by 1 h incubation with CldU and then subjected to analysis of replication 
fork movement. (A) Individual replication units were visualized by immunofluorescence for 
incorporated halogenated nucleotides in isolated DNA fibers, as described in Materials 
and Methods. Images of fibers from MRC5 cells infected with control or L3MBTL1 shRNAs 
are shown. (B) The mean DNA fiber length from MRC5 cells infected with control or 
L3MBTL1 shRNA was calculated by measuring at least 100 fibers in each experiment, and 
the results plotted. (C) The data for one representative experiment with MRC5 cells are 
plotted as percentage of DNA fibers with each specified length. (D) Mean DNA fiber length 
for U2OS cells infected with control or L3MBTL1 shRNA was calculated by measuring at 
least 100 fibers in each experiment and plotted. (E) The data derived from an experiment 
using U2OS cells are plotted as percentage of replication forks with the specified DNA 
fiber length indicated. 
Figure 12. L3MBTL1 interacts with components of the DNA replication machinery. 
(A) HA-L3MBTL1 was overexpressed in 293T cells, and cell lysates were 
immunoprecipitated and immunoblotted with the HA or rabbit IgG antibodies. (B) Flag-
L3MBTL1 was overexpressed in 293T cells, and cell lysates were immunoprecipitated with 
antibodies against Mcm2, Mcm5, or rabbit IgG. Following SDS/PAGE separation, gels 
were immunoblotted with Flag antibody to detect L3MBTL1. The immunoprecipitation of 
Mcm2 and Mcm5 proteins was verified by immunoblotting with the corresponding 
antibodies, using rabbit IgG as a control. 
 
Figure 13.  Characterization of undifferentiated control and L3MBTL1 knockdown 
(KD) human embryonic stem cells. (A) Schematic representation of L3MBTL1 gene 
showing the location for the short hairpin (shRNA) sequences cloned into the H1P-
HygroEGFP lentiviral plasmid. (B) Western blot of cytoplasmic and nuclear fractions from 
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H9 parental cells shows nuclear location of L3MBTL1. Oct4 (nuclear) and tubulin 
(cytoplasmic) were used as controls. (C) Microscopic images showing the undifferentiated 
stage for the wt parental, LUC shRNA, L3MBTL1-shRNA1, and shRNA2 H9 cells based 
on their expression of GFP. Whole colonies were imaged on an Olympus epifluorescence 
system under a 10× objective. Scale bar represents 100 µm. (D) Cell cycle analysis of 
undifferentiated control and L3MBTL1KD ES cells. Relative DNA content, assessed by PI 
staining, shows the proportion of cells in the G1, G2, and S phases. A representative 
example of 3 independent experiments is shown. (E) Reverse transcriptase qPCR 
analysis comparing the level of L3MBTL1, OCT-4, NANOG, and SOX2 mRNA expression 
in control and L3MBTL1-depleted cells. Statistical analysis was performed by 1-way 
ANOVA and Tukey posttest (*P<0.05). Error bars represent the standard deviation (n=3). 
(F) Fluorescent microscopy images of OCT-4 with a DAPI DNA counterstain using the 
Olympus epifluorescence system under a 20× objective. Scale bar represents 50 µm.  
 
Figure 14.  Morphological changes of spontaneously differentiated control and 
L3MBTL1 KD cells. (A) Photographs showing the morphological contrast between LUC 
shRNA and L3MBTL KD cells (left and right upper row, respectively); images were 
acquired using the Gel Doc System Quantity One software (BioRad). Lower row shows a 
magnified view of the differentiated L3MBTL1 KD cells (white circle); black lines show a 
phase-contrast image (left) and a DAPI/GFP fluorescence image (right). (B) L3MBTL1 KD 
cells fail to develop proper embryoid bodies. Fluorescent microscopic images showing EB 
derivation based on GFP expression for the LUC shRNA, shRNA1, and shRNA2 cell lines. 
Representative images of 3 independent experiments are shown. (C) Flow cytometry 
assay shows increasing cell death for the differentiated L3MBTL1 KD EB cells. Top plots 
show unstained control and L3MBTL1 KD EB cells and bottom plots show PE-Annexin V 
versus 7-AAD permeability profiles in the same cells. Apoptotic cells on the plots are 
Annexin V positive and PI negative (lower right quadrant), whereas necrotic cells are 
Annexin V positive and PI positive (upper right quadrant). (D) Expression of L3MBTL1, 
OCT-4, and NANOG in undifferentiated and differentiated state measured as relative level 
of mRNA/GAPDH. (E) mRNA expression levels of lineage cell markers SOX1 (ectoderm), 
AFP (endoderm), ACTC1 (mesoderm), and CG-β (trophoblast) in undifferentiated and 
differentiated states measured as relative level of mRNA/GAPDH. Statistical analysis was 
performed by 1-way ANOVA and Tukey posttest (*P < 0.05). Error bars represent the 
standard deviation (n = 3).  
 
Figure 15.  Reverse transcriptase qPCR analysis for lineage cell markers. (A) 
Relative levels of mRNA expression of trophoblast marker CDX2. Error bars represent the 
standard deviation (n = 3). (B) Trophoblast cell markers HAND1, GCM1, KRT7, and KRT8 
in undifferentiated and differentiated states measured as relative level of mRNA/GAPDH. 
Statistical analysis was performed by 1-way ANOVA and Tukey posttest (*P < 0.05). Error 
bars represent the standard deviation (n = 3). (C) Immunofluorescent detection of HAND1. 
White arrows indicate the nuclear location of HAND1 protein. Microscopy performed 
with Olympus epifluorescence system under a 40 · objective. Scale bar represents 50 µm. 
Representative images of 3 independent experiments are shown. (D) FACS analysis 
shows the percentage of spontaneously differentiated control and L3MBTL1 shRNA1 and 
shRNA2 cells expressing the trophectodermal (TE) marker HLA-G (red). Isotype control 
antibody staining is shown (black). Undifferentiated LUC shRNA and L3MBTL1 KD cells 
were used as negative controls for HLA-G staining (blue).  
 
Figure 16. L3MBTL1 knockdown mimics trophoblast differentiation induced by 
BMP4. Luciferase control with or without BMP4 and L3MBTL1 KD cells were cultured for 7 
days. (A) Reverse transcriptase qPCR analysis for L3MBTL1, OCT-4, CG-β, and HAND1 
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mRNA expression. Statistical analysis was by 2-way ANOVA and Bonferroni posttest (*P < 
0.05). Error bars represent the standard deviation (n = 3). (B) Phosphorylation of 
SMADS1/5/8 was examined by Western blot analysis in the homogenates of 
undifferentiated (day 1) and spontaneously differentiated (day 7) control LUC shRNA and 
L3MBTL1-KD cells. (C) Immunoassay for placental hormones CG-β and progesterone. 
Error bars represent the standard deviation (n = 3). (D) L3MBTL1 KD cells differentiate 
under defined conditions. Fluorescence images of typical neuronal rosette structures at 
day 9 of directed neuroectoderm differentiation for control LUC shRNA and L3MBTL1 KD 
cell lines (upper panel) are shown. Scale bar represents 50 mm. Representative images of 
3 independent experiments are shown. Reverse transcriptase qPCR analysis results for 
neuroectoderm markers SOX-1 and PAX6 mRNA expression (bottom panel) are also 
shown. Statistical analysis was performed by 2-way ANOVA and Bonferroni posttest (*P < 
0.05). Error bars represent the standard deviation (n = 3).  
 
Figure 17. L3MBTL1 regulates EKLF expression via SMAD5 in hematopoietic and 
embryonic stem cells. A) EKLF, NF-E2, GATA-1, LMO2, and EPOR expression levels 
were evaluated by qRT-PCR in L3MBTL1-KD CB CD34+ cells after 7 days of erythroid-
supporting culture (with SCF 100 ng/ml and Epo 6U/ml) compared to controls. GAPDH 
served as housekeeping control B) K562 erythroleukemia cells were crosslinked with 1% 
formaldehyde and immunoprecipitated with smad5 (cell signaling) and IgG antibody.  
Primers covering the smad binding motifs 29 across the upstream enhancer, the proximal 
promoter and the intronic enhancer of the EKLF were utilized. Data were normalized by 
10% input. K562-L3MBTL1-HA were retrovirally infect to express L3MBTL1-HA or MIGR1 
control c-DNA and crosslinked with 1% formaldehyde and immunoprecipitated with smad5 
(cell signaling) and IgG antibody. C) EKLF mRNA expression levels was evaluated by 
qRT-PCR in human ES cells +/- treatment with Dorsomorphin and SB431542 inhibitors. 
GAPDH served as housekeeping control. D) human embryonic stem cells were 
crosslinked with 1% formaldehyde and immunoprecipitated with L3MBTL1 and IgG 
antibody. Data were normalized by 10% input. The graph shows the location of the 
primers of the human smad5 promoter. 
 
Figure 18. Modulation of L3MBTL1 expression affects globin gene expression A) 
Globin gene expression was measured by qRT-PCR in cord blood (CB) derived L3MBTL1-
KD CD34+ cells after 7 days in liquid culture that supports erythroid differentiation. Data 
were calculated according to standard curve analysis, and normalized to GAPDH 
expression. B) Gamma globin gene expression was measured by WB in cord blood (CB) 
derived L3MBTL1-KD CD34+ cells after 7 days in liquid culture that supports erythroid 
differentiation. Tubulin served as loading control C) Globin gene mRNA levels were 
evaluated by qRT-PCR in L3MBTL1-HA overexpressing CB CD34+ cells after 3 days in 
liquid culture that supports erythroid differentiation. GAPDH served as the housekeeping 
gene and the data were calculated using a standard curve analysis. D) Gamma globin 
gene expression was measured in L3MBTL1-HA overexpressing. Tubulin served as 
loading control E) Globin gene mRNA expression was measured in stable L3MBTL1-KD 
human embryonic stem cells by qRT-PCR. Data were normalized by GAPDH expression 
and calculated as fold induction relative to controls. F) L3MBTL1-HA overexpressing K562 
cells were treated with 40 ng/ml BMP4 and gamma globin gene expression was evaluated 
by WB. Tubulin served as loading control. G) Gamma and beta globin gene expression 
levels in K562 cells +/- knock-down of L3MBTL1 and +/- Knock-down of EKLF. GAPDH 
served as housekeeping control  
 
Figure 19. knock-down of L3MBTL1 activates smad-mediated transcriptional 
response in patient-specific beta-thalassemic iPS cells A) Undifferentiated iPS cells 
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were transduced with a lentiviral vector expressing shRNA targeting L3MBTL1 or 
luciferase (and GFP). GFP+ cells maintain the morphologic and immunophenotypic 
features of stemness, based on Tra-181 expression B) Globin gene mRNA expression is 
analyzed by qRT-PCR in CD71+GlyA+ cells, which were differentiated from L3MBTL1-KD 
and control b-thal iPS cells. Data were normalized by GAPDH expression C) Gene 
expression profile (GEP) of undifferentiated L3MBTL1-KD iPS cells, compared to controls, 
based on microarray analysis. Results indicate duplicate experiments (control and hairpin 
1 and 2). D) mRNA expression levels of several genes, identified by microarray analysis, 
was confirmed by qPCR. Data were normalized by GAPDH expression and shown as 
shRNA vs control E) Gene Set Enrichment Analysis of L3MBTL1-KD iPS cells F) 
Expression levels of phospho smad 1/5/8, total smad5, phospho smad2, total smad2, and 
HHEX were evaluated in L3MBTL1-KD and control iPS cells by WB. Tubulin served as 
loading control. G) EKLF and L3MBTL1 expression were evaluated by WB assay in CB-
derived iPS cells. Tubulin served as loading control H) EKLF and L3MBTL1 expression 
were evaluated by WB assay in patient-specific derived iPS cells. Tubulin served as 
loading control. I) working model 
 
Figure 20. The Oncogenic JAK2 Mutants Interact More Strongly with PRMT5 than 
Wild-Type JAK2 and Gain the Ability to Phosphorylate PRMT5 (A) The V617F 
mutation enhances the interaction between JAK2 and PRMT5. 293T cells were transiently 
transfected with vectors expressing FLAG-PRMT5 alone (lane 2) or with HA-tagged wild-
type (lane 3), or V617F (lane 4) JAK2 proteins. Immunoprecipitation was performed using 
an anti-HA antibody and immunoblotting with anti-FLAG or anti-JAK2 antibodies.(B) Both 
the V617F and K539L mutations enhance the PRMT5/JAK2 association. HA-tagged 
PRMT5 was coexpressed in 293T cells with wild-type (lane 3), V617F (lane 4), or K539L 
(lane 5) JAK2 proteins. Proteins were precipitated by anti-HA immunoprecipitation, and the 
blots were probed with antibodies specific for HA, JAK2, or PRMT5.(C) Endogenous 
interaction between PRMT5 and JAK2V617F is detected in HEL cells. Proteins were 
precipitated from HEL cell extracts using two different anti- JAK2 antibodies; normal rabbit 
IgG was used as a control for the immunoprecipitation.(D) Interaction between HA-PRMT5 
and endogenous JAK2V617F is detected in HEL cells. Co-IP was performed using a HEL 
cell line stably expressing HA-PRMT5. Proteins were precipitated by either a normal 
mouse IgG or anti-HA antibody. Immunoblotting was performed using antibodies specific 
for JAK2 and PRMT5.(E) The N-terminal region of JAK2 interacts with PRMT5. The left 
diagram is of full-length JAK2 and various amino terminal-deleted JAK2 proteins with or 
without the V617F mutation. Numbers indicate the relevant amino acids. Right panel 
shows that HA-tagged JAK2 full-length or various amino terminal-deletion mutants were 
coexpressed in 293T cells with FLAG-PRMT5. JAK2 and any associated PRMT5 were 
pulled down using anti-HA immunoprecipitation. Membranes were immunoblotted with an 
anti-HA antibody to detect JAK2 and an anti-FLAG antibody to detect PRMT5. WTFL, wild-
type full-length JAK2 protein; VFFL, JAK2V617F full-length protein. 
 Figure 21. The Constitutively Active JAK2 Mutants Phosphorylate PRMT5 In Vivo( A) 
JAK2 phosphorylates PRMT5 in vitro. In vitro kinase assays were performed using 
bacterial-purified GST-PRMT5 and the active JAK2 kinase. The amount of protein in the 
reaction is indicated. Myelin basic protein (MBP) was used as a positive control (lane 
3).(B) PRMT5 is phosphorylated by JAK2V617F in vivo. HA-PRMT5 was cotransfected 
into 293T cells with an empty vector or with vectors expressing wild-type or V617F mutant 
JAK2 protein. PRMT5 was precipitated by anti-HA immunoprecipitation, and 
phosphorylation of PRMT5 was detected using a phosphotyrosine-specific antibody 
(PY350).(C) Both JAK2V617F and JAK2K539L phosphorylate PRMT5 in vivo. 293T cells 
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were transiently transfected with HA-PRMT5 alone or cotransfected with an increasing 
concentration of JAK2 wild-type, JAK2V617F- or JAK2K539L-expressing vector. HA-
PRMT5 was purified by anti-HA immunoprecipitation, and phosphorylation of PRMT5 was 
detected by immunoblotting with the PY350 antibody.(D) Activated wild-type JAK2 is 
unable to phosphorylate PRMT5 in vivo. 293T cells were transfected with vectors 
expressing the proteins indicated in the figure. Proteins were purified by anti-HA 
immunoprecipitation, and phosphorylation of PRMT5 and STAT5 was detected using an 
anti-phosphotyrosine antibody. Input was from 5% of the total lysate. JAK2 
phosphorylation was detected using an antibody specific for phospho-JAK2.(E) 
Endogenous PRMT5 is phosphorylated in HEL cells. HEL cells were treated with either 
DMSO or 2 µM JAK Inhibitor I for 16 hr. Phosphorylated proteins were purified using the 
PY99 anti-phosphotyrosine antibody. Normal mouse IgG was used as a control for the 
immunoprecipitation. The precipitated STAT5 and PRMT5 proteins were detected using 
anti-STAT5 and anti-PRMT5 antibodies, respectively. JI1, JAK Inhibitor I.(F) 
Phosphorylated PRMT5 is not detected in TF-1 cells. TF-1 cells cultured in growth medium 
supplemented with 2 ng/ml of recombinant human IL-3 were deprived of cytokine for 16 hr. 
The cells (5 × 106) were then treated with GM-CSF (25 ng/ml), Epo (20 U/ml), or Epo plus 
2 µM of JAK Inhibitor I (JI1) for 20 min. Phosphorylated STAT5 and PRMT5 proteins were 
immunoprecipitated using the PY99 antibody. 
Figure 22. Phosphorylation of PRMT5 by JAK2V617F Impairs Its Histone 
Methyltransferase Activity(A) Coexpression of JAK2V617F, but not the wild-type JAK2, 
impairs the ability of PRMT5 to methylate histone H4 in vitro. An in vitro methylation assay 
was performed using HA-PRMT5 purified from 293T cells transfected with HA-PRMT5 
alone (lanes 5–7) or cotransfected with MEP50 (lanes 2–4), wild-type JAK (lanes 8–10), or 
JAK2V617F (lanes 11–13). Increasing amount of proteins (10, 15, or 20 µl) were added to 
each methylation reaction with 2.5 µg recombinant H4 and 1 µCi of 3H-SAM. Even loading 
of the proteins (PRMT5 and histone H4) was visualized using Coomassie blue staining. 
EV, empty vector.(B) In vitro methylation assays were performed with recombinant H2A 
and similarly purified HA-PRMT5. Increasing amount of purified protein (10 or 20 µl) was 
added to the reaction.(C) Overexpression of the mutant JAK2 proteins, but not the wild-
type JAK2 protein, downregulates H2A/H4 R3 methylation. The core histones were 
purified from 293T cells transfected with either an empty vector or with vectors expressing 
the JAK2 proteins indicated in the figure. Methylation of H2A/H4 R3 was detected using a 
rabbit polyclonal antibody specific for H2A/H4 R3 symmetric dimethylation 
(H2A/H4R3me2s). An anti-histone H3 antibody was used to show the equal loading.(D) 
Inhibition of JAK2 kinase activity increases H2A R3 methylation in HEL cells. HEL cells 
were treated with DMSO or with the JAK2 inhibitors JAK Inhibitor I (1 µM) or CEP701 
(0.2 µM) for 2 hr. Histone methylation was detected in cell lysates using an antibody 
specific for symmetric dimethylation of H2A/H4 R3. JI1, JAK Inhibitor I.(E) Inhibition of 
JAK2 rapidly upregulates H2A R3 methylation in HEL cells. HEL cells were treated with 
TG101348 (3 µM) for 0, 1, 2, and 4 hr. JAK2 kinase inhibition was monitored by measuring 
STAT5 phosphorylation using an anti-phospho-STAT5 antibody. Phosphorylation of 
PRMT5 was detected with the phospho-specific PRMT5 antibody (P-PRMT5-747). 
Histones were purified by acidic extraction, and H2A R3 methylation was detected using 
an anti-H2A/H4R3me2s antibody. The levels of histone H3 and tubulin are shown as 
loading controls.(F) JAK2 inhibitors do not change the level of H2A R3 methylation in TF-1 
cells. TF-1 cells growing in medium supplemented with recombinant human IL-3 were 
treated with DMSO or JAK2 inhibitors (as indicated in the figure) for 2 hr. Histone 
methylation was detected using an anti-H2A/H4R3me2s antibody and STAT5 
phosphorylation detected using a phospho-STAT5 antibody. SS, steady state. Starved 
cells were deprived of IL-3 for 2 hr.(G) Gene expression profiles were generated using 
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Affymetrix HG133 GeneChips and CEP701 (0.5 µM)-treated or shPRMT5-treated HEL 
cells, versus controls (DMSO or a lentivirus expressing a scrambled shRNA, respectively). 
Genes reciprocally up- or downregulated ≥1.5-fold in both duplicate samples from drug-
treated samples, and the shPRMT5-treated samples are compared. The top shows the 
number of genes that are downregulated by CEP701 treatment and upregulated by 
knockdown of PRMT5. The bottom illustrates the number of genes that are upregulated by 
CEP701 treatment and downregulated by PRMT5 knockdown. 
Figure 23. Phosphorylation of PRMT5 by JAK2V617F Disrupts Its Association with 
MEP50(A) Tyrosine residues within PRMT5 that are potential sites of phosphorylation 
(279,282,285, 296,303,306) were converted to phenylalanine residues by site-directed 
mutagenesis. Wild-type or mutant HA-PRMT5 proteins were coexpressed with 
JAK2V617F protein in 293T cells and immunoprecipitated with an anti-HA antibody. 
Phosphorylation of PRMT5 was detected using a rabbit polyclonal anti-phosphotyrosine 
antibody (PY350).(B) HEL cells were treated with DMSO, JAK Inhibitor I (1 µM), or 
CEP701 (0.2 µM) overnight, and the phosphorylation of PRMT5 was detected by 
immunoblotting using a phospho-PRMT5 antibody (P-PRMT5-747) specific for the Y297, 
Y304, and Y307 phosphotyrosine residues in the PRMT5 protein. The level of PRMT5 and 
phospho-STAT5 are also shown.(C) Coexpression of JAK2V617F disrupts the 
PRMT5/MEP50 association. The HA-PRMT5/MEP50 complex was purified using an anti-
HA antibody from 293T cells expressing the proteins indicated in the figure. 
Phosphorylation of PRMT5 was confirmed by immunoblotting with an anti-phosphotyrosine 
antibody. Coprecipitated MEP50 was detected with an anti-MEP50 antibody.(D) The 
kinase activity of JAK2V617F is required to disrupt the PRMT5/MEP50 complex. DMSO or 
4 µM JAK Inhibitor I (JI1) was added to the 293T cells after transfection. Cells were 
collected 48 hr after transfection, and the HA-PRMT5/MEP50 complex was 
immunoprecipitated using an anti-HA antibody.(E) Phosphorylated PRMT5 isolated from 
HEL cells does not bind MEP50. HEL cells stably expressing myc-tagged MEP50 were 
subjected to immunoprecipitation using an anti-myc antibody. After overnight incubation, 
the flowthrough was saved, and the PRMT5/MEP50 complex was eluted from the beads. 
Proteins in the eluate and the flowthrough were precipitated by TCA precipitation and 
resolved by SDS-PAGE gels. The membranes were blotted using anti-PRMT5 and anti-
MEP50 antibodies, and the P-PRMT5-747 antibody, to quantify the amount of each protein 
in the various lanes. 
Figure 24. PRMT5 Activity Regulates Progenitor Cell Expansion/Differentiation in 
Human CD34+ Cells(A) Knockdown of PRMT5 promotes CFU formation. Isolated human 
CB CD34+ cells were transduced with lentiviruses expressing a scrambled shRNA or 
shRNA specific to PRMT5. GFP-positive cells were sorted 2 days after infection. Left 
panel shows that PRMT5 mRNA expression was detected by real-time PCR. Right panel 
illustrates that approximately 1 × 104 GFP-positive CD34+ cells were plated in 
methylcellulose culture supplemented with cytokines to support the formation of CFU-GM, 
CFU-GEMM, and BFU-E. Colonies were scored 2 weeks after the plating. The results 
shown here are the averages of two independent experiments with error bars indicating 
±SD.(B) Overexpression of PRMT5 inhibits colony formation. Isolated human CB CD34+ 
cells were transduced with lentiviruses expressing either GFP alone, or GFP together with 
HA-tagged wild-type PRMT5 or an HA-tagged M6 mutant form of PRMT5. GFP-positive 
cells were sorted, and 2 × 104 cells were used for CFU assays. The average results of two 
independent experiments are shown here. The error bars indicate ±SD.(C) Knockdown of 
PRMT5 promotes erythroid differentiation. GFP+ CD34+ cells were cultured in serum-free 
medium supplemented with cytokines supporting erythroid differentiation for 14 days. 
CD71-positive/Ter-115-positive cells were determined by FACS analysis.(D) PRMT5 
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overexpression inhibits erythroid differentiation. HA-PRMT5 or HA-PRMT5M6 was 
overexpressed in CB CD34+ cells, which were cultured in erythroid-promoting medium for 
7 days; erythroid differentiation was determined by FACS analysis, staining for CD71 (y 
axis) and Glycophorin A (x axis). pBGJR refers to the control lentiviral vector.(E) PRMT5 
overexpression inhibits colony formation in JAK2V617F-positive CD34+ cells isolated from 
patients with PV. CD34+ cells were isolated from phlebotomy units of patients with PV and 
transduced by control lentivirus or lentiviruses expressing HA-PRMT5 or HA-PRMT5M6. 
The 1 × 104 GFP+ cells were plated in methylcellulose with cytokines supporting GM, 
GEMM, and BFU colony formation. Colonies were scored 14 days after plating.(F) 
Phosphorylation of PRMT5 was detected in CD34+ cells isolated from patients with MPN. 
CD34+ cells were isolated from human umbilical cord blood (lane 1) or from ten 
phlebotomy units taken from patients with MPN (lanes 2–3 and 5–12). HEL cells were 
used as a positive control (lane 4). Phosphorylation of PRMT5 was detected using the P-
PRMT5-747 antibody. The total amount of PRMT5 was also assessed by immunoblotting. 
ET, essential thrombocythemia; PV, polycythemia vera; HEL, HEL leukemia cells. 
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High-grade gliomas are aggressive and uniformly
fatal tumors, composed of a heterogeneous popula-
tion of cells that include many with stem-cell-like
properties. The acquisition of stem-like traits might
contribute to glioma initiation, growth, and recur-
rence. Here we investigated the role of the transcrip-
tion factor myeloid Elf-1 like factor (MEF, also known
as ELF4) in gliomas. We found that MEF is highly ex-
pressed in both human and mouse glioblastomas
and its absence impairs gliomagenesis in a PDGF-
driven glioma mouse model. We show that modula-
tion of MEF levels in both mouse neural stem
cells and human glioblastoma cells has a signifi-
cant impact on neurosphere formation. Moreover,
we identify Sox2 as a direct downstream target of
MEF. Taken together, our studies implicate MEF as
a previously unrecognized gatekeeper gene in glio-
magenesis that promotes stem cell characteristics
through Sox2 activation.
INTRODUCTION
Malignant gliomas represent the most prevalent primary brain
tumor in adults and inevitably have a poor prognosis. Despite
the implementation of new therapeutic strategies, the median
survival of patients with Glioblastoma multiforme (GBM),
the most aggressive glioma variant, is only 14–16 months
and these tumors remain rapidly and uniformly fatal (Wen and
Kesari, 2008).836 Cell Stem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier InGBMs are very heterogeneous tumors that contain both
neoplastic and nonneoplastic cells, including endothelial,
stromal, and inflammatory cells (Charles et al., 2011). A fraction
of cells within the tumor, identified as glioma stem-like cells
(GSCs), share some common features with normal neural stem
cells (NSCs); they are multipotent and have the property of
self-renewal. These cells may either derive from adult undifferen-
tiated stem and progenitor cells or could acquire stem-like
properties as a result of the genetic alterations that promote
the tumorigenic process (Holmberg et al., 2011). When im-
planted into the brain of immunodeficient animals, these GSCs
are capable of generating new tumors at high efficiency (Galli
et al., 2004). Moreover, GSCs are remarkably resistant to the
chemotherapy and radiotherapy (Dean et al., 2005) used as
standard first-line treatment of patients with malignant gliomas.
Indeed, acquisition of stem-like characteristics likely contributes
to the malignant nature of high-grade gliomas and may be
responsible for the initiation, growth, and recurrence of these
tumors.
Myeloid Elf-1 like factor (MEF, also known as ELF4) is a
member of the ETS family of transcription factors, which
contains over 30 family members. Several ETS proteins can
function as oncogenes and show aberrant expression in solid
tumors as well as in hematological malignancies (Sashida
et al., 2010). While MEF has been proposed to function as
a tumor suppressor gene in some contexts, it could contribute
to tumor formation in mice as well as in humans (Mikkers et al.,
2002) (Sashida et al., 2010). Insight into its mechanism of action
has come from studies done in fibroblasts demonstrating MEF’s
ability to induce transformation by stimulatingMdm2 expression,
thereby downregulating p53-dependent responses, and by
inhibiting activation of Ink4a, thereby allowing unrestrained
phosphorylation of the retinoblastoma (Rb) protein (Sashida
et al., 2009). Some of the ETS proteins are known to playc.
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Figure 1. MEF in Human and Mouse
Gliomas
(A) MEF expression in the TCGA data set obtained
from humanGBM samples (n = 195) and nontumor
brain tissue (n = 10) (***p = 2.366e09, Student’s
t test).
(B) Kaplan Meier survival curves of TCGA GBM
patients: low level of MEF (calculated as less than
one standard deviation from the mean of diploid
tumors) significantly correlates with better overall
survival (***log-rank p value, p = 0.000386).
(C) Top panel: MEF mRNA level detected by RT
PCR is higher in PDGF-driven mouse GBMs (T)
compared to normal tissue (N). Data are normal-
ized to GAPDH expression. Results are presented
as mean ± SD (***p < 0.0001, Student’s t test).
Bottom panel: western blot showing that MEF
protein level is higher in PDGF-driven mouse
GBMs compared to normal tissue.
(D) Kaplan Meier survival curves of PDGF gliomas
generated in Ntv-a Mef+/+ versus Mef/ mice.
MEF loss increases overall survival and reduces
gliomagenesis (log-rank p value, *p = 0.02).
(E) Left panel: mouse gliomas lacking MEF show
significantly lower percentage of high-grade
versus low-grade tumors (Fisher’s exact test,
*p = 0.027); right panel: contingency table pre-
senting the number of high-grade (HG) tumors
versus low-grade (LG) tumors in the two different
genetic backgrounds.
See also Figure S1.
Cell Stem Cell
MEF Role in Pathogenesis of Gliomasa role in brain tumors (Uht et al., 2007), though so far no pub-
lished data are available regarding the role of MEF in normal
brain or in brain tumor biology. Here we show that MEF is highly
expressed in GBMs and it contributes to gliomagenesis by
promoting stem cell traits through direct activation of Sox2
expression.
RESULTS
MEF Is Highly Expressed in Human Gliomas and Its Loss
Impairs Glioma Formation in Mice
GBM represents a heterogeneous disease and recent genomic
analyses have quantified the expression level of a wide variety
of genes (Cancer Genome Atlas Research Network, 2008). We
analyzed the data set from The Cancer Genome Atlas (TCGA)
for GBMs and found MEF expression significantly elevated in
the tumor samples (n = 195) as compared to nontumor brain
tissue (n = 10) (p < 0.0001; Student’s t test) (Figure 1A and Table
S1 available online), without evidence for amplification at the
genomic level. Because MEF has previously been shown to
block the p53 pathway, we examined the p53 status of theseCell Stem Cell 11, 836–844,tumors and found no correlation between
MEF expression levels and p53 mutation
or deletion, suggesting that MEF may
function in a p53-independent manner in
glioma (Figure S1A available online).
A search conducted in the Oncomine
website (https://www.oncomine.org//) re-
vealed that in the Sun data set (Sun et al.,2006), which includes 81 human GBMs (grade IV), 25 anaplastic
astrocytomas (grade III), and 50 oligodendrogliomas (grade II),
MEF expression is significantly higher in GBMs than in lower
grade gliomas (p < 0.0001) (Figure S1B). To confirm these data
we analyzed MEF expression by qPCR in 25 human glioma
surgical samples from Memorial Sloan-Kettering Cancer Center
(MSKCC) (six oligodendrogliomas, seven anaplastic oligoden-
drogliomas, two anaplastic astrocytomas, and ten glioblas-
tomas) and found that MEF is significantly elevated in high-grade
versus low-grade gliomas (p = 0.02, Student’s t test) (Fig-
ure S1C). However, this difference might reflect a lower ratio of
tumor cells versus nontumor cells in the low-grade samples.
Lower levels of MEF were associated with a better prognosis
in a small cohort of acute myeloid leukemia patients (Fukushima
et al., 2003). We examined the TCGA GBM patient survival
data and found that low levels of MEF significantly correlated
with better overall survival in GBMs as well (log rank test,
p = 0.0008; Figure 1B). Gene expression profiling studies have
identified four molecular subclasses of GBMs based on tran-
scriptional signatures: Classical, Mesenchymal, Proneural and
Neural. Each of these subtypes has been associated withDecember 7, 2012 ª2012 Elsevier Inc. 837
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Figure 2. Mef Promotes Proliferation of
both Primary Brain Cultures and Human
Glioma Cell Lines
(A and B) Growth curve of primary brain cultures
derived fromMef/,Mef+/+ (A) andp53//Mef/,
p53//Mef+/+ (B) newborn mice.
(C–E) Growth curve of primary brain cells derived
from p53/ newborn mice (C) and human U87MG
and T98G glioma cell lines (D and E).
Results are presented as mean ± SD from
a representative of three experiments performed
in triplicate. *p < 0.05; **p < 0.001; ***p < 0.0001
(Student’s t test). See also Figure S2.
Cell Stem Cell
MEF Role in Pathogenesis of Gliomasspecific signaling alterations, such as EGFR, Ras, and PDGFR
pathway activation, respectively (Verhaak et al., 2010). When
the patients were stratified according to GBM subtypes, the
Proneural subclass showed the lowest level of MEF expression
(Figure S1D) and, within this subtype, lower levels of MEF also
correlated with better overall survival (Figure S1E). When we
looked at the IDH1 status, we found that the tumors with the
lowest MEF levels within the Proneural group were predomi-
nantly IDH1 mutant tumors, whereas IDH1 wild-type Proneural
tumors had a range of MEF levels similar to the other tumor types
(data not shown).
To determine whether MEF plays an active role in gliomagen-
esis, we used the RCAS/PDGF mouse glioma model, which
closely resembles the human Proneural GBM subtype. The
RCAS/tv-a system utilizes avian leukosis virus based vectors
(RCAS) to mediate gene transfer into somatic cells, engineered
to be transgenic for its receptor (tv-a). Specifically, we used Nes-
tin tv-a (Ntv-a) mice, where the tv-a receptor is under the control
of the Nestin promoter, a well-known marker of progenitor and
neural/glial cells. First, we evaluated MEF expression in an838 Cell Stem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier Inc.Ink4a/Arf null background, in which
PDGF is able to uniformly generate high-
grade gliomas that share hallmark histo-
logical features with human GBMs (Dai
et al., 2001). Using qPCR and Western
blot analysis, we found higher levels of
MEF mRNA and protein in these tumors
as compared to the contralateral normal
brain tissues (Figure 1C).
Next, to determine if lack of MEF
impacts on PDGF-induced gliomagene-
sis, Mef/ mice were crossed with
Ntv-a mice (which carry a wild-type
Ink4a/Arf locus) to generate Ntv-a Mef+/+
and Ntv-a Mef/ mice. A survival anal-
ysis of the two cohorts revealed that
loss of MEF significantly impaired
PDGF-induced glioma formation, with
MEF null mice living an average of
129 days (n = 22) and wild-type mice
living 59 days (n = 24) (p < 0.02, log rank
test) (Figure 1D). The tumors were then
scored and graded by histological
features (see Experimental Proceduresfor details). Tumors lacking MEF showed less aggressive
features, with significantly fewer high-grade gliomas (p = 0.02,
Fisher’s exact test) (Figure 1E). Thus,MEF can affect both glioma
formation and progression.
MEF Promotes Proliferation of both Mouse Primary
Brain Cultures and Human Glioma Cell Lines
As MEF has been shown to promote the transition of cells
from G1 to S (Liu et al., 2006; Sashida et al., 2009) we evalu-
ated its effect on proliferation, using both mouse primary brain
cultures and human glioma cell lines. The primary cultures
were generated from the whole brain of newborn pups, and
to investigate potential p53-independent effects, we used cells
from Mef+/+ and Mef/ mice and also from p53// Mef+/+
and p53//Mef/ mice. Cells lacking MEF grew more slowly
than the control cells (Figures 2A and 2B), while its overex-
pression in p53/ cells (Figure S2A) increased proliferation
(Figure 2C). Similarly, the overexpression of MEF in the human
U87MG and T98G glioma cell lines (Figures S2B and S2C) re-
sulted in higher rates of cell proliferation (Figures 2D and 2E).
Cell Stem Cell
MEF Role in Pathogenesis of GliomasThese data confirm the role of MEF in promoting the growth of
both mouse primary brain cultures and human glioma cell
lines.
MEFPromotesStemCell Characteristics inMouseNSCs
and Human Glioma Cell Lines
In recent years, an increasing number of studies have investi-
gated the connection between malignancy and ‘‘stemness,’’
focusing on how stem/progenitors cells, as well as neoplastic
cells, change their properties during the process of malignant
transformation. Several transcription factors are known to
induce pluripotent stem cells from differentiated cells, as well
as to maintain multipotency of NSCs (Patel and Yang, 2010).
Because MEF contributes to glioma formation and aggressive-
ness in vivo, we explored the possible role of MEF in promoting
stem cell characteristics.
NSCs and GSCs can be grown as spheres in culture, in the
absence of serum but in the presence of basic fibroblast growth
factor (bFGF) and epidermal growth factor (EGF). Although
sphere-forming assays cannot be considered an exact readout
of in vivo stem cell activity, they are useful to measure the
in vitro potential of cells to exhibit stem-cell-like traits (Pastrana
et al., 2011); therefore, we investigated whether MEF could influ-
ence the formation of neurospheres.
Freshly isolated Mef/ and Mef+/+ cells from postnatal non-
neoplastic brains were plated at different cell densities (10, 5,
and1cells/ml) in 24-well platesandgrown inneurospheremedium
for 2weeks to allow thegeneration of neurospheres.We thenper-
formed serial passages over the course of 8 weeks, generating
secondary, tertiary, and quaternary spheres. Spheres were me-
chanically dissociated every 2 weeks, and at each passage,
sphere number was assessed. We found that at a density of
1 cell/ml, lack of MEF significantly decreased generation of
secondary, tertiary, and quaternary neurospheres (Student’s
t test, p < 0.0001, at each passage) (Figure 3A). Similar results
were obtained at higher cell concentrations (5 and 10 cells/ml)
(FigureS3A).Moreover, cells lackingMEFunderwentmorpholog-
ical changes over time, with some of them becoming attached to
the bottom of the wells and presenting short elongation
processes (Figure S3B). To understand whether the decreased
sphere forming ability seen inMef/ cells was accompanied by
increased differentiation, we grew cells fromdissociated spheres
in 5% serum medium without FGF and EGF to evaluate their
differentiation potential. Phase contrast images revealed clear
differences in themorphologyof theMef+/+andMef/ cells, sug-
gesting that differentiation is more profound in cells lacking MEF
(Figure 3B). Immunofluorescence staining showed a significant
reduction in Nestin+ cells (p = 0.0006), together with a significant
increase in bothOlig2 andGFAP+ cells (p < 000.1 and p = 0.0481,
respectively, Student’s t test) inMef/ cells (Figures 3C and 3D).
These differences were detected also by Western blot analysis
(Figure 3E). Interestingly, most of the GFAP-positiveMef/ cells
showed the stellate morphology typical of astrocytes and
a brighter signal, which was confirmed by increased GFAP
protein levels measured by Western blot (Figure 3E). We failed
to detect Tuj-1+ cells in three of the four Mef/ samples, while
an average of 14.4% Tuj-1+ cells was found in four different
Mef+/+ samples (data not shown), which suggests thatMEFmight
also contribute to differentiation toward the neuronal lineage.CellTo determine whether lack of MEF could influence the stem
cell potential under more strict conditions, we generated primary
cell cultures obtained from the whole brain of newborn pups,
forced them to grow in serum for two passages, and switched
them to neurosphere medium. To evaluate possible p53-inde-
pendent effects, primary brain cultures were isolated from
different genetic backgrounds (Mef+/+, Mef/, p53//Mef+/+,
and p53// Mef/). Four days after the switch to neurosphere
medium, cells lacking MEF failed to form spheres, while both the
Mef+/+ and the p53//Mef+/+ cells were able to do so (p = 0.0003
and p = 0.0001, respectively, Student’s t test) (Figure 3F). The
impaired neurosphere formation of the p53//Mef/ cells
could be rescued by MEF re-expression (p = 0.00145, Student’s
t test) (Figure 3G and Figure S3C).
We then investigated whether MEF overexpression could
induce reprogramming signals under the same strict conditions,
influencing the sphere-forming ability of different primary and
glioma cells. We first overexpressed MEF in primary brain
cultures obtained from p53 null pups, using retroviral vectors
(Figure S2A). After antibiotic selection, the cells were grown in
serum for two passages and then switched to neurosphere
medium. We found that cells overexpressing MEF formed
more neurospheres than the control cells (p = 0.0012 at 24 hr,
p = 0.0017 at 72 hr; Student’s t test) (Figure 3H). Similar differ-
ences upon MEF overexpression were observed in the U87MG
and T98G human glioma cell lines (p < 000.1 and p < 000.1,
respectively, Student’s t test) (Figure 3I).
Lastly, we evaluated the impact of MEF on stem-like proper-
ties using human primary GSCs, with various genetic profiles.
Tumor samples, isolated from patients suffering from GBMs
and undergoing surgery at MSKCC, were dissociated and
initially grown in neurosphere medium as a monolayer on
plastic cell culture dishes coated with 10 ng/ml laminin. Specifi-
cally, we used the following cells: GBM1 (++PDGFRA, +EGFR,
MET, CDK6, PTEN, CDKN2A), GBM3 (++EGFR, +MET,
CDK6, CDKN2A,PTEN, carrying EGFRvIII mutation), and
GBM543 (++PDGFRA, ++CDK4, +(EGFR,MET,CDK6), PTEN)
(Ozawa et al., 2010; Pulvirenti et al., 2011). Using lentiviral
vectors to express shRNAs, we silenced MEF expression (Fig-
ure S3D) and found that decreased MEF levels lead to a signifi-
cant decrease in neurosphere formation in all of these three GSC
lines (p < 0.0001 for both shRNA#1 and shRNA#2), as compared
to nontargeting shRNA control (Figure 3J). Moreover, when we
performed limiting dilution neurosphere assays, we confirmed
that MEF knockdown leads to a reduced frequency of sphere-
forming cells (p < 000.1 for both shRNAs in each GSC line,
ELDA software) (Figure 3K).
Taken together, these data suggest a role for MEF in
promoting stem-cell-like features in both primary brain cultures
and glioma cell lines.
Sox2 Gene Is a Direct Target of MEF and Rescues
Sphere-Forming Ability in MEF-Defective Cells
To investigate possible mechanisms behind the ability of MEF to
promote stem-cell traits, we measured the expression level of
several genes related to pluripotency, including Sox2, Oct4,
Nanog, Klf4, Hes1, and Hey1, in MEF-transduced p53/
primary brain cells. Among these genes, we found that Sox2
and Oct4 expression was significantly increased by MEF. WeStem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier Inc. 839
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Figure 3. MEF Promotes Stem Cell Traits of both Primary Brain Cultures and Glioma Cell Lines
(A) Neurospheres isolated from newborn pups, withMef+/+ andMef/ genetic background, respectively: MEF loss led to impaired neurosphere formation after
serial passages.
(B) Phase contrast images showingmorphological changes betweenMef+/+ andMef/ brain cells grown in 5% serum, without bFGF and EGF, for 5 days to favor
differentiation.
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MEF Role in Pathogenesis of Gliomasobserved a 3.6-fold increase in Sox2 gene expression and a 3-
fold increase in Oct4 expression level (p = 0.02 and p = 0.013,
respectively, Student’s t test) (Figure 4A). Similarly, in U87MG
and T98G cells, MEF induced a 2.1 (p = 0.017) and 1.6 (p =
0.018) -fold increase in Sox2 levels and a 1.8 (p = 0.0025) and
1.6 (p = 0.0199) -fold increase in Oct4 levels (Figure 4B).
The Sox2 promoter is known to contain ETS binding sites
(Wiebe et al., 2000), though they have not been identified in the
Oct4 promoter; therefore, we focused on Sox2 as a possible
direct downstream target of MEF. We analyzed Sox2
expression in Mef+/+ versus Mef/ and p53//Mef+/+ versus
p53//Mef/ primary brain cells and found a significant reduc-
tion in Sox2 levels in the absence of MEF (p < 0.0001, Student’s
t test) (Figures 4C and 4D). To exclude the possibility that devel-
opmental adaptation to the lack of MEF resulted in decreased
Sox2 expression, we acutely knocked down MEF in p53 null
primary brain cultures (60%) and found a significant reduction
in Sox2 expression (p = 0.015 and p = 0.0059, respectively,
Student’s t test) (Figure 4E). Thus, both the acute loss and
chronic absence of MEF substantially decreases Sox2
expression.
To test whether MEF can activate the Sox2 promoter, we
transiently transfected a Sox2 promoter-driven luciferase
reporter plasmid (Kuwabara et al., 2004) into p53 null primary
brain cells, together with MEF or an empty vector control. As
shown in Figure 4F, MEF induced a greater than 3-fold increase
in luciferase activity from the Sox2 promoter (p < 0.0001,
Student’s t test) while having no effect on Hes1 promoter-
driven luciferase activity. We also investigated whether MEF
activates the Sox2 promoter in human glioma cell lines and
found a similar upregulation (p < 0.0001, Student’s t test)
(Figures 4G and 4H).
Having identified Sox2 as a transcriptional target of MEF, we
investigated whether Sox2 overexpression could rescue the
decrease in neurosphere formation seen in cells lacking MEF.
We overexpressed Sox2 in p53//Mef/ primary brain cultures
(Figure S4B) and grew them in neurosphere conditions. The
absence of neurospheres seen in cells lacking MEF was rescued
by Sox2 overexpression (p = 0.00018, Student’s t test), indi-
cating that Sox2 acts downstream of MEF to promote neuro-
sphere formation (Figure 4I).
To confirm that Sox2 gene regulation by MEF was direct, we
performed Chromatin Immunoprecipitation (ChIP) assays using
T98G glioma cells that were transduced with a pBabe retroviral(C and D) Immunofluorescence staining and quantification ofMef+/+ andMef/ b
is quantified as percentages of total Hoechst+ cells per image (10 fields of images
scale bars indicate 50 mm.
(E) Western blot comparing Mef/ to Mef+/+ brain cells: lack of MEF lead to dec
(F) Mef+/+, Mef/, p53//Mef+/+, and p53//Mef/ primary brain cultures gro
(G) Re-expression of MEF in p53/Mef/ cells rescues their ability to form neu
(H) Micrograph showing p53/ primary brain cells transfected with pBabe-emp
graphs on the bottom show average neurosphere number per field of view.
(I) MEF overexpressing human U87MG and T98G cell lines, cultured in neurosphe
bottom show average neurosphere number per field of view.
(J) Graph bar showing decreased neurosphere formation after MEF knockdown
(K) Graph representing limiting dilution neurosphere assays in patient-derived hu
vector and pGipz MEF shRNAs #1 and #2.
Results are presented as mean ± SD from a representative of three experimen
***p < 0.0001 (Student’s t test). See also Figure S3.
Cellvector expressing a FLAG-taggedMEF cDNA or a control vector.
Using an anti-FLAG ChIP assay, we found that in human glioma
cells, MEF protein is recruited to specific regions of the Sox2
gene (which covered 1.964, 1.672, and 1.324 kb from the
transcription starting site [TSS]; p values: 0.0009, 0.003,
0.0008, respectively). No direct binding was observed at the
farthest region (3.841 kb) (Figure 4J).
DISCUSSION
The regulation of stemness is of interest to many disciplines,
including developmental biology, regenerative medicine, degen-
erative disease, and cancer. Normal stem cells are known to
play critical roles in tissue development, differentiation, and
organogenesis (Vierbuchen et al., 2010). Several transcription
factors, such as Notch, Id1, Sox2, Oct4, and others, have been
reported to control different aspects of stemness, influencing
the delicate balance between stem cell maintenance and the
promotion of stem cell differentiation. In recent years, many
studies have shown that genes involved in normal stem cell
biology also play a relevant role in tumorigenesis (Nam and Ben-
ezra, 2009) (Venere et al., 2011).
Malignant gliomas are highly aggressive cancers composed of
a heterogeneous cell population, a fraction of which exhibits
stem-like characteristics (Vescovi et al., 2006). Whether GSCs
arise from normal NSCs or from neoplastic cells that have
acquired stem cell traits is still unclear; however, it has been
proposed that the acquisition of stem cell characteristics
through the activation of stem cell gene signatures can confer
malignant potential to gliomas (Holmberg et al., 2011).
We have shown that MEF, a member of the ETS family of tran-
scription factors, contributes to gliomagenesis and promotes
stem-like characteristics. MEF is highly expressed in both
human and mouse GBMs, and GBM patients with low levels of
MEF show a significantly better overall survival. This finding
was replicated in the RCAS/PDGF model where gliomas that
lack MEF had less aggressive histological features and better
overall survival.
Genes overexpressed in cancer can affect many different
biological processes including growth, stress response, block
of apoptosis, and stemness. Uncontrolled proliferation is a key
aspect of cancer cell behavior and we found that MEF promotes
the proliferation of bothmouse primary brain cultures and human
glioma cell lines, contributing to the pathogenesis of gliomas.rain cells grown in the above condition to favor differentiation. Positive staining
were taken from four different cell lines for each genotype,Mef/ andMef+/+);
reased Nestin and increased Olig2 and GFAP protein levels.
wn in neurosphere conditions. Scale bars indicate 100 mm.
rospheres when cultured in neurosphere conditions.
ty and pBabe-MEF retroviral vectors, cultured in neurosphere conditions. Bar
re conditions, formmore neurospheres compared to control. Bar graphs on the
in patient-derived human primary GBMs (GBM1, GBM3, and GBM543).
man primary GBMs (GBM1, GBM3, and GBM543) infected with pGipz control
ts performed in triplicate, unless otherwise specified. *p < 0.05; **p < 0.005;
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Figure 4. Sox2 Gene Is Regulated by MEF
(A and B) MEF overexpression in p53/ primary
brain cells as well as in U87MG and T98G human
glioma cell lines led to increased Sox2 expression.
Data are normalized to GAPDH expression.
(C and D) Lack of MEF decreases Sox2 expres-
sion. Data are normalized to GAPDH expression.
(E) Acute knockdown of MEF in p53/ primary
brain cells led to decreased Sox2 expression. Data
are normalized to GAPDH expression.
(F–H) Dual luciferase assays showing that MEF
activates Sox2 promoter in p53/ primary brain
cells as well as T98G and U87MG human glioma
cell lines.
(I) Sox2 overexpression in p53//Mef/ primary
brain cultures grown in neurosphere conditions
rescues their ability to form neurospheres. Scale
bar indicates 100 mm. Bar graph shows average
neurosphere number per field of view.
(J) ChIP experiments were performed on T98G
glioma cells using antibody to Flag. Plotted values
are relative enrichments (y axis) to 10% input and
measured for sites in the Sox2 promoter (x axis).
Antibody against IgG was used as a nonspecific
control.
Results are presented as mean ± SD from
a representative of three experiments performed in
triplicate. *p < 0.05; **p < 0.001; ***p < 0.0001
(Student’s t test). See also Figure S4.
Cell Stem Cell
MEF Role in Pathogenesis of GliomasAnother key feature of glioma malignancy is the activation of
neural and pluripotent stem cell gene expression signatures.
We found that mouse primary brain cells that lack MEF and
silencing of MEF in human primary glioblastoma stem-like cells
each lead to an impaired capacity to generate spheres, together
with an increased differentiation potential. Conversely, MEF
overexpression increases neurosphere formation of both mouse
primary brain cells and glioma cell lines. Collectively, our data
suggest that MEF plays a role in promoting stem-like traits,842 Cell Stem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier Inc.which might reflect changes in the stem
cell signature of both neoplastic and non-
neoplastic cells.
We have further implicated MEF in
promoting stem cell traits through direct
activation of Sox2 expression. The HMG-
box transcription factor Sox2 is known to
play an important role in maintaining
stem cell self-renewal within the central
nervous system (CNS) and this activity is
present in gliomas aswell (Pevny andNic-
olis, 2010). Sox2 has been described to
act as an oncogene in different human
cancers including gliomas. While the role
of Sox2 in normal brain and glioma cells
has been well documented, the transcrip-
tion factors that activate its expression in
these contexts are less clear (Denysenko
et al., 2010; Ikushima et al., 2009). We
identified Sox2 as a direct target of MEF
in mouse primary brain cells and human
glioma cell lines, because both acuteand chronic modulation of MEF levels affected Sox2 gene
expression and promoter activation. MEF directly binds to Sox2
promoter in T98Gglioma cells. We observed that overexpression
of Sox2 in p53//Mef/ cells was sufficient to rescue the
impaired ability of these cells to form neurospheres. Thus, our
data suggest that Sox2 is downstream of MEF and may be
responsible for its ability to modulate stem-like characteristics.
Given the cellular heterogeneity and molecular complexity of
gliomas, it is unclear in which contexts the stem cell property
Cell Stem Cell
MEF Role in Pathogenesis of Gliomasof self-renewal might represent a feature associated with
increased tumorigenic potential (Barrett et al., 2012). Addition-
ally, the so called ‘‘glioma stem-like cells’’ within different tumors
may vary in terms of proliferation rates, which might impact
their aggressiveness regardless of their self-renewal properties.
To date, it is often difficult to distinguish between the con-
tributions of proliferation versus self-renewal to the process of
gliomagenesis; nonetheless, self-renewal inevitably entails
proliferative events. Adding to the intricacy, acquisition of
reprogramming signals generated by alterations in specific
genes or pathways (Notch, Id1, Sox2, Oct4, etc.) might differen-
tially impact on these two diverse aspects.
Our work defines the role of MEF in promoting stem cell
features in both primary mouse brain cells and human glioblas-
toma cells via direct regulation of Sox2 expression, providing
insights into the multifaceted regulation of stemness. Further
work is necessary to better define the MEF/Sox2-mediated
acquisition of stem cell traits and whether it modulates the
response to chemotherapy and radiotherapy.
EXPERIMENTAL PROCEDURES
TCGA Analysis
TCGAdatawas downloaded from the TCGAData Portal (https://tcga-data.nci.
nih.gov/) or the cBio Cancer Genomics Portal (Cerami et al., 2012) (http://
cbioportal.org/). Subtype information was retrieved from Verhaak et al.
(2010). Low MEF expression in the TCGA data set was defined using the
median expression data (median of three platforms, see Verhaak et al.,
2010) as one standard deviation lower than the mean of all tumors. All other
analyses were performed using data from the Affymetrix U133 microarray
platform. Expression data was available for 195 tumors and 10 normal brain
samples (Table S1).
Generation of Primary Brain Cultures and Primary Brain
Neurosphere and Neurosphere Formation Assay
The Mef+/+, Mef/, p53/, and p53/Mef/ primary brain cultures were
prepared with mechanical dissociation of the whole brain from newborn
mice. The cells were then filtered through a 70 mm Nylon strainer and plated
in 10 cm culture dishes (with the procedure derived with minor modifications
from a previously described experimental method) (Dai et al., 2001). Mouse
primary brain cultures, as well as T98G and U87MG human glioma cell lines,
were plated at 20 cells/ml in neurosphere medium. Mouse primary brain neuro-
sphereswere isolated as previously described (Bleau et al., 2009) and plated at
different concentrations (10, 5, and 1 cell/ml). Human primary glioblastoma
neurospheres were freshly isolated from patients suffering from GBMs and
undergoing surgery at MSKCC. Primary GBM samples were dissociated,
plated at different concentrations (1, 0.5, 0.2, and 0.1 cells/ml) and grown in
neurosphere medium. Neurosphere medium consisted of NSC Basal Medium,
NSC proliferation supplements, 10 ng/ml EGF, 20 ng/ml basic-FGF, and 1 mg/
ml Heparin (Stem Cell Technologies, Vancouver, Canada). Neurosphere
number was established by counting the number of neurospheres per well
or, for U87MG and T98G, by taking pictures of the central part of the plates
and then counting the neurosphere number per field of view.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes four figures, Supplemental
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http://dx.doi.org/10.1016/j.ccr.2012.06.032SUMMARYRecurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative
neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic
and clinical data implicating ASXL1 mutations in myeloid malignancies, the mechanisms of transformation
by ASXL1 mutations are not understood. Here, we identify that ASXL1 mutations result in loss of polycomb
repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation. Through integration of
microarray data with genome-wide histonemodification ChIP-Seq data, we identify targets of ASXL1 repres-
sion, including the posterior HOXA cluster that is known to contribute to myeloid transformation. We demon-
strate that ASXL1 associates with the PRC2, and that loss of ASXL1 in vivo collaborates with NRASG12D to
promote myeloid leukemogenesis.INTRODUCTION
Recent genome-wide and candidate-gene discovery efforts
have identified a series of novel somatic genetic alterations in
patients with myeloid malignancies with relevance to pathogen-Significance
Mutations in genes involved in modification of chromatin have
malignancies. Here, we demonstrate a specific role for ASXL1,
malignancies, in polycomb repressive complex 2 (PRC2)-media
loss-of-function mutations in myeloid malignancies result in lo
genic target genes. Our data provide insight into how ASXL1m
regulation of Polycomb-mediated gene silencing. This approac
can be used to elucidate the function of mutations in epigenet
180 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.esis, prognostication, and/or therapy. Notably, these include
mutations in genes with known or putative roles in the epigenetic
regulation of gene transcription. One such example is the muta-
tions in the gene Addition of sex combs-like 1 (ASXL1), which
is mutated in z15%–25% of patients with myelodysplasticrecently been identified in patients with leukemias and other
a putative epigenetic modifier frequently mutated in myeloid
ted transcriptional repression in hematopoietic cells.ASXL1
ss of PRC2-mediated gene repression of known leukemo-
utations contribute to myeloid transformation through dys-
h also demonstrates how epigenomic and functional studies
ic modifiers in malignant transformation.
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiasyndrome and z10%–15% of patients with myeloproliferative
neoplasms and acute myeloid leukemia (Abdel-Wahab et al.,
2011; Bejar et al., 2011; Gelsi-Boyer et al., 2009). Clinical studies
have consistently indicated that mutations in ASXL1 are associ-
ated with adverse survival in myelodysplastic syndrome and
acute myeloid leukemia (Bejar et al., 2011; Metzeler et al.,
2011; Pratcorona et al., 2012; Thol et al., 2011).
ASXL1 is the human homolog of Drosophila Additional sex
combs (Asx). Asx deletion results in a homeotic phenotype char-
acteristic of both Polycomb (PcG) and Trithorax group (TxG)
gene deletions (Gaebler et al., 1999), which led to the hypothesis
that Asx has dual functions in silencing and activation of
homeotic gene expression. In addition, functional studies in
Drosophila suggested that Asx encodes a chromatin-associated
protein with similarities to PcG proteins (Sinclair et al., 1998).
More recently, it was demonstrated that Drosophila Asx forms
a complex with the chromatin deubiquitinase Calypso to form
the Polycomb-repressive deubiquitinase (PR-DUB) complex,
which removes monoubiquitin from histone H2A at lysine 119.
The mammalian homolog of Calypso, BAP1, directly associates
with ASXL1, and the mammalian BAP1-ASXL1 complex was
shown to possess deubiquitinase activity in vitro (Scheuermann
et al., 2010).
The mechanisms by which ASXL1 mutations contribute to
myeloid transformation have not been delineated. A series of
in vitro studies in non-hematopoietic cells have suggested
a variety of activities for ASXL1, including physical cooperativity
with HP1a and LSD1 to repress retinoic acid-receptor activity
and interaction with peroxisome proliferator-activated receptor
gamma (PPARg) to suppress lipogenesis (Cho et al., 2006; Lee
et al., 2010; Park et al., 2011). In addition, a recent study using a
gene-trap model reported that constitutive disruption of Asxl1
results in significant perinatal lethality; however, the authors
did not note alterations in stem/progenitor numbers in surviving
Asxl1 gene trap mice (Fisher et al., 2010a, 2010b). Importantly,
the majority of mutations in ASXL1 occur as nonsense mutations
and insertions/deletions proximal or within the last exon prior
to the highly conserved plant homeo domain. It is currently
unknown whether mutations in ASXL1 might confer a gain-of-
function due to expression of a truncated protein, or whether
somatic loss of ASXL1 in hematopoietic cells leads to specific
changes in epigenetic state, gene expression, or hematopoietic
functional output. The goals of this study were to determine the
effects of ASXL1 mutations on ASXL1 expression as well as the
transcriptional and biological effects of perturbations in ASXL1
which might contribute toward myeloid transformation.
RESULTS
ASXL1 Mutations Result in Loss of ASXL1 Expression
ASXL1 mutations in patients with myeloproliferative neoplasms,
myelodysplastic syndrome, and acute myeloid leukemia most
commonly occur as somatic nonsense mutations and inser-
tion/deletion mutations in a clustered region adjacent to the
highly conserved PHD domain (Abdel-Wahab et al., 2011;
Gelsi-Boyer et al., 2009). To assess whether these mutations
result in loss of ASXL1 protein expression or in expression of
a truncated isoform, we performed western blots using N- and
C-terminal anti-ASXL1 antibodies in a panel of human myeloidleukemia cell lines and primary acute myeloid leukemia samples,
which are wild-type or mutant for ASXL1. We found that myeloid
leukemia cells with homozygous frameshift/nonsense mutations
inASXL1 (NOMO1 and KBM5) have no detectable ASXL1 protein
expression (Figure 1A). Similarly, leukemia cells with heterozy-
gous ASXL1 mutations have reduced or absent ASXL1 protein
expression. Western blot analysis of ASXL1 using an N-terminal
anti-ASXL1 antibody in primary acute myeloid leukemia samples
wild-type and mutant for ASXL1 revealed reduced/absent full-
length ASXL1 expression in samples with ASXL1 mutations
compared to ASXL1 wild-type samples (Figure S1A available
online). Importantly, we did not identify truncated ASXL1 protein
products in mutant samples using N- or C-terminal directed anti-
bodies in primary acute myeloid leukemia samples or leukemia
cell lines. Moreover, expression of wild-type ASXL1 cDNA or
cDNA constructs bearing leukemia-associated mutant forms of
ASXL1 revealed reduced stability of mutant forms of ASXL1 rela-
tive to wild-type ASXL1, with more rapid degradation of mutant
ASXL1 isoforms following cycloheximide exposure (Figure S1B).
These data are consistent with ASXL1 functioning as a tumor
suppressor with loss of ASXL1 protein expression in leukemia
cells with mutant ASXL1 alleles.
ASXL1 Knockdown in Hematopoietic Cells Results
in Upregulated HOXA Gene Expression
Given that ASXL1 mutations result in loss of ASXL1 expression,
we investigated the effects of ASXL1 knockdown in primary
hematopoietic cells. We used a pool of small interfering RNAs
(siRNA) to perform knockdown of ASXL1 in primary human
CD34+ cells isolated from umbilical cord blood. ASXL1 knock-
down was performed in triplicate and confirmed by qRT-PCR
analysis (Figure 1B), followed by gene-expression microarray
analysis. Gene-set enrichment analysis (GSEA) of thismicroarray
data revealed a significant enrichment of genes found in a previ-
ously described gene expression signature of leukemic cells
from bone marrow of MLL-AF9 knock-in mice (Kumar et al.,
2009), as well as highly significant enrichment of a gene signa-
ture found in primary human cord blood CD34+ cells expressing
NUP98-HOXA9 (Figure S1C and Table S1) (Takeda et al., 2006).
Specifically, we found that ASXL1 knockdown in human primary
CD34+ cells resulted in increased expression of 145 genes out of
the 279 genes, which are overexpressed in the MLL-AF9 gene
expression signature (p < 0.05, FDR < 0.05). These gene expres-
sion signatures are characterized by increased expression of
posterior HOXA cluster genes, including HOXA5-9.
In order to ascertain whether loss of ASXL1 was associated
with similar transcriptional effects in leukemia cells, we per-
formed short hairpin RNA (shRNA)-mediated stable knockdown
of ASXL1 in the ASXL1-wild-type human leukemia cell lines
UKE1 (Figures 1C and 1D) and SET2 (Figure 1D) followed by
microarray and qRT-PCR analysis. Gene expression analysis in
UKE-1 cells expressing ASXL1 shRNA compared to control cells
revealed significant enrichment of the same HOXA gene expres-
sion signatures as were seen with ASXL1 knockdown in CD34+
cells (Figure 1C and Table S2). Upregulation of 50 HOXA genes
was confirmed by qRT-PCR in UKE1 (Figure 1D) cells and by
western blot analysis (Figure 1D) in SET2 cells expressing
ASXL1 shRNA compared to control. Quantitative mRNA profiling
(Nanostring nCounter) of the entire HOXA cluster revealedCancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc. 181
Figure 1. Leukemogenic ASXL1Mutations Are Loss-of-Function Mutations and ASXL1 Loss Is Associated with Upregulation of HOXA Gene
Expression
(A) Characterization of ASXL1 expression in leukemia cells with nonsense mutations in ASXL1 reveals loss of ASXL1 expression at the protein level in cells with
homozygous ASXL1 mutations as shown by western blotting using N- and C-terminal anti-ASXL1 antibodies.
(B) Displayed are the ASXL1-mutant cell line lines NOMO1 (homozygous ASXL1 R639X), K562 (heterozygous ASXL1 Y591Y/X), and KBM5 (homozygous ASXL1
G710X) and a panel ofASXL1-wild-type cell lines.ASXL1 siRNA in human primary CD34+ cells form cord blood results in upregulation ofHOXA5 andHOXA9with
ASXL1 knockdown (KD) as revealed by quantitative real-time PCR (qRT-PCR) analysis.
(C and D) Stable KD of ASXL1 in ASXL1-wild-type transformed human myeloid leukemia UKE1 cells (as shown by western blot) followed by GSEA reveals
significant enrichment of gene sets characterized by upregulation of 50 HOXA genes (C) as was confirmed by qRT-PCR (D). Statistical significance is indicated in
(D) by the p value and false-discovery rate (FDR). Similar upregulation of HOXA9 is seen by the western blot following stable ASXL1 KD in the ASXL1-wild-type
human leukemia SET2 cells.
Error bars represent standard deviation of expression relative to control. See also Figure S1 and Tables S1 and S2.
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiaupregulation of multiple HOXAmembers, including HOXA5, 7, 9,
and 10, in SET2 cells with ASXL1 knockdown compared to
control cells (Figure S1D). These results indicate consistent
upregulation of HOXA gene expression following ASXL1 loss in
multiple hematopoietic contexts.
ASXL1 Forms a Complex with BAP1 in Leukemia Cells,
but BAP1 Loss Does Not Upregulate HoxA Gene
Expression in Hematopoietic Cells
Mammalian ASXL1 forms a protein complex in vitro with the
chromatin deubiquitinase BAP1, which removes monoubiquitin
from histone H2A at lysine 119 (H2AK119) (Scheuermann et al.,
2010). In Drosophila loss of either Asx or Calypso resulted in
similar effects on genome-wide H2AK119 ubiquitin levels and
on target gene expression. Recent studies have revealed recur-
rent germline and somatic loss-of-function BAP1 mutations in
mesothelioma and uveal melanoma (Bott et al., 2011; Harbour
et al., 2010; Testa et al., 2011). However, we have not identified
BAP1mutations in patients with myeloproliferative neoplasms or182 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.acute myeloid leukemia (O.A.-W., J.P.P., and R.L.L., unpub-
lished data). Co-immunopreciptation studies revealed an asso-
ciation between ASXL1 and BAP1 in human myeloid leukemia
cells wild-type for ASXL1 but not in those cells mutant for
ASXL1 due to reduced/absent ASXL1 expression (Figure 2A).
Immunoprecipitation of FLAG-tagged wild-type ASXL1 and
FLAG-tagged leukemia-associated mutant forms of ASXL1 re-
vealed reduced interaction between mutant forms of ASXL1
and endogenous BAP1 (Figure S2A). Despite these findings,
BAP1 knockdown did not result in upregulation of HOXA5 and
HOXA9 in UKE1 cells, although a similar extent of ASXL1 knock-
down in the same cells reproducibly increased HOXA5 and
HOXA9 expression (Figure 2B). We obtained similar results
with knockdown of Asxl1 or Bap1 in the Ba/F3 murine hemato-
poietic cell line (Figure 2C). In Ba/F3 cells, knockdown of Asxl1
resulted in upregulated Hoxa9 gene expression commensurate
with the level of Asxl1 downregulation, whereas knockdown of
Bap1 does not impact Hoxa expression (Figure 2C). ASXL1
knockdown in SET-2 cells failed to reveal an effect of ASXL1
Figure 2. ASXL1 and BAP1 Physically
Interact in Human Hematopoietic Cells but
BAP1 Loss Does Not Result in Increased
HoxA Gene Expression
(A) Immunoprecipitation of BAP1 in a panel of
ASXL1-wild-type and mutant human myeloid
leukemia cells reveals co-association of ASXL1
and BAP1.
(B) Cells with heterozygous or homozygous
mutations inASXL1with reduced or absent ASXL1
expression have minimal interaction with BAP1
in vitro. BAP1 knockdown in the ASXL1/BAP1
wild-type human leukemia cell line UKE1 fails to
alter HOXA gene expression. In contrast, stable
knockdown of ASXL1 in the same cell type results
in a significant upregulation of HOXA9.
(C) Similar results are seen with knockdown of
Asxl1 or Bap1 in murine precursor-B lymphoid Ba/
F3 cells.
Error bars represent standard deviation of ex-
pression relative to control. See also Figure S2.
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fied histones from shRNA control and ASXL1 knockdown cells
(Figure S2B). By contrast, SET2 cells treated with MG132
(25 mM) had a marked decrease in H2AK119Ub, as has been
previously described (Dantuma et al., 2006). These data suggest
that ASXL1 loss contributes to myeloid transformation through
a BAP1-independent mechanism.
Loss of ASXL1 Is Associated with Global Loss
of H3K27me3
The results described above led us to hypothesize that ASXL1
loss leads to BAP1-independent effects on chromatin state
and on target gene expression. To assess the genome-wide
effects of ASXL1 loss on chromatin state, we performed chro-Cancer Cell 22, 180–193matin immunoprecipitation followed by
next generation sequencing (ChIP-seq)
for histone modifications known to be
associated with PcG [histone H3 lysine
27 trimethylation (H3K27me3)] or TxG
activity [histone H3 lysine 4 trimethylation
(H3K4me3)] in UKE1 cells expressing
empty vector or two independent vali-
dated shRNAs for ASXL1. ChIP-Seq data
analysis revealed a significant reduction
in genome-wide H3K27me3 transcrip-
tional start site occupancy with ASXL1
knockdown compared to empty vector
(p = 2.2 3 1016; Figure 3A). Approxi-
mately 20% of genes (n = 4,686) were
initially marked by H3K27me3 in their
promoter regions (defined as 1.5 kb
downstream and 0.5 kb upstream of
the transcriptional start site). Among
these genes, 27% had a 2-fold reduc-
tion in H3K27me3 (n = 1,309) and
66% had a 1.5-fold reduction in
H3K27me3 (n = 3,092), respectively,
upon ASXL1 knockdown. No significanteffect was seen on H3K4me3 transcriptional start site occu-
pancy with ASXL1 depletion (Figure 3A). We next evaluated
whether loss of ASXL1 might be associated with loss of
H3K27me3 globally by performing western blot analysis on
purified histones from UKE1 cells transduced with empty
vector or shRNAs for ASXL1 knockdown. This analysis revealed
a significant decrease in global H3K27me3 with ASXL1 loss
(Figure 3B), despite preserved expression of the core poly-
comb repressive complex 2 (PRC2) members EZH2, SUZ12,
and EED. Similar effects on total H3K27me3 levels were
seen following Asxl1 knockdown in Ba/F3 cells (Figure S3A).
These results demonstrate that ASXL1 depletion leads to a
marked reduction in genome-wide H3K27me3 in hematopoietic
cells., August 14, 2012 ª2012 Elsevier Inc. 183
Figure 3. ASXL1 Loss Is Associated with Loss of H3K27me3 and with Increased Expression of Genes Poised for Transcription
(A) ASXL1 loss is associated with a significant genome-wide decrease in H3K27me3 as illustrated by box plot showing the 25th, 50th, and 75th percentiles for
H3K27me3 and H3K4me3 enrichment at transcription start sites in UKE1 cells treated with an empty vector or shRNAs directed against ASXL1. The whiskers
indicate the most extreme data point less than 1.5 interquartile range from box and the red bar represents the median.
(B) Loss of ASXL1 is associated with a global loss of H3K27me3without affecting PRC2 component expression as shown bywestern blot of purified histones from
cells with UKE1 knockdown and western blot for core PRC2 component in whole cell lysates from ASXL1 knockdown UKE1 cells.
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ASXL1 Loss Inhibits PRC2 in Myeloid LeukemiaDetailed analysis of ChIP-seq data revealed that genomic
regions marked by large H3K27me3 domains in control cells
displayed more profound loss of H3K27me3 upon loss of
ASXL1. Genome-wide analysis of the ChIP-Seq data from
control and ASXL1 shRNA treated cells revealed that the sites
that lose H3K27me3 in the ASXL1 knockdown cells were on
average 6.6 kb in length, while the sites that maintained
H3K27me3 were on average 3.1 kb in length (p < 1016) (Fig-
ure S3B). This is visually illustrated by the reduction in
H3K27me3 at the posterior HOXA cluster (Figure 3C) and at
the HOXB and HOXC loci (Figure S3C). The association of
ASXL1 loss with loss of H3K27me3 abundance at the HOXA
locus was confirmed by ChIP for H3K27me3 in control and
ASXL1 knockdown cells followed by qPCR (ChIP-qPCR) across
the HOXA locus (Figure 3D). ChIP-qPCR in control and knock-
down cells revealed a modest increase in H2AK119Ub with
ASXL1 loss at the HOXA locus (Figure 3D), in contrast to the
more significant reduction in H3K27me3. In contrast to the
large decrease in H3K27me3 levels at the HOXA locus with
ASXL1 knockdown, a subset of loci had much less significant
reduction in H3K27me3, in particular at loci whose promoters
were marked by sharp peaks of H3K27me3 (Figure S3D). Inter-
section of gene expression and ChIP-Seq data revealed that
genes overexpressed in ASXL1 knockdown cells were simulta-
neously marked with both activating (H3K4me3) and repressive
(H3K27me3) domains in control cells (Figures 3E and 3F). This
finding suggests that the transcriptional repression mediated
by ASXL1 in myeloid cells is most apparent at loci poised for
transcription with bivalent chromatin domains. Indeed, the
effects of ASXL1 loss on H3K27me3 occupancy were most
apparent at genes whose promoters were marked by the dual
presence of H3K27me3 and H3K4me3 (Figure 3F). We cannot
exclude the possibility that H3K4me3 and H3K27me3 exist in
different populations within the homogeneous cell lines being
studied, but the chromatin and gene expression data are
consistent with an effect of ASXL1 loss on loci with bivalent
chromatin domains (Bernstein et al., 2006; Mikkelsen et al.,
2007).Enforced Expression of ASXL1 in Leukemic Cells
Results in Suppression of HOXA Gene Expression,
a Global Increase in H3K27me3, and Growth
Suppression
We next investigated whether reintroduction of wild-type
ASXL1 protein could restore H3K27me3 levels in ASXL1
mutant leukemia cells. We stably expressed wild-type ASXL1
in NOMO1 and KBM5 cells, homozygous ASXL1 mutant human(C) Loss of H3K27me3 is evident at the HOXA locus as shown by ChIP-Seq prom
shRNA knockdown of ASXL1.
(D) H3K27me3ChIP-Seq promoter track signals fromHOXA5 toHOXA13 in UKE1
primers used in ChIP-quantitative PCR (ChIP-qPCR) validation. ChIP for H3K27
ASXL1 knockdown confirms a significant decrease in H3K27me3 at the HOXA
H2AK119Ub levels at the same primer locations.
(E) Integrating gene-expression data with H3K27me3/H3K4me3ChIP-Seq identifi
in gene expression following ASXL1 loss at loci normally marked by the simultan
(F) Loss of H3K27me3 is seen at promoters normally marked by the presence of H
the control state.
See also Figure S3.leukemia cell lines, which do not express ASXL1 protein
(Figure 4A and Figure S4A). ASXL1 expression resulted in a
global increase in H3K27me3 as assessed by histone western
blot analysis (Figure 4A). Liquid chromotography/mass spec-
trometry of purified histones in NOMO1 cells expressing
ASXL1 confirmed a 2.5-fold increase in trimethylated H3K27
peptide and significant increases in dimethylated H3K27 in
NOMO1 cells expressing ASXL1 compared to empty vector
control (Figure 4B). ASXL1 add-back resulted in growth sup-
pression (Figure 4C) and in decreased HOXA gene expression
in NOMO1 cells (Figure 4D). ASXL1 add-back similarly resulted
in decreased expression of HOXA target genes in KBM5 cells
(Figures S4A and S4B). ChIP-qPCR revealed a strong enrich-
ment in ASXL1 binding at the HOXA locus in NOMO1 cells
expressing ASXL1, demonstrating that the HOXA locus is
a direct target of ASXL1 in hematopoietic cells (Figure 4E).ASXL1 Loss Leads to Exclusion of H3K27me3 and EZH2
from the HoxA Cluster Consistent with a Direct Effect of
ASXL1 on PRC2 Recruitment
We next investigated whether the effects of ASXL1 loss on
H3K27me3 was due to inhibition of PRC2 recruitment to
specific target loci. ChIP-qPCR for H3K27me3 in SET2
cells with ASXL1 knockdown or control revealed a loss of
H3K27me3 enrichment at the posterior HoxA locus with
ASXL1 knockdown (Figures 5A and 5B). We observed a
modest, variable increase in H3K4me3 enrichment at the
HOXA locus with ASXL1 depletion in SET2 cells (Figure 5C).
We similarly assessed H3K27me3 enrichment in primary bone
marrow leukemic cells from acute myeloid leukemia patients,
wild-type and mutant for ASXL1, which likewise revealed de-
creased H3K27me3 enrichment across the HOXA cluster in
primary acute myeloid leukemia samples with ASXL1
mutations compared to ASXL1-wild-type acute myeloid leu-
kemia samples (Figure 5D).
Given the consistent effects of ASXL1 depletion on
H3K27me3 abundance at the HOXA locus, we then evaluated
the occupancy of EZH2, a core PRC2 member, at the HoxA
locus. ChIP-Seq for H3K27me3 in native SET2 and UKE1 cells
identified that H3K27me3 is present with a dome-like enrich-
ment pattern at the 50 end of the posterior HOXA cluster (Fig-
ure 5A); ChIP-qPCR revealed that EZH2 is prominently enriched
in this same region in parental SET2 cells (Figure 5E). Impor-
tantly, ASXL1 depletion resulted in loss of EZH2 enrichment at
the HOXA locus (Figure 5E), suggesting that ASXL1 is required
for EZH2 occupancy and for PRC2-mediated repression of the
posterior HOXA locus.oter track signals across the HOXA locus in UKE1 cells treated with an EV or
cells treatedwith shRNA control or one of 2 anti-ASXL1 shRNAswith location of
me3 and H2AK119Ub followed by ChIP-qPCR in cells treated with control or
locus with ASXL1 knockdown but minimal effects of ASXL1 knockdown on
es a significant correlation between alterations in chromatin state and increases
eous presence of H3K27me3 and H3K4me3 in control cells.
3K27me3 alone or at promoters co-occupied by H3K27me3 and H3K4me3 in
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Figure 4. Expression of ASXL1 in ASXL1-Null Leukemic Cells Results in Global Increase in H3K27me2/3, Growth Suppression, and Suppres-
sion of HoxA Gene Expression
(A and B) ASXL1 expression in ASXL1 null NOMO1 cells is associated with a global increase in H3K27me3 as detected by western blot of purified histones (A) as
well as by quantitative liquid-chromatography/mass spectrometry of H3 peptides from amino acids 18–40 (B) (arrows indicate quantification of H3K27me1/2/3).
(C) ASXL1 overexpression results in growth suppression in 7-day growth assay performed in triplicate.
(D) Overexpression of ASXL1 was associated with a decrement in posteriorHoxA gene expression in NOMO1 cells as shown by qRT-PCR forHOXA5, 6, 7, and 9.
(E) This downregulation in HOXA gene expression was concomitant with a strong enrichment of ASXL1 at the loci of these genes as shown by chromatin
immunoprecipitation of ASXL1 followed by quantitative PCR with BCRRP1 as a control locus.
Error bars represent standard deviation of target gene expression relative to control. See also Figure S4.
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ASXL1 Loss Inhibits PRC2 in Myeloid LeukemiaASXL1 Physically Interacts with Members of the PRC2
in Human Myeloid Leukemic Cells
Given that ASXL1 localizes to PRC2 target loci and ASXL1 deple-
tion leads to loss of PRC2 occupancy and H3K27me2, we inves-
tigated whether ASXL1 might physically interact with the
PRC2 complex in hematopoietic cells. Co-immunoprecipitation
studies using an anti-FLAG antibody in HEK293T cells express-
ing empty vector, hASXL1-FLAG alone, or hASXL1-FLAG
plus hEZH2 cDNA revealed a clear co-immunoprecipitation of
FLAG-ASXL1 with endogenous EZH2 and with ectopically ex-
pressed EZH2 (Figure 6A). Similarly, co-immuniprecipitation of
FLAG-ASXL1 revealed physical association between ASXL1
and endogenous SUZ12 in 293T cells (Figure 6A). Immunopre-
cipitations were performed in the presence of benzonase to
ensure that the protein-protein interactions observed were
DNA-independent (Figure 6B) (Muntean et al., 2010).We then as-
sessed whether endogenous ASXL1 formed a complex with186 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.PRC2 members in hematopoietic cells. We performed IP for
EZH2 or ASXL1 followed by western blotting for partner proteins
in SET2 and UKE1 cells, which are wild-type for ASXL1, SUZ12,
EZH2, and EED. These co-immunoprecipitation assays all re-
vealed a physical association between ASXL1 and EZH2 in
SET2 (Figure 6B) and UKE1 cells (Figure S5). By contrast, immu-
noprecipitation of endogenous ASXL1 did not reveal evidence
of protein-protein interactions between ASXL1 and BMI1 (Fig-
ure S5). Likewise, immunoprecipitation of BMI1 enriched for
PRC1 member RING1A, but failed to enrich for ASXL1, suggest-
ing a lack of interaction between ASXL1 and the PRC1 repressive
complex (Figure 6C).
ASXL1 Loss Collaborates with NRasG12D In Vivo
We and others previously reported that ASXL1 mutations are
most common in chronic myelomonocytic leukemia and
frequently co-occur with N/K-Ras mutations in chronic
Figure 5. ASXL1 Loss Is Associated with
Loss of PRC2 Recruitment at the HOXA
Locus
(A) Chromatin-immunoprecipitation (ChIP) for
H3K27me3 and H3K4me3 followed by next-
generation sequencing reveals the abundance
and localization of H3K27me3 and H3K4me3 at
the HoxA locus in SET2 cells.
(B and C) ChIP for H3K27me3 (B) and H3K4me3
(C) followed by quantitative PCR (qPCR) across
the 50 HOXA locus in SET2 cells treated with an
empty vector or stable knockdown of ASXL1
reveals a consistent downregulation of H3K27me3
across the 50 HOXA locus following ASXL1 loss
and a modest increase in H3K4me3 at the
promoters of 50 HOXA genes with ASXL1 loss
[primer locations are shown in (A)].
(D) Similar ChIP for H3K27me3 followed by
qPCR across the HOXA locus in primary leu-
kemic blasts from two patients with ASXL1
mutations versus two without ASXL1 mutations
reveals H3K27me3 loss across the HOXA locus
in ASXL1 mutant cells.
(E) ChIP for EZH2 followed by qPCR at the 50 end
of HOXA locus in SET2 cells reveals loss of EZH2
enrichment with ASXL1 loss in SET2 cells. CHIP-
qPCR was performed in biologic duplicates and
ChIP-qPCR data is displayed as enrichment
relative to input. qPCR at the gene body of RRP1,
a region devoid of H3K4me3 or H3K27me3, is
utilized as a control locus.
The error bars represent standard deviation.
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ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiamyelomonocytic leukemia (Abdel-Wahab et al., 2011; Patel et al.,
2010). We therefore investigated the effects of combined
NRasG12D expression and Asxl1 loss in vivo. To do this, we
expressed NRasG12D in combination with an empty vector
expressing GFP alone or one of two different Asxl1 shRNA
constructs in whole bone marrow cells and transplanted theseCancer Cell 22, 180–193cells into lethally irradiated recipient
mice. We validated our ability to effec-
tively knock down ASXL1 in vivo by per-
forming qRT-PCR in hematopoietic cells
from recipient mice (Figure 7A and Fig-
ure S6A). Consistent with our in vitro
data implicating the HoxA cluster as an
ASXL1 target locus, we noted a marked
increase in HoxA9 and HoxA10 expres-
sion in bone marrow nucleated cells
from mice expressing NRasG12D in
combinationwith Asxl1 shRNAcompared
to mice expressing NRasG12D alone
(Figure 7B).
Expression of oncogenic NRasG12D
and an empty shRNA vector control led
to a progressive myeloproliferative
disorder as previously described (MacK-
enzie et al., 1999). In contrast, expression
of NRasG12D in combination with vali-
dated mASXL1 knockdown vectors re-sulted in accelerated myeloproliferation and impaired survival
compared with mice transplanted with NRasG12D/EV (median
survival 0.8 month for ASXL1 shRNA versus 3 months for control
shRNA vector: p < 0.005; Figure 7C) We also noted impaired
survival with an independent mASXL1 shRNA construct (p <
0.01; Figure S6B) Mice transplanted with NRasG12D/Asxl1, August 14, 2012 ª2012 Elsevier Inc. 187
Figure 6. ASXL1 Interacts with the PRC2 in Hematopoietic Cells
(A) Physical interaction between ASXL1 and EZH2 is demonstrated by transient transfection of HEK293T cells with FLAG-hASXL1 cDNA with or without hEZH2
cDNA followed by immunoprecipitation (IP) of FLAG epitope and western blotting for EZH2 and ASXL1.
(B) HEK293T cells were transiently transfected with FLAG-hASXL1 cDNA followed by IP of FLAG epitope and western blotting for SUZ12 and ASXL1. Endog-
enous interaction of ASXL1 with PRC2members was also demonstrated by IP of endogenous EZH2 and ASXL1 followed by western blotting of the other proteins
in whole cell lysates from SET2 cells.
(C) Lysates from the experiment shown in (B) were treated with benzonase to ensure nucleic acid free conditions in the lysates prior to IP as shown by ethidium
bromide staining of an agarose gel before and after benzonase treatment. IP of endogenous EZH2 and embryonic ectoderm development (EED) in a panel of
ASXL1-wild-type and mutant human leukemia cells reveals a specific interaction between ASXL1 and PRC2 members in ASXL1-wildype human myeloid
leukemia cells. In contrast, IP of the PRC1 member BMI1 failed to pull down ASXL1.
See also Figure S5.
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compared with NRasG12D/EV transplanted mice (Figures 7D
and 7E; Figure S6C). Histological analysis revealed a significant
increase in myeloid infiltration of the spleen and livers of
mice transplanted with NRasG12D/Asxl1 shRNA (Figure S6D).
Mice transplanted with NRasG12D/Asxl1 shRNA, but not
NRasG12D/EV, experienced progressive, severe anemia (Fig-
ure 7F). It has previously been identified that expression of onco-
genic K/N-Ras in multiple models of human/murine hematopoi-
etic systems results in alterations in the erythroid compartment
(Braun et al., 2006; Darley et al., 1997; Zhang et al., 2003). We
noted an expansion of CD71high/Ter119high erythroblasts in the
bonemarrow ofmice transplantedwithNRasG12D/Asxl1 shRNA
compared with NRasG12D/EV mice (Figure S6E). We also noted
increased granulocytic expansion in mice engrafted with
NRasG12D/Asxl1 shRNA positive cells, as shown by the pres-
ence of increased neutrophils in the peripheral blood (FigureS6D)
and the expansion of Gr1/Mac1 double-positive cells in the bone
marrow by flow cytometry (Figure S6F).
Previous studies have shown that hematopoietic cells from
mice expressing oncogenic Ras alleles or other mutations that
activate kinase signaling pathways do not exhibit increased
self-renewal in colony replating assays (Braun et al., 2004;
MacKenzie et al., 1999). This is in contrast to the immortalization
of hematopoietic cells in vitro seen with expression of MLL-AF9188 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.(Somervaille and Cleary, 2006) or deletion of Tet2 (Moran-Crusio
et al., 2011). Bone marrow cells from mice with combined over-
expression of NRasG12D plus Asxl1 knockdown had increased
serial replating (to five passages) compared to bone marrow
cells from mice engrafted with NRasG12D/EV cells (Figure 7G).
These studies demonstrate that Asxl1 loss cooperates with
oncogenic NRasG12D in vivo.
DISCUSSION
The data presented here identify that ASXL1 loss in hematopoi-
etic cells results in reduced H3K27me3 occupancy through inhi-
bition of PRC2 recruitment to specific oncogenic target loci.
Recent studies have demonstrated that genetic alterations in
the PRC2 complex occur in a spectrum of human malignancies
(Bracken and Helin, 2009; Margueron and Reinberg, 2011;
Sauvageau and Sauvageau, 2010). Activating mutations and
overexpression of EZH2 occur most commonly in epithelial
malignancies and in lymphoid malignancies (Morin et al., 2010;
Varambally et al., 2002). However, there are increasing genetic
data implicatingmutations that impair PRC2 function in the path-
ogenesis of myeloid malignancies. These include the loss-of-
function mutations in EZH2 (Abdel-Wahab et al., 2011; Ernst
et al., 2010; Nikoloski et al., 2010) and less common somatic
loss-of-function mutations in SUZ12, EED, and JARID2 (Score
Figure 7. Asxl1 Silencing Cooperates with
NRasG12D In Vivo
(A) Retroviral bone marrow transplantation of
NRasG12D with or without an shRNA for Asxl1
resulted in decreased Asxl1 mRNA expression as
shown by qRT-PCR results in nucleated peripheral
blood cells from transplanted mice at 14 days
following transplant.
(B) qRT-PCR revealed an increased expression
of HOXA9 and HOXA10 but not MEIS1 in the
bone marrow of mice sacrificed 19 days following
transplantation.
(C) Transplantation of bone marrow cells bear-
ing overexpression of NRasG12D in combination
with downregulation of Asxl1 led to a significant
hastening of death compared to mice transplanted
with NRasG12D/EV.
(D–F) Mice transplanted with NRasG12D/ASXL1
shRNA experienced increased splenomegaly (D)
and hepatomegaly (E), and progressive anemia
(F) compared with mice transplanted with
NRasG12D + an empty vector (EV).
(G) Bone marrow cells from mice with combined
NRasG12D overexpression/Asxl1 knockdown re-
vealed increased serial replating compared with
cells from NRasG12D/EV mice. Error bars repre-
sent standard deviation relative to control. Asterisk
indicates p < 0.05 (two-tailed, Mann Whitney
U test).
See also Figure S6.
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lodysplastic syndrome, and chronic myelomonocytic leukemia.
The data from genetically-engineered mice also support this
concept with Ezh2 overexpression models, revealing evidence
of promotion of malignant transformation (Herrera-Merchan
et al., 2012), and recent studies demonstrate a role for Ezh2
loss in leukemogenesis (Simon et al., 2012). Thus, it appears
that alterations in normal PRC2 activity and/or H3K27me3 abun-
dance in either direction may promote malignant transformation.
Our data implicate ASXL1 mutations as an additional genetic
alteration that leads to impaired PRC2 function in patients withCancer Cell 22, 180–19myeloid malignancies. In many cases,
patients present with concomitant
heterozygous mutations in multiple
PRC2 members or in EZH2 and ASXL1;
these data suggest that haploinsuffi-
ciency for multiple genes that regulate
PRC2 function can cooperate in hemato-
poietic transformation through additive
alterations in PRC2 function.
Many studies have investigated how
mammalian PcG proteins are recruited
to chromatin in order to repress gene
transcription and specify cell fate in
different tissue contexts. Recent in silico
analysis suggested that ASXL proteins
found in animals contain a number of
domains that likely serve in the recruit-
ment of chromatin modulators and tran-
scriptional effectors to DNA (Aravind andIyer, 2012). Data from ChIP and co-immunoprecipita-
tion experiments presented here suggest a specific role for
ASXL1 in epigenetic regulation of gene expression by facilitating
PRC2-mediated transcriptional repression of known leukemic
oncogenes. Thus, ASXL1may serve as a scaffold for recruitment
of the PRC2 complex to specific loci in hematopoietic cells, as
has been demonstrated for JARID2 in embryonic stem cells
(Landeira et al., 2010; Pasini et al., 2010; Peng et al., 2009;
Shen et al., 2009).
Recent data suggested that ASXL1 might interact with BAP1
to form a H2AK119 deubiquitanase (Scheuermann et al., 2010).3, August 14, 2012 ª2012 Elsevier Inc. 189
Cancer Cell
ASXL1 Loss Inhibits PRC2 in Myeloid LeukemiaHowever, our data suggest that ASXL1 loss leads to BAP1-
independent alterations in chromatin state and gene expression
in hematopoietic cells. These data are consonant with recent
genetic studies, which have shown that germline loss of BAP1
increases susceptibility to uveal melanoma and mesothelioma
(Testa et al., 2011; Wiesner et al., 2011). In contrast, germline
loss of ASXL1 is seen in the developmental disorder Bohring-
Opitz Syndrome (Hoischen et al., 2011), but has not, to date,
been observed as a germline solid tumor susceptibility locus.
Whether alterations in H2AK119 deubiquitanase function due
to alterations in BAP1 and/or ASXL1 can contribute to leukemo-
genesis or to the pathogenesis of other malignancies remains to
be determined.
Integration of gene expression and chromatin state data
following ASXL1 loss identified specific loci with a known role
in leukemogenesis that are altered in the setting of ASXL1muta-
tions. These include the posterior HOXA cluster, including
HOXA9, which has a known role in hematopoietic transforma-
tion. We demonstrate that ASXL1 normally serves to tightly regu-
late HOXA gene expression in hematopoietic cells, and that loss
of ASXL1 leads to disorderedHOXA gene expression in vitro and
in vivo. Overexpression of 50 HOXA genes is a well-described
oncogenic event in hematopoietic malignancies (Lawrence
et al., 1996), and previous studies have shown thatHOXA9 over-
expression leads to transformation in vitro and in vivo when
co-expressed with MEIS1 (Kroon et al., 1998). Interestingly,
ASXL1 loss was not associated with an increase in MEIS1
expression, suggesting that transformation by ASXL1mutations
requires the co-occurrence of oncogenic disease alleles which
dysregulate additional target loci. These data and our in vivo
studies suggest that ASXL1 loss, in combination with co-occurr-
ing oncogenes, can lead to hematopoietic transformation and
increased self-renewal. Further studies in mice expressing
ASXL1 shRNA or with conditional deletion of Asxl1 alone and
in concert with leukemogeneic disease alleles will provide addi-
tional insight into the role of ASXL1 loss in hematopoietic stem/
progenitor function and in leukemogenesis.
Given that somatic mutations in chromatin modifying enzymes
(Dalgliesh et al., 2010), DNAmethyltransferases (Ley et al., 2010),
and other genes implicated in epigenetic regulation occur
commonly in human cancers, it will be important to use epige-
nomic platforms to elucidate how these disease alleles con-
tribute to oncogenesis in different contexts. The data here
demonstrate how integrated epigenetic and functional studies
can be used to elucidate the function of somatic mutations in
epigenetic modifiers. In addition, it is likely that many known
oncogenes and tumor suppressors contribute, at least in part,
to transformation through direct or indirect alterations in the
epigenetic state (Dawson et al., 2009). Subsequent epigenomic
studies of human malignancies will likely uncover novel routes
to malignant transformation in different malignancies, and thera-
peutic strategies that reverse epigenetic alterations may be of
specific benefit in patientswithmutations in epigeneticmodifiers.EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and nonessential amino190 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.acids. Human leukemia cell lines were cultured in RPMI-1640 medium supple-
mented with 10% FBS+1 mM hydrocortisone+10% horse serum (UKE1 cells),
RPMI-1640 supplemented with 10% FBS (K562, MOLM13, KCL22, KU812
cells), RPMI-1640 supplemented with 20% FBS (SET2, NOMO1, Monomac-6
cells), or IMDM+20%FBS (KBM5 cells). For proliferation studies, 13 103 cells
were seeded in 1ml volume of media in triplicate and cell number was counted
manually daily for 7 days by Trypan blue exclusion.
Plasmid Constructs, Mutagenesis Protocol, Short Hairpin RNA, and
Small Interfering RNA
See Supplemental Information.
Primary Acute Myeloid Leukemia Patient Samples and ASXL1,
BAP1, EZH2, SUZ12, and EED Genomic DNA Sequencing Analysis
Approval was obtained from the institutional review boards at Memorial Sloan-
Kettering Cancer Center and at the Hospital of the University of Pennsylvania
for these studies, and informed consent was provided according to the Decla-
ration of Helsinki. Please see Supplemental Information for details on DNA
sequence analysis.
Western Blot and Immunoprecipitation Analysis
Western blots were carried out using the following antibodies: ASXL1 (Clone
N-13; Santa Cruz (sc-85283); N-terminus directed), ASXL1 (Clone 2049C2a;
Santa Cruz (sc-81053); C terminus directed), BAP1 [clone 3C11; Santa Cruz
(sc-13576)], BMI1 (Abcam ab14389), EED (Abcam ab4469), EZH2 (Active
Motif 39933 or Millipore 07-689), FLAG (M2 FLAG; Sigma A2220), Histone
H3 lysine 27 trimethyl (Abcam ab6002), Histone H2A Antibody II (Cell
Signaling Technologies 2578), Ubiquityl-Histone H2AK119 (Clone D27C4;
Cell Signaling Technologies 8240), RING1A (Abcam ab32807), SUZ12 (Abcam
ab12073), and total histone H3 (Abcam ab1791), and tubulin (Sigma, T9026).
Antibodies different from the above used for immunoprecipitation include:
ASXL1 [clone H105X; Santa Cruz (sc-98302)], FLAG (Novus Biological
Products; NBP1-06712), and EZH2 (Active Motif 39901). Immunoprecipitation
and pull-down reactions were performed in an immunoprecipitation buffer
(150 mM NaCl, 20 mM Tris (pH 7.4–7.5), 5 mM EDTA, 1% Triton, 100 mM
sodium orthovanadate, protease arrest (Genotec), 1 mM PMSF, and phenyl-
arsene oxide). To ensure nuclease-free immunoprecipitation conditions,
immunoprecipitations were also performed using the following methodology
(Muntean et al., 2010): cells were lysed in BC-300 buffer (20 mM Tris-
HCl (pH 7.4), 10% glycerol, 300 mM KCl, 0.1% NP-40) and the cleared lysate
was separated from the insoluble pellet and treated with MgCl2 to 2.5 mM and
benzonase (Emanuel Merck, Darmstadt) at a concentration of 1,250 U/ml. The
lysate was then incubated for 1–1.5 hr at 4. The reaction was then stopped
with addition of 5 mM EDTA. DNA digestion is confirmed on an ethidium
bromide agarose gel. We then set up our immunoprecipitation by incubating
our lysate overnight at 4.
Histone Extraction and Histone LC/MS Analysis
See Supplemental Information.
Gene Expression Analysis
Total RNA was extracted from cells using QIAGEN’s RNeasy Plus Mini kit
(Valencia, CA, USA). cDNA synthesis, labeling, hybridization, and quality
control were carried out as previously described (Figueroa et al., 2008). Ten
micrograms of RNA was then used for generation of labeled cRNA according
to the manufacturer’s instructions (Affymetrix, Santa Clara, CA, USA). Hybrid-
ization of the labeled cRNA fragments and washing, staining, and scanning of
the arrays were carried out as per instructions of the manufacturer. Labeled
cRNA from CD34+ cells treated with either ASXL1 siRNA or controls were
analyzed using the Affymetrix HG-U133-Plus2.0 platform and from UKE1 cells
using the Illumina Href8 array. All expression profile experiments were carried
out using biological duplicates. ‘‘Present’’ calls in R80% of samples were
captured and quantile normalized across all samples on a per-chip basis.
Raw expression values generated by Genome Studio (Illumina) were filtered
to exclude probesets having expression values below negative background
in R80% of samples. Probesets remaining after background filtering were
log-2 transformed and quantile normalized on a per-chip basis. qRT-PCR
was performed on cDNA using SYBR green quantification in an ABI 7500
Cancer Cell
ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiasequence detection system. The sequences of all qRT-PCR primers are listed
in the Supplemental Information.
Chromatin Immunoprecipitation and Antibodies
ChIP experiments for H3K4me3, H3K27me3, and H3K36me3 were carried
out as described previously (Bernstein et al., 2006; Mikkelsen et al., 2007).
Cells were cross-linked in 1% formaldehyde, lysed, and sonicated with
a Branson 250 Sonifier to obtain chromatin fragments in a size range
between 200 and 700 bp. Solubilized chromatin was diluted in ChIP dilution
buffer (1:10) and incubated with antibody overnight at 4C. Protein A
sepharose beads (Sigma) were used to capture the antibody-chromatin
complex and washed with low salt, LiCl, as well as TE (pH 8.0) wash
buffers. Enriched chromatin fragments were eluted at 65C for 10 min, sub-
jected to cross-link reversal at 65C for 5 hr, and treated with Proteinase K
(1 mg/ml), before being extracted by phenol-chloroform-isoamyl alcohol, and
ethanol precipitated. ChIP DNA was then quantified by QuantiT Picogreen
dsDNA Assay kit (Invitrogen). ChIP experiments for ASXL1 were carried
out on nuclear preps. Cross-linked cells were incubated in swelling buffer
(0.1 M Tris pH 7.6, 10 mM KOAc, 15 mM MgOAc, 1% NP40), on ice for
20 minutes, passed through a 16G needle 20 times and centrifuged to
collect nuclei. Isolated nuclei were then lysed, sonicated, and immu-
noprecipitated as described above. Antibodies used for ChIP include
anti-H3K4me3 (Abcam ab8580), anti-H3K27me3 (Upstate 07-449), anti-
H3K36me3 (Abcam ab9050), and anti-ASXL1 [clone H105X; Santa Cruz
(sc-98302)], and Ubiquityl-Histone H2AK119 (Clone D27C4; Cell Signaling
Technologies 8240).
Sequencing Library Preparation, Illumina/Solexa Sequencing, and
Read Alignment and Generation of Density Maps
See Supplemental Information.
HOXA Nanostring nCounter Gene Expression CodeSet
Direct digital mRNA analysis of HOXA cluster gene expression was performed
using a Custom CodeSet including each HOXA gene (NanoString Technolo-
gies). Synthesis of the oligonucleotides was done by NanoString Technolo-
gies, and hybridization and analysis were done using the Prep Station and
Digital Analyzer purchased from the company.
Animal Use, Retroviral Bone Marrow Transplantation, Flow
Cytometry, and Colony Assays
Animal care was in strict compliance with institutional guidelines established
by the Memorial Sloan-Kettering Cancer Center, the National Academy
of Sciences Guide for the Care and Use of Laboratory Animals, and the
Association for Assessment and Accreditation of Laboratory Animal Care
International. All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at Memorial Sloan-Kettering
Cancer Center. See Supplemental Information for more details on animal
experiments.
Statistical Analysis
Statistical significance was determined by the Mann-Whitney U test and
Fisher’s exact test using Prism GraphPad software. Significance of survival
differences was calculated using Log-rank (Mantel-Cox) test. p < 0.05 was
considered statistically significant. Normalized expression data from CD34+
cord blood was used as a Gene Set Enrichment Analysis query of the C2 data-
base (MSig DB) where 1,000 permutations of the genes was used to generate
a null distribution. A pre-ranked gene list, containing genes upregulated at
least log2 0.5-fold, in which the highest ranked genes corresponds to the
genes, with the largest fold-difference between Asxl1 hairpin-treated UKE1
cells and those treated with empty vector, was used to query the C2 MSig
DB as described above.
ACCESSION NUMBERS
All microarray data used in this manuscript are deposited in Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under GEO accession number
GSE38692. The ChIP-Seq data are deposited under GEO accession number
GSE38861.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.06.032.ACKNOWLEDGMENTS
This work was supported by a grant from the Starr Cancer Consortium to
R.L.L. and B.E.B., by grants from the Gabrielle’s Angel Fund to R.L.L. and
O.A.-W., by a grant from the Anna Fuller Fund to R.L.L., and by an NHLBI grant
to B.E.B. (5U01HL100395). I.A. and B.E.B. are Howard Hughes Medical Insti-
tute Early Career Scientists. A.M. is a Burroughs Wellcome Clinical Transla-
tional Scholar and Scholar of the Leukemia and Lymphoma Society. X.Z.
and S.D.N. are supported by a Leukemia and Lymphoma Society SCOR
award, and F.P. is supported by an American Italian Cancer Foundation award.
O.A.-W. is an American Society of Hematology Basic Research Fellow and is
supported by a grant from the NIH K08 Clinical Investigator Award
(1K08CA160647-01). J.P.P. is supported by an American Society of Hema-
tology Trainee Research Award.
Received: January 7, 2012
Revised: May 21, 2012
Accepted: June 28, 2012
Published: August 13, 2012REFERENCES
Abdel-Wahab, O., Pardanani, A., Patel, J., Wadleigh, M., Lasho, T., Heguy, A.,
Beran, M., Gilliland, D.G., Levine, R.L., and Tefferi, A. (2011). Concomitant
analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomono-
cytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25,
1200–1202.
Aravind, L., and Iyer, L.M. (2012). The HARE-HTH and associated domains:
Novel modules in the coordination of epigenetic DNA and protein modifica-
tions. Cell Cycle 11, 119–131.
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-
Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D., and Ebert,
B.L. (2011). Clinical effect of point mutations in myelodysplastic syndromes.
N. Engl. J. Med. 364, 2496–2506.
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry,
B., Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin struc-
ture marks key developmental genes in embryonic stem cells. Cell 125,
315–326.
Bott, M., Brevet, M., Taylor, B.S., Shimizu, S., Ito, T., Wang, L., Creaney, J.,
Lake, R.A., Zakowski, M.F., Reva, B., et al. (2011). The nuclear deubiquitinase
BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in
malignant pleural mesothelioma. Nat. Genet. 43, 668–672.
Bracken, A.P., and Helin, K. (2009). Polycomb group proteins: navigators of
lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773–784.
Braun, B.S., Tuveson, D.A., Kong, N., Le, D.T., Kogan, S.C., Rozmus, J., Le
Beau, M.M., Jacks, T.E., and Shannon, K.M. (2004). Somatic activation of
oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloprolifera-
tive disorder. Proc. Natl. Acad. Sci. USA 101, 597–602.
Braun, B.S., Archard, J.A., Van Ziffle, J.A., Tuveson, D.A., Jacks, T.E., and
Shannon, K. (2006). Somatic activation of a conditional KrasG12D allele
causes ineffective erythropoiesis in vivo. Blood 108, 2041–2044.
Cho, Y.S., Kim, E.J., Park, U.H., Sin, H.S., and Um, S.J. (2006). Additional sex
comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent
coactivator for retinoic acid receptor. J. Biol. Chem. 281, 17588–17598.
Dalgliesh, G.L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A.,
Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010). Systematic
sequencing of renal carcinoma reveals inactivation of histone modifying
genes. Nature 463, 360–363.Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc. 191
Cancer Cell
ASXL1 Loss Inhibits PRC2 in Myeloid LeukemiaDantuma, N.P., Groothuis, T.A., Salomons, F.A., and Neefjes, J. (2006). A
dynamic ubiquitin equilibrium couples proteasomal activity to chromatin re-
modeling. J. Cell Biol. 173, 19–26.
Darley, R.L., Hoy, T.G., Baines, P., Padua, R.A., and Burnett, A.K. (1997).
Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells.
J. Exp. Med. 185, 1337–1347.
Dawson, M.A., Bannister, A.J., Go¨ttgens, B., Foster, S.D., Bartke, T., Green,
A.R., and Kouzarides, T. (2009). JAK2 phosphorylates histone H3Y41 and
excludes HP1alpha from chromatin. Nature 461, 819–822.
Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V.,
Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., et al. (2010). Inactivatingmutations
of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet.
42, 722–726.
Figueroa, M.E., Reimers, M., Thompson, R.F., Ye, K., Li, Y., Selzer, R.R.,
Fridriksson, J., Paietta, E., Wiernik, P., Green, R.D., et al. (2008). An integrative
genomic and epigenomic approach for the study of transcriptional regulation.
PLoS One 3, e1882.
Fisher, C.L., Lee, I., Bloyer, S., Bozza, S., Chevalier, J., Dahl, A., Bodner, C.,
Helgason, C.D., Hess, J.L., Humphries, R.K., and Brock, H.W. (2010a).
Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb
group and genetically interacts with Cbx2 in mice. Dev. Biol. 337, 9–15.
Fisher, C.L., Pineault, N., Brookes, C., Helgason, C.D., Ohta, H., Bodner, C.,
Hess, J.L., Humphries, R.K., and Brock, H.W. (2010b). Loss-of-function
Additional sex combs-like1 mutations disrupt hematopoiesis but do not cause
severe myelodysplasia or leukemia. Blood 115, 38–46.
Gaebler, C., Stanzl-Tschegg, S., Heinze, G., Holper, B., Milne, T., Berger, G.,
and Ve´csei, V. (1999). Fatigue strength of locking screws and prototypes used
in small-diameter tibial nails: a biomechanical study. J. Trauma 47, 379–384.
Gelsi-Boyer, V., Trouplin, V., Ade´laı¨de, J., Bonansea, J., Cervera, N.,
Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009).
Mutations of polycomb-associated gene ASXL1 in myelodysplastic
syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145,
788–800.
Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A.,
Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010).
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330,
1410–1413.
Herrera-Merchan, A., Arranz, L., Ligos, J.M., de Molina, A., Dominguez, O.,
and Gonzalez, S. (2012). Ectopic expression of the histone methyltransferase
Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat
Commun 3, 623.
Hoischen, A., van Bon, B.W., Rodrı´guez-Santiago, B., Gilissen, C., Vissers,
L.E., de Vries, P., Janssen, I., van Lier, B., Hastings, R., Smithson, S.F.,
et al. (2011). De novo nonsense mutations in ASXL1 cause Bohring-Opitz
syndrome. Nat. Genet. 43, 729–731.
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A.M., and
Sauvageau, G. (1998). Hoxa9 transforms primary bone marrow cells through
specific collaboration with Meis1a but not Pbx1b. EMBO J. 17, 3714–3725.
Kumar, A.R., Li, Q., Hudson, W.A., Chen, W., Sam, T., Yao, Q., Lund, E.A., Wu,
B., Kowal, B.J., and Kersey, J.H. (2009). A role for MEIS1 in MLL-fusion gene
leukemia. Blood 113, 1756–1758.
Landeira, D., Sauer, S., Poot, R., Dvorkina, M., Mazzarella, L., Jørgensen, H.F.,
Pereira, C.F., Leleu, M., Piccolo, F.M., Spivakov, M., et al. (2010). Jarid2 is
a PRC2 component in embryonic stem cells required for multi-lineage differen-
tiation and recruitment of PRC1 and RNA Polymerase II to developmental
regulators. Nat. Cell Biol. 12, 618–624.
Lawrence, H.J., Sauvageau, G., Humphries, R.K., and Largman, C. (1996). The
role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem
Cells 14, 281–291.
Lee, S.W., Cho, Y.S., Na, J.M., Park, U.H., Kang, M., Kim, E.J., and Um, S.J.
(2010). ASXL1 represses retinoic acid receptor-mediated transcription
through associating with HP1 and LSD1. J. Biol. Chem. 285, 18–29.192 Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc.Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E.,
Kandoth, C., Payton, J.E., Baty, J., Welch, J., et al. (2010). DNMT3A mutations
in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433.
MacKenzie, K.L., Dolnikov, A., Millington, M., Shounan, Y., and Symonds, G.
(1999). Mutant N-ras induces myeloproliferative disorders and apoptosis in
bone marrow repopulated mice. Blood 93, 2043–2056.
Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its
mark in life. Nature 469, 343–349.
Metzeler, K.H., Becker, H., Maharry, K., Radmacher, M.D., Kohlschmidt, J.,
Mro´zek, K., Nicolet, D., Whitman, S.P., Wu, Y.Z., Schwind, S., et al. (2011).
ASXL1 mutations identify a high-risk subgroup of older patients with primary
cytogenetically normal AML within the ELN Favorable genetic category.
Blood 118, 6920–6929.
Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G.,
Alvarez, P., Brockman, W., Kim, T.K., Koche, R.P., et al. (2007). Genome-wide
maps of chromatin state in pluripotent and lineage-committed cells. Nature
448, 553–560.
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D.,
Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., et al.
(2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal
and myeloid transformation. Cancer Cell 20, 11–24.
Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R.,
Paul, J.E., Boyle, M., Woolcock, B.W., Kuchenbauer, F., et al. (2010).
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large
B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185.
Muntean, A.G., Tan, J., Sitwala, K., Huang, Y., Bronstein, J., Connelly, J.A.,
Basrur, V., Elenitoba-Johnson, K.S., and Hess, J.L. (2010). The PAF complex
synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
Cancer Cell 17, 609–621.
Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M.,
To¨nnissen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de
Witte, T., et al. (2010). Somatic mutations of the histone methyltransferase
gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665–667.
Park, U.H., Yoon, S.K., Park, T., Kim, E.J., and Um, S.J. (2011). Additional sex
comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via
reciprocal regulation of peroxisome proliferator-activated receptor gamma.
J. Biol. Chem. 286, 1354–1363.
Pasini, D., Cloos, P.A., Walfridsson, J., Olsson, L., Bukowski, J.P., Johansen,
J.V., Bak,M., Tommerup, N., Rappsilber, J., and Helin, K. (2010). JARID2 regu-
lates binding of the Polycomb repressive complex 2 to target genes in ES cells.
Nature 464, 306–310.
Peng, J.C., Valouev, A., Swigut, T., Zhang, J., Zhao, Y., Sidow, A., and
Wysocka, J. (2009). Jarid2/Jumonji coordinates control of PRC2 enzymatic
activity and target gene occupancy in pluripotent cells. Cell 139, 1290–1302.
Pratcorona, M., Abbas, S., Sanders, M., Koenders, J., Kavelaars, F.,
Erpelinck-Verschueren, C., Zeilemaker, A., Lowenberg, B., and Valk, P.
(2012). Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence
and prognostic value. Haematologica 97, 388–392.
Sauvageau, M., and Sauvageau, G. (2010). Polycomb group proteins: multi-
faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7,
299–313.
Scheuermann, J.C., de Ayala Alonso, A.G., Oktaba, K., Ly-Hartig, N., McGinty,
R.K., Fraterman, S., Wilm, M., Muir, T.W., and Mu¨ller, J. (2010). Histone H2A
deubiquitinase activity of the Polycomb repressive complex PR-DUB.
Nature 465, 243–247.
Score, J., Hidalgo-Curtis, C., Jones, A.V., Winkelmann, N., Skinner, A., Ward,
D., Zoi, K., Ernst, T., Stegelmann, F., Dohner, K., et al. (2012). Inactivation of
polycomb repressive complex 2 components in myeloproliferative and myelo-
dysplastic/myeloproliferative neoplasms. Blood 119, 1208–1213.
Shen, X., Kim, W., Fujiwara, Y., Simon, M.D., Liu, Y., Mysliwiec, M.R., Yuan,
G.C., Lee, Y., and Orkin, S.H. (2009). Jumonji modulates polycomb activity
and self-renewal versus differentiation of stem cells. Cell 139, 1303–1314.
Simon, C., Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S.,
Boucher, G., Chagnon, P., Drouin, S., Lambert, R., et al. (2012). A key role
Cancer Cell
ASXL1 Loss Inhibits PRC2 in Myeloid Leukemiafor EZH2 and associated genes in mouse and human adult T-cell acute
leukemia. Genes Dev. 26, 651–656.
Sinclair, D.A., Milne, T.A., Hodgson, J.W., Shellard, J., Salinas, C.A., Kyba, M.,
Randazzo, F., and Brock, H.W. (1998). The Additional sex combs gene of
Drosophila encodes a chromatin protein that binds to shared and unique
Polycomb group sites on polytene chromosomes. Development 125, 1207–
1216.
Somervaille, T.C., and Cleary, M.L. (2006). Identification and characterization
of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer
Cell 10, 257–268.
Takeda, A., Goolsby, C., and Yaseen, N.R. (2006). NUP98-HOXA9 induces
long-term proliferation and blocks differentiation of primary human CD34+
hematopoietic cells. Cancer Res. 66, 6628–6637.
Testa, J.R., Cheung, M., Pei, J., Below, J.E., Tan, Y., Sementino, E., Cox, N.J.,
Dogan, A.U., Pass, H.I., Trusa, S., et al. (2011). Germline BAP1 mutations
predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025.Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E.M., Krauter, J., Wagner,
K., Chaturvedi, A., Sharma, A., Wichmann, M., et al. (2011). Prognostic signif-
icance of ASXL1 mutations in patients with myelodysplastic syndromes.
J. Clin. Oncol. 29, 2499–2506.
Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha,
C., Sanda, M.G., Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, A.P., et al.
(2002). The polycomb group protein EZH2 is involved in progression of pros-
tate cancer. Nature 419, 624–629.
Wiesner, T., Obenauf, A.C., Murali, R., Fried, I., Griewank, K.G., Ulz, P.,
Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011). Germline
mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018–
1021.
Zhang, J., Socolovsky, M., Gross, A.W., and Lodish, H.F. (2003). Role of Ras
signaling in erythroid differentiation of mouse fetal liver cells: functional anal-
ysis by a flow cytometry-based novel culture system. Blood 102, 3938–3946.Cancer Cell 22, 180–193, August 14, 2012 ª2012 Elsevier Inc. 193
DOI: 10.1126/science.1201662
, 765 (2011);333 Science
 et al.Lan Wang
Lysine Acetylation
The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific
 This copy is for your personal, non-commercial use only.
 clicking here.colleagues, clients, or customers by 
, you can order high-quality copies for yourIf you wish to distribute this article to others
 
 here.following the guidelines 
 can be obtained byPermission to republish or repurpose articles or portions of articles
 
 ): February 26, 2013 www.sciencemag.org (this information is current as of
The following resources related to this article are available online at
 http://www.sciencemag.org/content/333/6043/765.full.html
version of this article at: 
including high-resolution figures, can be found in the onlineUpdated information and services, 
http://www.sciencemag.org/content/suppl/2011/07/13/science.1201662.DC1.html 
can be found at: Supporting Online Material 
 http://www.sciencemag.org/content/333/6043/765.full.html#related
found at:
can berelated to this article A list of selected additional articles on the Science Web sites 
 http://www.sciencemag.org/content/333/6043/765.full.html#ref-list-1
, 14 of which can be accessed free:cites 29 articlesThis article 
 http://www.sciencemag.org/content/333/6043/765.full.html#related-urls
6 articles hosted by HighWire Press; see:cited by This article has been 
 http://www.sciencemag.org/cgi/collection/medicine
Medicine, Diseases
subject collections:This article appears in the following 
registered trademark of AAAS. 
 is aScience2011 by the American Association for the Advancement of Science; all rights reserved. The title 
CopyrightAmerican Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 
(print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by theScience 
 
o
n
 F
eb
ru
ar
y 
26
, 2
01
3
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
Cellulose-, pectin-, and hemicellulose-degrading
enzymes (GH families 5, 61, 3, and 28) were
prominent, and GH5 endoglucanase (S. lacrymans
S7.9 database protein ID, 433209) and GH74
endoglucanase/xyloglucanase (S. lacrymans S7.9
database protein ID, 453342) were up-regulated
greater than 100-fold.
We conclude that brown rot fungi have cast off
the energetically expensive apparatus of lignin-
olysis and acquired alternative mechanisms of ini-
tial attack. Wood decomposition by S. lacrymans
may involve metabolically driven nonenzymatic
disruption of lignocellulose with internal breakage
of cellulose chains by highly localized ∙OH radical
action. Mycelia in split plates mimicking realistic
nutrient heterogeneity (fig. S1) produced variegatic
acid (VA), an iron-reducing phenolate (Fig. 2, A
to C), via the Boletales atromentin pathway, which
was recruited in S. lacrymans for the Fenton’s re-
action. The genome was rich in secondary metab-
olism genes (table S15), including a putative
atromentin locus (24). Mycelium imports amino
acids to sites of wood colonization (25), which is
consistent with observed up-regulation of oligo-
peptide transporters on wood (table S12). Local-
izing variegatic acid production towell-resourced
parts of the mycelium could enhance Fenton’s
chemistry in contact with wood.
Wood colonization is presumably followed
by coordinated induction of the decay machin-
ery revealed in the wood-induced transcriptome
(Fig. 3 and fig. S4). GHs and oxidoreductases
accounted for 20.7% of transcripts, accumulating
greater than fourfold on wood relative to glucose
medium (fig. S4 and table S12). Iron reduction
mechanisms included an enzyme harboring a
C terminal cellulose-binding module (S. lacrymans
S7.9 database protein ID, 452187) (fig. S5)
that is up-regulated 122-fold on wood substrate
(fig. S4 and table S12). This enzyme, which is
present in Ph. chrysosporium but absent from
P. placenta (26), is a potential docking mecha-
nism for localizing iron reductase activity, and
hence ∙OH generation, on the surface of micro-
crystalline cellulose. Cellulose-targeted iron re-
duction, combined with substrate induction of
variegatic acid biosynthesis, might explain the
particular ability of brown rot fungi in Boletales
to degrade unassociated microcrystalline cellu-
lose without the presence of lignin (27).
Thus, comparative genomics helps us under-
stand the molecular processes of forest soil
fungi that drive the element cycles of forest bi-
omes (28). Sequenced forest Agaricomycetes
revealed shared patterns of gene family contrac-
tions and expansions associated with emergences
of both brown rot saprotrophy and ectomycor-
rhizal symbiosis. In Boletales, loss of aggressive
ligninolysis might have permitted brown rot tran-
sitions to biotrophic ectomycorrhiza, which is pro-
moted in soils impoverished in nitrogen by brown
rot residues, and by the nutritional advantage con-
ferred by the connection to a mycorrhizal net-
work. S. lacrymans and other fungi cultured with
conifer roots (29) ensheath Pinus sylvestris roots
with a mantle-like layer (fig. S6), suggesting nu-
trient exchange.
The chronology of divergences in extant fungal
nutritional mode (Fig. 1A) matches the predicted
major diversification in conifers (18), suggesting
that the boreal forest biome may have origi-
nated via genetic coevolution of above- and below-
ground biota.
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The Leukemogenicity of AML1-ETO
Is Dependent on Site-Specific
Lysine Acetylation
Lan Wang,1 Alexander Gural,1 Xiao-Jian Sun,2 Xinyang Zhao,1 Fabiana Perna,1 Gang Huang,1
Megan A. Hatlen,1 Ly Vu,1 Fan Liu,1 Haiming Xu,1 Takashi Asai,1 Hao Xu,1 Tony Deblasio,1
Silvia Menendez,1 Francesca Voza,1 Yanwen Jiang,3 Philip A. Cole,4 Jinsong Zhang,5
Ari Melnick,3 Robert G. Roeder,2 Stephen D. Nimer1*
The chromosomal translocations found in acute myelogenous leukemia (AML) generate
oncogenic fusion transcription factors with aberrant transcriptional regulatory properties.
Although therapeutic targeting of most leukemia fusion proteins remains elusive, the
posttranslational modifications that control their function could be targetable. We found that
AML1-ETO, the fusion protein generated by the t(8;21) translocation, is acetylated by the
transcriptional coactivator p300 in leukemia cells isolated from t(8;21) AML patients, and that this
acetylation is essential for its self-renewal–promoting effects in human cord blood CD34+ cells
and its leukemogenicity in mouse models. Inhibition of p300 abrogates the acetylation of
AML1-ETO and impairs its ability to promote leukemic transformation. Thus, lysine
acetyltransferases represent a potential therapeutic target in AML.
Histone-modifying enzymes can regulatethe binding of specific chromatin-bindingproteins to histone marks and can change
the affinity of the histones for DNA (1, 2). These
enzymes also affect nonhistone proteins, and
posttranslational modifications of transcription
factors such as p53 or AML1 (which is required
for definitive hematopoietic development) can
www.sciencemag.org SCIENCE VOL 333 5 AUGUST 2011 765
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regulate their protein-protein interactions and
their activity (1–3). For instance, p300 binds to the
C terminus of AML1 and acetylates its N ter-
minus, promoting its activating function (4, 5).
When AML1 is fused to ETO (a nuclear protein
that interacts with co-repressor molecules) by the
t(8;21) translocation, the p300-binding region
of AML1 is lost from the AML1-ETO fusion
protein (hereafter abbreviated as A-E).
Studies of hematopoietic development and
specific gene promoter function indicate that A-E
is generally considered to act as a transcription re-
pressor via recruitment of co-repressors (such
as NCoR and SMRT) and histone deacetylases
(6–8). Although A-E also up-regulates target gene
expression (9, 10), information about the mech-
anisms of gene activation or the importance of
the up-regulated genes is sparse. We have shown
that the NHR1 domain in A-E binds HEB, a class
I basic helix-loop-helix protein (i.e., an E protein)
(11). To explore the importance of this domain to
the leukemia-promoting properties of A-E, we
compared the effects of “wild-type”A-Ewith those
of the A-E ∆NHR1 construct (which lacks amino
acids 245 to 436) on the self-renewal and differ-
entiation potential of human CD34+ hematopoi-
etic stem/progenitor cells (HSPCs) isolated from
cord blood.
After confirming the expression of Flag-tagged
A-E and A-E ∆NHR1 by Western blotting (fig.
S1A), we examined HSPC self-renewal with the
use of CAFC (cobblestone area-forming cell) as-
says (12, 13). Unlike A-E, A-E ∆NHR1 did not
increase the number of CAFCs present at week 5
(Fig. 1A and fig. S3C), nor did it promote the
maintenance of CD34+ HSPCs growing in liquid
culture (5.1% for A-E ∆NHR1 versus 22.1% for
A-E and 3.7% for the MIGR1 control); these find-
ings indicate the essential role of theNHR1 (amino
acids 245 to 436) domain in the self-renewal–
promoting effects of A-E in this model (Fig. 1B
and fig. S1B).
To determine whether the NHR1 domain is
required for the inhibitory effect of A-E on dif-
ferentiation, we grew A-E ∆NHR1–transduced
cells in liquid culture with erythroid or myeloid
differentiation–promoting cytokines for 9 days.
Both the A-E– and A-E ∆NHR1–expressing cells
showed a similar decrease in glycophorin A,
CD71, and CD11b expression (fig. S1C). Thus,
loss of the NHR1 domain affects the self-renewal
signals provided by A-E, but not the delay (or
block) in myelo-erythroid differentiation.
To investigate how the NHR1 domain of A-E
promotes self-renewal, we used microarray-based
expression assays to compare the transcriptome
of the A-E– and A-E ∆NHR1–transduced hu-
man HSPCs (versus control MIGR1-transduced
HSPCs). Several potential regulators of HSC
1Molecular Pharmacology and Chemistry Program, Sloan-
Kettering Institute, Memorial Sloan-Kettering Cancer Center,
New York, NY 10065, USA. 2Laboratory of Biochemistry and
Molecular Biology, Rockefeller University, 1230 York Avenue,
New York, NY 10065, USA. 3Division of Hematology/Oncology,
Department of Medicine, Weill Cornell Medical College, New
York, NY 10065, USA. 4Department of Pharmacology and Mo-
lecular Sciences, Johns Hopkins University School of Medicine,
Baltimore, MD 21205, USA. 5Department of Cancer and Cell
Biology, University of Cincinnati College of Medicine, 3125
Eden Avenue, Cincinnati, OH 45267, USA.
*To whom correspondence should be addressed. E-mail:
nimers@mskcc.org
Fig. 1. The enhanced self-renewal capacity and transcriptional activation induced by A-E in human
HSPCs requires the NHR1 domain. (A) The NHR1 domain (amino acids 245 to 436) is required for A-E
to increase CAFC formation by human CD34+ cells transduced with the indicated retroviral vector. The
number of cobblestone areas at week 5 is shown (T SD; n = 3). (B) Deletion of NHR1 affects the ability
of A-E to promote self-renewal in liquid culture. CD34 expression was examined weekly in MIGR1-,
A-E–, and A-E ∆NHR1–transduced human CD34+ cells (TSD; n = 3). (C) M-CSFR, GM-CSF, and IL-3
promoter activity was examined in cells transfected with MIGR1, A-E, or A-E ∆NHR1 (T SD; n = 3). All
values were standardized to the level of Renilla luciferase activity.
Fig. 2. The NHR1 domain of A-E interacts with p300, which potentiates its transcriptional activating
properties. (A) The NHR1 domain is required for the interaction of A-E with p300. An antibody to Flag
was used for immunoprecipitation (IP); antibodies to p300 or Flag were used for Western blotting (WB).
(B) AE9a also interacts with p300. An antibody to hemagglutinin (HA) was used for immunoprecip-
itation; antibodies to p300 or HA were used for Western blotting. (C) Knockdown of p300 decreased the
expression of A-E–activated target genes. Kasumi-1 cells were transduced with shRNAs against p300 or
a control shRNA. Quantitative polymerase chain reaction (qPCR) was performed to quantify the level of
target gene expression (T SD; n = 3). (D) A-E and p300 colocalize on some A-E up-regulated genes, as
shown by ChIP-seq assays. Representative examples of A-E and p300 co-occupancy are shown as custom
tracks in the UCSC genome browser. The locations of the Runx1 consensus binding sites are shown by
green lines on the x axis. DNA binding was also analyzed by qPCR amplification of the regions indicated
by the red and green arrows on the x axis (T SD; n = 3).
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self-renewal (Id1, p21, and Egr1) were up-regulated
by A-E but not by A-E ∆NHR1 (14–16) (fig. S3E).
Similarly, A-E ∆NHR1 was much less transactivat-
ing than A-E on theM-CSFR promoter (Fig. 1C)
(17). In contrast, the differentiation-promoting
genes,C/EBPa andPU.1, that are down-regulated
by A-E are still down-regulated by A-E∆NHR1
(18, 19) (fig. S3E), and both the IL-3 and GM-CSF
promoters were similarly down-regulated by A-E
and A-E ∆NHR1 (Fig. 1C). These results suggest
that the NHR1 domain is required for transcrip-
tional activation but not repression by A-E, and is
required for the effects of A-E on self-renewal
but not differentiation.
We next examined whether A-E directly binds
p300. Baculovirus-expressed A-E and p300 di-
rectly interact in vitro (fig. S6B), and an antibody
to ETO coimmunoprecipitated the endogenous
A-E and p300 proteins in human Kasumi-1 leu-
kemia cells, which do not express ETO (fig. S6B).
We generated several A-E or ETO deletion mu-
tants in order to map the p300-binding domain in
A-E (Fig. 2A and fig. S1D). Both A-E and ETO
bound p300, and although deletions of the NHR2
domain in either ETO or A-E had no effect on
p300 binding, deletion of theNHR1 domain (ami-
no acids 245 to 436) completely abrogated this
binding (Fig. 2A and fig. S1D). Furthermore,
the A-E exon 9a protein, an alternatively spliced
form of A-E that lacks NHR3 and NHR4 (de-
picted in fig. S2A), also interacts with p300 (Fig.
2B). Given that ETO can bind both co-repressor
molecules and p300, ETOmay function as a fast-
response adaptor protein, inducing transcriptional
activation or repression depending on the signal-
ing pathways activated in the cell.
To determine whether p300 is important for
the up-regulation of A-E target gene expression,
we knocked down p300 inKasumi-1 cells with the
use of two different short hairpin RNAs (shRNAs);
we found significant decreases in the levels of Id1,
p21, and Egr1mRNA but no change in the levels
of C/EBPa or PU.1mRNA (Fig. 2C), indicating
that p300 is essential for A-E–mediated transcrip-
tional activation. To identify genes potentially reg-
ulated by A-E and p300, we performed ChIP-seq
(chromatin immunoprecipitation sequencing) as-
says using antibodies to p300 and ETO and the
A-E–expressing Kasumi-1 cells. We found that the
promoters of the Id1, p21, and Egr1 genes (genes
activated by A-E) were co-occupied by A-E and
p300 (Fig. 2D and fig. S5C). In contrast, p300
did not colocalize with A-E at the promoter (or en-
hancer) of the C/EBPa gene, which is repressed
by A-E (Fig. 2D and fig. S5C). Thus, p300 can
contribute to the ability of A-E to function as a
transcriptional activator, and both can target sim-
ilar transcriptional regulatory regions.
Given that p300 acetylates a variety of protein
targets, we examined whether A-E is acetylated
by p300 by overexpressingA-E and p300 in 293T
cells. A-E, but not ETO, was acetylated by p300,
localizing the potential acetylation sites to the
AML1 portion of A-E (amino acids 1 to 177)
(fig. S1E). Deletion of the Runt domain (amino
acids 49 to 177) did not affect A-E acetylation
(fig. S1E), leaving Lys24 and Lys43 as the only
candidate acetylation sites (fig. S2A). We mu-
tated Lys24 and Lys43 to arginine, separately and
together (i.e., K24R, K43R, and K24R/K43R),
and then used an antibody to acetyl lysine to
confirm that both Lys24 and Lys43 are acetylated
by p300 (Fig. 3A). As predicted, acetylation of
Lys43 was abrogated after deletion of the NHR1
domain (amino acids 245 to 436), the region re-
sponsible for the A-E/p300 interaction (Fig. 3B).
The Lys24 and Lys43 residues are highly conserved
in other vertebrates (fig. S2B), which suggests
that their acetylation may be conserved through-
out evolution.
To define how acetylation of A-E affects its
functions, we compared the effects of “wild-type”
A-E and the A-E K24R, K43R, and K24R/K43R
mutant proteins on the in vitro behavior of trans-
duced human HSPCs (fig. S3A). Like A-E, A-E
K24R increased the number of CAFCs present at
week 5, whereas A-E K43R and A-E K24R/K43R
did not (fig. S3, B and C). The K43R mutation
also abrogated the effect of A-E on self-renewal,
whereas the A-E K24R mutant protein retained
this effect (fig. S3D). Thus, acetylation of A-E
at Lys43 is essential for its self-renewal–promoting
effects in human HSPCs [and for its effects on
the self-renewal–promoting genes Id1, p21, and
Egr1 (fig. S3E)].
To investigate the role of A-E acetylation in
leukemogenesis in vivo, we expressed the wild
type and the K24R, K43R, and K24R/K43R mu-
tant forms of the AE9a protein (the isoform of
A-E that can induce leukemia in mouse models
by itself) in fetal liver HSPCs by means of retro-
viral transduction and transplantation assays (20).
We examined the peripheral blood, bone marrow,
and spleen of the mice 15 weeks after transplan-
tation, and found large numbers of blast cells in
the AE9a and AE9a K24R mice, but not in the
AE9aK43RorAE9aK24R/K43Rmice (fig. S4D).
The AE9a K43R mice also had normal white
blood cell counts and platelet counts and displayed
less anemia than did the AE9a mice (fig. S4B),
whereas the blood counts of the AE9a K24Rmice
were as abnormal as those of the AE9amice. The
AE9a K43R mice also had far fewer c-kit+ im-
mature peripheral blood cells at 15 weeks than
did the AE9a mice or the AE9a K24R mice, and
Fig. 3. The acetylation of A-E Lys43 by p300 is required for A-E–induced leukemogenesis. (A) Acetylation
of Flag-tagged A-E by p300. Antibodies to Flag or to acetyl lysine were used for immunoprecipitation or
Western blotting. (B) The ability of A-E to bind p300 is required for its lysine acetylation. Antibodies to
Flag or to acetyl A-E Lys24 or Lys43 were used for immunoprecipitation or Western blotting. (C) Lethally
irradiated recipient mice were injected with HSPCs transduced with AE9a or AE9a DNHR1. The number of
GFP+ c-kit+ cells in the peripheral blood is shown 15 weeks after transplant. (D) Survival of mice receiving
AE9a-transduced or AE9a mutant–transduced HSPCs (P < 0.0001, n = 15 per group). (E) Acetylation of
A-E Lys43 was detected in blast cells from t(8;21)+ leukemia patients. Antibodies to ETO, acetyl A-E Lys43,
or AML1 were used for immunoprecipitation or Western blotting (29).
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the cells retained expression of CD45 (fig. S4C).
All of the mice that received AE9a-transduced
HSPCs developed AML; the median survival of
the AE9a mice and the AE9a K24R mice was
145 and 173 days, respectively (P < 0.001). How-
ever, the median survival of the AE9a K43R and
AE9a K24R/K43R mice was 328 days and “not
reached,” respectively (Fig. 3D). Note that AE9a
is also acetylated on Lys43 in vivo, as assessed in
AML cells isolated from the spleens of fully leu-
kemic mice (fig. S4E).
Because the NHR1 domain is required for the
acetylation of A-E Lys43, we also examined
whether its deletion affected the leukemogen-
icity of AE9a. At 15 weeks after transplanta-
tion, the AE9a ∆NHR1 mice had normal white
blood cell counts and less anemia than did the
AE9a mice (fig. S1F). The AE9a ∆NHR1 mice
also had far fewer GFP+ c-kit+ immature cells in
the peripheral blood than did the AE9a mice at
15 weeks (0.8% versus 14%) (Fig. 3C). This in
vivo result differs from what has been reported
using smaller NHR1 domain deletions, perhaps
reflecting the size of the deletion or the use of
different model systems (21–24).
Together, these results indicate that acetyla-
tion of AE9a at Lys43 is required for AE9a-
induced leukemogenesis in mice. Note that A-E,
A-E K24R, A-E K43R, and A-E K24R/K43R
are expressed at similar levels in the 293T cells
(fig. S5A) and they have similar DNA binding
activity in electrophoretic mobility shift assays
(fig. S5B) (25). To determine whether A-E is
acetylated in t(8;21) leukemia patient samples,
we analyzed two A-E–positive patient samples
and found detectable A-E Lys24 and A-E Lys43
acetylation in both (Fig. 3E and fig. S3G).
To define whether acetylation of A-E is re-
quired to inhibit differentiation, we examined
the level of glycophorin A and CD11b expres-
sion on transduced cells grown in differentiation-
driving cytokines. Both A-E and A-E K24R/K43R
triggered a similar decrease in the expression of
these differentiation markers (fig. S3F). Thus, the
absence of A-E Lys43 acetylation affects the self-
renewal signals provided by A-E, but not the
delay or block of differentiation, which is con-
sistent with its effects on the myeloid differen-
tiation genes C/EBPa and PU.1 (fig. S3E). We
performed mass spectrometry and found that a
Lys43-acetylated A-E peptide (but not the non-
acetylated peptide) preferentially bound a vari-
ety of proteins, including several components of
the transcriptional pre-initiation complex (TAF).
We performed peptide pull-down assays and found
binding of both TAF7 and TAFII250 (Fig. 4C).
This suggests that the acetylation of A-E Lys43,
which is critical for A-E–induced transcriptional
activation, may work at least in part by promot-
ing the recruitment of bromodomain-containing
TAF proteins. Of course, histone acetyltransferases
other than p300 may also contribute to the acet-
ylation of A-E, and the Lys43-containing region
may recruit transcription factors or other coac-
tivators in addition to bromodomain-containing
proteins.
Given the importance of the interaction of
A-E with p300, and its subsequent acetylation,
we assessed whether inhibiting p300 function by
means of RNA interference or chemical inhibitors
would alter leukemia cell growth. Knockdown
of p300 decreased the level of A-E acetylation
(fig. S6A) and decreased the expression of Id1,
p21, and Egr1 (Fig. 2C). We also treated pri-
mary t(8;21)+ leukemia cells isolated from pa-
tients, as well as t(8;21)+ Kasumi-1 cells with the
p300 inhibitor Lys-CoA-Tat and a second p300
inhibitor C646 (26, 27); both inhibitors decreased
the levels of Id1, p21, and Egr1 mRNA as well
as the levels of acetylated A-E Lys43 and histone
H3 (Fig. 4B and fig. S6A). Lys-CoA-Tat also
inhibited the growth of the t(8;21) positive pri-
mary patient leukemia cells and Kasumi-1 cells
(as did C646), with little effect on the growth of
normal human HSPCs (Fig. 4A and fig. S6C).
Furthermore, both Lys-CoA-Tat and C646 in-
hibited the growth of MO-91, U937, and HEL
cells, with minimal effect on THP-1, Mono-Mac-1,
or HL60 cells (fig. S6C). Thus, other acetylated
proteins—perhaps the nonhistone substrates of
p300—may regulate the sensitivity of cells to
p300 inhibition, which suggests that inhibition
of p300 function could have broader therapeutic
potential in AML.
We next used two different mouse leukemia
models to examine the effect of p300 inhibitors
on leukemia cell growth in vivo. We treated 3 ×
106 AE9a-expressing or MLL-AF9–expressing
leukemia cells ex vivo with Lys-CoA-Tat or C646
for 12 hours before injecting the cells into sub-
lethally irradiated C57Bl/6 mice (day 0) (28).
Both p300 inhibitors reduced the number of im-
mature GFP+ c-kit+ cells in the AE9a mice (fig.
S7A), leading to lower white blood cell counts,
less anemia, and less thrombocytopenia relative
to the recipients of DDDD-Tat–treated or C37-
treated AE9a cells (fig. S7B). These p300 inhib-
itors significantly increased the median survival
from 36 days to 54 days for Lys-CoA-Tat and
from 32 days to 43 days for C646 (P < 0.0001;
fig. S7C). In contrast, Lys-CoA-Tat did not af-
fect the survival of the MLL-AF9 leukemia mice,
and C646 had only a minimal effect on MLL-
AF9–driven leukemia, increasing the median
survival from 23 days to 28 days (fig. S7C).
Thus, p300 inhibitors can block the transcrip-
tional activating function of A-E and decrease
the growth of A-E–expressing leukemia cells,
providing a potentially therapeutic approach to
t(8;21) AML (and possibly other AML subtypes
as well).
Our results show that acetylation of A-E (and
AE9a) by p300 is required for their leukemogenic
effects in a human preleukemia model and a
mouse AML model. The NHR1 domain of A-E
Fig. 4. Inhibition of p300 or lysine acetylation blocks
leukemogenesis by inhibiting cell growth of A-E–activated
target genes. (A) Lys-CoA-Tat (50 mM) inhibited the growth
of primary t(8;21)+ leukemia cells and Kasumi-1 cells
(T SD; n = 3) but not HL-60 cells or normal human CD34+ HSPCs. (B) Lys-CoA-Tat (50 mM) blocks A-E
Lys43 and histone H3 acetylation in Kasumi-1 cells, as detected by antibodies to acetyl A-E Lys43 or to
histone H3. (C) The binding of TAFII250 and TAF7 to A-E peptides that contain acetylated or unacetylated
Lys24 or Lys43 was studied using a peptide pull-down assay. Antibodies to TAFII250 or TAF7 were used for
Western blotting. (D) A hypothetical model showing how p300, and acetylation of A-E by p300, might
cooperate to induce leukemia.
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provides a docking site for p300, allowing A-E
and p300 to colocalize at the regulatory regions
of many A-E up-regulated genes, including those
involved in self-renewal (e.g., Id1, p21, and Egr1).
The critical consequence of this interaction is that
A-E is acetylated—an event essential for its self-
renewal–promoting effects and its ability to activate
gene expression. Thus, even though A-E can
bind p300 and presumably bring it to chromatin
where it can acetylate histone residues, it is the
acetylation of A-E itself that is the key step, per-
haps at least in part by recruiting bromodomain-
containing proteins such as TAFII250 or TAF7
(see our model for A-E–induced leukemogenesis
in Fig. 4D). The discovery that site-specific lysine
acetylation of the AML1-ETO oncogenic fusion
protein contributes potently to leukemogenesis
suggests that inhibition of its acetylation merits
exploration as a possible therapeutic strategy for
t(8;21)+ leukemia.
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Cartilage Acidic Protein–1B (LOTUS),
an Endogenous Nogo Receptor
Antagonist for Axon Tract Formation
Yasufumi Sato,1* Masumi Iketani,1* Yuji Kurihara,1 Megumi Yamaguchi,1 Naoya Yamashita,1
Fumio Nakamura,1 Yuko Arie,1 Takahiko Kawasaki,2 Tatsumi Hirata,2 Takaya Abe,3
Hiroshi Kiyonari,3 Stephen M. Strittmatter,4 Yoshio Goshima,1,5† Kohtaro Takei1,5†
Neural circuitry formation depends on the molecular control of axonal projection during
development. By screening with fluorophore-assisted light inactivation in the developing
mouse brain, we identified cartilage acidic protein–1B as a key molecule for lateral olfactory
tract (LOT) formation and named it LOT usher substance (LOTUS). We further identified Nogo
receptor–1 (NgR1) as a LOTUS-binding protein. NgR1 is a receptor of myelin-derived axon
growth inhibitors, such as Nogo, which prevent neural regeneration in the adult. LOTUS
suppressed Nogo-NgR1 binding and Nogo-induced growth cone collapse. A defasciculated LOT
was present in lotus-deficient mice but not in mice lacking both lotus- and ngr1. These findings
suggest that endogenous antagonism of NgR1 by LOTUS is crucial for normal LOT formation.
Spatially represented information in specificregions is a common feature of the nervoussystem and is essential for higher brain
function. Specificity of neural connections that
ensures the precise relay of information is re-
quired for establishing such spatial representa-
tion of information. In these processes, various
types of repulsive and attractive guidance mol-
ecules and their receptors have crucial roles (1).
The olfactory bulb (OB) is the first relay for
olfactory information. The axons of early-generated
mitral cells emerge from the OB at embryonic
day (E) 12.5 in the mouse; thereafter, they grow
laterally and then elongate caudally at the sur-
face of the telencephalon (2, 3). This projection
of mitral cells, termed the lateral olfactory tract
(LOT), is stereotypically organized in the higher
olfactory centers (4, 5). The LOT is a good ex-
perimental system for analysis of the molecular
mechanisms underlying neural circuit formation,
because LOT formation can be visualized by an-
terograde tracing with the lipophilic dialkylcar-
bocyanine (DiI) or by immunohistochemistry of
the LOT marker protein neuropilin-1 (Nrp1) in
whole-mount samples of brain and its develop-
mental process can be observed in an organotypic
culture system. Therefore, we used these tech-
niques to screen for molecules that function in
LOT formation.
We established a molecular targeting method
by modifying the fluorophore-assisted light in-
activation (FALI) technique (6, 7) (fig. S1). FALI,
generally known as chromophore-assisted light
inactivation, is an acute protein-ablation tech-
nique directed by binding of fluorescein iso-
thiocyanate (FITC)–labeled antibodies. Light
irradiation at a wavelength of 490 nm induces
local generation of oxygen radicals (singlet ox-
ygen) from the fluorophore, which react chemi-
cally with the nearby target antigen and inactivate
it (fig. S1A).Wemodified the technique to perform
continuous protein inactivation during periods
of 24 hours and longer (fig. S1B). The protein
inactivation can be achieved with nonneutral-
izing antibodies. To identify the molecules that
function for LOT formation, we generatedmono-
clonal antibodies (mAbs) produced with a ho-
mogenate of protein extract from the developing
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ArticleTet2 Loss Leads to Increased Hematopoietic
Stem Cell Self-Renewal and Myeloid Transformation
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DOI 10.1016/j.ccr.2011.06.001SUMMARYSomatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant
proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating
TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development
have not been delineated. We report here an animal model of conditional Tet2 loss in the hematopoietic
compartment that leads to increased stem cell self-renewal in vivo as assessed by competitive transplant
assays. Tet2 loss leads to a progressive enlargement of the hematopoietic stem cell compartment and even-
tual myeloproliferation in vivo, including splenomegaly, monocytosis, and extramedullary hematopoiesis. In
addition, Tet2+/ mice also displayed increased stem cell self-renewal and extramedullary hematopoiesis,
suggesting that Tet2 haploinsufficiency contributes to hematopoietic transformation in vivo.INTRODUCTION
Genetic studies of patients withmyeloidmalignancies have iden-
tified recurrent somatic alterations in themajority of patients with
myeloproliferative neoplasms (MPNs), myelodysplastic syn-
dromes (MDSs), and acute myeloid leukemia (AML). A subset
of myeloid disease alleles can be classified into two distinctSignificance
Recurrent somatic mutations in TET2 and in other genes that r
with myeloid malignancies and in other cancers. However, the
model. We report here that Tet2 loss leads to increased stem
Consistent with human mutational data, Tet2 loss leads to mye
cytic proliferation. In addition, haploinsufficiency for Tet2 confe
that the monoallelic TET2 mutations found in most patients c
strates that reduction in TET2 expression or function lea
transformation.complementation groups: one class that includes mutations
that activate oncogenic signaling pathways, and a second class
of mutations that perturbs myeloid differentiation (Gilliland and
Griffin, 2002). However, recent studies have suggested that
this model of myeloid transformation does not accurately repre-
sent the biologic and clinical heterogeneity of MPN, MDS, and
AML, and that not all leukemogenic disease alleles can beegulate the epigenetic state have been identified in patients
effects of Tet2 loss have not yet been studied in an in vivo
cell self-renewal and to progressive stem cell expansion.
loproliferation in vivo, notable for splenomegaly and mono-
rs increased self-renewal andmyeloproliferation, suggesting
an contribute to myeloid transformation. This work demon-
ds to enhanced stem cell function in vivo and myeloid
Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc. 11
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Tet2 Controls HSC Development and Transformationclassified by their ability to directly affect signaling and/or differ-
entiation. Consonant with this notion, recent studies have identi-
fied recurrent mutations of known and putative epigenetic
modifiers in patients with myeloid malignancies. These include
somatic mutations in chromatin-modifying enzymes (Ernst
et al., 2010; Nikoloski et al., 2010) and in DNAmethyltransferases
(Ley et al., 2010; Yamashita et al., 2010). In addition, biologic
studies of recurrent chromosomal translocations, including
MLL fusions, have shown that leukemogenic fusion proteins alter
epigenetic regulation in hematopoietic cells, resulting in changes
in chromatin state at specific loci (Dorrance et al., 2006; Krivtsov
et al., 2008). Taken together, these data suggest that somatic
alterations in genes that regulate the epigenetic state of hemato-
poietic cells are a common pathogenetic event in leukemogen-
esis (Abdel-Wahab and Levine, 2010). Importantly, recent
studies have identified recurrent mutations in epigenetic master
regulators in lymphoid malignancies (Morin et al., 2010) and in
solid tumors (van Haaften et al., 2009; Varela et al., 2011), sug-
gesting that mutational dysregulation of the epigenetic
machinery is a common theme in oncogenic transformation.
Recent studies have identified a novel class of somatic muta-
tions in myeloid malignancies. Specifically, somatic deletions
and loss-of-function mutations in the ten-eleven translocation
2 (TET2) gene were identified in 10%–20% of patients with
MDS and MPN (Delhommeau et al., 2009; Langemeijer et al.,
2009); subsequent studies identified recurrent TET2 mutations
in patients with chronic myelomonocytic leukemia (CMML) and
AML (Abdel-Wahab et al., 2009; Jankowska et al., 2009), and
demonstrated that TET2 mutations were associated with
adverse outcome in intermediate-risk AML (Metzeler et al.,
2011). Within the TET family of proteins, TET1, TET2, and TET3
have been shown to modify DNA by hydroxylating 5-methylcyto-
sine (5mC) (Ko et al., 2010; Tahiliani et al., 2009), and the TET2
mutant proteins observed in these patients with myeloid malig-
nancies have been shown to be deficient in this enzymatic func-
tion (Ko et al., 2010). In addition, recent work demonstrated that
mutations in the metabolic enzymes IDH1 and IDH2 (Mardis
et al., 2009; Parsons et al., 2008; Ward et al., 2010; Yan et al.,
2009) are mutually exclusive with TET2 mutations, and that
production of 2-hydroxyglutarate by neomorphic IDH1/2 mutant
proteins (Dang et al., 2009) inhibits TET2 catalytic activity (Fig-
ueroa et al., 2010; Xu et al., 2011). Taken together, these data
indicate that mutations that impair 5-hydroxymethylation repre-
sent a novel mechanism of transformation in myeloid
malignancies.
Although there are extensive genetic data implicating TET2
mutations in myeloid transformation, the consequences of Tet2
loss in hematopoietic development have not been delineated.
Recent in vitro studies using shRNA-based approaches have
suggested a role for TET2 in regulating myeloid differentiation
(Figueroa et al., 2010; Ko et al., 2010) and in regulating stem/
progenitor cell proliferation (Figueroa et al., 2010). In order to
elucidate the function of Tet2 in hematopoiesis in vivo, we
describe here the characterization of conditional deletion of
Tet2 in the hematopoietic compartment demonstrating a role
for Tet2 in regulating hematopoietic stem cell renewal and differ-
entiation. These findings provide a model for human disease in
which the loss of Tet2, often through the loss of a single allele,
leads to increased self-renewal and myeloid transformation,12 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.and provides insight into how mutations in epigenetic modifiers
contribute to malignant transformation.
RESULTS
Tet2-Expression Silencing Leads to Increased Replating
Capacity
We first investigated the effects of Tet2 silencing in hematopoi-
esis by transducing whole mouse bone marrow cells with retro-
viral vectors encoding validated Tet2 shRNA vectors (Figueroa
et al., 2010), and sorting for GFP-positive cells. Stable shRNA-
mediated knockdown led to stable reductions in TET2 expres-
sion by 50%–70% (Figure 1A). Because TET2 is an enzyme
that hydroxylates 5mC on DNA, its knockdown should lead to
loss of 5-hydroxylation of methylcytosine (5hmC). We used
a mass spectrometry-based approach (Shah et al., 2010) to
demonstrate that Tet2 silencing results in a significant reduction
in 5hmC in GFP+ hematopoietic cells stably expressing Tet2
shRNAs (Figure 1B). GFP+ cells were then plated in methylcellu-
lose for CFU in vitro assays. We observed no significant differ-
ences in the number or the lineage specificity of Tet2-expressing
and Tet2-silenced colonies after the first plating. However, at the
second plating there was a 2-fold increase in the number of colo-
nies expressing Tet2-specific shRNAs (Figure 1C). Strikingly,
Tet2-silenced cells retained the ability to serially replate and
generate colonies, although essentially no wild-type colonies
were detected after the second plating. In agreement with the
putative acquisition of a more immature phenotype, Tet2
shRNA-expressing colonies upregulated c-Kit, a hematopoietic
stem and progenitor cell marker (Figure 1D). These initial studies
demonstrated that Tet2 silencing reduces global 5hmC levels
and increases the replating capacity of hematopoietic stem
and progenitor cells.
Generation of a Conditional Tet2 Knockout Allele
Although these studies provide important information on TET2
function, hematopoiesis is a dynamic process that is most accu-
rately studied in vivo. Thus, we decided to conditionally inhibit
Tet2 gene expression in the hematopoietic compartment. We
first assessed Tet2 expression by performing qRT-PCR of sorted
hematopoietic stem/progenitor subsets (LSK: Lin Sca-1+
c-Kit+; common myeloid progenitor [CMP]: Lin Sca-1c-Kit+,
FcgRlo CD34+; GMP: Lin Sca1 c-Kit+ FcgR+CD34+, MEP:
Lin Sca-1 c-Kit+ FcgR-CD34) and in differentiated hemato-
poietic lineages. Expression studies revealed that Tet2 expres-
sion was ubiquitously expressed in the hematopoietic compart-
ment, including in stem and progenitor subsets and in mature
myeloid and lymphoid cells (Figure 2A). Purified human CD34+
peripheral blood-mobilized cells also demonstrated expression
of TET2 in human hematopoietic stem cells (see Figure S1A
available online). Two different TET2 isoforms are expressed,
including a shorter isoform b that lacks the C-terminal enzymatic
domain. To understand the nature and location of TET2 muta-
tions in human myeloid malignancies and how this would inform
our mouse model, we analyzed TET2 mutations from 991
patients with a variety of myeloid malignancies (MPN, CMML,
and AML). Exon 3 in the murine Tet2 locus encodes for approx-
imately half of the TET2 protein; analysis from the mutational
data identifies the corresponding exon 3 of human TET2 as the
Figure 1. In Vitro Tet2-Expression Silencing
Leads to Increased Serial Replating
(A) Quantification of the shRNA-mediated Tet2
knockdown efficiency using qRT-PCR.
(B) Quantification of 5hmC by LC/MS of control
(MSCV-IRES-GFP) versus Tet2 knockdown-
derived cells after retroviral transduction and GFP
sorting.
(C) CFU assay of bone marrow-derived cells in-
fected with control or Tet2 shRNA virus. Colony
counts were scored every 14 days.
(D) Upregulation of surface c-Kit expression in
progenitors expressing Tet2-specific shRNA. *p <
0.026. Error bars represent ± SD.
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including a large number of nonsense mutations, insertions,
and deletion mutations that truncate the protein. Specifically,
we found that 41.5% (51 of 123) of TET2 mutations occurred in
the first coding exon of TET2 (exon 3), whereas 29.3% (36 of
123) of TET2 mutations occurred in the last coding exon (exon
11) (Abdel-Wahab et al., 2009; Figueroa et al., 2010) (Figure 2B;
Figure S1B). Moreover, the largest proportion of mutations that
results in a premature stop codon occurs in exon 3 (Figure 2B).
In addition, exon 3 of Tet2 is contained within the two described
Tet2 transcripts (Tet2a and Tet2b), which are both expressed in
the hematopoietic compartment (Figure S1A). Therefore, we
decided to target exon 3 using homologous recombination. We
utilized ES cell targeting to insert two LoxP sites flanking exon
3, as well as an Frt-flanked neomycin selection cassette in the
upstream intron (Figure 2C). The generated mice (Tet2f/f) were
initially crossed to a germline Flp-deleter murine line to eliminate
the neomycin cassette, and then subsequently crossed to IFNa-
inducible Mx1-cre, the hematopoietic-specific Vav-cre, and the
germline EIIa-cre mice (Ku¨hn et al., 1995; Lakso et al., 1996;
Stadtfeld and Graf, 2005). Figures 2D and 2E demonstrate the
efficient targeting of the locus and the generation of a recom-
bined (E) allele upon Cre recombinase expression in hematopoi-
etic cells. Although Tet2 was recently suggested to play an
important role in ES cell differentiation (Ito et al., 2010; Koh
et al., 2011), EIIa-cre+Tet2/ mice were born with the expected
Mendelian ratios with normal growth and organ development.
These data suggested that other members of the Tet family
may have redundant functions in embryonic development and
in homeostasis of different tissues. Vav-Cre-mediated deletion
led to a compete silencing of Tet2 expression in the bone
marrow, thymus, and spleen of Vav-cre+Tet2f/f animals. Interest-
ingly, Tet2-expression silencing was not accompanied by
changes in expression of either Tet1 or Tet3, whichwere both ex-
pressed in hematopoietic cells at similar levels before and after
Tet2 deletion (Figure 2F).Cancer Cell 20, 1Tet2 Deletion Leads to an
Enhanced Repopulating Capacity
of Hematopoietic Progenitors
In Vitro
Given that RNAi-mediated Tet2 silencing
led to increased replating potential, we
assessed whether deletion of TET2 in
different hematopoietic subsets led tosimilar effects. We performed methylcellulose CFU assays using
FACS-sorted Linc-Kit+ progenitors and LSK CD150+ HSC from
Vav-cre+Tet2/ and Vav-cre+Tet2+/+ mice. In both cases, Tet2-
deficient cells demonstrated serial replating capacity (for at least
ten replatings followed by continuous liquid culture for 4 addi-
tional months), whereas Tet2+/+ counterparts differentiated and
did not generate colonies after the second plating (Figure 3A).
Tet2/ colonies were more homogeneous and less differenti-
ated and contained cells with a promyeloblastic morphology
(Figure 3B). Indeed, expression of c-Kit, a classical marker of
hematopoietic progenitors and the receptor for stem cell factor,
was upregulated significantly in Tet2/ and was expressed in
nearly all Tet2/ cells in the third plating and beyond (Figure 3C).
Furthermore, the c-Kit-expressing cells also upregulated the
myeloid progenitor markers CD34 and FcgR (Figure 3C). Inter-
estingly, comparison of gene expression profiles of Tet2/ cells
at the fifth plating (CFU5) to different stem and progenitor popu-
lations showed that Tet2/ cells share a common gene expres-
sion programwith CMPs, suggesting that these are indeed c-Kit+
myeloid progenitors with the ability to replate indefinitely in
culture (Figure S2). Tet2/ myeloid progenitor cells were also
characterized by increased expression of the self-renewal regu-
lators Meis1 and Evi1, and by reduced expression of multiple
myeloid-specific factors (including Cebpa, Cebpd, Mpo, and
Csf1), more consistent with multipotent LSK cells than
committedCMPorGMP (Figure S2; data not shown). These find-
ings are consistent with the shRNA knockdown experiments
shown in Figure 1 and suggest that Tet2 loss leads to enhanced
serial replating ability in vitro.
Tet2 Deletion Leads to Progressive Defects
in Hematopoiesis
We next performed detailed analysis of in vivo hematopoiesis in
Tet2/ mice. Detailed phenotypic characterization of young
(4–6 weeks) Vav-Cre+Tet2/ mice failed to reveal gross
alterations in bone marrow stem/progenitor numbers or in the1–24, July 12, 2011 ª2011 Elsevier Inc. 13
Figure 2. Generation of a Conditional Tet2 allele
(A) qRT-PCR showing relative expression levels of Tet2 in purified progenitor and mature mouse hematopoietic stem and progenitor subsets.
(B) Exon distribution of TET2 mutations found in patients with AML and CMML.
(C) Schematic depiction of the targeted Tet2 allele. Exon 3 is targeted and flanked by LoxP sites upon Frt-mediated deletion of the NEO cassette.
(D) Verification of correct homologous recombination using Southern blots on targeted ES cells.
(E) Verification of VavCre-mediated excision using genomic PCR. Recombined (D), floxed, and wild-type Tet2 alleles are shown.
(F) Efficiency of Tet2 knockout using qRT-PCR in purified bone marrow c-Kit+ cells, total thymus, and spleen. Expression of Tet1 and Tet3 in wild-type and
Tet2-deficient bone marrow cells reveals no differences in Tet1 and Tet3 expression with Tet2 deletion. Error bars represent ± SD.
See also Figure S1.
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Tet2 Controls HSC Development and Transformationmyeloid compartment (Figure 4A, first panel). Likewise, there
were no effects on the differentiation of lymphocyte lineages in
the bone marrow (data not shown). However, detailed FACS
analysis of Tet2/ spleens from young mice identified signifi-14 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.cant extramedullary hematopoiesis, as defined by a significant
increase in the absolute numbers of c-Kit+ (data not shown),
LSK cells (including CD150+ HSC), and myeloid progenitors
(Figures 4B and 4C). Moreover, purification of Tet2+/+ and
Figure 3. Tet2 Deficiency Leads to
Increased Serial Replating Ability In Vitro
(A) Left panel shows a methylcellulose CFU assay
using LSK CD150+-purified cells. Absolute
number of colonies is shown at different platings.
A similar CFU assay using Lineagec-Kit+ cells is
shown in the right panel.
(B) Morphology of generated colonies either at the
2nd or 4th plating. Cytospins of the colonies are
shown.
(C) Left panels illustrate upregulation of surface c-
Kit expression at the 2nd and 4th plating. Right
panels show cell surface expression of CD34 and
FcgR on LincKit+ Tet2/ cells by the 4th plating.
A representative example of at least three inde-
pendent experiments is shown for each assay.
Error bars represent ± SD.
See also Figure S2.
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and subsequent transcriptome analysis revealed that Tet2/
LSK cells display a significant enrichment of a CMPgene expres-
sion signature (Figure S3; Experimental Procedures), suggesting
that Tet2 loss leads to aberrant hematopoiesis in vivo.
We next analyzed older (20 week) Tet2/ animals to deter-
mine the consequences of Tet2 loss on long-term hematopoi-
esis. At 20 weeks after Tet2 deletion, we noted an increase in
the size of the bone marrow LSK compartment (Figure 4A,
second panel). This phenotype was not accompanied by expan-
sion of a specific stem or multipotential progenitor compartment
as defined by the utilization of CD150/CD48 marker labeling.
Further analysis of the progenitor compartment showed
a marked increase in the GMP population, which includes
progenitors of monocytes and granulocytes (Figure 4A).
However, the most striking effects of Tet2 deletion were noted
in the spleen of these animals; Tet2/ but not Tet2+/+ mice dis-
played splenomegaly at 20 weeks of age, which was associatedCancer Cell 20, 1with an increase in the proportion of total
CD11b+ cells (see below). Notably, extra-
medullary hematopoiesis was prominent,
with a significant increase in the absolute
number of LSK (Figures 4B and 4C) as
well as CD150+ HSC (not shown) cells.
These combined studies suggested that
Tet2 deletion leads to progressive
defects in blood differentiation and to
a significant elevation of extramedullary
hematopoiesis.
Tet2-Deficient Hematopoietic Stem
Cells Show Increased Self-Renewal
Ability In Vivo
Because we have previously shown that
Tet2 deletion leads to increased replating
capacity in vitro, we tested the ability of
Tet2/ cells to compete directly against
wild-type counterparts in an in vivo
transplantation setting. We mixed iden-
tical numbers of either Mx1-cre+-
Tet2WT/WTCD45.2+ or Mx1-cre+Tet2f/fCD45.1+/CD45.2+ BM from littermate mice with wild-type
CD45.1+ bone marrow and transplanted them in lethally irradi-
ated CD45.1+ recipients (Figure 5A). Four weeks after transplan-
tation, equal engraftment (approximately 50:50) rates were de-
tected in peripheral blood, and subsequently, Tet2 deletion
was induced by polyI-polyC injections. The presence of the
Tet2-recombined allele was verified using genomic PCR of
peripheral blood mononuclear cells. Chimerism was followed
by FACS assessment of peripheral blood staining for CD45.1
versus CD45.2 (or CD45.1+45.2+). As evident from Figure 5B,
upon Tet2 deletion, Tet2/ chimerism increased rapidly
because these cells outcompeted their wild-type counterparts.
Indeed, at 23 weeks after polyI-polyC deletion, more than 95%
of the peripheral blood cells (both myeloid and lymphoid) were
Tet2/ (Figure 5C). To define in detail the developmental stage
in which Tet2/ cells outcompete Tet2-expressing cells, we
have analyzed transplanted recipients 23 weeks after polyI-
polyC injection. Analysis of the LT-HSC compartment indicated1–24, July 12, 2011 ª2011 Elsevier Inc. 15
Figure 4. Tet2 Deletion Leads to Progressive Defects in Bone Marrow and Extramedullary Hematopoiesis
(A) FACS analysis of bone marrow stem and progenitor populations of Tet2/ (vav-Cre+Tet2f/f) and wild-type (vav-Cre+Tet2WT/WT) at two different ages (4–6 and
20 weeks). Antibody stainings are as indicated.
(B) Identical antibody labeling as in (A) but using spleen cells from Tet2/ (vav-Cre+Tet2f/f) and wild-type (vav-Cre+Tet2WT/WT) mice.
(C) Absolute numbers of spleen LSK cells in Tet2/ (vav-Cre+Tet2f/f) and wild-type (vav-Cre+Tet2WT/WT) mice at two different ages. p values are shown for each
comparison. For all experiments shown in this figure, there are eight for each genotype. Error bars represent ± SD.
See also Figure S3.
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suggesting that TET2-deficient HSC has the ability to outcom-
pete wild-type counterparts. Once established, this bias toward
the Tet2/ cells was also observed in downstream bone16 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.marrow multipotent progenitors (MPP1,2), myeloid progenitors
(CMP), bone marrow mature CD11b+ monocytes, and B220+
lymphocytes (Figures 5D and 5E). Competitive transplant studies
using VavCre+-Tet2/ HSC demonstrated that TET2-deficient
Cancer Cell
Tet2 Controls HSC Development and Transformationcells outcompeted wild-type cells to a similar extent, further sup-
porting our previous findings (Figure S4). These studies confirm
that Tet2 function regulates the self-renewal of adult HSC.
Tet2-Deficient Animals Develop CMML-like Disease
We next performed a detailed phenotypic analysis of
Tet2/VavCre+ mice 20 weeks after deletion. We found that
Tet2/ animals, but not Tet2+/+ littermates, were characterized
by progressive leukocytosis; this was associated with neutro-
philia and a marked increase in peripheral monocyte counts
(Figures 6A and 6B and Table 1; Table S1). Peripheral blood anal-
ysis revealed that by week 20, approximately 70%of the Tet2/
VavCre+mice developed significant peripheral blood monocyto-
sis (Figure S5). Myeloid dysplasia was apparent in both bone
marrow and peripheral lymphoid tissue, as defined by myeloid
left shift (presence of blasts, promyelocytes, myelocytes, or
metamyelocytes). In addition, presence of hypogranular cyto-
plasm or abnormal segmentation of the nuclei was detected in
the Tet2-deficient animals (Figures 6B and 6D; data not shown).
Moreover, Tet2/ mice had significantly enlarged spleens
(Figure 6C) compared to littermate controls (p < 0.05). Detailed
pathologic analysis revealed that approximately all Tet2/
mice by week 20 developed significant splenomegaly (spleen
weight >250 mg), consistent with significant myeloproliferation.
Histopathologic analysis revealed that Tet2/ mice, but not
Tet2+/+ littermate controls, had prominent histologic evidence
of disease, including significant destruction of spleen architec-
ture, infiltration of the liver and lung, as well as bonemarrow neu-
trophilia and monocytosis (Figure 6D). FACS analysis of the
spleen of these mice revealed a significant enlargement of
both the CD11b+ and CD11b+Gr1+ populations, consistent
with granulocytic and monocytic expansion (Figure 6E). Collec-
tively, these studies demonstrate that Tet2 loss is associated
with myeloproliferation in vivo, and suggest that TET2mutations
contribute to increased stem cell self-renewal and to progressive
myeloid expansion in vivo. Although splenomegaly and leukocy-
tosis are observed in a spectrum of myeloid malignancies, the
constellation of splenomegaly, extramedullary hematopoiesis,
neutrophilia, and monocytosis is most consistent with human
CMML. TET2mutations are most commonly observed in human
CMML, with somatic loss-of-function mutations in more than
40% of well-annotated CMML patient cohorts (Abdel-Wahab
et al., 2009; Jankowska et al., 2009). In agreement with the
murine data, detailed clinical and molecular analysis of patients
with CMML revealed that patients with TET2-mutant CMML pre-
sented with splenomegaly, elevated peripheral blood WBC, and
monocytosis (Figure S1B). Moreover, TET2-mutant CMML was
characterized by a paucity of co-occurring cytogenetic abnor-
malities: 5.9% of patients with TET2 mutant had cytogenetic
abnormalities versus 61.3% of patients with TET2-wild-type
CMML (p = 0.018) (Figures S1B and S1C). These studies sug-
gested that Tet2 deletion leads to progressive myeloproliferation
in vivo with cardinal features of human CMML.
Tet2 Haploinsufficiency Is Sufficient to Initiate Aberrant
Hematopoiesis In Vitro and In Vivo
Although a small subset of patients with leukemia presents with
biallelic TET2mutations and/or deletions, themajority of patients
present with monoallelic TET2 loss (Abdel-Wahab et al., 2009;Jankowska et al., 2009). We performed DNA and cDNA
sequencing of patient samples with monoallelic TET2mutations
and demonstrated that these patients continue to express the
wild-type allele (Figure S6). These data suggest the possibility
that haploinsufficiency for TET2 may result in alterations in self-
renewal, hematopoietic differentiation, and susceptibility to
myeloid transformation. Therefore, we performed phenotypic
analysis of Tet2+/ (Vav-Cre+Tet2WT/f) mice. We first purified
CD150+ HSC from the bone marrow of Tet2 heterozygotes and
plated them in methylcellulose cultures. Similar to Tet2/ cells,
Tet2+/ cells were able to serially replate (Figure 7A), unlike
wild-type HSC that failed to generate colonies after the second
plating. Likewise, Tet2+/ cells generated colonies with a similar
immunophenotype as Tet2/ cells. This was demonstrated by
an immature, promyeloblastic morphology and the upregulation
of the cell surface markers c-Kit, CD34, and FcgR (Figures 7B
and 7C; data not shown). Furthermore, competitive reconstitu-
tion experiments, performed as described in Figure 5A, demon-
strated that Tet2+/, but not Tet2+/+, cells were able to outcom-
pete wild-type counterparts, albeit with slower kinetics than
Tet2/ cells (Figures 7D–7H). Indeed, 23 weeks post-deletion,
more than 70%of peripheral blood cells were Tet2+/, consistent
with increased long-term self-renewal with loss of a single Tet2
allele. Moreover, in a noncompetitive setting, 20-week-old
Vav-Cre+Tet2WT/fmice showed increased circulating monocytes
(Figure 7I) andextramedullary hematopoiesis (Figures 7Jand7K),
with a significant increase of both Lineageneg c-Kit+ and LSK cells
(Figure 7J; data not shown). These data clearly demonstrate that
Tet2 loss leads to dose-dependent effects on hematopoiesis and
on myeloid transformation, and that monoallelic TET2 loss is an
important pathogenetic event in myeloid malignancies.
DISCUSSION
The identification of recurrent somatic loss-of-function muta-
tions in TET2 provides genetic evidence that mutational inactiva-
tion of enzymes that regulate cytosine hydroxymethylation is
a common pathogenetic event in myeloid malignancies
(Delhommeau et al., 2009; Ko et al., 2010; Langemeijer et al.,
2009). In addition, genetic and functional studies suggest that
neomorphic IDHmutations contribute tomyeloid transformation,
at least in part, by inhibiting TET enzymatic function (Figueroa
et al., 2010; Xu et al., 2011). Although genetic and in vitro studies
suggested a role for TET2 in regulating hematopoietic differenti-
ation and stem/progenitor cell expansion, to our knowledge, the
in vivo effects of Tet2 loss had not previously been described.
Here, we report the effects of Tet2 loss in the hematopoietic
compartment, which has allowed us to make several important
observations. First, we found that Tet2 loss leads to increased
replating capacity in vitro, and that Tet2-deficient cells had
enhanced repopulating activity in competitive reconstitution
assays consistent with enhanced HSC function in vivo. Second,
Tet2 loss led to progressive myeloproliferation in vivo, with
features characteristic of human CMML. In addition we found
that Tet2 haploinsufficiency confers increased self-renewal to
stem/progenitor cells and to extramedullary hematopoiesis,
suggesting that heterozygous loss of TET2, as is commonly
observed in myeloid malignancies, is sufficient to contribute to
myeloid transformation in vivo.Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc. 17
Figure 5. Tet2–/– Hematopoietic Stem Cells Show Increased Repopulating Ability Consistent with Increased Self-Renewal
(A) Schematic depiction of the competitive transplantation scheme. Tet2/ cells are double positive for CD45.1/CD45.2markers. Tet2wild-type cells are CD45.2
single positive cells.
(B) Percentage of CD45.1 versus CD45.2 total chimerism in the peripheral blood of recipient animals (n = 15 for each genotype). Time (weeks) denotes the time
after the termination of polyI-polyC injections.
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Tet2 Controls HSC Development and TransformationOur in vivo investigation of the effects of Tet2 loss is consis-
tent with several observations emanating from previous genetic
and functional studies. The presence of TET2 mutations in
a significant proportion of patients with MPN, MDS, and AML
is consistent with the notion that TET2 loss confers increased
self-renewal to stem/progenitor cells in vivo, which then leads
to acquisition of mutations that direct the phenotype of TET2-
mutant hematopoietic cells (Haeno et al., 2009; Tefferi, 2010).
These data are also consistent with previous xenotransplanta-
tion studies of a small cohort of TET2 mutant primary MPN
samples that demonstrated that TET2-mutant MPN cells could
engraft NOD-SCID mice (Delhommeau et al., 2009). In addition,
genetic studies of patients with MPN that subsequently trans-
formed to AML identified TET2 mutations as a recurrent
somatic mutation during progression from MPN to AML
(Abdel-Wahab et al., 2010; Schaub et al., 2010). Our data impli-
cate increased self-renewal as a putative mechanism of trans-
formation by TET2 mutations, which contribute to disease
initiation and progression. Our transcriptional data suggest
that Tet2 loss leads to increased expression of myeloid-specific
and self-renewal gene programs. However, subsequent studies
will have to functionally investigate which downstream targets
of Tet2 loss are required to confer enhanced self-renewal on
stem/progenitor cells. Recent work suggested that TET
proteins regulate embryonic stem cell self-renewal and differen-
tiation (Ito et al., 2010; Koh et al., 2011). Taken together, the
data suggest that Tet2 deletion likely has effects at multiple
stages in hematopoietic differentiation, and that regulation of
hydroxymethylation by TET enzymes controls stem cell self-
renewal and differentiation in different cellular contexts.
However, to our knowledge, the exact mechanisms by which
perturbations in TET enzyme function remain to be delineated.
This is particularly evident given recent studies suggesting
a dynamic interplay between changes in TET1-mediared hy-
droxymethylation and other epigenetic marks in regulating
gene expression (Ficz et al., 2011; Williams et al., 2011; Wu
et al., 2011), and it is likely additional alterations in the epige-
netic state cooperate with TET2 mutations in malignant
transformation.
In addition to effects of Tet2 loss on self-renewal, we found
that Tet2 loss led to progressive myeloproliferation in vivo. Two
recent studies used RNAi-mediated Tet2 knockdown in vitro to
suggest that TET2 depletion led to impaired hematopoietic
differentiation and to preferential myeloid commitment (Figueroa
et al., 2010; Ko et al., 2010). These data are consistent with our
in vivo data because we observe progressive hematopoietic
stem/progenitor cell expansion and myeloproliferation in vivo
with Tet2 deletion or haploinsufficiency notable for neutrophilia,
monocytosis, and splenomegaly. Although these features are
seen, to a varying degree, in different myeloid malignancies,
they are most commonly observed in human CMML, suggesting(C) Representative FACS plots showing CD45.1/CD45.2 (Tet2/) and CD45.2 (Te
CD11b+, and lymphoid B220+ cells. Two time points (weeks 0 and 23) are shown
(D) Representative FACS plots showing CD45.1/CD45.2 (Tet2/) and CD45.2 (
progenitor (MPP1, MPP2, and CMP) compartments. Analysis performed at week
(E) Similar stainings quantifying CD45.1/CD45.2 (Tet2/) and CD45.2 (Tet2+/+)
populations. Week 23 stainings are shown (n = 5 for each genotype). Error bars
See also Figure S4.that Tet2 loss in the absence of other genetic lesions favors
progressive myelomonocytic expansion. This is consistent with
the observations that TET2 mutations are most common in
CMML (Abdel-Wahab et al., 2009; Jankowska et al., 2009) and
that TET2-mutant CMML is characterized by fewer additional
somatic cytogenetic alterations compared to TET2-wild-type
CMML (Figures S1B and S1C). Most importantly, we demon-
strate that Tet2 haploinsufficiency is sufficient to confer
increased self-renewal to stem/progenitor cells and to promote
myeloproliferation in vivo. Given that the vast majority of patients
with TET2-mutant hematopoietic malignancies retain a wild-type
copy of TET2, our data provide functional evidence that loss of
a single TET2 allele can contribute to transformation.
Collectively, the presented data implicate TET2 as a master
regulator of normal and malignant hematopoiesis. It is likely
that TET2 has distinct roles in other hematopoietic lineages,
and may contribute to transformation in lymphoid malignancies
or even in epithelial tumors. These data also suggest that
dysregulation of hydroxymethylation by mutations in the TET
family of enzymes and by other somatic mutations may
contribute to malignant transformation in other contexts. In
addition it is possible that therapies that modulate hydroxyme-
thylation levels might be of benefit in malignancies character-
ized by loss of TET enzyme function by inhibiting malignant
stem cell self-renewal. Moreover, our studies provide insight
into mechanisms of transformation by a novel class of muta-
tions found in myeloid malignancies and in other tumors, and
we predict that subsequent studies will identify additional muta-
tions in epigenetic modifiers, which contribute to neoplasia by
similar mechanisms.
EXPERIMENTAL PROCEDURES
Animals
All animals were housed at New York University School of Medicine or at
Memorial Sloan-Kettering Cancer Center. All animal procedures were con-
ducted in accordance with the Guidelines for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Commit-
tees (IACUCs) at New York University School of Medicine andMemorial Sloan-
Kettering Cancer Center.
Generation of Tet2-Deficient Mice
The Tet2 allele was deleted by targeting exon 3. Briefly, we have inserted two
LoxP sites flanking exon 3, as well as an Frt-flanked neomycin selection
cassette in the upstream intron (Figure 3A). Ten micrograms of the targeting
vector was linearized by NotI and then transfected by electroporation of
BAC-BA1 (C57BL/63 129/SvEv) hybrid embryonic stem cells. After selection
with G418 antibiotic, surviving clones were expanded for PCR analysis to
identify recombinant ES clones. Secondary confirmation of positive clones
identified by PCR was performed by Southern blotting analysis. DNA was
digested with ScaI and electrophoretically separated on a 0.8% agarose gel.
After transfer to a nylon membrane, the digested DNA was hybridized with
a probe targeted against the 30 or 50 external region. DNA from C57Bl/6 (B6),
129/SvEv (129), and BA1 (C57Bl/6 3 129/SvEv) (Hybrid) mouse strains wast2+/+) stainings and chimerism in whole peripheral mononuclear cells, myeloid
.
Tet2+/+) stainings and chimerism within the bone marrow stem (LT-HSC) and
23 after polyI-polyC injection.
expression in bone marrow myeloid (CD11b+) and lymphoid (B220+) mature
represent ± SD.
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Figure 6. Tet2–/– Animals Develop Myeloid Neoplasia Reminiscent of Human CMML
(A) Left panel shows automated peripheral blood enumeration of whole blood cells (WBC). Right panel illustrates manual differential counts of neutrophils and
monocytes showing blood monocytosis (nR 3 for each genotype).
(B) Representative images of peripheral blood smears from Tet2+/+ and Tet2/ mice at 20 weeks of age (nR 3 for each genotype).
(C) Splenomegaly in 20-week-old Tet2/ (Vav-Cre+Tet2f/f) animals. Littermate wild-type (Vav-Cre+Tet2WT/WT) controls at 20 weeks are used (n = 5 mice).
(D) Histologic (H&E) analysis of Tet2/ and control tissues (bone marrow, spleen, liver, and lung) is shown, illustrating disrupted spleen architecture, monocytic
infiltrations in liver and lung, and bone marrow neutrophilia (n = 5 for each genotype).
(E) Left panels show FACS analysis of spleen CD11b and Gr-1-expressing populations. A representative FACS plot from each genotype is shown. Right panel
illustrates total cell number of CD11b+ cells in the spleen of Tet2+/+ and Tet2/ mice at 20 weeks of age. Error bars represent ± SD.
See also Figure S5.
Cancer Cell
Tet2 Controls HSC Development and Transformationused as wild-type controls. Positive ES clones were expanded and injected
into blastocysts.
The generated mice (Tet2f/f) were initially crossed to a germline Flp-deleter
(Jackson Laboratories), to eliminate the neomycin cassette, and subsequently
to the IFNa-inducible Mx1-cre (Jackson Laboratories), the hematopoietic-
specific Vav-cre, and the germline EIIa-cre (Ku¨hn et al., 1995; Stadtfeld and
Graf, 2005; Lakso et al., 1996). The Vav-Cre transgenic line was generated
by the Graf laboratory (Stadtfeld and Graf, 2005) and was a gift from Virginia
Shapiro (Mayo Clinic).20 Cancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc.In Vivo Studies
Tet2 conditional and control mice received five intraperitoneal injections of
poly(I:C) every other day at a dose of 20 mg/g of bodyweight starting at 2weeks
post-birth. For the hematopoietic-specific Vav-cre line, Tet2f/f VavCre+, Tet2f/w
VavCre+, and Tet2w/w VavCre+mice were analyzed between 2 and 20 weeks of
age. Thymus, bone marrow, spleen, and peripheral blood were analyzed by
flow cytometry and formalin-fixed paraffin-embedded tissue sections stained
with hematoxylin and eosin. Peripheral blood was smeared on a slide and
stained using the Giemsa-Wright staining method. Tissue sections and blood
Table 1. Tet2 Deficiency Leads to Progressive Peripheral
Leukocytosis
Genotype WBC (3 109/l) HCT (%) PLT (3 109/l) No.
4–6 Weeks
Tet2+/+ 5.48 ± 1.54 40.32 ± 8.70 367 ± 66 11
Tet2+/ 6.61 ± 1.95 49.63 ± 5.90 365 ± 59 7
Tet2/ 6.66 ± 2.04 50.06 ± 4.70 352 ± 85 9
20 Weeks
Tet2+/+ 5.43 ± 1.35 46.29 ± 5.56 498 ± 171 8
Tet2+/– 8.77 ± 1.90a 52.55 ± 4.42 559 ± 119 10
Tet2/ 10.00 ± 2.28a 52.45 ± 11.18 517 ± 124 13
Peripheral blood analysis (automated) at 4–6 and 20 weeks of age. See
also Table S1.
a p% 0.01.
Cancer Cell
Tet2 Controls HSC Development and Transformationsmears were evaluated by a hematopathologist. Deletion of the Tet2 allele and
transcript was measured by genomic PCR and quantitative real-time PCR.Gene Expression Analysis
LSK and CMP cells were sorted from Tet2+/+ Mx-1+, Tet/Mx-1+ littermate
mice 4 weeks post-deletion via pIC injection. Additionally, cells were obtained
from serial replating of CD150+-sorted Tet2-deficient cells. RNA was isolated
using RNeasy RNA isolation kit (QIAGEN) according to manufacturer’s
protocol. A portion of total RNA (5 ng) from target cell populations was ampli-
fied and then labeled with the Ovation RNA Amplification System v2 and
Ovation cDNA Biotin System (NuGEN). The resulting cDNA was hybridized
to GeneChip MG 430 2.0 arrays according to the array manufacturer’s recom-
mendations (Affymetrix). The Affymetrix gene expression-profiling data were
normalized using the previously published Robust Multi-array Average
(RMA) algorithm using the GeneSpring GX software (Agilent, Palo Alto, CA,
USA). The gene expression intensity presentation was generated with Gene-
Spring GX software and Multi Experiment Viewer software. Hierarchical clus-
tering on genes and samples was performed using Euclidean distance as
a metric and average linkage method (Bolstad et al., 2003).Gene Set Enrichment Analysis
Gene Set Enrichment Analysis was performed using GSEA (Subramanian
et al., 2005) http://www.broadinstitute.org/gsea/, using gene set as permuta-
tion type, 1000 permutations, and log2 ratio of classes as metric for ranking
genes. Independent stem cell gene expression signatures are obtained by
http://franklin.imgen.bcm.tmc.edu and Ng et al. (2009).
The ‘‘CMP signature’’ gene sets were generated using a systematic
approach based on the comparison of gene expression arrays from wild-
type LSK and wild-type GMP. Genes that were significantly modulated in
CMP compared to LSK (over 1.33-fold; p < 0.05) were used to define CMP
versus LSK_UP gene set containing upregulated genes and CMP versus
LSK_DWN containing downregulated genes.In Vitro Colony-Forming Assays
CD150+ LSK aswell as ckit+ cells were sorted from the bonemarrow of Tet2/
VavCre+, Tet2+/ MxCre+, Tet2/ Mx-1Cre+, Tet2+/+ VavCre+, or Tet2+/+
Mx-1Cre+ mice and seeded at a density of 500 cells/replicate for the
CD150+ subset and 2000 cells/replicate for the cKit+ subset into cytokine-sup-
plemented methylcellulose medium (Methocult, M3434; STEMCELL Technol-
ogies). Colonies propagated in culture were scored at day 7. Representative
colonies were isolated from the plate for cytospins. Remaining cells were
resuspended, counted, and a portion was stained for c-kit (clone 2B8;
BioLegend), and replated (4000 cells/replicate) for a total of 5 platings (7, 14,
21, 28, and 35 days). Cytospins were performed by resuspending in warm
PBS and spun onto the slides at 350 3 g for 5 min. Slides were air-dried
and stained using the Giemsa-Wright method.Bone Marrow Transplantation
Freshly dissected femurs and tibias were isolated from Tet2w/w Mx-1Cre+
CD45.2+, Tet2f/w Mx-1Cre+CD45.2+, or Tet2f/f Mx-1Cre+ CD45.1+/CD45.2+
mice. Hence, Tet2-deficient animals are expressing both CD45.2 and
CD45.1 markers, whereas Tet2 heterozygous animals and Tet2 wild-type
control animals are expressing only the CD45.2 marker. Bone marrow was
flushed with a 1 cc insulin syringe into PBS supplemented with 3% fetal bovine
serum. The bone marrow was spun at 0.53 g by centrifugation at 4C, and red
blood cells were lysed in ammonium chloride-potassium bicarbonate lysis
buffer for 3 min on ice. After centrifugation, cells were resuspended in PBS
plus 3% FBS, passed through a cell strainer, and counted. Finally, 0.5 3 106
total bone marrow cells of Tet2w/w Mx-1Cre+ CD45.2+, Tet2f/w
Mx-1Cre+CD45.2+, or Tet2f/f Mx-1Cre+ CD45.1+/CD45.2+ cells were mixed
with 0.5 3 106 wild-type CD45.1+-support bone marrow and transplanted
via retro-orbital injection into lethally irradiated (two times 550 Gy) CD45.1+
host mice. Chimerism was measured by FACS in peripheral blood at 4 weeks
post-transplant (week 0, pre-polyI-polyC). Deletion of Tet2was initiated at this
time point via five intraperitoneal injections of polyI-polyC at a dose of 20 mg/g
of body weight. Chimerism for the duration of the experiment was subse-
quently followed via FACS in the peripheral blood every 2 weeks (week 0, 2,
4, 6, 8, 10, 12, 14, and 16 after polyI-polyC injection). Additionally, for each
bleeding, whole blood cell counts were measured on a blood analyzer, and
peripheral blood smears were scored. Chimerism in the bone marrow, spleen,
and thymus was evaluated at 10 and 14 weeks via animal sacrifice and subse-
quent FACS analysis.
Mouse Bone Marrow Infections and shRNA Colony Assays
Bone marrow was harvested from the femur of wild-type C57Bl/6 mice. After
red cell lysis, the bone marrow was cultured in media containing RPMI/10%
FBS and IL-3 (7 ng/ml), IL-6 (10 ng/ml), and stem cell factor (10 ng/ml). The
next day, cells were infected with MSCV retroviral vectors for control and
Tet2 shRNAs containing IRES GFP. Targets for shRNAs can be found in
Supplemental Experimental Procedures. Cells were infected twice in the
presence of polybrene and then sorted for GFP+ cells 48 hr following second
infection. A total of 13 104 cells was plated per well in Methocult (STEMCELL
Technologies) supplemented with IL-3 (20 ng/ml), IL-6 (10 ng/ml), SCF
(10 ng/ml), GMCSF (10 ng/ml), TPO (50 ng/ml), and Flt3L (100 ng/ml). Colonies
were scored 14 days after seeding, recollected in PBS, and then recultured in
Methocult at 13 104 cells. Tet2 knockdown was confirmed by qRT-PCR using
Thermo Scientific Verso cDNA Kit and SYBR green quantification in an ABI
7500 sequence detection system.
5hmC Quantification
Genomic DNA was purified using Purgene DNA purification kit (QIAGEN).
Genomic DNA was hydrolyzed and analyzed in triplicate for the relative levels
of 5hmC by liquid chromatography-electrospray ionization tandem mass
spectrometry (Shah et al., 2010).
Patient Samples and Sequencing
Approval was obtained from the institutional review boards of Memorial Sloan-
Kettering Cancer Center, Dana-Farber Cancer Institute, and MD Anderson
Cancer Center. Patients provided written informed consent in all cases at
time of enrollment. DNA sequencing methods and primer sequences for
TET2 have been described previously (Abdel-Wahab et al., 2009). A total of
389 AML samples were obtained at diagnosis from patients enrolled in the
Eastern Cooperative Oncology Group’s (ECOG) E1900 clinical trial. Samples
were deidentified at the time of inclusion. A total of 354 MPN, 69 CMML,
and an additional 119 AML samples were analyzed with characteristics
previously described (Abdel-Wahab et al., 2009). Approval was obtained
from the institutional review boards of Memorial Sloan-Kettering Cancer
Center, Dana-Farber Cancer Institute, and MD Anderson Cancer Center.
DNA sequencing methods and primer sequences for TET2 have been
described previously (Abdel-Wahab et al., 2009).
Human CD34+ Stem Cell Isolation
Peripheral blood was collected from normal bone marrow transplant donors
who underwent stem cell mobilization with GCSF. Remainder excess aliquots
were used for CD34+ cell isolation. CD34+ HSPCs were purified by positiveCancer Cell 20, 11–24, July 12, 2011 ª2011 Elsevier Inc. 21
Figure 7. Tet2 Haploinsufficiency Is Able to Initiate Aberrant In Vitro and In Vivo Hematopoiesis
(A) Methylcellulose CFU assay using LSK CD150+ cells (Lin, cKit+, Sca-1+, CD150+). An average of the absolute number of colonies is shown for sequential
platings (1–5) (n = 5).
(B) Representative FACS plot of colony-forming assay showing c-Kit expression at the 2nd and 4th plating.
(C) Giemsa-Wright staining of colonies formed from Tet2+/ CD150+ LSKs (Vav-Cre+Tet2WT/f). Images of cytospins are shown.
(D) Graph represents chimerism between CD45.2 (Tet2+/) and CD45.1 (Tet2+/+) in the peripheral blood from a competitive transplantation assay over time
(0–23 weeks). Experimental strategy is described in Figure 5A. Blue line indicates wild-type:wild-type cohorts, and red indicates Tet2+/:wild-type cohorts (n = 5
mice).
(E) Representative FACS plots showing CD45.1/CD45.2 chimerism in the peripheral blood from CD45.1 (Tet2+/+) and CD45.2 (Tet2+/) cohorts before (week 0)
and after deletion (23 weeks after polyI-polyC).
(F–H) Representative FACS plots showing CD45.1 (Tet2+/+)/CD45.2 (Tet2+/) chimerism at 23 weeks post-deletion in myeloid and lymphoid populations in the
peripheral blood (F), in the bone marrow (G), and in the bone marrow stem and progenitor cell compartment (H).
(I) Left panel shows automated peripheral blood enumeration of whole blood cells (WBC). Right panel illustrates manual differential counts of neutrophils and
monocytes showing monocytosis (nR 3 for each genotype).
(J) Representative FACS plot showing increased frequency of LSKs in the spleen of Tet2+/ mice. Right panel depicts absolute number of LSKs in the spleen of
wild-type and Tet2+/ mice (n = 5 for each genotype).
(K) H&E of spleen from 20-week-old Tet2+/ mice. Error bars represent ± SD.
See also Figure S6.
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Cancer Cell
Tet2 Controls HSC Development and Transformationselection using the Midi-magnetic-activated cell sorting LS+ separation
columns and isolation kit (Miltenyi). RNA was collected using the QIAGEN
RNeasy kit.ACCESSION NUMBERS
Microarray data can be accessed under GEO accession number GSE27816.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:10.
1016/j.ccr.2011.06.001.
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Most cancers arise from multiple molecular lesions, and functional redundancy of affected pathways limits the utility of specific molecularly targeted drugs. A better 
understanding of the molecular aberrations that maintain the 
malignant phenotype of cancer cells would enable more efficient 
targeting of tumor-promoting molecules and aid the development 
of more effective and less toxic anticancer treatments.
Application of genomics technologies, including large-scale 
genome sequencing, has led to the identification of many gene 
mutations in various cancers, emphasizing the complexity of this 
disease1,2. However, such genetic analyses intrinsically lack the abil-
ity to elucidate the functional complexity of signaling networks that 
are aberrantly activated as a consequence of the identified genetic 
defect(s). Thus, the development of complementary proteomic 
methodologies to identify molecular lesions intrinsic to tumors in a 
patient- and disease stage–specific manner must follow.
Most proteomic strategies are limited to measuring protein 
expression in a particular tumor but are unable to provide infor-
mation on the functional importance of such findings3. Some 
functional information can be obtained using antibodies directed 
at specific proteins or post-translational modifications, and by 
activity-based protein profiling using small molecules targeting the 
active site of certain enzymes4–7. Although such methods allow one 
to query a specific pathway or post-translational modification, they 
are not well suited to capture more global information regarding the 
malignant state3.
To maintain homeostasis, cells use intricate molecular machin-
eries comprising thousands of proteins that are programmed to 
execute well-defined functions. Dysregulation of these pathways, 
through protein misexpression or mutation, provides biological 
advantages that confer the malignant phenotype. At the molecular 
level, this requires cells to invest energy in maintaining the  stability 
and function of these proteins, and for this reason cancer cells 
co-opt molecular chaperones, including Hsp90 (refs. 8,9).
Hsp90 has important roles in maintaining the transformed 
phenotype8,9. Hsp90 and its associated cochaperones assist in 
the correct folding of cellular proteins, collectively referred to as 
‘client proteins’, many of which are effectors of signal transduction 
pathways controlling cell growth, differentiation, the DNA-damage 
response and cell survival. Tumor cell addiction to these proteins 
(that is, through mutations, aberrant expression, improper cellu-
lar translocation and so on) thus makes them critically reliant on 
Hsp90 (ref. 9).
Although Hsp90 is expressed in all cells and tissues, tumors pref-
erentially contain Hsp90 in a higher-order multi-chaperone com-
plex with high affinity for certain Hsp90 inhibitors, whereas normal 
tissues harbor a latent, uncomplexed Hsp90 that has low affinity for 
these inhibitors10.
Based on these data, we hypothesize that small molecules able 
to target tumor-enriched Hsp90 complexes can be used to affinity 
capture Hsp90-dependent oncogenic client proteins. When com-
bined with bioinformatic analysis, this should enable the creation of 
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Most cancers are characterized by multiple molecular alterations, but identification of the key proteins involved in these 
 signaling pathways is currently beyond reach. We show that the inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 
complexes and affinity captures Hsp90-dependent oncogenic client proteins. We have used PU-H71 affinity capture to design a 
proteomic approach that, when combined with bioinformatic pathway analysis, identifies dysregulated signaling networks and 
key oncoproteins in chronic myeloid leukemia. The identified interactome overlaps with the well-characterized altered proteome 
in this cancer, indicating that this method can provide global insights into the biology of individual tumors, including primary 
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Hsp90 species, which is not dictated by Hsp90 expression alone, is predictive of the cell’s sensitivity to Hsp90 inhibition. 
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a detailed molecular map of transformation-specific lesions that can 
guide the development of combination therapies that are optimally 
effective for a specific patient.
Here we describe an Hsp90 inhibitor-based chemical biology– 
proteomics–bioinformatics approach to discover oncogenic pro-
teins and pathways in chronic myeloid leukemia (CML). We show 
that the method provides a global overview of the Hsp90 interac-
tome in malignant cells, and that this interactome represents a sub-
stantial fraction of the functional malignant proteome8,9.
resUlTs
Heterogeneous Hsp90 presentation in cancer cells
To investigate the interaction of small-molecule Hsp90 inhibitors 
with tumor Hsp90 complexes, we used agarose beads that were 
covalently attached to either geldanamycin or PU-H71 (referred 
to as GM and PU beads, respectively). Both geldanamycin and 
PU-H71, which are chemically distinct agents, interact with and 
inhibit Hsp90 by binding to a regulatory pocket in its N-terminal 
domain11. For comparison, we generated agarose beads coupled to 
an anti-Hsp90 antibody (H9010).
First, we evaluated the binding of these agents to Hsp90 in lysates 
from breast cancer cells and CML cells. Four consecutive immuno-
precipitation steps with H9010, but not with a nonspecific IgG, quan-
titatively depleted Hsp90 from these extracts (Fig. 1a). In contrast, 
sequential pull-downs with PU or GM beads removed only a limited 
fraction of total cellular Hsp90 (Fig. 1b and Supplementary Results, 
Supplementary Fig. 1a,b). Specifically, in MDA-MB-468 breast can-
cer cells, the combined PU bead fractions represented ~20–30% of 
the total Hsp90 pool, and further addition of fresh PU bead aliquots 
failed to precipitate the Hsp90 remaining in the lysate (Fig. 1b, PU 
beads). This PU-H71-depleted, remaining Hsp90 fraction, although 
inaccessible to the small molecule, maintained affinity for H9010 
(Fig. 1b, H9010). From this we conclude that a substantial fraction 
of Hsp90 in the MDA-MB-468 cell extracts was still in a native con-
formation but not reactive with PU-H71.
To exclude the possibility that changes in Hsp90’s configu-
ration in cell lysates make it unavailable for binding to immo-
bilized PU-H71 but not to the antibody, we analyzed binding of 
radiolabeled 131I-PU-H71 to Hsp90 in intact cancer cells (Fig. 1c). 
Binding of 131I-PU-H71 to Hsp90 in several cancer cell lines 
saturated at a well-defined, although distinct, number of sites 
per cell (Fig. 1c).
We quantified the fraction of cellular Hsp90 bound by PU-H71 
in MDA-MB-468 cells. First, we determined that Hsp90 represented 
2.66–3.33% of the total protein in these cells, a value in close agree-
ment with the reported abundance of Hsp90 in other tumor cells9. 
Approximately 41.65 × 106 MDA-MB-468 cells were lysed to yield 
3,875 μg of protein, of which between 103.07 μg and 129.04 μg 
was Hsp90. One cell, therefore, contained (2.47–3.09) × 10−6 μg, 
(2.74–3.43) × 10−11 μmols or (1.64–2.06) × 107 molecules of Hsp90. 
In MDA-MB-468 cells, 131I-PU-H71 bound to, at most, 5.5 × 106 
of the available cellular binding sites (Fig. 1c), which amounts to 
26.6–33.5% of the total Hsp90 (calculated as 5.5 × 106/(1.64–2.06) × 
107*100). This value is markedly similar to that obtained with PU 
bead pull-downs in cell extracts (Fig. 1b), confirming that PU-H71 
binds to a fraction of Hsp90 in MDA-MB-468 cells that represents 
approximately 30% of the total Hsp90 pool, and validating the use 
of PU beads to efficiently isolate this pool. In K562 and other estab-
lished t(9;22)+ CML cell lines, PU-H71 bound 10.3–23% of the total 
cellular Hsp90 (Fig. 1c and Supplementary Fig. 1b,c).
Next, we extended our studies to several primary leukemia cells 
and to normal blood cells. Among these were primary chronic- and 
blast-phase CML and acute myeloid leukemia (AML) samples that 
contained both blasts (malignant cell population) and lympho-
cytes (normal cell population), CD34+ cells isolated from the cord 
blood of healthy donors, total mononuclear cells from peripheral 
blood and also peripheral blood leukocytes (PBLs) (Fig. 1c–e and 
Supplementary Figs. 1d and 2a–h). We used a fluorescein-labeled 
PU-H71 (PU-FITC) and flow cytometric analysis to determine 
PU-H71 binding to distinct cell populations.
PU-H71 efficiently bound to Hsp90 in K562 cells and in 
CML and AML blasts with a half-maximal inhibitory concen-
tration (IC50) of 116 nM, 201 nM and 425 nM, respectively 
(Fig. 1d). In contrast, its affinity for Hsp90 in normal blood cells 
was weaker, with IC50 values higher than 2,000 nM (Fig. 1d and 
Supplementary Fig. 1d). Hsp90 is highly expressed in these 
normal blood cells, as indicated by substantial binding of the 
Hsp90 antibody (Supplementary Fig. 1d).
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Cells with the highest avidity for PU-H71 were also the most 
sensitive to killing by this agent (Fig. 1e and Supplementary Figs. 
1e and 2). When evaluated in a panel of CML and AML cell lines 
and primary samples, we noted a good correlation between PU-H71 
binding to Hsp90 and its cell-killing potential (Supplementary 
Figs. 1e and 2).
Collectively, these data confirm that certain Hsp90 inhibitors 
bind preferentially to a subset of Hsp90 species that is more abun-
dant in cancer cells than in normal cells (Supplementary Fig. 3a). 
Abundance of this species is not dictated solely by the amount 
of Hsp90 expression and is predictive of cellular sensitivity to 
Hsp90 inhibition.
PU-H71 selects for oncoprotein–Hsp90 complex species
Next we performed immunoprecipitations and chemical precipita-
tions with beads coated with H9010-specific antibody and those car-
rying PU, and analyzed the associated client cargo in each case. We 
first investigated K562 CML cells because this cell line coexpresses the 
aberrant Bcr-Abl protein, a constitutively active kinase, and its nor-
mal counterpart c-Abl. These two Abl species are clearly separable by 
molecular weight and are therefore easily distinguishable by western 
blot (Fig. 2a, lysate). We observed that H9010, but not a nonspecific 
IgG, isolated Hsp90 complexed with both Bcr-Abl and Abl (Fig. 2a 
and Supplementary Fig. 3b,c, H9010). Comparison of immuno-
precipitated Bcr-Abl and Abl (Fig. 2a,b, H9010) with the fraction of 
each protein remaining in the supernatant (Fig. 2b, remaining super-
natant), indicated that H9010 did not preferentially enrich for Hsp90 
bound to either mutant or wild-type Abl in K562 cells.
In contrast, PU-H71-bound Hsp90 preferentially isolated 
Bcr-Abl protein (Fig. 2a,b, PU beads). Following depletion of 
the Hsp90–Bcr-Abl species by PU beads (Fig. 2b,c, PU beads), 
H9010 precipitated the remaining Hsp90–Abl species (Fig. 2b,c, 
H9010). PU beads retained selectivity for Hsp90–Bcr-Abl at sub-
stantially saturating conditions (that is, excess of lysate and beads; 
Supplementary Fig. 4a). As further confirmation of the bio-
chemical selectivity of PU-H71 for the Bcr-Abl–Hsp90 complex, 
Bcr-Abl was more susceptible to degradation by PU-H71 than was 
Abl (Fig. 2d). We confirmed the selectivity of PU-H71 for the aber-
rant Abl in other established t(9;22)+ CML cell lines (Supplementary 
Fig. 4b) and in primary CML samples (Supplementary Fig. 4c).
PU-H71 selects for Hsp90 bound to cochaperones
To further differentiate between the PU-H71-isolated and antibody-
isolated Hsp90 fractions, we evaluated the cochaperone constitu-
ency of both species8. The fraction of Hsp90 bound to Bcr-Abl also 
associated with several cochaperones, including Hsp70, Hsp40, HOP 
and HIP (Fig. 2c, PU beads), as well as additional cochaperones 
(Supplementary Data Set 1a–d). These findings strongly  suggest 
that PU-H71 recognizes cochaperone-associated Hsp90. After 
depletion by PU beads, the Hsp90 pool detected by H9010, shown 
to include Hsp90–Abl complexes, did not contain cochaperones 
(Fig. 2c, H9010), although their abundant expression was detected 
in the lysate (Fig. 2c, remaining supernatant). Cochaperones were 
isolated by H9010 in total cell extract (Supplementary Fig. 3b,c).
These findings suggest the existence of distinct pools of Hsp90 
that are preferentially bound to either Bcr-Abl or Abl in CML cells 
(Fig. 2e). H9010 recognizes both pools, whereas PU-H71 selects 
for the Bcr-Abl–Hsp90 species. Our data also suggest that Hsp90 
may use and require more acutely the classical cochaperones Hsp70, 
Hsp40 and HOP when it modulates the activity of aberrant (that 
is, Bcr-Abl) but not normal (that is, Abl) proteins (Supplementary 
Fig. 3a). In accord with this hypothesis, we find that Bcr-Abl is more 
sensitive than Abl to knockdown of Hsp70 in K562 cells (Fig. 2f and 
Supplementary Fig. 3d).
Not all Hsp90 inhibitors trap Hsp90–oncoprotein complexes
We next evaluated whether other inhibitors that interact with the 
N-terminal ATP pocket of Hsp90, including the synthetic inhibitors 
SNX-2112 and NVP-AUY922 and the natural product geldanamy-
cin11, could selectively isolate similar Hsp90 species (Fig. 2g). SNX 
beads showed selectivity for Bcr-Abl–Hsp90, whereas NVP beads 
behaved similarly to H9010 and did not discriminate between 
Bcr-Abl–Hsp90 and Abl–Hsp90 species (see SNX versus NVP 
beads, respectively; Fig. 2g). Although GM beads also recognized 
a subpopulation of Hsp90 in cell lysates (Supplementary Fig. 1a), 
they were much less efficient than were PU beads in co-precipitating 
Bcr-Abl (Fig. 2g, GM beads). The ineffectiveness of GM in trapping 
Hsp90–client protein complexes was previously reported12.
PU-H71 identifies additional Hsp90 oncoclient proteins
To determine whether selectivity towards oncoprotein–Hsp90 
complexes was a general property of PU-H71, we tested several 
additional well-defined Hsp90 client proteins in other tumor cell 
lines13,14 (Supplementary Fig. 4d–f). In agreement with our results 
in K562 cells, H9010 precipitated Hsp90 bound to both mutant 
B-Raf expressed in SKMel28 melanoma cells and to wild-type B-Raf 
expressed in CCD18Co normal colon fibroblasts (Supplementary 
Fig. 4e). PU and GM beads, however, selectively recognized Hsp90 
bound to mutant B-Raf, showing little recognition of Hsp90 bound 
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with oncoproteins and cochaperones. (a) representative western 
blot of Hsp90 complexes in K562 extracts isolated by precipitation 
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to wild-type B-Raf (Supplementary Fig. 4e). Still, GM beads were 
measurably less efficient than PU beads in co-precipitating the 
mutant client protein. We obtained similar results for other Hsp90 
clients12 (Supplementary Fig. 4d–f).
PU beads identify the aberrant signalosome in cMl
The data presented above suggest that PU-H71, which specifically 
interacts with Hsp90 (ref. 15; Supplementary Fig. 5), preferentially 
selects for oncoprotein–Hsp90 species and traps Hsp90 in a client-
binding conformation (Fig. 2). Therefore, we examined whether PU 
beads could be used as a tool to investigate the cellular complement 
of oncogenic Hsp90 client proteins. Because the aberrant Hsp90 
clientele is hypothesized to comprise proteins most crucial for 
the maintenance of the tumor phenotype8,9,16, this approach could 
potentially identify critical signaling pathways in a tumor-specific 
manner. To test this hypothesis, we performed an unbiased analysis 
of the protein cargo isolated by PU beads in K562 cells, in which at 
least some of the key functional lesions are known17,18.
We subjected the protein cargo isolated from cell lysate using 
PU beads or control beads to proteomic analysis by nano–liquid 
chromatography coupled to tandem mass spectrometry (nano-
LC-MS/MS). We carried out initial protein identification using 
the Mascot search engine, and further evaluated our results using 
Scaffold Proteome Software (Supplementary Data Set 1a–f). Among 
the PU bead–interacting proteins was Bcr-Abl (see Bcr and Abl1, 
Supplementary Data Set 1a), confirming our previous data (Fig. 2).
We then used Ingenuity Pathway Analysis (IPA) to build biologi-
cal networks from the identified proteins (Fig. 3a, Supplementary 
Fig. 6a–g and Supplementary Data Set 1e,f). IPA assigned PU-H71-
isolated proteins to 13 networks associated with cell death, cell cycle, 
cell growth and proliferation. These networks overlap well with known 
canonical CML signaling pathways (Supplementary Fig. 6a).
In addition to signaling proteins, we identified proteins that 
regulate carbohydrate and lipid metabolism, protein synthesis, gene 
expression, and cellular assembly and organization. These findings 
are in accord with the postulated broad roles of Hsp90 in maintain-
ing cellular homeostasis and in being an important mediator of cell 
transformation8,9,16,19.
Following identification by MS, we further validated a number of 
key proteins by chemical precipitation and western blotting, in both 
K562 cells and in primary CML blasts (Fig. 3b,c and Supplementary 
Fig. 4b,c). We also queried the effect of PU-H71 on the steady-state 
concentrations of these proteins to further support their Hsp90-
regulated expression and stability8 (Fig. 3b).
The top-scoring networks enriched on the PU beads were those 
used by Bcr-Abl to propagate aberrant signaling in CML: the PI3K-
AKT-mTOR-, Raf-MAPK- and NFκB-mediated signaling pathways 
(network 1, 22 focus molecules, score = 38, and network 2, 22 focus 
molecules, score = 36; Supplementary Data Set 1f). We created 
connectivity maps for these networks to investigate the relationship 
between component proteins (Supplementary Fig. 6b,c). These 
maps were simplified for clarity, retaining only major pathway com-
ponents and relationships (Fig. 3a).
The PI3K-AKT-mTOR pathway. Activation of the PI3K-AKT-
mTOR pathway has emerged as an essential signaling mechanism 
in Bcr-Abl leukemogenesis17. Of particular interest in this pathway 
is the mammalian target of rapamycin (mTOR), which is consti-
tutively activated in Bcr-Abl-transformed cells. A recent study 
reported that both mTORC1 and mTORC2 are activated in Bcr-Abl 
cells20. We identified both mTOR and key activators of mTOR, such 
as RICTOR, RAPTOR, Sin1 (MAPKAP1) and the class 3 PI3Ks 
PIK3C3 (hVps34) and PIK3R4 (VPS15)21, in the PU-H71–Hsp90 
pull-downs (Fig. 3b,c, Supplementary Figs. 4c and 6b, and 
Supplementary Data Set 1a,d).
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The NF-κB pathway. Activation of nuclear factor-κB (NF-κB) is 
required for Bcr-Abl transformation of primary bone marrow cells 
and for Bcr-Abl-transformed hematopoietic cells to form tumors 
in nude mice22. PU-H71-isolated proteins enriched in this pathway 
include NF-κB as well as NF-κB activators, including IKBKAP, TANK-
binding kinase 1 (TBK-1) and TAK1-binding protein 1 (TAB1)23 
(Supplementary Data Set 1a,d). Recently, Bcr-Abl-induced activa-
tion of the NF-κB cascade in myeloid leukemia cells was shown to 
be largely mediated by tyrosine-phosphorylated PKD2 (or PRKD2)24 
which we identify here to be a PU-H71–Hsp90 interactor (Fig. 3b,c, 
Supplementary Figs. 4c and 6c, and Supplementary Data Set 1a,d).
The Raf–MAPK pathway. Key effectors of the MAPK pathway, 
also activated in CML17,22, including Raf-1, A-Raf, ERK, p90RSK, 
Vav and several MAPKs, are included in the PU-H71–Hsp90-
bound pool (Fig. 3b,c, Supplementary Figs. 4c and 6b, and 
Supplementary Data Set 1a,d). IPA connects the MAPK pathway 
to key elements of many signal transduction pathways including 
the PI3K-AKT-mTOR, STAT and focal adhesion pathways (Fig. 3a 
and Supplementary Fig. 6b–e).
The STAT pathway. The STAT pathway is also activated in CML 
and confers cytokine independence and protection against apop-
tosis22, and was enriched by PU-H71 chemical precipitation (net-
work 8, 20 focus molecules, score = 14; Supplementary Fig. 6d and 
Supplementary Data Set 1f). Both STAT5 and STAT3 were associ-
ated with PU-H71–Hsp90 complexes (Fig. 3b,c and Supplementary 
Data Set 1a,d). In CML, STAT5 activation by phosphorylation is 
driven by Bcr-Abl17. Bruton agammaglobulinemia tyrosine kinase 
(BTK), constitutively phosphorylated and activated by Bcr-Abl in 
pre–B lymphoblastic leukemia cells25, can also signal through STAT5 
(ref. 26). BTK is another Hsp90-regulated protein that we identi-
fied in CML (Fig. 3b,c, Supplementary Fig. 4c and Supplementary 
Data Set 1a,d). In addition to phosphorylation, STATs can be 
activated in myeloid cells by calpain (CAPN1)-mediated proteo-
lytic cleavage, leading to truncated STAT species27. CAPN1 is also 
found in PU-H71-bound Hsp90 pull-downs, as is activated Ca2+–
calmodulin-dependent protein kinase IIγ (CaMKIIγ) activated in 
CML by Bcr-Abl28 (Supplementary Data Set 1a,d).
The focal adhesion pathway. The focal adhesion pathway was 
well represented in PU-H71 pull-downs (network 12, 16 focus 
molecules, score = 13; Supplementary Fig. 6e and Supplementary 
Data Set 1f). The focal adhesion–associated proteins paxillin, 
FAK, vinculin, talin and tensin are constitutively phosphorylated 
in Bcr-Abl-transfected cell lines29,30, and these too were isolated in 
PU-H71–Hsp90 complexes (Fig. 3a).
Other pathways. Other important transforming pathways in 
CML, driven by MYC31 (network 7, 15 focus molecules, score = 22) 
and TGF-β32 (network 10, 13 focus molecules, score = 18) 
were identified here as well (Supplementary Fig. 6a,f,g and 
Supplementary Data Set 1f). Among the identified networks 
were also those important for disease progression and aberrant 
cell cycle and proliferation of CML (networks 3–6, 9, 11 and 13; 
Supplementary Fig. 6a and Supplementary Data Set 1f).
In summary, PU-H71 pull-down enriched for a broad cross-
section of proteins that participate in signaling pathways vital to 
the malignant phenotype of CML. Interaction of PU-H71-bound 
Hsp90 with the aberrant CML signalosome was retained in primary 
CML samples (Fig. 3c and Supplementary Fig. 4c).
PU-H71 cargo contributes to the malignant phenotype
To demonstrate that the networks identified by PU beads are 
important for transformation in K562, we next showed that inhibi-
tors of key nodal proteins from individual networks (Fig. 3a, 
yellow boxes—Bcr-Abl, NFκB, mTOR, MEK and CAMKII) diminish 
the growth and proliferation potential of K562 cells (Table 1 and 
Supplementary Fig. 7a).
Next we showed that PU beads identified a set of Hsp90 interactors 
with no known role in CML, but which also contribute to the trans-
formed phenotype. The histone-arginine methyltransferase CARM1, 
a transcriptional coactivator of many genes33, was validated in the 
PU bead pull-downs from CML cell lines and primary CML cells 
(Fig. 3b,c and Supplementary Fig. 4b,c). This is the first reported 
link between Hsp90 and CARM1, although other arginine methyl-
transferases, such as PRMT5, have been shown to be Hsp90 clients 
in ovarian cancer cells34. Although elevated amounts of CARM1 are 
implicated in the development of prostate and breast cancers, little is 
known about the importance of CARM1 in CML leukomogenesis33. 
CARM1 was essentially entirely captured by the Hsp90 species recog-
nized by PU beads (Fig. 4a), and it was also sensitive to degradation 
by PU-H71 (Fig. 3b). Therefore, CARM1 may be a previously unre-
ported Hsp90 oncoprotein in CML. Indeed, knockdown experiments 
with CARM1 but not control short hairpin RNAs (shRNAs), showed 
reduced viability and enhanced apoptosis in K562 (Fig. 4b).
To demonstrate that the presence of proteins in PU-H71 pull-
downs is due to their participation in aberrantly activated signaling 
and not merely their abundant expression, we compared PU bead 
pull-downs from K562 and Mia-PaCa-2, a pancreatic cancer cell 
line (Supplementary Data Set 1a). Although both cell lines express 
large amounts of STAT5 protein (Fig. 4c), we noted activation of 
the STAT5 pathway, as demonstrated by STAT5 phosphorylation 
(Fig. 4c) and DNA binding35, in only the K562 cells. In accordance, 
this protein was identified only in the K562 PU bead pull-downs 
(Supplementary Data Set 1a and Supplementary Fig. 7b). In con-
trast, we identified activated STAT3 in PU-H71–Hsp90 complexes 
from both K562 (Fig. 3b) and Mia-PaCa-2 cell extracts (Fig. 4d).
We identified the mTOR pathway using PU beads in both K562 and 
Mia-PaCa-2 cells (Supplementary Fig. 7b) and, indeed, its pharma-
cological inhibition by PP242, a selective inhibitor that targets the ATP 
domain of mTOR36, was toxic to both cells. In contrast, the Abl inhibi-
tor Gleevec37 was toxic to only K562 cells (Table 1 and Supplementary 
Fig. 7a,c). Both cell lines express Abl but only K562 has the oncogenic 
Bcr-Abl (Fig. 4c), and PU beads identified Abl, as Bcr-Abl, in K562 
but not in Mia-PaCa-2 cells (Supplementary Fig. 7b).
PU-H71 identifies a new sTaT activation mechanism
PU bead pull-downs contain several proteins, including Bcr-Abl17, 
CAMKIIγ 28, FAK29, vav-1 (ref. 38) and PRKD2 (ref. 24), that are 
constitutively activated in CML. These are classical Hsp90-regulated 
clients that depend on Hsp90 for their stability because their steady-
state concentrations decrease upon Hsp90 inhibition8,9 (Fig. 3b). 
Constitutive activation of STAT3 and STAT5 is also reported in 
CML17,22. These proteins, however, do not fit the criteria of classical 
Hsp90 client proteins, because STAT5 and STAT3 concentrations 
remain essentially unchanged upon Hsp90 inhibition (Fig. 3b). The 
PU-H71 pull-downs also contained proteins that may constitute 
active signaling megacomplexes, such as mTOR, VPS32, VPS15 and 
Table 1 | Ic50 values for the indicated compounds in cell proliferation assays
drug or cell line pu-h71 gleevec pp242 as703026 bms-345541 Kn-93
K562 0.13 ± 0.02 0.33 ± 0.07 2.00 ± 0.10 1.07 ± 0.10 8.60 ± 0.30 5.75 ± 0.60
mia-PaCa-2 0.15 ± 0.01 >10.00 0.70 ± 0.14 NA NA NA
Cells were treated for 72 h with the indicated inhibitors, and the effect on cell growth was analyzed. The half-maximal inhibitory concentration (IC50) is indicated in μm. Data are presented as means ± s.d. (n = 3). 
NA, not available.
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RAPTOR20. Furthermore, PU-H71–Hsp90 complexes contained 
adapter proteins such as GRB2, DOCK, CRKL and EPS15, which 
link Bcr-Abl to key effectors of multiple aberrantly activated sig-
naling pathways in K562 (refs. 6,17; Fig. 3a). Their expression also 
remained unchanged upon Hsp90 inhibition (Fig. 3b). We there-
fore wondered whether the contribution of Hsp90 to certain onco-
genic pathways extends beyond its classical folding and stabilizing 
activity. Specifically, we hypothesized that Hsp90 might also act as 
a scaffolding molecule to maintain signaling complexes in an active 
configuration, as has been previously postulated16,39.
Hsp90 binds to and influences the conformation of sTaT5
To investigate this hypothesis further we focused on STAT5, which is 
constitutively phosphorylated in CML40. The overall concentration 
of p-STAT5 is determined by the balance of phosphorylation and 
dephosphorylation events. The high concentrations of p-STAT5 in 
K562 cells may reflect either an increase in upstream kinase  activity 
or a decrease in protein tyrosine phosphatase (PTPase) activity. 
A direct interaction between Hsp90 and p-STAT5 could also modu-
late the amount of p-STAT5 in cells.
To dissect the relative contributions of these potential mecha-
nisms, we first investigated the effect of PU-H71 on the main kinases 
and PTPases that regulate STAT5 phosphorylation in K562 cells. 
Bcr-Abl directly activates STAT5 without the need for JAK phospho-
rylation40. Concordantly, STAT5 phosphorylation rapidly decreased 
in the presence of the Bcr-Abl inhibitor Gleevec (Fig. 5a, Gleevec). 
While Hsp90 regulates Bcr-Abl stability, the reduction in steady-
state Bcr-Abl concentrations following Hsp90 inhibition requires 
more than 3 h41. Indeed, we observed no change in Bcr-Abl expres-
sion (Fig. 5a, PU-H71, Bcr-Abl) or function, as evidenced by no 
decrease in CRKL phosphorylation (Fig. 5a, PU-H71, p-CRKL and 
CRKL), with PU-H71 in the time interval during which p-STAT5 
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concentrations were reduced (Fig. 5a, PU-H71, p-STAT5). Also, we 
saw no change in the activity and expression of HCK, a kinase acti-
vator of STAT5 in 32Dcl3 cells transfected with Bcr-Abl42 (Fig. 5a, 
HCK and p-HCK). We also excluded the possibility of a change in 
PTPase activity, because the expression and activity of SHP2, the 
major cytosolic STAT5 phosphatase43, was not altered in this time 
interval (Fig. 5a, SHP2 and p-SHP2), nor were the concentrations 
of SOCS1 and SOCS3, which form a negative-feedback loop that 
switches off STAT signaling37 (Fig. 5a, SOCS1 and SOCS3). Thus, 
no effect on STAT5 phosphorylation in the 0–90-min interval can 
be attributed to a change in kinase or phosphatase activity upon 
Hsp90 inhibition.
Because most p-STAT5, but not STAT5, is bound to Hsp90 in 
CML cells (Fig. 5b), we hypothesized that the cellular concentra-
tions of activated STAT5 are fine-tuned by direct binding to Hsp90. 
The activation and inactivation cycle of STATs entails their tran-
sition between different dimer conformations44. We found that 
STAT5 is more susceptible to trypsin cleavage when bound to 
Hsp90 (Fig. 5c), indicating that binding of Hsp90 directly modu-
lates the conformational state of STAT5, potentially keeping it in a 
conformation unfavorable for dephosphorylation and/or favorable 
for phosphorylation. To investigate this possibility, we used a pulse-
chase strategy in which orthovanadate (Na3VO4), a nonspecific 
PTPase inhibitor, was added to cells to block dephosphorylation of 
STAT5. We then determined the residual concentration of p-STAT5 
at several later time points (Fig. 5d and Supplementary Fig. 7d). In 
the absence of PU-H71, p-STAT5 accumulated rapidly, whereas in 
its presence, cellular p-STAT5 concentrations were diminished. The 
kinetics of this process (Fig. 5d) were similar to the rate of p-STAT5 
steady-state reduction (Fig. 5a, PU-H71).
Hsp90 supports sTaT5-mediated transcription
The biological activity of STAT5 also requires its nuclear transloca-
tion and direct binding to its various target genes40,44. We wondered 
whether Hsp90 might also facilitate the transcriptional activation of 
STAT5-regulated genes, and thus participate in promoter-associated 
STAT5 transcription complexes. We found that STAT5 is constitu-
tively active in K562 cells and binds to a STAT5-binding consensus 
sequence. STAT5 activation and DNA binding were partially abro-
gated, in a dose-dependent manner, upon Hsp90 inhibition with 
PU-H71 (Fig. 5e). Furthermore, quantitative chromatin immuno-
precipitation (ChIP) assays in K562 cells revealed the presence 
of both Hsp90 and STAT5 at the critical STAT5 targets MYC and 
CCND2 (Fig. 5f). Neither protein was present at intergenic control 
regions (data not shown). Accordingly, PU-H71 (1 μM) decreased 
the mRNA abundance of the STAT5 target genes CCND2, MYC, 
CCND1, BCL-XL and MCL1 (ref. 45), but not of the control genes 
HPRT and GAPDH (Fig. 5g).
Collectively, these data show that STAT5 activity is positively 
regulated by Hsp90 in CML cells (Fig. 5h). Our findings are con-
sistent with a scenario whereby Hsp90 binding to STAT5 modulates 
the conformation of the protein to alter STAT5 phosphorylation and 
dephosphorylation kinetics. In addition, Hsp90 maintains STAT5 in 
an active conformation in STAT5-containing transcriptional com-
plexes. Considering the complexity of the STAT pathway, other 
potential mechanisms cannot be excluded. Therefore, in addition to 
its role in promoting protein stability, Hsp90 promotes oncogenesis 
by maintaining client proteins in an active configuration.
DIscUssIoN
We present herein a rapid and simple chemical-proteomics method 
for surveying tumor oncoproteins (Supplementary Fig. 8). The 
method takes advantage of PU-H71’s ability to (i) preferentially bind 
to a pool of Hsp90 associated with oncogenic client proteins, and 
(ii) trap Hsp90 in an oncoclient-bound configuration. We propose that 
this approach provides a powerful tool to dissect, tumor-by-tumor, 
molecular lesions that are characteristic of distinct cancers. Because 
of the initial chemical-precipitation step, which purifies and enriches 
the aberrant protein population as part of PU bead–bound Hsp90 
complexes, the method does not require expensive SILAC labeling 
or two-dimensional gel separation of samples. Instead, protein cargo 
from PU bead pull-downs is simply eluted in SDS buffer and sub-
mitted to standard SDS-PAGE, and then the separated proteins are 
extracted and trypsinized for LC-MS/MS analysis.
Although this method presents a unique approach to identify-
ing the oncoproteins that maintain the malignant phenotype of 
tumor cells, one needs to be aware that, similar to other chemical 
or antibody-based proteomics techniques, it has potential limita-
tions46. For example, ‘sticky’ or abundant proteins may bind in a 
nondiscriminatory way to proteins isolated by PU beads. Second, 
although we have presented several lines of evidence that PU-H71 
is specific for Hsp90, one must consider that, at the high concentra-
tion of PU-H71 present on the beads, some nonspecific binding to a 
few non-Hps90 proteins is unavoidable.
Despite these potential limitations, we have used this method to 
carry out the first global evaluation of Hsp90-dependent aberrant 
signaling pathways in CML. The Hsp90 interactome identified by 
PU-H71 affinity purification overlaps substantially with the well-
characterized CML signalosome, indicating that this method can 
identify a large part of the complex web of pathways and proteins 
that define the molecular basis of this leukemia. When applied 
to less well-characterized tumor types, this method may provide 
unpredicted targets for combinatorial therapy.
We believe the functional proteomics method described here 
will assist identification of the critical proteome subset that is dys-
regulated in individual tumors, including primary patient speci-
mens. Thus, tumor-specific Hsp90 client profiling could ultimately 
yield an approach for personalized therapeutic targeting of tumors 
(Supplementary Fig. 8).
Our work also proposes that Hsp90 forms biochemically distinct 
complexes in cancer cells (Supplementary Fig. 3a). In this view, a 
major fraction of cancer cell Hsp90 retains ‘housekeeping’ chaper-
one functions similar to normal cells, whereas a functionally distinct 
Hsp90 pool that is enriched or expanded in cancer cells specifically 
interacts with the oncogenic proteins required to maintain tumor 
cell survival. Perhaps this Hsp90 fraction represents a cell stress– 
specific form of chaperone complex that is expanded and constitu-
tively maintained in the tumor cell context. Our data suggest that it 
may execute functions necessary to maintain the malignant pheno-
type. One such role is to regulate the folding of mutated (that is, 
mB-Raf) or chimeric (that is, Bcr-Abl) proteins8,9. We now present 
experimental evidence for an additional role; that is, to facilitate 
scaffolding and complex formation of molecules involved in aber-
rantly activated signaling complexes.
What distinguishes the PU-H71-binding fraction of Hsp90 from 
the non–PU-H71-binding fraction? This is a complex question that 
remains under active investigation. Although both Hsp90α and 
Hsp90β isoforms are recognized by PU-H71, our data provide evi-
dence for at least one difference between Bcr-Abl–Hsp90 (PU-H71 
preferring) and Abl–Hsp90 (PU-H71 nonpreferring) chaperone 
complexes. That is, Bcr-Abl–Hsp90 chaperone complexes contain 
a number of cochaperones (suggesting that an active chaperon-
ing process is underway, further supported by the sensitivity of 
Bcr-Abl to the silencing of Hsp70), whereas Abl–Hsp90 complexes 
lack associated cochaperones (probably representing sequestered but 
not actively chaperoned Abl, supported by the insensitivity of Abl to 
Hsp70 knockdown). Finally, we have observed a differential impact 
of Hsp90 phosphorylation on PU-H71 and geldanamycin binding. 
These findings, which are being pursued further, suggest that various 
Hsp90 inhibitors may be uniquely affected by specific post-transla-
tional modifications to the chaperone. Taken together, these prelimi-
nary observations suggest that PU-H71 recognizes an Hsp90 fraction 
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that is participating in an active chaperone cycle, and that this char-
acteristic is not necessarily shared by other Hsp90 inhibitors.
Our work uses chemical tools to provide new insights into the 
heterogeneity of tumor-associated Hsp90 and harnesses the bio-
chemical features of a particular Hsp90 inhibitor to identify tumor-
specific biological pathways and proteins. We believe the functional 
proteomics method described here will allow identification of the 
critical proteome subset that becomes dysregulated in distinct 
tumors. This will allow for the identification of new cancer mecha-
nisms, as exemplified by the STAT5 mechanism, the identification 
of new oncoproteins, as exemplified by CARM1, and the identifica-
tion of therapeutic targets for the development of rationally com-
bined targeted therapies complementary to Hsp90.
MeTHoDs
Cell lines and primary cells. The CML cell lines K562, Kasumi-4, MEG-01 and 
KU182, triple-negative breast cancer cell line MDA-MB-468, HER2+ breast cancer 
cell line SKBr3, melanoma cell line SK-Mel-28, prostate cancer cell lines LNCaP 
and DU145, pancreatic cancer cell line Mia-PaCa-2 and colon fibroblast cell line 
CCCD18Co were obtained from the American Type Culture Collection. The 
CML cell line KCL-22 was obtained from the Japanese Collection of Research 
Bioresources. The NIH-3T3 fibroblast cells were transfected as described41. Cells 
were cultured in DMEM in F12 (MDA-MB-468, SKBr3 and Mia-PaCa-2), RPMI 
(K562, SK-Mel-28, LNCaP, DU145 and NIH-3T3) or MEM (CCD18Co) supple-
mented with 10% (v/v) fetal bovine serum (FBS), 1×  l-glutamine and 1× penicillin 
and streptomycin (Pen/Strep). Kasumi-4 cells were maintained in IMDM supple-
mented with 20% (v/v) FBS, 10 ng ml−1 granulocyte macrophage colony-stimulating 
factor (GM-CSF) and 1× Pen/Strep. PBLs (n = 3) and cord blood (n = 5) were 
obtained from patient blood purchased from the New York Blood Center. We lay-
ered 35 ml of the cell suspension over 15 ml of Ficoll-Paque plus (GE Healthcare). 
Samples were centrifuged at 2,000 r.p.m. for 40 min at 4 °C, and the leukocyte 
interface was collected. Cells were plated in RPMI medium with 10% (v/v) FBS 
and used as indicated. Primary human chronic and blast crisis CML and AML cells 
were obtained with informed consent. The manipulation and analysis of specimens 
was approved by the University of Rochester, Weill Cornell Medical College and 
University of Pennsylvania Institutional Review Boards. Mononuclear cells were 
isolated using Ficoll-Paque (Pharmacia Biotech) density gradient separation. Cells 
were cryopreserved in freezing medium consisting of IMDM, 40% (v/v) FBS, and 
10% (v/v) DMSO or in CryoStor CS-10 (Biolife). When cultured, cells were kept in a 
humidified atmosphere of 5% CO2 at 37 °C.
Cell lysis for chemical precipitation and immunoprecipitation. Cells were lysed 
by collecting them in Felts buffer (20 mM HEPES, 50 mM KCl, 5 mM MgCl2, 
0.01% (w/v) NP-40, freshly prepared 20 mM Na2MoO4 (pH 7.2–7.3)) with added 
1 μg μl−1 protease inhibitors (leupeptin and aprotinin), followed by three succes-
sive freeze (in dry ice) and thaw steps. Total protein concentration was determined 
using the BCA kit (Pierce) according to the manufacturer’s instructions.
Immunoprecipitation. The Hsp90 antibody (H9010) or normal IgG (Santa Cruz 
Biotechnology) was added at a volume of 10 μl to the indicated amount of cell lysate, 
together with 40 μl of protein G agarose beads (Upstate), and the mixture incubated 
at 4 °C overnight. The beads were washed five times with Felts lysis buffer and 
 separated by SDS-PAGE, followed by a standard western blotting procedure.
Chemical precipitation. Hsp90 inhibitors beads or control beads, containing an 
Hsp90 inactive chemical (2-methoxyethylamine) conjugated to agarose beads, were 
washed three times in lysis buffer. Unless otherwise indicated, the bead conjugates 
(80 μl) were then incubated at 4 °C with the indicated amounts of cell lysate  
(120–500 μg), and the volume was adjusted to 200 μl with lysis buffer. Following 
incubation, bead conjugates were washed five times with the lysis buffer and 
 proteins in the pull-down were analyzed by western blotting. For depletion studies, 
two to four successive chemical precipitations were performed, followed by immu-
noprecipitation steps, where indicated.
Statistical analysis. Unless otherwise indicated, data were analyzed by unpaired 
two-tailed t-tests as implemented in GraphPad Prism (version 4; GraphPad 
Software). A P-value of less than 0.05 was considered significant. Unless otherwise 
noted, data are presented as the mean ± s.d or mean ± s.e.m. of duplicate or tripli-
cate replicates. Error bars represent the s.d or s.e.m. of the mean. If a single panel is 
presented, data are representative of two or three individual experiments.
Additional methods. Detailed methodology is described in the Supplementary 
Methods section on line. 
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RED CELLS, IRON, AND ERYTHROPOIESIS
Depletion of L3MBTL1 promotes the erythroid differentiation of human
hematopoietic progenitor cells: possible role in 20q polycythemia vera
*Fabiana Perna,1 *Nadia Gurvich,1 Ruben Hoya-Arias,1 Omar Abdel-Wahab,2 Ross L. Levine,2 Takashi Asai,1
Francesca Voza,1 Silvia Menendez,1 Lan Wang,1 Fan Liu,1 Xinyang Zhao,1 and Stephen D. Nimer1
1Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute and 2Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering
Cancer Center, New York, NY
L3MBTL1, the human homolog of the
Drosophila L(3)MBT polycomb group tu-
mor suppressor gene, is located on chro-
mosome 20q12, within the common de-
leted region identified in patients with 20q
deletion-associated polycythemia vera,
myelodysplastic syndrome, and acute my-
eloid leukemia. L3MBTL1 is expressed
within hematopoietic CD34 cells; thus, it
may contribute to the pathogenesis of
these disorders. To define its role in hema-
topoiesis, we knocked down L3MBTL1
expression in primary hematopoietic
stem/progenitor (ie, CD34) cells isolated
from human cord blood (using short hair-
pin RNAs) and observed an enhanced
commitment to and acceleration of ery-
throid differentiation. Consistent with this
effect, overexpression of L3MBTL1 in pri-
mary hematopoietic CD34 cells as well
as in 20q cell lines restricted erythroid
differentiation. Furthermore, L3MBTL1
levels decrease during hemin-induced
erythroid differentiation or erythropoietin
exposure, suggesting a specific role for
L3MBTL1 down-regulation in enforcing
cell fate decisions toward the erythroid
lineage. Indeed, L3MBTL1 knockdown en-
hanced the sensitivity of hematopoietic
stem/progenitor cells to erythropoietin
(Epo), with increased Epo-induced phos-
phorylation of STAT5, AKT, and MAPK as
well as detectable phosphorylation in the
absence of Epo. Our data suggest that
haploinsufficiency of L3MBTL1 contrib-
utes to some (20q) myeloproliferative
neoplasms, especially polycythemia vera,
by promoting erythroid differentiation.
(Blood. 2010;116(15):2812-2821)
Introduction
Deletion of the long arm of chromosome 20 (20q) represents the
second most common primary chromosomal abnormality in the
hematologic malignancies, after the Philadelphia chromosome.1
The 20q abnormality is observed in 10% of patients with
myeloproliferative neoplasms (MPNs), most commonly polycythe-
mia vera (PV),2 in 4% of patients with myelodysplastic syndrome,3
and in 1% to 2% of patients with acute myeloid leukemia.4
Inactivation (or haploinsufficiency) of putative tumor suppressors
on 20q has been proposed to explain the pathogenesis of these
disorders.
We have been studying L3MBTL1, the human homolog of the
Drosophila tumor suppressor gene, lethal(3)malignant brain tu-
mor,5 whose inactivation results in overgrowth of adult optic
neuroblasts and ganglion mother cells of the larval brain.6 We
demonstrated that human L3MBTL1 functions as a transcriptional
repressor,7 and after crystallizing the MBT repeat domain,8 deter-
mined that L3MBTL1 compacts chromatin by binding monomethy-
lated and dimethylated lysine residues in histones H1 (H1K26) and
H4 (H4K20).9,10 Two mutational analyses of small numbers of
20q patient samples found no mutation in the nondeleted allele of
L3MBTL1,11,12 suggesting that haploinsufficiency of L3MBTL1
would have to contribute to these disorders.
Despite the known role of L3MBTL1 in affecting chromatin
structure, the function of L3MBTL1 in hematopoiesis is largely
unknown. To define the role of L3MBTL1 in normal human
hematopoiesis and its potential role in the 20qmyeloid disorders,
we used RNA interference to reduce L3MBTL1 expression in
human cord blood (CB) CD34 hematopoietic stem/progenitor
cells (HSPCs). We found that L3MBTL1 knockdown accelerated
erythroid differentiation and increased signaling in response to
erythropoietin (Epo), as well as low-level activation of the JAK-
STAT, MAP kinase, and AKT signaling pathways in the absence of
Epo. Similarly, we were able to impair erythroid differentiation by
overexpressing L3MBTL1 in primary hematopoietic CD34 cells
and in 20q cell lines. Thus, L3MBTL1 regulates human erythro-
poiesis, and lack of L3MBTL1 could contribute to the pathogenesis
of 20q disorders, in particular PV.
Methods
Purification and in vitro primary culture of human CB CD34
cells
Mononuclear cells were isolated from CB (obtained from the New York
Blood Center on a contractual basis) by Ficoll-Hypaque Plus density
centrifugation. CD34 HSPCs were purified by positive selection using the
Midi-magnetic-activated cell sorting LS separation columns and isolation
kit (Miltenyi). CD34 cells were cultured in Iscove modified Dulbecco
medium (IMDM, Cellgro) containing 20% BIT 9500 medium (Stem Cell
Technologies) supplemented with stem cell factor (SCF; 100 ng/mL),
Fms-like tyrosine kinase 3 (FLT-3; 10 ng/mL), interleukin-6 (IL-6; 20 ng/
mL), and thrombopoietin (TPO; 100 ng/mL; these cytokines were pur-
chased from PeproTech).
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Generation of lentiviruses and infection of primary
hematopoietic CD34 cells
Lentiviral vectors were produced by transfection of 293T cells, accord-
ing to standard protocols.13 After 24 hours of growth, CD34 cells were
infected with high-titer lentiviral concentrated suspensions, in the
presence of 8 g/mL polybrene (Sigma-Aldrich). Sequences targeted by
short hairpin RNAs (shRNAs) were: GGAAAGACGATGACGGAAA
(shLUC), GTAGTGAGTTGTAGATAAA (sh1), GGTCAGTCATAGTG-
GAGAA (sh2), and GCCTGCACTTTGATGGGTATT (sh3). shRNAs
were cloned into the H1p HygroEGFP14 (shLUC, sh1, and sh2) or LKO
vectors (empty vector and sh3). The luciferase-directed shRNA, cloned
into the H1 vector, was used as control.15 A detailed description of the
Figure 1. Knockdown of L3MBTL1 promotes the erythroid differentiation of human hematopoietic CD34 progenitor cells. (A) Lentiviral constructs expressing
shRNAs targeting luciferase (control) or L3MBTL1 (sh1 and sh2) led to efficient knockdown in primary CB CD34 cells, as assessed by Western blot and quantitative RT-PCR.
shRNAs of a different backbone (empty vector and sh3) also yielded efficient knockdown of L3MBTL1. All the presented data were confirmed using both sets of constructs.
(B) Expression of CD71 and GlyA on human HSPCs, as assayed by flow cytometric analysis at days 7, 9, and 11 of Epo-induced culture. (C) Expression of CD71 and GlyA on
human HSPCs, cultured with different concentrations of Epo, as assayed by flow cytometric analysis at 7 days. (D) Cells from panel B were stained with May-Grunwald-Giemsa
on day 7 of Epo-induced culture, and their morphology was captured by light microscopy. (E) Epo-exposed cells at days 7, 9, and 11 of Epo-induced culture were resuspended
in benzidine solution, and cells that stained dark blue-green were scored as positive.
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constructs is provided in supplemental Figure 1 (available on the Blood
Web site; see the Supplemental Materials link at the top of the online
article).
Flow cytometry
Transduced CB CD34 cells were sorted for green fluorescence (GFP)
and CD34 expression after staining with an allophycocyanin (APC)–
conjugated anti-CD34 antibody (BD Biosciences PharMingen), using a
fluorescence-activated cell sorting (FACS) Vantage cell sorter. Trans-
duced K562 cells, cultured in RPMI medium supplemented with 10%
fetal bovine serum, were sorted for GFP 72 hours after the infection.
Cells were harvested for flow cytometry on days 7, 9, and 11 in
cytokine-driven liquid culture. Cells were stained with the following
antibodies: CD34-APC (BD Biosciences PharMingen), CD11b-
phycoerythrin (PE; Immunotech), CD14-PE (Immunotech), CD71-APC
(BD Biosciences PharMingen), glycophorin A-PE (Invitrogen), and
CD41-PE (Immunotech) and analyzed by FACS. Analysis of progenitor
cell populations was performed by staining cells with the following
antibodies: CD3-PECy5, CD4-PECy5, CD7-PECy5, CD8-PECy5, CD10-
PECy5, CD19-PECy5, CD20-PECy5, CD2-PECy5, CD11b-PECy5,
CD56-PECy5, GPA-PECy5, CD45RA-FITC, CD38-PECy7, CD34-
APC, and IL-3-PE (BioLegend) and CD45RA-V450 (BD Biosciences
PharMingen). The characterization of specific progenitor cell subsets
(common myeloid progenitor [CMP], granulocyte-monocyte progeni-
tor [GMP], and megakaryocyte-erythrocyte progenitor [MEP]) was
performed by FACS analysis according to the methods described by
Park et al.16
Cytokine-driven liquid culture conditions and isolation of MPN
samples
CD34 cells were cultured in 20% BIT in IMDM, with different cytokines
to support erythroid, myeloid, or megakaryocytic cell differentiation. The
erythroid cultures contained Epo (6 IU/mL) and SCF (100 ng/mL); the
myeloid cultures SCF (100 ng/mL), FLT-3 (10 ng/mL), IL-3 (20 ng/mL),
IL-6 (20 ng/mL), granulocyte-macrophage colony-stimulating factor (GM-
CSF; 20 ng/mL), and granulocyte colony-stimulating factor (G-CSF;
20 ng/mL); the megakaryocytic cultures SCF (100 ng/mL), TPO (100 ng/
mL), and IL-11 (50 ng/mL); and the basic cultures SCF (100 ng/mL), FLT-3
(10 ng/mL), IL-6 (20 ng/mL), and TPO (100 ng/mL). Epo and G-CSF were
purchased from Amgen, and the other cytokines were purchased from
PeproTech.
CD34 cells were isolated from PV patient phlebotomy samples or
essential thrombocythemia/myelofibrosis patient peripheral blood samples
(obtained on an Memorial Sloan-Kettering Cancer Center Institutional
Review Board–approved protocol) and cultured in serum-free stem cell
expansion media supplemented with SCF (100 ng/mL), IL-3 (20 ng/mL),
IL-6 (10 ng/mL), and Epo (0.5 IU/mL) every other day. Cells were
harvested at day 7 or day 9 for Western blot assays. The cells were more
than 70% CD71/Glycophorin A (GlyA) double-positive at these times of
collection.
Figure 2. L3MBTL1 knockdown specifically promotes erythroid, but not myeloid or megakaryocytic, differentiation of human CD34 cells. (A) L3MBTL1 expression
levels were assessed by quantitative RT-PCR in normal CD34 CB cells. The cells were placed in different culture conditions stimulating erythroid, myeloid, and
megakaryocytic differentiation for 2, 5, and 7 days. Total RNA was extracted from 2  105 cells. (B) Seventy-two hours after lentiviral infection, GFPCD34 cells were cultured
in myeloid conditions for 7, 9, and 11 days, and the expression of myeloid-specific markers CD11b (CD14 and CD33 not shown) was assessed by flow cytometric analysis
(n  3). (C) Seventy-two hours after lentiviral vector infection, the GFPCD34 cells were cultured in megakaryocytic conditions for 7, 9, and 11 days, and expression of the
megakaryocytic-specific marker CD41 was assessed by flow cytometric analysis (n  3). (D) GFPCD34 cells, 72 hours after lentiviral vector infection, were cultured in
erythroid conditions for 7, 9, and 11 days, and expression of the erythroid-specific marker GlyA was assessed by flow cytometric analysis (n  3).
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Cytospin preparations, Giemsa staining, and benzidine
staining
A total of 2 105 cells were centrifuged into slides for 5 minutes at 33g and
air dried. Cells were stained with May-Grunwald-Giemsa stains and
observed under light microscope for morphologic analysis. Benzidine
staining was performed as described previously.17
RNA extraction and quantitative real-time RT-PCR
For quantitative reverse-transcription polymerase chain reaction (RT-PCR),
total RNA was isolated from 2 105 cells using the RNeasy mini kit
(QIAGEN), and then subjected to reverse transcription with random
hexamers (SuperScript III kit; Invitrogen). Real-time PCR reactions were
performed using an ABI 7500 sequence detection system. A list of PCR
primers is available on request.
Methylcellulose colony and LTC-IC assays
CFU assays. A total of 1 104 GFP CD34 transduced cells were plated
(in duplicate) in methylcellulose with Epo (5 IU/mL), SCF (50 ng/mL),
IL-3 (20 ng/mL), IL-6 (20 ng/mL), G-CSF (20 ng/mL), and GM-CSF
(20 ng/mL). Burst-forming units–erythroid (BFU-E), granulocyte-macro-
phage colony-forming units (CFU-GM), and CFU-granulocyte erythrocyte
macrophage megakaryocyte colonies (GEMM) were scored 14 days after
seeding. For the long-term culture–initiating cell (LTC-IC) assays, 4 105
GFPCD34 cells were grown on MS-5 stromal cells in IMDM, supple-
mented with 12.5% horse serum, 12.5% fetal bovine serum, 4mM
L-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, and 1M
hydrocortisone. Medium was half-replenished every week, and cobblestone
areas were scored at week 5. At week 5, cells were harvested and plated in
methylcellulose medium with cytokines, as described for the CFU assay.
The images were captured by the Leica MZFL3 Stereoscope with a
0.5 plan objective. The camera used was a QImaging RetigaEx and
Volocity Software 4.3.0 was used to acquire the images digitally.
Antibodies
The following antibodies were used for Western blot assays: the affinity-
purified anti-L3MBTL1 antibody,7 pSTAT5 (Cell Signaling), STAT5 (Cell
Signaling), pMAPK1/2 (Cell Signaling), MAPK (Cell Signaling), pAKT
(Cell Signaling), AKT (Cell Signaling), pFOXO1/3 (Cell Signaling), JNK
(Santa Cruz Biotechnology), JAK2 (Cell Signaling), p16 (Santa Cruz
Biotechnology), and Raf-1 (Santa Cruz Biotechnology).
Ras activation assay
Ras-GTP was precipitated from total cell lysates using the Ras activation
assay kit, purchased from Millipore, according to the manufacturer’s
instructions.
Overexpression assays
Retroviral vectors were produced by transfection of Phoenix A cells with
the MIGR1 control or MIGR1 full-length L3MBTL1-HA c-DNA plas-
mids,9 according to standard protocols.13 CMK, U937, HEL, and K562 cells
were grown in RPMI medium supplemented with 10% fetal bovine serum
and infected with high-titer retroviral suspensions in the presence of
8 g/mL polybrene (Sigma-Aldrich). Seventy-two hours after infection, the
GFP-positive cells were sorted by FACS.
Results
Knockdown of L3MBTL1 accelerates erythroid differentiation of
human hematopoietic CD34 progenitor cells
To investigate the function of L3MBTL1 in human hematopoiesis,
we knocked down L3MBTL1 in CD34 human CB cells, using
lentiviruses expressing shRNAs targeting L3MBTL1, and 72 hours
after infection documented the efficient knockdown of L3MBTL1
mRNA and protein in the sorted GFP CD34 cells by quantitative
RT-PCR and Western blot, for several different shRNA constructs
(Figure 1A). These cells were then placed in Epo-driven liquid
culture (6 IU/mL), and the expression of CD71 and GlyA was
monitored by flow cytometry at different time points. The genera-
tion of mature erythroid precursor cells (CD71/GlyA double-
positive cells) was consistently faster and more efficient for the
L3MBTL1-KD cells, compared with the control vector-infected
cells (Figure 1B; supplemental Figure 2). Furthermore, although
CD71/GlyA double-negative cells were prominently found among
the control cells, there were no CD71/GlyA double-negative cells
after L3MBTL1-KD. These observations were consistently seen
using several different shRNA constructs targeting L3MBTL1,
demonstrating enhanced erythroid differentiation after L3MBTL1
depletion.
To evaluate the sensitivity of L3MBTL1-KD cells to Epo, we
measured GlyA and CD71 expression by FACS analysis in the
L3MBTL1-KD HSPCs after plating these cells in culture with SCF
(100 ng/mL) and different doses of Epo (0.5, 2, 4, and 6 U/mL). At
the lowest concentration of Epo (0.5 IU/mL), and at all tested
Figure 3. Knockdown of L3MBTL1 induces further erythroid differentiation of
K562 erythroleukemia cells. (A) K562 cells, grown in RPMI medium supplemented
with 10% fetal bovine serum, without exogenous cytokines or hemin, were infected
with lentiviral constructs targeting luciferase (shLUC) or L3MBTL1 (sh1 and sh2).
GFP cells, sorted by FACS at 72 hours after infection, were analyzed for GlyA
expression by flow cytometry. (B) GFP K562 cells, before and after exposure to
hemin (50M) for 4 days, were stained with benzidine to assess their Hb content.
(C) K562 cells were treated with 50M hemin for 4 days and the L3MBTL1 mRNA
level assessed in the hemin-exposed versus the nontreated cells by quantitative
RT-PCR (n  3).
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concentrations of Epo, the L3MBTL1-KD cells showed acceler-
ated erythroid maturation compared with control cells (2.4-, 1.8-,
1.6-, and 1.6-fold, respectively; Figure 1C).
Consistent with the immunophenotypic evidence, these cells
also showed morphologic evidence of erythroid differentiation
after L3MBTL1-KD. As erythroid differentiation proceeds, eryth-
roblasts display a gradual decrease in cell size, increase in
chromatin condensation, and increase in hemoglobin (Hb) concen-
tration,18 and indeed, the L3MBTL1-KD cells appeared smaller
with more condensed chromatin than the control cells (which
displayed a larger, more homogeneous, and eccentrically placed
nucleus, as seen in Figure 1D). Likewise, benzidine staining
revealed a 6.6-fold enrichment of Hb-containing cells compared
with controls at day 7 of culture, consistent with the time of highest
immunophenotypic difference, with a 1.7-fold and 1.3-fold enrich-
ment at days 9 and 11 of culture (Figure 1E). These results further
indicate a role for L3MBTL1 in regulating the erythroid differentia-
tion of human HSPCs.
L3MBTL1 expression decreases during normal erythroid
differentiation of human HSPCs
To investigate whether changes in L3MBTL1 expression are only
seen during erythroid differentiation, we cultured normal CB
CD34 cells in various cytokine cocktails that preferentially
support erythroid, myeloid, or megakaryocytic differentiation and
evaluated L3MBTL1 expression (by quantitative RT-PCR) at differ-
ent time points. L3MBTL1 is down-regulated on differentiation
generally, but especially in cells exposed to the erythroid-
promoting cytokines SCF plus Epo (Figure 2A). These cells
maintain a low-level L3MBTL1 expression over time, whereas the
cells grown under other culture conditions show a rebound in
L3MBTL1 expression by day 7.
Given the increased erythroid differentiation after L3MBTL1-
KD, we also assessed whether L3MBTL1-KD altered myeloid
and/or megakaryocytic differentiation. L3MBTL1-KD and control
GFP CD34 cells grown in G-CSF–driven liquid culture showed
similar expression of myeloid-specific cell surface markers (CD11b,
CD14, or CD33, Figure 2B; and data not shown). Similarly, we
observed no effect on the expression of the megakaryocyte marker
CD41 in TPO-driven cultures (Figure 2C), demonstrating that
L3MBTL1 depletion specifically affects erythroid differentiation
(Figure 2D).
To investigate whether known regulators of erythropoiesis were
up-regulated after L3MBTL1-KD, we quantified the level of
Epo-receptor, GATA-1, FOG-1, NF-E2, LMO2, and FKLF mRNA
expression in L3MBTL1-KD CD34 cells plated in Epo-induced
liquid cultures and found an “erythroid signature,” as shown in
supplemental Figure 3. However, none of these genes was up-
regulated in the L3MBTL1-KD CD34 cells, 72 hours after viral
infection, before they were plated in cytokine-induced culture
conditions, even though we did find down-regulation of PU.1,
RUNX1, and CEBP mRNA (data not shown), genes known to be
Figure 4. L3MBTL1-KD leads to expansion of erythroid progenitors in long-term culture. (A) Sorted 4  105 GFP CD34 were plated on MS5 stromal cell layer and
cultured for 5 weeks. At week 5, the colonies were examined using an inverted optical microscope. The red arrows indicate the cobblestone area forming cells in the wt and
shLUC figures. The red arrows indicate the overgrowth of progenitor cells (predominantly erythroid) in the sh1 and sh2 photographs. (B) The expression of GlyA on floating cells
from 5-week LTC-IC cultures was evaluated by flow cytometry. (C) CAFC colony numbers were evaluated at week 5 of MS-5 stromal cell–based culture (n  2). (D) Week 5
LTC-IC cells were plated on methylcellulose, and the secondary BFU-E colonies were scored after 10 days. The ratio of BFU-E colonies is shown, based on BFU-E numbers in
the control cells.
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down-regulated during erythropoiesis. Thus, we cannot attribute
the pro-erythroid effects of L3MBTL1-KD to changes in any of
these “erythroid-associated genes,” at this time.
Knockdown of L3MBTL1 induces leukemia cell differentiation
toward the erythroid lineage
To determine whether L3MBTL1-KD can also affect the differen-
tiation of leukemia cells, we used lentiviral vectors to express
shRNA-targeting luciferase (shLUC) or L3MBTL1 (sh1 and sh2) in
K562 cells. We sorted GFP cells (by FACS) 72 hours after
infection and as seen in CB cells, KD of L3MBTL1 in K562 cells
increased GlyA expression, compared with control cells (Figure
3A; supplemental Figure 4), and led to higher benzidine staining
before and after hemin exposure (Figure 3B). As hemin is known to
trigger the erythroid differentiation of K562 cells17 and activate
globin gene expression,19 we studied L3MBTL1 expression in
K562 erythroleukemia cells after hemin exposure. Four days of
hemin exposure (at 50M) markedly decreased the level of
L3MBTL1 mRNA (Figure 3C) commensurate with an increase in
benzidine-positive cells and increased globin gene expression (data
not shown). Thus, L3MBTL1 loss can induce erythroid differentia-
tion in leukemia cells as well as in normal human HSPCs.
Loss of L3MBTL1 leads to expansion of erythroid progenitors
in long-term cultures
To elucidate the role of L3MBTL1 in the earliest stem/progenitor
cells, we performed LTC-IC assays, culturing 4 105 GFP
CD34 transduced cells on MS5 stromal cells. We observed an
impressive expansion of progenitor cells from the L3MBTL1-KD
cells at week 5. The L3MBTL1-KD cells grew mostly on top of the
MS5 layer, in sheets of cells rather than cobblestones, whereas the
control cells formed normal cobblestones that grew underneath the
stromal layer (Figure 4A). To define the nature of these cells, we
used flow cytometry to define their lineage-specific cell surface
marker profile. The L3MBTL1-KD showed strikingly higher GlyA
expression compared with control cells, suggesting that these cells
are erythroid progenitors (Figure 4B). Furthermore, when the week
5 culture of the LTC-IC assay cells was plated in methylcellulose,
we observed a greater number of BFU-E among the KD cells than
the control cells (Figure 4D). Nonetheless, KD of L3MBTL1 did
decrease stem cell frequency in both limiting dilution and bulk
CAFC assays (Figure 4C).
These findings suggest that L3MBTL1 knockdown may not only
promote the premature differentiation of erythroid committed cells but
may also recruit more progenitor cells to differentiate toward the
erythroid lineage. Indeed, when we sorted the L3MBTL1-KD cells into
the CMP(CD34CD38IL3RCD45RLin), MEP(CD34CD38
IL3RCD45RLin), and GMP(CD34CD38IL3RCD45R
Lin) progenitor cell subsets, we found a modest increase of the MEP
and GMP populations, at the expense of the CMP cells (supplemental
Figure 5). This implies that loss of L3MBTL1 in progenitor cells can
also drive them to differentiate. To further address this issue, we
evaluated the ability of L3MBTL1-KD HSPCs to maintain CD34
expression over time. Whereas CD34 expression was initially higher in
the KD cells, by day 11 we found no difference in CD34 expression
Figure 5. Proliferation potential of L3MBTL1-KD human hematopoietic progenitor cells. (A) The maintenance of CD34 expression was evaluated in L3MBTL1-KD CB
cells by flow cytometry. GFPCD34 CB cells were cultured with SCF, FLT-3, IL-6, and TPO. *P  .005. (B) Cell counts of L3MBTL1-KD CB cells were monitored at different
time points in liquid culture with SCF, FLT-3, IL-6, and TPO. (C) Seventy-two hours after lentiviral infection, sorted GFPCD34 HPCs were placed in CFU assays and the
number of CFUs quantified. (D) p57 mRNA expression was assessed by quantitative RT-PCR in L3MBTL1-KD HPCs, with and without exposure to 200pM TGF-1 for 2 hours
(n  2).
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between the KD and the control cells (Figure 5A). Given these findings,
we evaluated whether the commitment toward the erythroid lineage that
follows L3MBTL1 down-modulation impairs the proliferative potential
of HSPCs. Cell counts at each time point (days 7, 9, and 11) revealed
slower growth of KD-HSPCs compared with control cells in liquid
cultures with SCF, IL-3, TPO, and FLT-3 (Figure 5B), or Epo, G-CSF,
and TPO (data not shown). We also evaluated the clonogenic ability of
sorted CD34 L3MBTL1-KD HSPCs in CFU assays and found
decreased progenitor frequency compared with controls; all types of
colonies were less frequent (Figure 5C).
As the cell’s proliferative potential appears to be slightly
decreased after L3MBTL1-KD, we tested the sensitivity of HSPCs
to transforming growth factor- (TGF-). We treated CD34 cells
with 200pM TGF-, which induces the expression of p5720; we
observed a greater induction of p57 mRNA in L3MBTL1-KD cells
at 2 hours compared with control cells (Figure 5D); no change in
p57 expression was observed in the KD cells in the absence of
TGF-.
L3MBTL1-KD alters the Epo-dependent and Epo-independent
phosphorylation of STAT5, AKT, and MAP kinase
To investigate the effect of L3MBTL1-KD on intracellular signal-
ing pathways, we prepared lysates from CD34 L3MBTL1-KD
cells cultured in Epo for 1 week and performed Western blot
analyses. We found increased signaling downstream of the Epo
receptor, with consistently greater phosphorylation of AKT, FOXO
1/3, and MAPK and variably increased phosphorylation of JAK2
and STAT5, compared with controls (Figure 6A-B). RAS-GTP and
Raf-1 protein levels were decreased in the L3MBTL1-KD cells,
consistent with the enhanced erythroid maturation (Figure 6C,E).
Overall, this pattern of activation mirrors the activation of signaling
pathways seen in similarly cultured CD34 HSPCs isolated from
JAK2V617F MPN patients (Figure 6A).
To determine whether knockdown of L3MBTL1 can contribute
to the Epo-independent erythroid cell growth found in MPN
patients, we placed sorted CD34 L3MBTL1-KD cells in Epo-free
culture media supplemented with SCF, IL-6, FLT-3, and TPO for
1 week and found a small GlyA-positive (ie, erythroid progenitor)
cell population in the L3MBTL1-KD cells (Figure 6D). Despite the
absence of Epo, phosphorylation of STAT5 and AKT was clearly
seen (Figure 6E). Moreover, L3MBTL1-KD cells also displayed
increased p16INK4a expression (Figure 6E), a protein associated
with the induction of erythropoiesis in primary PV samples.21,22
To assess whether decreased L3MBTL1 expression could be
implicated in the pathogenesis of non-20q MPNs, we evaluated
the expression of L3MBTL1 in granulocytes obtained from
75 MPN patients, 28 patients with PV, and 47 patients with ET
(who did not show loss of 20q) and compared it with the level of
expression in granulocytes obtained from 10 normal donors using
Affymetrix HGU133a.2 arrays. We observed a more than or equal
to 20% decrease in the expression of L3MBTL1 in 43% of the PV
samples (12 of 28) and 62% of the essential thrombocythemia
samples (29 of 47) compared with the normal controls (P  .001
and P  .001, respectively; data not shown). This suggests that
down-regulation of L3MBTL1 may also play a role in non-20q
myeloproliferative neoplasms.
L3MBTL1 restricts erythroid differentiation
To address the function of L3MBTL1 in 20q disorders and to
explore the mechanism by which L3MBTL1 affects erythroid
differentiation, we overexpressed the full-length L3MBTL1-HA
c-DNA in 3 human 20q hematopoietic cell lines (ie, HEL, CMK,
and U937 cells) and in K562 cells. We sorted the GFP cells and
evaluated GlyA expression by FACS analysis: L3MBTL1-HA
expressing cells showed decreased expression of glycophorin A
Figure 6. Primary hematopoietic cells lacking
L3MBTL1 show Epo-independent phosphorylation of
STAT5, AKT, and MAP kinase. (A) Primary GFPCD34
cells were harvested after one week in erythroid culture
and lysed, according to standard protocols. Cultured
CD34 cells from MPN patients bearing the JAK2V617F
mutation were harvested after 1 week of culture in Epo.
Phosphorylation of STAT5, AKT, and MAPK was as-
sessed by Western blot. The protein levels of JAK2,
STAT5, AKT, MAPK, and L3MBTL1 were also assessed.
(B) Primary GFP CD34 cells were harvested after one
week in erythroid culture and FOXO phosphorylation, and
JNK expression levels were assessed by Western blot
assay. Tubulin serves as a loading control for panels
A, B, and E. (C) A total of 2  107 GFP CD34 cells,
plated in erythroid culture conditions, were tested for Ras
activation, by detection of GTP-bound Ras. Cells were
lysed and incubated with (GST)-Raf-RBD fusion protein
coupled to glutathione agarose beads. GTP-bound Ras
was detected by Western blotting using an isoform-
specific antibody. (D) Expression of the erythroid markers
CD71 and GlyA was evaluated on L3MBTL1-KD CB cells
cultured without Epo, in SCF, FLT-3, IL-6, and TPO.
(E) After 1 week in culture without Epo, the GFP CD34
cells were lysed, and phosphorylation of STAT5 and AKT
was assessed by Western blot analysis. The protein
levels of JAK2, STAT5, AKT, MAPK, Raf-1, p16, and
L3MBTL1 were also assessed.
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(Figure 7A), suggesting that L3MBTL1 restricts erythroid differen-
tiation. The decreased GlyA expression was seen in CMK (58% vs
86%) and U937 cells (0.5% vs 9%), as well as in HEL (85% vs
93%) and K562 cells (71% vs 84%).
We also overexpressed L3MBTL1 in primary human CD34
cells, obtaining an almost 200-fold increase in L3MBTL1 expres-
sion, as documented by quantitative RT-PCR (Figure 7D). We
placed the sorted GFP CD34 cells in Epo-induced liquid culture
and consistently found a decreased percentage of CD71/GlyA
cells (62% vs 70%) after 3 days of culture (Figure 7C). The milder
decrease in GlyA expression seen in primary human CD34 cells,
compared with the 20q cells, may reflect the normal genetic
background of the transduced cells and their intrinsic growth rates.
Overexpression of L3MBTL1 in HEL cells did decrease the
expression of p16INK4 (Figure 7B), further suggesting that L3MBTL1
may affect erythropoiesis by regulating (ie, repressing) p16 expres-
sion. Further studies are needed to address this issue.
Discussion
Haploinsufficiency of the polycomb group (PcG) gene L3MBTL1
has been identified in patients with 20q-associated myeloid
malignancies,11,12 but whether this has functional relevance for
these disorders has not been previously determined. We have
demonstrated that L3MBTL1 loss induces the erythroid differentia-
tion of human HSPCs and therefore could contribute to the most
common 20q-associated hematologic disorder, PV. Further,
L3MBTL1-KD CD34 cells show an enhanced response to Epo,
resulting in the more rapid development of immunophenotypically
and morphologically mature erythroblasts with increased hemoglo-
bin content, compared with control cells. We have demonstrated
the increased sensitivity of L3MBTL1 knockdown hematopoietic
stem/progenitor cells to Epo at different concentrations of Epo and
at very early time points. The erythroid commitment that follows
L3MBTL1-KD occurs early, based on the erythroid progenitor cell
expansion seen in the LTC-IC assay. However, the observed
changes in the frequency of the different human progenitor cell
subsets (decreased CMP and increased GMP and MEP cells) may
indicate a second effect, in the committed progenitor cell population.
L3MBTL1 is classified as a polycomb group protein, and recent
evidence suggests that PcG proteins regulate stem cell pluripotency
by maintaining the repression of lineage-specifying genes that
trigger the differentiation process.23,24 L3MBTL1 is down-regulated
on Epo- or hemin-induced erythroid differentiation. L3MBTL1 is
also down-regulated, or at least is less abundant in MEP cells
compared with more immature stem cells or progenitor cell
populations (such as CMP), which suggests that erythroid differen-
tiation may require “silencing” of L3MBTL1 function. As a
compactor of euchromatin, L3MBTL1 could serve as an epigenetic
brake on erythroid commitment. Gene expression profiling of cells
treated with Epo supports this hypothesis, as L3MBTL1 is one of
the genes most strongly down-regulated on Epo exposure.25
Pr-Set7, an H4K20-specific methyltransferase that physically asso-
ciates with L3MBTL1 and is responsible for the H4K20 methyl
mark that serves as a docking site for L3MBTL1 binding, is also
down-regulated in hemin-treated K562 cells,9,26 which suggests
that, by binding chromatin and maintaining repression of its target
genes, L3MBTL1 impairs erythroid differentiation.
Recently, the ability of reactive oxygen species to trigger the
precocious differentiation of Drosophila stem cells into all 3 mature
blood cell types has been linked to down-regulation of PcG
expression.27 This down-regulation is associated with JNK activa-
tion, and it triggers differentiation toward lamellocyte but not
plasmatocyte or crystal cell differentiation, somewhat similar to the
effects of L3MBTL1 KD on erythroid, but not myeloid or
megakaryocytic, lineages. Reactive oxygen species triggers FOXO
activation27; similarly, we found increased phosphorylation/
Figure 7. L3MBTL1 restricts erythroid differentiation.
(A) GlyA expression was assessed by FACS in the
L3MBTL1-HA expressing CMK, U937, HEL, and K562
cells compared with the MIGR1 (empty vector) trans-
duced cells. (B) p16 protein expression levels were
determined by Western blot analysis in L3MBTL1-HA
HEL cells versus the MIGR1 (empty vector) control HEL
cells. JNK and L3MBTL1 levels are also shown. Tubulin
served as the loading control. (C) GlyA expression in
L3MBTL1-HA expressing CD34 cells after 3 days of
culture with SCF 100 ng/mL and Epo 6 IU/mL, compared
with the MIGR1 (empty vector) transduced cells.
(D) L3MBTL1 mRNA expression levels in retrovirally
infected CD34 cells, quantified by quantitative PCR
(n  3).
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activation of the STAT5, AKT/FOXO, and MAPK pathways in
L3MBTL1-KD HSPCs, even in the absence of Epo. Such Epo-
independent signaling is a hallmark of the MPNs, especially PV.
PcG members specifically repress the JAK-STAT pathway in the
Drosophila eye imaginal disc,28 and our data suggest that L3MBTL1
acts in a fashion similar to regulate erythroid differentiation.
We also found increased expression of p16INK4a in
L3MBTL1-KD cells. Increased expression of p16INK4A is also
found in erythroid colony-forming cells isolated from patients with
PV.21 p16 has been linked to erythroid differentiation and apoptosis
in erythroleukemia cells22 and may play a role in mediating the
effects of L3MBTL1 in erythropoiesis because we also observed
down-regulation of p16 after L3MBTL1 overexpression. Like p16
up-regulation, down-regulation of FoxOs by L3MBTL1-KD could
also contribute to the decreased CAFC frequency seen after
L3MBTL1-KD.29 Although we previously reported that
L3MBTL1-KD can increase c-myc levels in some cell types, and
cyclin E or cyclin A levels in others,10,30 we did not observe such
increases in the human CD34 cells at the time points assayed (data
not shown). Such increases are seen in terminally differentiated
cells (such as 293T cells) and may be needed for cells to manifest a
strong proliferative response to L3MBTL1-KD.
In future studies, we wish to determine whether L3MBTL1 loss
can cooperate with the constitutively activated mutant JAK2
kinases found in patients with MPNs. There appears to be a
relationship between del20q and the occurrence of the JAK2
V617F mutation. In one study of 29 patients with 20q deletion,
28 were found to be JAK2 V617F.31 In another study of MPN
patient samples, the JAK2V617F/JAK2 burden was 2% to 25%
of the clonal cells, even though all of the clonal cells had
del20q.32 Whereas these studies suggest that the 20q deletion
may represent one of several pre-JAK2 events (others being
mutations in TET2, ASXL1, c-CBL, or currently unknown
proteins),33,34 Schaub et al have reported that del20q may occur
after the acquisition of JAK2V617F in some clones.35 It is
possible that, during the genesis of the MPNs, the acquisition of
additional genetic mutations (ie, JAK2V617F) allows L3MBTL1-
deficient cells to override the antiproliferative mechanisms
elicited by p16 or MAPK activation.
L3MBTL1 plays a key role in hematopoiesis by regulating the
erythroid differentiation of HSPCs. Given that L3MBTL1 is located
within the common deleted region on 20q seen in patients with PV,
our data suggest that loss of L3MBTL1 is important in the
pathogenesis of such disorders.
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ETV6-ABL1-positive “chronic myeloid leukemia”:
clinical and molecular response to tyrosine
kinase inhibition
While great progress has been achieved in the clinical
management and molecular understanding of Ph+ chron-
ic myeloid leukemia (CML), little is known about the
optimal approach to monitor and treat patients with
ETV6-ABL1+ myeloproliferative neoplasms. Nine BCR-
ABL1-negative CML patients with a variant ABL1 gene
(9q34) rearrangement, involving fusion to ETV6 aka TEL
(12p13) have been reported thus far.1-9 The ETV6-ABL1
fusion gene has also been identified in 3 patients with
chronic myeloproliferative neoplasms other than “chron-
ic myeloid leukemia” (cMPN) as well as 7 patients with
BCR-ABL1 negative acute lymphoblastic leukemia and 4
patients with acute myeloid leukemia.10, 11 Of the 9 cases
of ETV6-ABL1+ chronic myeloid leukemia, only 2 were
treated with a TKI in chronic phase4, 5 and only one of
these reached a complete remission with a modest follow
up of seven months (no molecular monitoring was per-
formed).4 Among the other published ETV6-ABL1+
reports, one patient was treated with a second generation
TKI for a relapsed cMPN.12 We provide the first molecular
documentation of sustained remission of ETV6-ABL1+
chronic phase “chronic myeloid leukemia” (CML requires
a BCR-ABL1 fusion according to the most recent 2008
WHO classification) to TKI. Molecular monitoring for the
ETV6-ABL1 transcript is important given the fact that
conventional karyotyping frequently fails to detect a
cryptic translocation, i.e. the t(9;12). We provide evidence
that treatment of ETV6-ABL1+ “chronic myeloid
leukemia” with imatinib results in downregulation of C-
MYC, BCL-XL, ID1 and NUP98, mediators of BCR-ABL1
transforming activity. Moreover, we found no associated
mutations in UTX, ASXL1, EZH2, TET2 and IDH1/2 sug-
gesting that ETV6-ABL1+ “chronic myeloid leukemia”
may be as tyrosine kinase focused as BCR-ABL1 driven
disease.
The patient is a 36-year male who was found to have
splenomegaly and a total white blood cell (WBC) count
of 55¥109/L (57% neutrophils, 6% lymphocytes, 1%
monocytes, 3% eosinophils, 2% basophils, 7%
metamyelocytes, 24% myelocytes). Lactate dehydroge-
nase was elevated at 653 IU/L. Bone marrow biopsy
revealed myeloid hyperplasia suggestive of a myeloprolif-
erative disorder. qRT-PCR for BCR-ABL1 translocation
was negative. No BCR-ABL1 fusion signal was observed
in interphase FISH analysis using BCR (22q11.2) and
ASS-ABL1 (9q34) probes. Instead, 80% of interphase
nuclei showed a variant signal pattern consisting of two
signals for BCR and three signals for ASS-ABL1 consis-
tent with rearrangement of ABL1 at 9q34 but not BCR at
22q11. Cytogenetic G-banding analysis and FISH showed
t(9;12)(q34;p13) in an otherwise normal karyotype
(Figure 1A and B). RT-PCR detected the ETV6-ABL1
translocation and the patient was diagnosed with ETV6-
ABL1+ CML-like disorder. Given the persistence of night
sweats and fevers, and the persistent disease despite
hydroxyurea at 1,000mg daily (WBC decreased to 7¥109
cells/L after one month of hydroxyurea) imatinib mesy-
late, 400mg daily, was initiated. The patient tolerated
imatinib and achieved a complete hematological remis-
sion after three months of treatment (WBC 5.6¥109
cells/L). FISH testing after three months of imatinib
revealed no evidence of rearrangement at the BCR or
ETV6 loci (Figure 1B). 
To follow the patient’s response to therapy more sen-
sitively, qRT-PCR was performed using primers for ETV6
and ABL1 (Online Supplementary Appendix).
Quantification of the ETV6-ABL1 transcript level in
peripheral blood cells one month prior to initiation of
imatinib revealed 2,160¥103 ETV6-ABL1 copies/μg RNA.
After one month of treatment, ETV6-ABL1 transcript
level dropped to 495¥103 copies/μg RNA. The ETV6-
ABL1 transcript became undetectable by seven months of
treatment, indicating a complete and rapid molecular
response. The patient’s molecular response closely mir-
rored normalization of the WBC count (Figure 2A). We
also evaluated the expression of BCR-ABL1 target genes
C-MYC, BCL-XL, ID1 and NUP98, pre- and post-imatinib
treatment (Figure 2B). The expression of these genes
closely mirrored ETV6-ABL1 expression: imatinib down-
regulated their expression. The patient has continued to
342 haematologica | 2011; 96(2)
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Figure 1. Diagnosis of ETV6-ABL1 positive CML. (A) G-banded
karyotype showing t(9;12)(q34;p13) in the bone marrow sam-
ple from the patient with a clinical diagnosis of chronic
myeloid leukemia. No additional cytogenetic abnormalities
were observed (data not shown). (B) Bone marrow interphase
cells showing rearrangements, as three signals were seen for
ABL1 (orange) and ETV6 (green) genes by hybridization with
BCR/ABL1 (upper left) and ETV6/AML1 (lower left) FISH
probes. N.B. Only two signals were detected for the BCR
(green, upper left) and AML1 (orange, lower left) loci; seven
months after treatment with imatinib, no rearrangements
were seen, as only two signals were generated by the ABL1
and ETV6 genes following hybridization with the BCR/ABL1
(upper right) and ETV6/AML1 (lower right) FISH probes.
A B Pre-imatinib Post-imatinib
BCR-ABL 1
probe
9 12
ETV6-AML
probe
do well on imatinib 400mg/day with no evidence of
ETV6-ABL1 transcript by qRT-PCR for the past five years.
Somatic mutations in UTX, ASXL1, and TET2 have
been reported in chronic myeloid leukemia and muta-
tions in EZH2 and IDH1/2 in myeloid malignancies other
than CML. We found no somatic alterations in these
genes in the DNA extracted from whole blood prior to
imatinib treatment, nor when the patient was in a molec-
ular remission.
Our studies indicate that ETV6-ABL1+ “chronic
myeloid leukemia” can be sensitive to imatinib and there
is significant overlap of molecular targets of ETV6-ABL1
with those of BCR-ABL1, suggesting that the ETV6-ABL1
fusion protein may trigger similar oncogenic cascades as
BCR-ABL1. Finally, we were able to exclude mutations in
any of the recently identified “myeloid” genes including
UTX, ASXL1, EZH2, TET2 and IDH1/2 suggesting that
the pathogenesis of ETV6-ABL1+ “chronic myeloid
leukemia” may be as tyrosine kinase focused as BCR-
ABL1 driven disease. 
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Cytogenetically complex SEC31A-ALK fusions are
recurrent in ALK-positive large B-cell
lymphomas
Fusion tyrosine kinases involving anaplastic lym-
phoma kinase (ALK) are central to the pathogenesis of
numerous malignancies, in which they represent impor-
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Figure 2. Response to Imatinib in an ETV6-ABL1 positive chronic
myeloid leukemia. (A) White blood cell count and peripheral blood
qRT-PCR analysis of ETV6-ABL1 transcript levels pre-imatinib and
throughout imatinib treatment. (B) Concomitant with decreases in
ETV6-ABL1 transcript levels, decreases in C-MYC, ID1, BCL-XL, and
NUP-98 transcripts were also seen. The patient remains in hema-
tological remission with no identifiable ETV6-ABL1 transcripts in
the peripheral blood after approximately five years of imatinib. 
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L3MBTL1 polycomb protein, a candidate tumor
suppressor in del(20q12) myeloid disorders, is
essential for genome stability
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The l3mbtl1 gene is located on the long arm of chromosome 20
(q12), within a region commonly deleted in several myeloid malig-
nancies. L3MBTL1 is a human homolog of the Drosophila polycomb
L(3)MBT tumor suppressor protein and thus a candidate tumor sup-
pressor in del(20q12) myeloid disorders. We used the loss-of-func-
tion approach to explore the possible tumor suppressive mecha-
nism of L3MBTL1 and found that depletion of L3MBTL1 from
human cells causes replicative stress, DNA breaks, activation of
the DNA damage response, and genomic instability. L3MBTL1
interacts with Cdc45, MCM2-7 and PCNA, components of the
DNA replication machinery, and is required for normal replication
fork progression, suggesting that L3MBTL1 causes DNA damage,
at least in part, by perturbing DNA replication. An activated DNA
damage response and genomic instability are common features in
tumorigenesis and a consequence of overexpression of many on-
cogenes. We propose that the loss of L3MBTL1 contributes to the
development of 20q− hematopoietic malignancies by inducing rep-
licative stress, DNA damage, and genomic instability.
H4K20me1/2 binding protein | chromatin reader
The l3mbtl1 gene is located on the long armof chromosome 20q,within a region on 20q12 commonly deleted in several myeloid
malignancies, including myeloproliferative neoplasms, myelodys-
plastic syndromes, and acute myeloid leukemia (1). It has been
proposed that the 20q12 locus contains one or more tumor sup-
pressors, which when lost contribute to the development of these
disorders. L3MBTL1 is a human homolog of the Drosophila
polycomb group (PcG) proteinL(3)MBT.Homozygousmutations
of the Drosophila l3mbt gene cause malignant transformation of
the adult optic neuroblasts and ganglion mother cells in the larval
brain (2). Somatic, focal deletions of other humanL3MBTL family
members, the l3mbtl2 and l3mbtl3 genes, have recently been found
in human medulloblastoma (3). These ﬁndings suggest that
L3MBTL1 is a candidate tumor suppressor gene in myeloid ma-
lignancies associated with 20q12 deletions.
The L3MBTL1 protein contains three MBT repeats, which as-
sume a three-bladed propeller-like architecture, as well as a Zn
ﬁnger and an SPM dimerization domain (4, 5). We previously
demonstrated that L3MBTL1 functions as anHDAC-independent
transcriptional repressor (6) that binds preferentially tomono- and
dimethylated lysines of histones via the second of its three MBT
repeats (7, 8). The threeMBTdomains of L3MBTL1 are sufﬁcient
to compact nucleosomal arrays. This compaction requires that the
nucleosome contain a mono- or dimethylated lysine 26 on histone
H1b or lysine 20 on histone H4 (H4K20) (7). L3MBTL1 binds to
chromatin most prominently during the S phase of the cell cycle,
concomitant with the appearance of the monomethylated H4K20
(H4K20me1) mark (8), suggesting that the biological function of
L3MBTL1 may be related to DNA replication.
The accurate duplication of DNA during replication is es-
sential for maintaining genomic stability, as uncorrected errors
made during this process can lead to DNA breaks, which gen-
erate mutations and/or chromosomal translocations that can
promote tumorigenesis (9). DNA breaks resulting from replica-
tive stress trigger an ATM/ATR-dependent DNA damage re-
sponse (DDR), which prevents the proliferation of cells with
damaged DNA by inducing either cell cycle arrest or apoptosis.
An activated DDR is present in precancerous lesions from tis-
sues of different origins, and many overexpressed oncogenes
cause replicative stress and activation of the DDR. When cou-
pled with mutations in checkpoint and/or DNA repair genes,
these abnormalities can lead to cancer (10–12).
In this study we examined the function of L3MBTL1 in mam-
malian cells and found that L3MBTL1 interacts with several
components of the DNA replication machinery. Depletion of
L3MBTL1 in cells was sufﬁcient to trigger the DDR and pro-
mote genomic instability. Thus, L3MBTL1 is essential for main-
taining DNA replication, providing a mechanism for its role as
a putative tumor suppressor protein.
Results
Depletion of L3MBTL1 Inhibits Cell Proliferation and Causes G2/M
Arrest. To assess the role of L3MBTL1 in cell cycle regulation, we
depleted L3MBTL1 mRNA and protein in U2OS cells using
lentiviral vectors that expressed several shRNAs directed against
its ORF. Down-regulation of L3MBTL1 mRNA and protein was
achieved efﬁciently with three different shRNAs (≥90% knock-
down; Fig. 1 A and B). The depleted cells were monitored for
S phase entry by using BrdU incorporation, and we detected
amarked decrease of S phase cells and the accumulation of cells in
the G2/M phase (Fig. 1C and Fig. S1A). This effect was also ob-
served in MRC5 normal diploid ﬁbroblasts, Cal51, T98G, and
K562 cells following L3MBTL1 knockdown (Fig. S1 B–D), dem-
onstrating that it is not cell-type speciﬁc; it occurred in non-
cancerous cells as well as hematopoietic K562 cells. These ﬁndings
indicate that these cell cycle effects are relevant to the myeloid
compartment.
Depletion of L3MBTL1 Generates DNA Breaks. Cell cycle alterations
triggered by L3MBTL1 depletion suggest that cells may be ex-
periencing replicative stress, leading to DNA damage. To verify
this hypothesis, we examined two DNA damage markers, the
production of the phosphorylated histone H2A.x (γH2A.x),
which localizes to sites of double-stranded DNA breaks (DSBs)
(13), and the distribution of 53BP1, which is recruited to DNA
within minutes following DNA damage by binding to H4K20me2
and possibly other modiﬁed histones (14). We observed an in-
crease in both γH2A.x and 53BP1 foci following L3MBTL1 de-
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pletion with all three shRNAs in U2OS (Fig. 2 A and B) and in
MRC5 ﬁbroblasts (Fig. S2A).
We also measured the formation of DNA strand breaks in
L3MBTL1-depleted cells using the comet assay, which visualizes
damaged DNA on a single-cell level (15). Comet tails were de-
tected in depleted U2OS cells (Fig. 2C and Fig. S2B), MRC5 and
Cal51 cells (Fig. 2D), indicatingDNA strand breakage.We treated
MRC5 ﬁbroblasts with varying doses of gamma irradiation to es-
tablish a range of tail moments (Fig. 2D) and determined that
depletion of L3MBTL1 caused extensive DNA damage, similar to
that induced by 5 Gy of irradiation.
Loss of L3MBTL1 Activates the DDR and Affects H4K20 Methylation
Status. DNA damage triggers a checkpoint response that prevents
cells from progressing into mitosis. To explore this pathway, we
ﬁrst examined the phosphorylation of the ATM kinase, one hall-
mark of the DDR pathway (16), and detected increased phospho-
ATM foci that overlapped with 53BP1 foci in L3MBTL1-depleted
cells (Fig. 3A). We also examined whether the downstream com-
ponents of theATR/ATM-triggeredDDRpathwaywere activated
following L3MBTL1 depletion using immunoblotting to monitor
changes in phosphorylation of the key components of this system,
including Chk1 and Chk2. As shown in Fig. 3B, increased levels of
phospho-Ser317-Chk1, phospho-Ser345-Chk1, and phospho-
Thr68-Chk2weredetected in cells at 24, 48, and 72hpostinfection,
similar to that observed in cells irradiated with 10 Gy.
Depletion of L3MBTL1 altered the activities as well as the
levels of a number of proteins associated with checkpoint regu-
Fig. 2. Depletion of L3MBTL1 generates DNA breaks. (A)
U2OS cells infected with one of several shRNAs against
L3MBTL1 or with control shRNAwere stained with antibodies
against 53BP1 and γH2A.x. (B) DNA damage foci were quan-
titated in control and L3MBTL1 knockdown cells based on
whether they containedmore or less thanﬁve foci per cell. (C)
The tail moment was calculated and plotted from three in-
dependent comet assays of U2OS cells treated with control
shRNA or L3MBTL1 shRNA U2OS cells at 24 and 48 h after in-
fection. (D) Calculated tail moments from comet assays of
control and L3MBTL1-depleted MRC5 and Cal51 cells 48 h af-
ter infectionareplotted. The tailmomentwas calculated from
comet assays of control MRC5 cells vs. cells irradiated with the
indicated dose of gamma irradiation and the data plotted.
Fig. 1. L3MBTL1 depletion inhibits cell proliferation and
causes G2/M arrest. U2OS cells were infected with control
shRNA or one of several different lentiviral shRNAs target-
ing L3MBTL1. Levels of L3MBTL1 mRNA (A) and protein (B)
were measured by quantitative RT-PCR and immunoblotting
48 h after infection. L3MBTL1 mRNA levels detected were
adjusted for loading discrepancies using Hprt mRNA as the
loading standard, and the levels of mRNA detected were
plotted as a percent of the L3MBTL1 observed in U2OS cells
infected with control shRNA. To quantitate depletion of
L3MBTL1, the relative protein levels of L3MBTL1 were ad-
justed using the α-tubulin loading control and quantiﬁed
relative to the protein level present in the control sample
(set as 1). (C) U2OS cells were infected with control shRNA or
with L3MBTL1 shRNA #3. After 48 h, cells were incubated
with BrdU, stained with BrdU-APC antibody and propidium
iodide (PI), and analyzed by ﬂow cytometry. The distribution
of BrdU (y axis) and PI (x axis) is plotted.
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lation and the DDR pathway (Fig. 3 B–D). These include: (i) the
formation of phospho-Tyr15-Cdc2, a modiﬁcation that inhibits
Cdc2 kinase activity, which is required for cell cycle progression
into mitosis (17) (Fig. 3B and Fig. S3A); (ii) the up-regulation of
p21 and p53, downstream effectors of the DDR pathway, as well
as Rad51, which plays a key role in double-strand break repair by
homologous recombination (Fig. 3C and Fig. S3B), and (iii) an
increase in the level of γH2A.x (Fig. 3D and Fig. S3C), in
keeping with the data shown in Fig. 2. We also observed an in-
crease in the amount of H4K20me2 (40- to 90-fold), which plays
important roles in DNA replication and DNA damage recogni-
tion (18), but detected little effect on the levels of H4K20me1.
Conversely, overexpression of L3MBTL1 in U937 cells that have
monoallelic loss of the commonly deleted region of 20q had the
opposite effect, namely, a decrease in H4K20me2 and an in-
crease in H4K20me1 (Fig. 3E). Collectively, these data show that
the DDR pathway is strongly activated following depletion of
L3MBTL1 and suggest that changes in the level of H4K20 di-
methylation could contribute to these effects.
We, and others, have found L3MBTL1 complexed with Rb/
E2F proteins repressed the activation of some E2F target genes,
including c-myc and Cyclin E1, two established oncogenes (7,
8, 19, 20). We tested whether these genes were up-regulated
in L3MBTL1 knockdown cells, but noted no changes in their
levels at 48 h following lentiviral infection with shRNAs against
L3MBTL1 (Fig. S3D). Thus, induction of the DDR following
L3MBTL1 depletion cannot be explained by the enhanced ex-
pression of c-myc or Cyclin E1.
L3MBTL1 Depletion Slows the DNA Replication Forks Movement. The
presence of DNA damage and activation of the DDR suggest that
depletion of L3MBTL1 may trigger defects in DNA replication.
We examined DNA replication fork progression by DNA ﬁber
analyses. For this purpose, control and L3MBTL1-depleted cells
were sequentially pulsed for 1 h each with IdU and CldU, lysed,
and DNA ﬁbers spread on slides. The ﬁbers were labeled with
antibodies to IdU and CldU and ﬂuorescence-labeled secondary
antibodies. Fibers containing green IdU ﬂuorescent label ﬂanked
on each side with the red CldU ﬂuorescent label represent DNA
molecules formed by bidirectional movement of replication forks.
Fig. 4A shows DNA ﬁbers isolated from control and L3MBTL1-
depleted MRC5 ﬁbroblasts. The length of the green IdU-labeled
ﬁbers, indicating DNA replicated from origins, was shorter in
depleted cells than in ﬁbers isolated from control cells. Further-
more, the total length of red CldU- and green IdU-labeled ﬁbers
was shorter in L3MBTL1-depleted cells than in control cells, in-
dicating slower replication fork movement. The average length of
DNA ﬁbers from L3MBTL1-depleted cells and control cells was
16.8 μM and 31.7 μM, respectively (Fig. 4B); 78% of the DNA
ﬁbers from L3MBTL1-depleted cells were <20 μM, whereas 33%
of ﬁbers from control cells were this length (Fig. 4C). Similar data
were obtained using U2OS cells, indicating that this effect is not
cell-type speciﬁc (Fig. 4 D and E). The average rate of fork pro-
gression in L3MBTL1-depleted cells was ∼40% slower than in
control cells, indicating that L3MBTL1 is required for the normal
progression of DNA replication forks.
L3MBTL1 Interacts with Components of DNA Replication Machinery.
Because L3MBTL1 appears to play a role in replication fork
progression, we tested whether it interacted with components of
the DNA replication machinery. We overexpressed HA-tagged
L3MBTL1 in 293T cells, and examined its interaction with mem-
Fig. 3. Depletion of L3MBTL1 activates the DDR. (A) Control
and L3MBTL1-depleted U2OS cells were stained with anti-
bodies against 53BP1 and phospho-ATM (pATM) 48 h post-
infection. (B) U2OS cells infected with control or L3MBTL1
shRNAs were harvested 24, 48, and 72 h postinfection and
immunoblotted with the indicated antibodies to detect acti-
vation of the DDR. Unirradiated cells (unirr) and cells har-
vested 1 h following 10 Gy of gamma irradiation (γ-irr) were
used as negative and positive controls for activated DDR
proteins. (C) Lysates from control and L3MBTL1-depleted
U2OS cells were isolated 24 and 48 h postinfection, and the
levels of Rad51, p53, p21, and actin determined by immuno-
blotting with the indicated antibodies. (D) Lysates from U2OS
cells infected with three different shRNAs against L3MBTL1
were harvested at 48 h and immunoblotted with antibodies
directed against γH2A.x, H4K20me1, H4K20me2, histone H3,
and tubulin. (E) Histones were extracted from U937 cells that
overexpress L3MBTL1 or that contain empty vector control
and immunoblotted for H4K20me1, H4K20me2, and histone
H3 (loading control).
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bers of theMCM2-7 complex, a critical component of the putative
replicative helicase. As shown in Fig. 5A, HA-tagged L3MBTL1
interacted with the MCM2-7 complex, and L3MBTL1 was
immunoprecipitated by antibodies against MCM2 and MCM5
(Fig. 5B). Cdc45 and theGINS complex forma replicative helicase
complex with MCM2-7 (CMG complex) (21) that travels with the
replication fork (22). These ﬁndings prompted us to examine
whether L3MBTL1 interacted with these components as well as
other replication proteins. As shown in Fig. 5A, the interaction of
L3MBTL1 with Cdc45 was detected, whereas an interaction with
Sld5 (a subunit of the GINS complex) was not observed. Inter-
actions with PCNA, the DNA sliding clamp required for proc-
essivity of the replicative DNA polymerases, were also noted,
whereas interaction with Fen-1, an enzyme involved in DNA re-
pair and lagging strand processing, was not observed (Fig. 5A).We
also examined whether the levels of replication proteins were af-
fected by depletion of L3MBTL1 in U2OS cells. As shown in Fig.
S4, we did not ﬁnd signiﬁcant changes. Thus, L3MBTL1 interacts
with a number of proteins that play roles in different stages of
DNA replication, consistent with the notion that it affects repli-
cation. The mechanisms contributing to these effects remain to be
investigated.
Discussion
In this study we demonstrate that depletion of L3MBTL1 in-
duces DNA damage and slows cell cycle progression by arresting
cells in the G2/M phase. L3MBTL1 interacts with components of
the DNA replication machinery (MCM2-7 proteins, Cdc45, and
PCNA) and is required for the normal movement of DNA rep-
lication forks. These ﬁndings suggest that L3MBTL1 inﬂuences
multiple aspects of DNA replication and repair.
The methylation status of H4K20 is important in DNA repli-
cation and DDR pathways (18). SUV4-20 methyltransferase cat-
alyzes the di- and trimethylation of H4K20, and Suv4-20 knock-
out mice, which can only form theH4K20me1 derivative, are more
sensitive to DNA damage than wild-type mice (23). Loss of Pr-
Set7, a histone methyltransferase that monomethylates lysine 20
on histone H4, induces DNA damage in human, mouse, and Dro-
sophila cells. Pr-Set7 has also been implicated in DNA replication
(24–29).We previously established that L3MBTL1 binds to mono-
and dimethylated H4K20, and interacts directly with PR-Set7. The
binding of L3MBTL1 to chromatin occurs during S phase, coin-
cidental with the appearance of H4K20me1, suggesting that it
binds to the mark to exert its effects (8). Depletion of L3MBTL1
resulted in a marked increase in H4K20me2 levels (Fig. 3D),
possibly by allowing dimethylation of H4K20 by Suv4-20 histone
methyltransferase. The biological effects observed following de-
pletion of L3MBTL1 closely parallel those resulting from the loss
of Pr-Set7, suggesting that the ability of L3MBTL1 to recognize
and bind to the H4K20me1 mark produced by Pr-Set7 plays an
important role in maintaining genomic stability.
Fig. 4. Depletion of L3MBTL1 alters the pro-
gression of DNA replication forks. MRC5 and
U2OS cells infected with control or L3MBTL1
shRNA were incubated for 1 h with IdU followed
by 1 h incubation with CldU and then subjected to
analysis of replication fork movement. (A) In-
dividual replication units were visualized by im-
munoﬂuorescence for incorporated halogenated
nucleotides in isolated DNA ﬁbers, as described in
Materials and Methods. Images of ﬁbers from
MRC5 cells infected with control or L3MBTL1
shRNAs are shown. (B) The mean DNA ﬁber
length from MRC5 cells infected with control or
L3MBTL1 shRNA was calculated by measuring at
least 100 ﬁbers in each experiment, and the
results plotted. (C) The data for one representa-
tive experiment with MRC5 cells are plotted as
percentage of DNA ﬁbers with each speciﬁed
length. (D) Mean DNA ﬁber length for U2OS cells
infected with control or L3MBTL1 shRNA was
calculated by measuring at least 100 ﬁbers in each
experiment and plotted. (E) The data derived
from an experiment using U2OS cells are plotted
as percentage of replication forks with the spec-
iﬁed DNA ﬁber length indicated.
Fig. 5. L3MBTL1 interacts with components of the DNA replication ma-
chinery. (A) HA-L3MBTL1 was overexpressed in 293T cells, and cell lysates
were immunoprecipitated and immunoblotted with the HA or rabbit IgG
antibodies. (B) Flag-L3MBTL1 was overexpressed in 293T cells, and cell lysates
were immunoprecipitated with antibodies against Mcm2, Mcm5, or rabbit
IgG. Following SDS/PAGE separation, gels were immunoblotted with Flag
antibody to detect L3MBTL1. The immunoprecipitation of Mcm2 and Mcm5
proteins was veriﬁed by immunoblotting with the corresponding antibodies,
using rabbit IgG as a control.
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At present, it is unclear how L3MBTL1 contributes to geno-
mic stability and inﬂuences fork progression. Its role in fork
progression may relate to its function in maintaining genomic
stability, as L3MBTL1 depletion triggers the DDR, which leads
to checkpoint activation and a halt in replication. Recently, Qin
et al. (30) found that loss of L3MBTL1 in mice does not alter
H4K20 methylation or result in tumor formation. Differences
between the Qin et al. study (30) and ours may reﬂect the effects
caused by the acute loss of L3MBTL1 vs. its chronic absence in
the knockout mice, where functional compensation by another
L3MBTL family member could occur. Furthermore, H4K20
methylation levels may be controlled differently in ES cells than
in the normal, human diploid ﬁbroblasts that we have studied. As
oncogenesis is a multistep process, it seems highly likely that
additional molecular events are needed to induce tumorigenesis.
Interactions between L3MBTL1 and Cdc45 and MCM2-7 sug-
gest that L3MBTL1 may have a more direct role in DNA repli-
cation; however, further studies will be required to deﬁne the
functional signiﬁcance of these interactions and to determine
whether the position of L3MBTL1 is within or external to nucle-
osomes, because nucleosome deposition occurs behind the fork on
newly synthesized DNA. L3MBTL1 may also prevent the con-
version of the H4K20me1 mark to H4K20me2 by Suv4-20, as we
detected an increase inH4K20me2 in cells depleted of L3MBTL1.
Though L3MBTL1 is degraded during mitosis (8), depletion of
L3MBTL1 before the G2/M transition leads to the generation of
the H4K20me2, which recruits 53BP1, thereby promoting the
DDR and hindering normal replication. Normally, Suv4-20 acts
during theM and G1 phases to convert H4K20me1 to H4K20me2
(31). This methylation step may occur primarily in the absence of
chromatin-bound L3MBTL1. Consistent with this notion, we
found that L3MBTL1 depletion slowed replication fork pro-
gression and increased the formation of 53BP1 foci. Whether re-
moval of L3MBTL1 from the H4K20me1 mark is required for the
DDR, by triggering the H4K20me2 generation and subsequent
binding of 53BP1, will require further investigation.
DNA damage and genomic instability promote oncogenesis
(32), and tumor samples isolated from patients at diagnosis often
show constitutive activation of DNA damage signaling (10, 11).
This DDRactivation is most prominent in early, preinvasive stages
of a diverse group of cancers. Overexpression of activated onco-
genes, such as c-myc, H-Ras, Cdc25A, cyclin E1, and E2F1, in
multiple cell types leads to a strong DDR activation (10, 33–35)
and recapitulates the ﬁndings seen in precancerous lesions. This
phenomenon is also relevant to hematopoietic malignancies, as
both the PML-RARα and AML1-ETO leukemia-associated fu-
sion proteins trigger the DDR in normal hematopoietic cells (36).
Mechanistic studies implicate oncogene-induced DNA replication
stress, including replication fork collapse and formation of double-
stranded breaks, as the stimulus that evokes the DDR response
(12), and in the case of c-myc, the induction of DNA damage was
shown to result from its direct involvement in DNA replication
(37). Although this response acts as a barrier against oncogene-
induced transformation, acquired mutations in DNA-damage
checkpoint proteins, such as p53 or ATM, could permit cells with
damaged DNA to slip through the checkpoints and progress to
a full-blown cancer (38).
We have shown that the depletion of L3MBTL1, a candidate
tumor suppressor gene, leads to the activation of the DDR.
Failure to correct DNA damage caused by the loss of L3MBTL1
could lead to genomic instability and the development of a my-
eloid malignancy. Indeed, we detected an increased number of
speciﬁc breaks, gaps, and exchanges in metaphase chromosome
spreads of L3MBTL1 knockdown cells (Fig. S5). Drosophila
L3MBTL was found to be part of the Myb/E2F2/RBF complex,
which has roles in both transcription and replication (18, 39), and
human L3MBTL1 is also found in similar complexes (7). More-
over, Lin-61, the Caenorhabditis elegans homolog of L3MBTL1,
has been implicated in maintaining genomic integrity (40, 41).
These observations suggest that the role of L3MBTL1 in DNA
replication and genome stability may be evolutionary conserved,
implying that the loss of L3MBTL1 contributes to the develop-
ment of 20q12 hematopoietic malignancies by causing DNA
damage and genomic instability.
Materials and Methods
Lentiviral and Retroviral Transduction. Lentiviral shRNA constructs were pur-
chased from the TRC shRNA library at Thermo Scientiﬁc Open Biosystems
and modiﬁed by subcloning the GFP gene instead of the puromycin gene into
the pLKO.1 vector as a marker of viral integration. shRNA sequences against
L3MBTL1 were gcctgcactttgatgggtatt (shRNA 1), gctggagtcatggctatgatt
(shRNA 2), and gcagtcactcacaacaagaat (shRNA 3). shRNA with scrambled
sequences in the same vector was used as a negative control. To produce len-
tiviruses, 293T cells were transfected with the shRNA constructs and helper
plasmids (the envelope construct pMD2G and the packaging construct
psPAX2) using the calcium phosphate method. To produce the retroviruses for
the overexpression assays, Phoenix-A cells were transfected with either HA-
tagged L3MBTL1 or emptyMIGR1 vector construct. Lentiviruses or retroviruses
were harvested by collecting and ﬁltering supernatants 48 and 72 h after
transfection, and concentratedby centrifugationat 4 °C for2h at 25,000 rpm in
a Beckman L7-55 Ultracentrifuge. Target cells were infected with concen-
trated virus in the presence of 8 μg/mL polybrene by centrifugation at 450 × g
for 45 min.
Cell Cycle Analysis by Flow Cytometry. Cells were collected by trypsinization
and ﬁxed in 70% ethanol. They were washed with PBS, stained with 50 μg/mL
propidium iodide and 0.5 μg/mL RNase A (both from Sigma-Aldrich), and
analyzed by ﬂow cytometry. For BrdU/propidium iodide staining, cells were
incubated with 1 mM BrdU for 1 h and then stained with BrdU-APC antibody
and propidium iodide, according to the instructions in the BrdU Flow Kit (BD
Biosciences). Minimally, 105 cells were analyzed on the BD FACSCalibur ﬂow
cytometer, and the data were collected using BD Cell Quest Pro software
and analyzed using FlowJo software (Tree Star).
Immunoblotting and Coimmunoprecipitations. U2OS cells were lysed in lysis
buffer [20mMTris-HCl (pH 8), 0.5%Nonidet P40, 0.5%Tween 20, 1mMEDTA,
1 mM DTT, 150 mM NaCl, 1 mM PMSF and protease inhibitor mixture (Cal-
biochem)], and then brieﬂy sonicated and centrifuged. The protein concen-
tration was measured using the Bradford assay (Bio-Rad), and equal amounts
of protein were loaded on NuPage gels (Invitrogen). Protein transfer was
conducted onto Immobilon-P PVDFmembrane (Millipore), and themembranes
immunoblotted with antibodies to the following proteins: phospho-Ser-317
Chk1, phospho-Ser354 Chk1, phospho-Thr68 Chk2, phospho-Tyr15 Cdc2, p53
(all from Cell Signaling), actin, Rad51, p21, geminin (all from Santa Cruz),
α-tubulin (Sigma Aldrich), γH2A.x (Biolegend), H4K20me1, H4K20me3, H3 (all
fromMillipore). The anti-L3MBTL1 antibody was described previously (6). For
coimmunoprecipitations, whole-cell extracts were prepared from 293T cells
overexpressing HA-tagged L3MBTL1 using the same lysis buffer as above.
The lysates for coimmunoprecipitations were treated with 1,000 units/mL of
benzonase (Sigma Aldrich) overnight at 4 °C to degrade DNA and RNA. They
were also treated with 50 μg/mL ethidium bromide to disrupt DNA-protein
complexes and exclude DNA-mediated protein-protein interactions (42). The
lysates were incubated overnight at 4 °C with HA-agarose beads (Roche) or
normal rat IgG serum (Santa Cruz) followed by protein A agarose beads
(Roche). The coimmunoprecipitates were washed four times with lysis buffer
containing 250 mM NaCl before immunoblotting for the following proteins:
MCM2-7 (all from Bethyl Laboratories), PCNA (Millipore), Cdc45, Fen-1, Sld5
(all from Santa Cruz). For reciprocal coimmunoprecipitation, Flag-tagged
L3MBTL1 was overexpressed in 293T cells, and lysates treated as above were
immunoprecipitated with antibodies against Mcm2, Mcm5, or rabbit IgG,
followed by adsorption to protein A agarose beads.
Quantitative RT-PCR. U2OS cells were harvested and RNA prepared by RNeasy
Plus Mini Kit (Qiagen); cDNA was synthesized using SuperScript III RT-PCR kit
(Invitrogen). Quantitative PCR was conducted on an ABI7500 Real-Time PCR
systemusing SYBRGreen PCRmix (both fromApplied Biosystems) and primers
corresponding to the genes of interest. Primer sequences are available up-
on request.
Comet Assay. DNA breaks were measured using the Comet Assay Reagent Kit
(Trevigen) with minor modiﬁcations. Brieﬂy, cells embedded in low-melting
point agarose on a slide were lysed, treated with alkali, and electrophoresed
in 1× TBE buffer for 40 min at 1 V/cm, stained with propidium iodide, and
imaged under the ﬂuorescent microscope. To evaluate the extent of DNA
damage present in each sample, the average tail moment (a product of
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percent DNA in tail and tail length) of 100 cells was calculated using Com-
etScore software (Tritek).
Immunocytochemistry. Cells were plated on coverslips, thenﬁxed inmethanol,
permeabilized with 0.25% Triton-X/PBS, blocked in 2% FBS/PBS, and in-
cubated with primary antibody for 1 h, followed by secondary antibody
conjugated with a ﬂuorescent probe for 30 min, both at room temperature.
Cells were stained with DAPI, mounted onto coverslips in mounting medium
(Vector Labs), and imaged on Leica Upright confocal microscope or Carl Zeiss
ﬂuorescent microscope using appropriate ﬁlters. The primary antibodies used
were directed against γH2A.x (Millipore), 53BP1 (Novus Biologicals), and
phospho-Ser1981 ATM (Cell Signaling), and secondary antibodies used were
anti-rabbit Alexa488 and anti-mouse Alexa568 (both from Invitrogen).
Quantitation of the DNA damage foci was determined by scoring foci of at
least 100 cells per treatment used.
DNA Fiber Analyses. Control and L3MBTL1 knockdown U2OS and MRC5 cells
were sequentially labeled with 50-μM IdU and 250-μM CldU for 1 h each. DNA
ﬁber spreads were prepared as described previously with some modiﬁcations
(43). Brieﬂy, three aliquots of cells were resuspended in PBS at 1 × 106 cells/mL,
spotted onto amicroscope slide, and lysed with 15 μL of spreading buffer [0.5%
SDS in 200mMTris-HCl (pH 7.4), 50mMEDTA].After 6min, slideswere tilted 15°
to allow lysates to slowly move down the slide, and the resulting DNA spreads
were air-dried, ﬁxed in 3:1 methanol/acetic acid, and stored at 4 °C overnight.
The slides were then treated with 2.5 M HCl for 30 min, incubated in blocking
buffer (1% BSA/0.05% Tween 20/PBS) for 1 h followed by 1 h at room temper-
ature with 1:500 rat anti-BrdU antibody (Abcam; to detect CldU) plus 1:100
mouse anti-BrdU (BD Biosciences; to detect IdU), diluted in blocking buffer, fol-
lowed by incubation for 30 min in 1:350 Alexa488-conjugated goat anti-rat an-
tibody and 1:350 Alexa595-conjugated goat anti-mouse antibody (Invitrogen).
Slides were air-dried and mounted in Prolong Gold antifade reagent (Invitro-
gen). Microscopy was carried out using a Zeiss LSM 5 Live Confocal microscope,
and the ﬁber lengths were measured using Volocity software (PerkinElmer).
Metaphase Spreads. Cal51 cells were treated with Karyomax solution (Invi-
trogen) for 5 h and then lysed with 75 mM KCl. Cells were ﬁxed with a 3:1
methanol/acetic acid solution, dropped onto slides, dried, and stained with
DAPI. The metaphase chromosomes were imaged under the Carl Zeiss mi-
croscope and evaluated for abnormalities such as chromatid and chromo-
some breaks, gaps, and exchanges.
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L3MBTL1 Deficiency Directs the Differentiation of Human
Embryonic Stem Cells Toward Trophectoderm
Ruben Hoya-Arias,1 Mark Tomishima,2 Fabiana Perna,1 Francesca Voza,1 and Stephen D. Nimer1
Human embryonic stem cells (hESCs) can be used to study the early events in human development and,
hopefully, to understand how to differentiate human pluripotent cells for clinical use. To define how L3MBTL1,
a chromatin-associated polycomb group protein with transcriptional repressive activities, regulates early events
in embryonic cell differentiation, we created hESC lines that constitutively express shRNAs directed against
L3MBTL1. The L3MBTL1 knockdown (KD) hESCs maintained normal morphology, proliferation, cell cycle
kinetics, cell surface markers, and karyotype after 40 passages. However, under conditions that promote
spontaneous differentiation, the L3MBTL1 KD cells differentiated into a relatively homogeneous population of
large, flat trophoblast-like cells, unlike the multilineage differentiation seen with the control cells. The differ-
entiated L3MBTL1 KD cells expressed numerous trophoblast markers and secreted placental hormones.
Although the L3MBTL1 KD cells could be induced to differentiate into various embryonic lineages, they adopted
an exclusive trophoblast fate during spontaneous differentiation. Our data demonstrate that depletion of
L3MBTL1 does not affect hESC self-renewal, rather it enhances differentiation toward extra-embryonic
trophoblast tissues.
Introduction
Human embryonic stem cells (hESCs) are derived fromthe inner cell mass of early preimplantation blastocysts;
they self-renew and are pluripotent. They can be maintained
in an undifferentiated state, but can also be induced to dif-
ferentiate into cell types characteristic of all 3 germ layers and
of extra-embryonic tissues, offering the potential to model
aspects of mammalian development and disease. Indeed,
progress made over the past decade has determined that di-
recting hESCs toward specific cell fates requires similar ki-
netics and signaling pathways as those required during
development [1].
The trophoblast is an essential extra-embryonic tissue that
arises from pluripotent trophectoderm (TE) during mam-
malian development. Interplay between transcriptional,
epigenetic, and physiological factors governs TE cell fate.
Several transcription factors including Cdx2, Tead4, Eomes,
Gata3, Elf5, Ets2, and Tcfap2c are involved in TE lineage
specification and its further expansion [2–8]. Differential
epigenetic modifications including DNA methylation [9] and
the distribution of histone modifications and their modifying
enzymatic complexes [10–13] contribute to lineage identity in
the early embryo by regulating the appropriate gene ex-
pression profiles. Because in vitro cell fate decisions are
similar to those made during development in vivo, hESCs
can be exploited to reveal critical aspects of human devel-
opment.
The Drosophila lethal 3 malignant brain tumor protein,
D-l(3)mbt, functions as a tumor suppressor in the larval brain
[14]. The gene encoding its human homolog, L3MBTL1, is
located on chromosome 20q12, within a region commonly
deleted in myeloid malignancies [15], suggesting that it may
also function as a tumor suppressor in mammals. L3MBTL1
functions as a transcriptional repressor [16] and chromatin
compactor [17]; in vitro biochemical studies have shown that
the L3MBTL1 MBT domains can compact nucleosomal ar-
rays dependent on the mono- or dimethylation of histone
H4K20 and H1bK26 [17,18]. We have recently demonstrated
that L3MBTL1 depletion enhances the differentiation of he-
matopoietic stem cells toward the erythroid lineage [19], and
its depletion from differentiated, malignant cell lines causes
replicative stress, DNA breaks, activation of the DNA dam-
age response, and genomic instability [20].
We hypothesized that as a chromatin-associated protein
with repressor properties, changes in the level of L3MBTL1
activity could alter the chromatin structure and influence the
ability of hESCs to either self-renew or commit to differen-
tiation. To test this hypothesis, we generated and character-
ized 2 independent and stable clones of L3MBTL1-depleted
hESCs, using a lentiviral vector system to express short
hairpin RNAs (shRNAs) directed against L3MBTL1 mRNA.
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Although the self-renewal properties of L3MBTL1 knock-
down (KD) hESCs were retained, we observed striking
morphological changes when L3MBTL1 KD hESCs sponta-
neously differentiated and established that they spontane-
ously differentiate into trophoblast-like cells. L3MBTL1
appears to be an important regulator of early cell fate deci-
sions during mammalian development.
Materials and Methods
shRNA design and cloning
The design and cloning of shRNAs into the H1P-Hygro/
EGFP lentiviral plasmid was done essentially as previously
described [21]. RNA sequences were selected using the
Dharmacon SMARTselection design software. Forward and
reverse oligonucleotides were resuspended at a concentra-
tion of 5mM, heated to 95C for 5min, and allowed to cool to
RT overnight. After annealing, the duplexes were cloned into
SmaI/XbaI sites of an H1P shRNA cassette. The sequences
targeted by the shRNAs are as follows: L3MBTL1 shRNA1:
5¢-GTAGTGAGTTGTAGATAAA-3¢; L3MBTL1 shRNA2: 5¢-
GTGGAATCATTGACAGAAA-3¢; luciferase control shRNA:
5¢-CCCGGAAAGACGATGACGG-3¢.
Cell culture and differentiation protocols
hESC line H9 (WA-09) cells were cultured on a feeder layer
of mouse embryonic fibroblast (MEFs), purchased from Glo-
balStem, and plated on gelatin-coated tissue culture plates. ES
cells weremaintained in an undifferentiated state in human ES
(HES)media (DMEM:F12; Invitrogen) supplementedwith 20%
knockdown serum replacement (Invitrogen), 1% nonessential
amino acids (Invitrogen), 0.1 mmol/L 2-mercaptoethanol
(Invitrogen), 1 mmol/L l-glutamine (Invitrogen), and 6ng/
mL FGF2 (R&D Systems). Cells were passaged using Dispase
(neural protease; Worthington Bioscience).
Spontaneous differentiation was induced by plating
control and L3MBTL1KD cells in feeder-free conditions on
Matrigel (BD Bioscience)-coated dishes in HES medium
without FGF2 for 2 weeks; cells were fed daily. The day on
which the cells were seeded was defined as day 1.
Embryoid bodies (EBs) were generated by culturing con-
trol and L3MBTL1 KD cells in low-cell-binding dishes for 14
days with the same medium used in spontaneous differen-
tiation. EBs were collected by gravity and fed every other
day.
The directed differentiation to trophoblast was achieved
by culturing the cells on Matrigel-coated dishes in HES me-
dium in the presence of exogenous BMP4 (100 ng/mL), as
previously described [22]. Differentiation toward neu-
roectoderm was performed using a published protocol [23].
Briefly, control and L3MBTL1 KD cells were cocultured on
MS-5 stroma cells and fed with KSR medium supplemented
with SB431542 (10mM/mL) and dorsomorphin (600 nM/mL)
during the first 7 days; then cells were fed only with KSR
medium until day 14.
Production of stable L3MBTL1-deficient embryonic
stem cell lines
The H1P-HygroEGFP plasmid expressing shRNA against
L3MBTL1 was cotransfected with plasmids pMD2.G and
psPAX2 into 293T cells to make lentiviral particles. Virus-
containing media was collected, filtered, and concentrated by
ultracentrifugation. Viral titers were measured by serial di-
lution on 293T cells followed by flow cytometry analysis
after 48 h. For transduction, lentiviral vectors were added to
H9 cells maintained without feeders on Matrigel-coated
plates. To select clones, colonies were treated with Accutase
(Innovative CT/ISC Bioexpress) for 30min at 37C, leaving a
single-cell suspension. The Accutase was neutralized with 3
volumes of HES medium and the cells were resuspended by
pipetting before being filtered using a 70-mm nylon filter
(Falcon, BD Bioscience). The cells were centrifuged and wa-
shed 2· with HES media and then 2· in ice-cold PBS with
1% BSA. The pelleted cells were resuspended in 100mL ice-
cold PBS with 1% BSA supplemented with 10mM Y27632
(ROCK inhibitor purchased from Calbiochem). GFP-positive
cells were sorted using a BD FACSAria cell sorter (BD
Bioscience) and resuspended in HES media with 10mM
Y27632 and penicillin/streptomycin 1,000U/mL and re-
plated on MEF feeders. Y27632 and penicillin/streptomycin
were maintained in the medium until the first colonies ap-
peared. Several clones for each shRNA construct were se-
lected and quantitative polymerase chain reaction (qPCR)
analysis was performed to ascertain viral copy number and
the efficiency of L3MBTL1 knockdown.
Reverse transcriptase and real time polymerase
chain reaction
Total RNA was isolated from undifferentiated and dif-
ferentiated hESCs growing as monolayers using the RNea-
sy Plus Kit (Qiagen). cDNA was synthesized from 1 mg total
RNA using Moloney murine leukemia virus RT (Promega) in
1 · transcription buffer containing 0.5 mmol/L oligo dT
(Promega) and 400mmol/L deoxyribonucleotides (dNTPs).
Reverse transcriptase (RT) qPCR was performed with the
ABI 7500 real-time PCR system with SYBR green (ABI) and
200 nM of forward and reverse primers. A standard curve
was generated for each primer pair, and genes of interest
were assigned a relative expression value interpolated from
the standard curve using the threshold cycle (Ct). Gene ex-
pression was normalized against the level of GAPDH ex-
pression. All reactions were done in duplicate, and at least 4
technical and 2 biological replicates were performed. PCR
primer sequences are shown in Table 1 and Supplementary
Table S1.
Immunofluorescence
Cultured cells were washed twice with PBS before being
fixed in 4% paraformaldehyde at room temperature. Cells
were washed 3 times with PBS before permeabilization with
wash buffer (0.3% Triton X-100 and 1.0% bovine serum al-
bumin in PBS) for at least 5min. The primary antibody (di-
luted in wash buffer) was added to the cells for 2 h at room
temperature, and then the cells were washed 3 times in wash
buffer before the addition of the secondary antibody (diluted
in wash buffer) for 1 h at room temperature. The cells were
washed 3 times with PBS and stored at 4C. The primary
antibodies OCT-3/4 (4 mg/mL; sc-5279), HAND1 (0.4 mg/
mL; Ab11846), and L3MBTL1 (1:50 dilution) previously de-
scribed [16] were detected using the appropriate secondary
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antibodies conjugated with Alexa Fluor 546 (Molecular
Probes). Negative controls consisted of no primary antibody,
no secondary antibody, or the appropriate IgG isotype con-
trol as indicated. DAPI counterstaining was performed on
fixed cells to visualize all cellular nuclei.
Western blot analysis
Total cellular protein extracts were prepared using RIPA
buffer (SIGMA R0278) supplemented with Halt Protease
Inhibitor Cocktail (Thermo Scientific 78430) according to the
manufacturer’s instructions. Nuclear and cytoplasmic ex-
tracts were prepared using the PIERCE kit (78833) for sub-
cellular fractionation; 40 mg of protein extracts were
electrophoresed on a 4–12% denaturing gel and electro-
blotted onto a nitrocellulose membrane. The membrane was
incubated with different antibodies at 4C overnight and
then incubated with the indicated secondary antibodies at
room temperature for 1 h. The Pierce Enhanced Chemilu-
minescence kit was used to detect antibody reactivity, ac-
cording to the manufacturer’s instructions.
Cell cycle/DNA and flow cytometry analysis
To analyze DNA content, control and L3MBTL1 KD ES
cells were cultured on Matrigel-coated tissue culture-trea-
ted dishes, harvested by trypsinization, washed with PBS,
and fixed in 70% EtOH at 4C. The cells were washed
with PBS, resuspended in propidium iodide solution
(5 mg/mL) containing 10mg/mL RNase, mixed, and incu-
bated 45min at 37C. Flow cytometric data were acquired
on a BD FACSCalibur (BD Biosciences) using CellQuest Pro
version 6.0. Propidium iodide was excited by the 488 nm
laser and fluorescence emission was measured in fluo-
rescence parameter 3 (FL3) with the standard 670LP
filter. Doublets were excluded by gating out high FL3-W
(width) cells. Single cells were analyzed for percentages of
G1/G0, S, and G2/M in MultiCycle AV (Innovative Cell
Technologies).
Detection of trophoblast marker HLA-G in L3MBTL1 KD
spontaneously differentiated cells was performed by im-
munostaining with an APC-labeled anti-human HLA-G
(eBioscience 17-9957 clone 87G) using 0.125mg/sample;
7-AAD (5 mg/mL) staining served to exclude dead cells from
subsequent analysis. For each sample, 5· 104 cells were an-
alyzed on a FACS Calibur flow cytometer (BD Biosciences)
using CELLQuest (BD Biosciences); data analysis was per-
formed using the FlowJo software (Tree Stars, Inc.).
Immunoassays
Media were collected from growing cells and stored at
- 20C until assay. Chorionic gonadotropin (CG-b) and
progesterone levels were measured using ELISA kits, as in-
dicated by the manufacturer (Calbiotech).
Statistical analysis
Data were analyzed using PRISM Version 5.04 (GraphPad
Software, Inc.). Sample comparison was performed using 1-
way analysis of variance (ANOVA) followed by a post-hoc
Tukey test or 2-way ANOVA followed by a post-hoc Bon-
ferroni test, with the level of significance set at P < 0.05.
Results
L3MBTL1 knockdown does not affect embryonic
stem cell renewal
We initially screened 10 different shRNAs that target
L3MBTL1 using K562 cells (data not shown) and used the 4
most efficient shRNAs to transduce H9 hESCs. Ultimately, 2
shRNAs were used (shRNA1 and shRNA2) (Fig. 1A) that
most consistently knocked down L3MBTL1 in H9 cells
compared with the H9 cells expressing a nontargeting, lu-
ciferase-specific hairpin (LUC shRNA) and the parental H9
cell line. Overall, 11 L3MBTL1 KD ES cell clones were gen-
erated. Western blot (Fig. 1B) and immunofluorescence
analysis (Supplementary Fig. S1; Supplementary Data are
Table 1. List of Oligonucleotides Used in Reverse Transcriptase qPCR
Gene Forward Reverse
L3MBTL1 AGAGGAAGCGCAGGGAATA CACGACCAGCATTCCTTCTT
OCT4 CCTCCAGCAGATGCAAGAA ATTGGAAGGTTCCCAGTCG
NANOG CCTCCAGCAGATGCAAGAA ATTGGAAGGTTCCCAGTCG
CDX2 GTCTTTTTTCTCTTCCCTTCCC CAACAACACAAACTCCCCC
SOX2 ACCAGCGCATGGACAGTTA ATGTAGGTCTGCGAGCTG GT
AFP CTTCCAAACAAAGGCAGCA ATGTACATGGGCCACATCC
SOX1 ATGCACCGCTACGACATGG CTCATGTAGCCCTGCGAGTTG
ACTC1 CCCTGGAGAAGAGCTATGAAC GGAAGGTAGATGGAGAGAGAA G
CGB GTGGAGAAGGAGGGCTGC GGCGGCAGAGTGCACATT
HAND1 TGCCTGAGAAAGAGAACCAG ATGGCAGGATGAACAAACAC
KRT 7 TGAATGATGAGATCAACTTCCTCAG GCAGTCCCAGATCTCCGACA
KRT 8 GATCGCCACCTACAGGAAGCT ACTCATGTTCTGCATCCCAGACT
GCM1 GAGCCTGGAGACCGAGAAC TTGCGAAGATCTGAGCCC
PAX6 CGGAGTGAATCAGCTCGGTG CCGCTTATACTGGGCTATTTTGC
GAPDH GGTCGGAGTCAACGGATTT GCCCCACTTGATTTTGGAG
l3mbtl1, l(3)mbt-like 1 (Drosophila); OCT4, POU class 5 homeobox 1; NANOG, nanog homeobox; CDX2, caudal type homeobox 2; SOX2,
SRY (sex-determining region Y)-box 2; AFP, alpha-fetoprotein; SOX1, SRY (sex-determining region Y)-box 1; ACTC1actin, alpha, cardiac
muscle 1; GCB, chorionic gonadotropin, beta polypeptide; HAND1, heart and neural crest derivatives expressed 1; KRT7/8, keratin 7/8;
GCM1, glial cells missing homolog 1; PAX6, paired box 6; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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available online at www.liebertonline.com/scd) confirm the
nuclear localization of L3MBTL1 in ES cells. The L3MBTL1
KD hESCs showed normal colony morphology (Fig. 1C),
normal cell cycle kinetics (Fig. 1D), an unchanged pattern of
cell surface markers, and a normal karyotype in prolonged
culture (data not shown) when cultured under normal hESC
growth conditions. We obtained an *70% reduction in
L3MBTL1 mRNA levels (using either shRNA1 or shRNA2)
and observed a small decrease in the levels of the plur-
ipotency-promoting OCT-4, NANOG, and SOX2 transcrip-
tion factor mRNAs (Fig. 1E). Immunofluorescence analysis
confirmed the normal expression and localization of OCT-4
protein in all cell lines (Fig. 1F). Thus, L3MBTL1 depletion
does not detectably affect the undifferentiated state of hESCs.
L3MBTL1 knockdown impairs embryonic cell
production during spontaneous differentiation
To determine whether loss of L3MBTL1 affects differen-
tiation, we withdrew FGF2 from HES media and grew the
hESCs under either adherent or nonadherent conditions,
inducing their spontaneous differentiation. hESCs were
maintained for 2 weeks under adherent culture conditions as
colonies, using Matrigel-coated dishes. Depletion of
L3MBTL1 had clear morphological consequences, as all 11
clones derived from the shRNA1- or shRNA2-expressing
hESCs generated differentiated colonies composed of large,
flat mononucleated cells by days 7–14. In contrast, the con-
trol luciferase knockdown H9 cells and the parental line H9
generated mixed colonies composed of many different cell
morphologies (Fig. 2A and data not shown). We also ob-
served morphological consequences in the EBs generated
from L3MBTL1 KD cells under nonadherent conditions; in
contrast to the control cells, the L3MBTL1 KD cells failed to
give rise to typical EB structures containing differentiated
cell types. Starting at day 5 of differentiation, the L3MBTL1
KD EBs underwent significant cell death that continued until
day 14, indicating defects in differentiation, whereas control
cells developed into characteristic EB structures (Fig. 2B).
Flow cytometric analysis for Annexin V binding and 7-AAD
permeability confirmed an increased cell death in the
L3MBTL1 KD cells compared with the control cells at day 7
of differentiation (Fig. 2C).
To characterize the differentiation state of the L3MBTL1
KD cells in monolayer cultures, we performed reverse tran-
scriptase qPCR analysis to quantify the expression of a va-
riety of pluripotent and lineage-specific markers.
Differentiated control and L3MBTL1 KD cells were evalu-
ated and significant differences were seen. As expected, the
pluripotency markers OCT-4 and NANOG were reduced in
both the L3MBTL1 KD and the control KD cells compared
with the undifferentiated cells (Fig. 2D). Of note, L3MBTL1
levels were upregulated at least 3-fold in the differentiated
controls compared with the undifferentiated controls, sug-
gesting a potential role for L3MBTL1 in the earliest stages of
differentiation. However, the shRNA constructs continued to
suppress L3MBTL1 mRNA levels despite the increased ex-
pression that have occurred during normal differentiation
(Fig. 2D). Quantification of lineage marker expression shows
downregulation of the SOX1 (ectoderm) and AFP (endo-
derm) markers in the L3MBTL1 KD cells, compared with
their increased levels in the differentiated controls. Interest-
ingly, we observed a substantial upregulation in the ex-
pression of ACTC1 (mesoderm) and the trophoblast marker
chorionic gonadotropin (CG-b) in the L3MBTL1 KD in con-
trast to the differentiated control cells (Fig. 2E). We also
performed reverse transcriptase qPCR analysis to assess the
expression of additional lineage markers including NEU-
ROD1, SOX2, MAP2 (ectoderm); HNFA4, FOXA2, PECAM1
(endoderm); and MIXL1, RUNX1, and RUNX2 (mesoderm).
These studies confirmed that ectoderm, endoderm, and me-
soderm derivatives are severely reduced, and of the meso-
dermal markers, only RUNX1 was upregulated in the
L3MBTL1 KD cells (3-fold) compared with the differentiated
control cells (Supplementary Fig. S2). Consistent with this
finding, RUNX1 has been reported to be an L3MBTL1 target
gene in K562 cells [24]. These results show that L3MBTL1 KD
cells have a bias to differentiate into trophectoderm follow-
ing FGF2 withdrawal, whereas ectoderm and endoderm
differentiation appears to be blocked.
L3MBTL1 knockdown promotes differentiation
of hESCs toward trophectoderm
The flat cell morphology (Fig. 2A) and the greater than
18-fold upregulation of CG-b in the differentiated L3MBTL1
KD cells (Fig. 2E) led us to examine the expression of other
trophoblast markers, including CDX2 [25–27], HAND1 [28–
31], KRT7, KRT8, and GCM1 [22,27,31–34]. CDX2 mRNA
upregulation parallels the appearance of morphological
changes in spontaneously differentiated L3MBTL1 KD cells by
days 6–7, reaching a peak on day 9; in contrast, HAND1,
KRT7, KRT8, and GCM1 mRNAs peak at day 14. The ex-
pression pattern of these markers further indicates that
L3MBTL1 KD cells primarily differentiate into trophoblast
cells (Fig. 3A, B). We have confirmed that HAND1 protein is
FIG. 1. Characterization of undifferentiated control and L3MBTL1 knockdown (KD) human embryonic stem cells.
(A) Schematic representation of L3MBTL1 gene showing the location for the short hairpin (shRNA) sequences cloned into the
H1P-HygroEGFP lentiviral plasmid. (B) Western blot of cytoplasmic and nuclear fractions from H9 parental cells shows
nuclear location of L3MBTL1. Oct4 (nuclear) and tubulin (cytoplasmic) were used as controls. (C) Microscopic images
showing the undifferentiated stage for the wt parental, LUC shRNA, L3MBTL1-shRNA1, and shRNA2 H9 cells based on
their expression of GFP. Whole colonies were imaged on an Olympus epifluorescence system under a 10· objective. Scale bar
represents 100 mm. (D) Cell cycle analysis of undifferentiated control and L3MBTL1KD ES cells. Relative DNA content,
assessed by PI staining, shows the proportion of cells in the G1, G2, and S phases. A representative example of 3 independent
experiments is shown. (E) Reverse transcriptase qPCR analysis comparing the level of L3MBTL1, OCT-4, NANOG, and SOX2
mRNA expression in control and L3MBTL1-depleted cells. Statistical analysis was performed by 1-way ANOVA and Tukey
posttest (*P < 0.05). Error bars represent the standard deviation (n = 3). (F) Fluorescent microscopy images of OCT-4 with a
DAPI DNA counterstain using the Olympus epifluorescence system under a 20 · objective. Scale bar represents 50 mm. Color
images available online at www.liebertonline.com/scd
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expressed in differentiated L3MBTL1 KD cells by immuno-
fluorescence (Fig. 3C) and that more than 80% of the cells
analyzed at day 14 of differentiation have trophectoderm
phenotype, as indicated by the expression of HLA-G (Fig. 3D).
To further examine the differentiation of L3MBTL1 KD
cells into trophoblasts, we directed control cells toward tro-
phoblasts using BMP4 [22]. We compared the gene expres-
sion pattern of the BMP4-treated control (LUC shRNA) cells
with the spontaneously differentiated L3MBTL1 KD cells
and found similar but higher trophoblast marker expression
(CG-b and HAND1) in the BMP4-treated control cells
(Fig. 4A). Of note, L3MBTL1 expression decreased at least
4-fold in the control cells treated with BMP4 compared with
untreated LUC shRNA control, which is also consistent with
the notion that downregulation of L3MBTL1 allows tropho-
blast formation to proceed in hESCs (Figs. 2D and 4A). To
further investigate the role of BMP signaling, we measured
the level of phosphorylated SMAD proteins (SMAD 1/5/8)
during the spontaneous differentiation of the LUC shRNA
and L3MBTL1 KD cells. We found an increased level of
phospho-SMAD 1/5/8 in differentiated L3MBTL1 KD cells
compared with the control cells (Fig. 4B). We also measured
the secretion of the placental hormones CG-b and proges-
terone into the medium from spontaneously differentiated
L3MBTL1 KD cells and also the untreated and BMP4-treated
controls. L3MBTL1 KD and BMP4-treated control cells show
a continuous increase in the concentration of both hormones,
with the hormone secretion by the knockdown cells being
nearly as high as from the BMP-treated control (Fig. 4C).
These results show that L3MBTL1 KD cells differentiate
into functional trophoblast cells, which indicates the role
of L3MBTL1 in regulating the spontaneous differentiation of
embryonic derivatives.
Directed differentiation is not impaired
in L3MBTL1 KD cells
L3MBTL1 KD cells did not express ectoderm markers un-
der conditions that allow spontaneous differentiation (Fig.
2D). However, to determine whether directed differentiation
was affected in L3MBTL1 KD cells, we induced neural dif-
ferentiation by coculturing them on MS-5 stromal cells for 2
weeks according to an established protocol [23]. We observed
neuronal rosette formation on day 8 with all clones (Fig. 4D,
upper panel), demonstrating that L3MBTL1 KD cells can
differentiate into neuroectoderm if provided with a suffi-
ciently strong signal. Further, reverse transcriptase qPCR
analysis found a similar level of induction of the neuroecto-
dermal markers SOX1 and PAX6 in the knockdown versus the
control cell lines (Fig. 4D, lower panel). We also directed the
differentiation of L3MBTL1 KD hESC toward hema-
toendothelial cells (CD31+CD34+ ) using a previously re-
ported protocol [35] and found that the KD cells responded to
these differentiation signals as well, albeit less efficiently than
to the controls (data not shown). These results indicate that
L3MBTL1 KD does not impair hESC differentiation toward
embryonic neuroectoderm or hematoendothelial cells when
potent differentiation-promoting signals are provided.
Discussion
Undifferentiated ES cells generally contain more permis-
sive chromatin with higher levels of activating marks (lysine
acetylation) and lower levels of repressive marks (H3 lysine
K9 and K27 methylation), whereas differentiated ES cells
generally display silenced chromatin structure [36]. One of
the great challenges in human stem cell biology is to un-
derstand the mechanisms that selectively silence certain
gene-rich regions of the genome, to allow the production of
the full range of cell types found in the adult. Compacted
chromatin is generally found during differentiation, but very
little is known about the individual proteins that differen-
tially silence genes and affect the outcome of differentiation.
In this study, we found that knocking down the epigenetic
‘‘reader’’ L3MBTL1 strongly influences the differentiation
potential of hESCs toward trophectoderm under conditions
wherein spontaneous differentiation occurs, without affect-
ing hESC self-renewal in the undifferentiated state.
L3MBTL1 KD hESCs can be cultured continuously with no
noticeable changes in their behavior, morphology, or cell
cycle status and only minor changes in the RNA levels of the
pluripotency markers OCT-4, NANOG, or SOX2 (Fig. 1C–E),
which suggests that L3MBTL1 does not play a critical role in
maintaining the undifferentiated status or self-renewal po-
tential of hESCs.
Nonetheless, L3MBTL1 KD clearly impaired the develop-
mental potential of hESCs in spontaneous differentiation
assays. Withdrawal of FGF2 triggered profound changes in
the differentiated L3MBTL1 KD cells under adherent condi-
tions with loss of ectoderm, endoderm, and mesoderm
marker expression; this implies that L3MBTL1 KD cells have
limited pluripotency. The differentiated L3MBTL1 KD cells
FIG. 2. Morphological changes of spontaneously differentiated control and L3MBTL1 KD cells. (A) Photographs showing
the morphological contrast between LUC shRNA and L3MBTL KD cells (left and right upper row, respectively); images were
acquired using the Gel Doc System Quantity One software (BioRad). Lower row shows a magnified view of the differentiated
L3MBTL1 KD cells (white circle); black lines show a phase-contrast image (left) and a DAPI/GFP fluorescence image (right).
(B) L3MBTL1 KD cells fail to develop proper embryoid bodies. Fluorescent microscopic images showing EB derivation based
on GFP expression for the LUC shRNA, shRNA1, and shRNA2 cell lines. Scale bars: 0.2mm (4· ); 100 mm (10· ). Re-
presentative images of 3 independent experiments are shown. (C) Flow cytometry assay shows increasing cell death for the
differentiated L3MBTL1 KD EB cells. Top plots show unstained control and L3MBTL1 KD EB cells and bottom plots show
PE-Annexin V versus 7-AAD permeability profiles in the same cells. Apoptotic cells on the plots are Annexin V positive and
PI negative (lower right quadrant), whereas necrotic cells are Annexin V positive and PI positive (upper right quadrant).
(D) Expression of L3MBTL1, OCT-4, and NANOG in undifferentiated and differentiated state measured as relative level of
mRNA/GAPDH. (E) mRNA expression levels of lineage cell markers SOX1 (ectoderm), AFP (endoderm), ACTC1 (meso-
derm), and CG-b (trophoblast) in undifferentiated and differentiated states measured as relative level of mRNA/GAPDH.
Statistical analysis was performed by 1-way ANOVA and Tukey posttest (*P < 0.05). Error bars represent the standard
deviation (n= 3). Color images available online at www.liebertonline.com/scd
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FIG. 3. Reverse transcriptase qPCR analysis for lineage cell markers. (A) Relative levels of mRNA expression of trophoblast
marker CDX2. Error bars represent the standard deviation (n = 3). (B) Trophoblast cell markers HAND1, GCM1, KRT7, and
KRT8 in undifferentiated and differentiated states measured as relative level of mRNA/GAPDH. Statistical analysis was
performed by 1-way ANOVA and Tukey posttest (*P < 0.05). Error bars represent the standard deviation (n = 3). (C) Im-
munofluorescent detection of HAND1. White arrows indicate the nuclear location of HAND1 protein. Microscopy performed
with Olympus epifluorescence system under a 40 · objective. Scale bar represents 50mm. Representative images of 3 inde-
pendent experiments are shown. (D) FACS analysis shows the percentage of spontaneously differentiated control and
L3MBTL1 shRNA1 and shRNA2 cells expressing the trophectodermal (TE) marker HLA-G (red). Isotype control antibody
staining is shown (black). Undifferentiated LUC shRNA and L3MBTL1 KD cells were used as negative controls for HLA-G
staining (blue). Color images available online at www.liebertonline.com/scd
1896
FIG. 4. L3MBTL1 knockdown mimics trophoblast differentiation induced by BMP4. Luciferase control with or without
BMP4 and L3MBTL1 KD cells were cultured for 7 days. (A) Reverse transcriptase qPCR analysis for L3MBTL1, OCT-4, CG-b,
and HAND1 mRNA expression. Statistical analysis was by 2-way ANOVA and Bonferroni posttest (*P < 0.05). Error bars
represent the standard deviation (n = 3). (B) Phosphorylation of SMADS1/5/8 was examined by Western blot analysis in the
homogenates of undifferentiated (day 1) and spontaneously differentiated (day 7) control LUC shRNA and L3MBTL1-KD
cells. (C) Immunoassay for placental hormones CG-b and progesterone. Error bars represent the standard deviation (n= 3).
(D) L3MBTL1 KD cells differentiate under defined conditions. Fluorescence images of typical neuronal rosette structures at
day 9 of directed neuroectoderm differentiation for control LUC shRNA and L3MBTL1 KD cell lines (upper panel) are shown.
Scale bar represents 50mm. Representative images of 3 independent experiments are shown. Reverse transcriptase qPCR
analysis results for neuroectoderm markers SOX-1 and PAX6 mRNA expression (bottom panel) are also shown. Statistical
analysis was performed by 2-way ANOVA and Bonferroni posttest (*P < 0.05). Error bars represent the standard deviation
(n = 3). Color images available online at www.liebertonline.com/scd
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do express trophectoderm markers (Figs. 2E and 3B, D), and
in fact, the increased expression of CDX2 is consistent with
the L3MBTL1 KD cells being restricted to a trophoblast fate
(Fig. 3A) [37]. Cdx2 acts early in the lineage hierarchy and its
overexpression triggers embryonic stem cells to differentiate
into trophoblast stem cells [26,27]. Overall, these changes
could explain the failure of these cells to form typical EB
structures in nonadherent assays. It is also possible that
genomic instability during EB development could explain
the increased cell death seen in L3MBTL1 KD cells (Fig. 2B,
C), as we recently reported [20]. In contrast, the differenti-
ated control cells maintained expression of embryonic line-
age markers, and consistent with their upregulation of
L3MBTL1, the expression of trophoblast markers was absent.
The production of extra-embryonic trophoblast cells from
the L3MBTL1 KD cells resembles the effect of BMP4 on hESCs
[22]. BMP4 directs hESCs toward trophoblast with increased
SMAD 1/5/8 phosphorylation, CG-b secretion, and HAND1
expression, which occurs concomitantly with a marked de-
crease in L3MBTL1 expression (Fig. 4A, B). Both the BMP4-
stimulated hESCs and the L3MBTL1 KD cells secrete placental
hormones, demonstrating that knockdown of L3MBTL1
drives hESCs to become trophoblast-like cells (Fig. 4C). The
lack of other embryonic cell types derived from L3MBTL1KD
cells is not absolute, as L3MBTL1 KD cells can still form neural
tissue and hematoendothelial cells in response to strong in-
ductive signals. This suggests that L3MBTL1 may promote the
retention of pluripotency of hESCs, at least in part by blocking
trophoblast differentiation.
Thus, L3MBTL1 may play a role in the earliest cell fate
decisions involved in human development, most likely by
repressing genes involved in trophectoderm differentiation.
Such a phenotype was recently described for Mbd3, a com-
ponent of the Mi-2/NURD repressor complex [38]. L3MBTL1
may promote chromatin compaction via its recognition of
mono- and dimethylated states of H4K20 by L3MBTL1 [17,18]
or by recruiting additional chromatin remodelers to block the
trophectoderm differentiation of hESCs. In Drosophila,
dl(3)MBT has been shown to bind histone H4 K20 mono-
methyl in close association with the dRPD3 histone deacety-
lase, resulting in deacetylation of histone H4 K5/K12 [39].
However, we found that L3MBTL1 can repress gene expres-
sion in an HDAC-independent fashion [16]. L3MBTL1 could
be a central component of a repressive complex that loses its
function after L3MBTL1 KD. It is likely that multiple chro-
matin regulators control the differentiation process. For in-
stance, the histone methyltransferase SETDB1 was recently
shown to repress trophectoderm differentiation of mouse
ESCs via H3K9 methylation [40]. The degree of histone H4K20
methylation is dynamically regulated during hESC differen-
tiation. Mass spectrometry (MS) studies have revealed that a
large percentage of histone H4 is dimethylated in undiffer-
entiated hESCs (*65%) with some unmethylated (*20%) and
some monomethylated (*10%) or trimethylated (*5%) resi-
dues. Following TPA treatment, unmethylated lysines are
largely converted to dimethyllysines, and electron transfer
dissociation-MS experiments have identified histone H4 K20
as the target of both methylation events [41]. Mice deficient for
Suv4-20 h1/2, a H4K20 methyltransferase, display loss of di-
and trimethyl H4K20 with consequent embryonic lethality
[42]. ESCs have a poised epigenetic state that maintains
chromatin in a structure ready for quick cell fate decisions
[10]. The inner cell mass and trophectoderm possess different
gene expression profiles. Consequently, their epigenetic pro-
files should also differ. We have not seen noticeable differ-
ences in the level of HP1g, which binds L3MBTL1, or in H3K9
trimethylation, a heterochromatin mark recognized by HP1g,
between the spontaneously differentiated trophoblast cells
and the induced neuroectoderm cells (Supplementary Fig.
S3A). Nonetheless, epigenetic disturbance during the early
events of differentiation may be a consequence of knocking
down L3MBTL1, explaining the lineage selectivity of hESCs
toward the trophectoderm fate.
In summary, L3MBTL1 KD hESCs proliferate normally in
the undifferentiated state, but are impaired in their ability to
spontaneously differentiate toward embryonic tissues, and
preferentially differentiate into trophoblast tissue (Supple-
mentary Fig. S3B). Further studies are required to establish
the molecular basis of the lineage selectivity that occurs after
L3MBTL1 knockdown.
Summary
To define how L3MBTL1, a chromatin-associated poly-
comb group protein with transcriptional repressive activities,
regulates early events in embryonic cell differentiation, we
created hESC lines that constitutively express shRNAs di-
rected against L3MBTL1. Although the L3MBTL1 KD cells
could be induced to differentiate into embryonic neuroecto-
derm, they adopted an exclusive trophoblast fate during
spontaneous differentiation. The data suggest that L3MBTL1
depletion does not affect hESC self-renewal but impacts
pluripotency; depletion of L3MBTL1 directs hESC differen-
tiation toward extra-embryonic tissues, rather than embryo-
derived tissues.
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Dear Editor,
Posterior reversible encephalopathy syndrome (PRES) is a
neurological condition characterized by headache, visual
disturbances, seizures, and altered mental status, associated
with computed tomography (CT) and magnetic resonance
(MR) findings of symmetrical edema mainly in the posterior
cerebral areas [1]. Controversy exists on the pathogenesis of
PRES, considered to be probably caused by either vasogenic
edema due to a loss of the autoregulatory mechanisms of
cerebral flow [2, 3] associated with acute blood pressure
(BP) increase or by direct endothelial damage.
We report two adult patients with acute myeloblastic
leukemia (AML) who developed PRES during induction
chemotherapy. The first case was a 22-year-old woman
diagnosed with AML associated to multilineage dysplasia.
Chemotherapy consisted of daunorubicin, etoposide, and
standard dose (100 mg/m2) cytarabine by continuous infu-
sion (c.i.) for 10 days. While the patient was still aplastic,
she developed posterior headache, emesis, generalized seiz-
ures, and hypertension (BP, 170/100 mmHg). Brain CT
showed bilateral hypodense areas due to edema in the
temporo-occipito-parietal white matter; MR allowed to de-
fine more clearly the extensive and nearly symmetrical
hyperintense areas on long TE sequences in cortical and
subcortical regions of the temporo-occipito-parietal lobes
of both hemispheres (Fig. 1a). Treatment consisted of diu-
retics, glycerol, and phenobarbital, and her condition im-
proved in a few days. After 2 weeks, MR showed an
improvement of the edema (Fig. 1b). Complete remission
was documented on day +50. After the consolidation treat-
ment, the patient relapsed in 4 months, before any attempt to
perform autologous stem cell transplant could be made, and
died of disease progression.
The second patient was a 57-year-old woman suffering
from idiopathic hypertension and diagnosed with AML
secondary to a 2-year history of myelodysplasia. Cytogenet-
ics showed a complex caryotype. She started chemotherapy
with daunorubicin, etoposide, and standard dose cytara-
bine by c.i. for 7 days. On day +3, blood pressure rapidly
increased probably due to fluid overload. On day +8, while
in cytopenia, the patient developed septic shock from E.
coli complicated by SIRS with multiple organ failure,
followed shortly after by the onset of neurological symp-
toms (i.e., confusion, visual disturbances with right hemi-
anopsia, aphasia, left hemiparesis). Brain CT showed
cortico-subcortical mildly hypodense areas in both
parieto-occipital lobes, predominantly in the right hemi-
sphere, described as an ischemic process (Fig. 1c and d).
Despite supportive therapy including diuretics and mannitol,
the neurological and clinical conditions rapidly worsened
precluding the possibility to perform an MR examination;
the patient died within 3 days.
Even if hypertensive encephalopathy, eclampsia, immu-
nosuppressive treatments, and renal failure are the most
commonly reported causes of PRES, this syndrome has also
been described during cytotoxic treatment for hematological
malignancies in the pediatric setting [4–7]. In adults, PRES
has been reported in patients with NHL after CHOP or
different regimens and, in one patient, with multiple myeloma
[8, 9]. This is the first report of PRES in adults with AML,
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where cytotoxic chemotherapy, BP lability, and sepsis play a
key role in the pathogenesis of this neurological syndrome
which should be promptly recognized and treated to avoid
irreversible damage.
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Fig. 1 a Case 1: Brain MR
imaging (FLAIR sequence),
showing hyperintense lesions in
the subcortical white matter of
the temporo-occipital regions
with some cortical involvement
consistent with vasogenic ede-
ma. b Case 1: Follow-up MR
image (FLAIR sequence)
obtained 2 weeks later, showing
almost complete resolution of
the lesions. c, d Case 2: Non-
enhanced CT. Mildly hypo-
dense areas involving both
cortical and subcortical matter
in the right occipito-parietal re-
gion associated to subcortical
matter involvement in the left
parietal region, with some sul-
cal effacement
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Aplastic anemia: immunosuppressive therapy in 2010
Antonio M. Risitano, Fabiana PernaDepartment of Biochemistry and MedicalBiotechnologies, Federico II University of Naples, Naples, Italy
Abstract
Acquired aplastic anemia (AA) is the typical
bone marrow failure syndrome characterized
by an empty bone marrow; an immune-medi-
ated pathophysiology has been demonstrated
by experimental works as well as by clinical ob-
servations. Immunusuppressive therapy (IST)
is a key treatment strategy for aplastic anemia;
since 20 years the standard IST for AA patients
has been anti-thymocyte globuline (ATG) plus
cyclosporine A (CyA), which results in re-
sponse rates ranging between 50% and 70%,
and even higher overall survival. However, pri-
mary and secondary failures after IST remain
frequent, and to date all attempts aiming to
overcome this problem have been unfruitful.
Here we review the state of the art of IST for
AA in 2010, focusing on possible strategies to
improve current treatments. We also discuss
very recent data which question the equality of
different ATG preparations, leading to a pos-
sible reconsideration of the current standards
of care for AA patients.
Introduction
Aplastic anemia (AA) is the most typical
example of bone marrow failure, character-
ized by an empty or fatty bone marrow
leading to the subsequent pancytopenia.1 Re-
cently it has been reported that in some
adults AA may be due to inherited abnormal-
ities.2 However, idiopathic AA is usually con-
sidered an immune-mediated disease.3 Ac-
cording to the most accepted view, self-reac-
tive T cells cause a damage of the hematopoi-
etic stem cells (and possibly of committed
progenitors) through a cell-cell interaction
(via Fas/Fas-L, granzyme, perforine)4 and the
production of inhibitory cytokines such as
IFN-γ, TNF-α and TGF-β.5-7 The role of T cells
was confirmed by the identification, in vivo,
of oligoclonal T cells,8-10 and by the demon-
stration of their pathogenic role either in
vitro or in vivo.10,11 All these findings make
the immune system the therapeutic target in
AA patients; immunosuppressive (IS) regi-
mens have been largely developed in the past
years, exploiting agents that affect distinct
steps of the immune response.Immunosuppression for aplastic anemiaThe standard immunosuppression: anti-thymocyte globuline plus cyclosporine A
Initial observations showed that some AA pa-
tients failing donor engraftment following allo-
geneic stem cell transplantation rescued autolo-
gous hematopoiesis12 and that in other patients
treatment with anti-lymphocyte globuline (ALG)
resulted beneficial.13,14 In fact, the efficacy of
immunosuppressive treatment (IST) by ALG
was confirmed in a prospective, placebo-con-
trolled, randomized trial, in 1983.15 In order to
improve the response rate and reduce the risk
of subsequent relapse, several immunosuppres-
sive agents have been associated to anti-thymo-
cyte globuline (ATG) or ALG (such as corticos-
teroids,16 androgens)17,18 but cyclosporine A
(CyA) only resulted in an increased response
rate,19 with an improved long-term failure-free
survival.20 Since the early ‘90s, ATG + CyA was
considered the standard IST for AA patients,
with an expected 50-60% probability of response
and 60% overall survival at one year.21-23
The most recent studies have shown im-
proved overall survival (above 80% at 1 year),
regardless of the initial response to IST,24-26
likely due to a better supportive care and sal-
vage treatment (mainly SCT). However, treat-
ment-failure remains a major problem after
first-line IST. In fact, about one third of AA pa-
tients do not respond to their initial IST; in
addition, within responders patients, half of
them require long-term IS maintenance treat-
ment by CyA to sustain the response. In fact,
recent studies showed that CyA-dependency
ranges between 25 and 50% of patients and
the patients who require long-term CyA treat-
ment present the higher risk to relapse
(about 30-50% of responders).22-24 Further-
more, the development of clinical paroxysmal
nocturnal hemoglobinuria is seen in about
10% of AA patients after IST;27 clonal evolu-
tion to myelodysplastic syndromes (MDS) or
acute leukemias (AML) accounts for about
10-15% of treatment-failures,24,28 and solid tu-
mors account for an additional 10%.29 Thus, a
substantial fraction of AA patients cannot be
considered cured by IST, and understanding
the underlying causes is necessary to develop
salvage strategies.30 While secondary failures
suggest a flare-up of the underlying immune
process, the causes accounting for primary
failures (which occur in one third of patients)
may include: i) non-immune pathophysiology
(e.g., due to misdiagnosis of hypoplastic
MDS, or to inherited forms associated to mu-
tation in telomerase complex genes);31 ii) an
insufficient delivered IS (in fact, some refrac-
tory patients may respond to further IST);32-34
iii) a third explanation is the exhaustion of
the hematopoietic stem cells, which would
hamper any hematological recovery regard-
less the control of the pathogenic immune-at-
tack. This latter hypothesis seems supported
by the recent data showing that baseline
telomere length is the most powerful pre-
dictor of long-term survival in AA patients re-
ceiving IST.35 In fact, shorter telomeres were
associated with increased relapse rate and
clonal evolution (including monosomy 7),
suggesting that they are a reliable marker for
functional hematopoietic stem cell damage
(possibly linked to the replicative stress of
residual cells). If confirmed, these data will
provide an informative tool to identify AA pa-
tients who may benefit from an early trans-
plant strategy rather than IST.Improving standard ATG-based immunosuppression: additional oralternative IS agents
To improve the results obtained with the
standard ATG + CyA, several investigators tried
to deliver an intensified IS by adding a third IS
agent, possibly with a distinct (hopefully syn-
ergistic) mechanism of action. However, this
strategy did not result in a substantial benefit.
The purine synthesis inhibitor mycophenolate
mofetil (MMF) was tested in a prospective
study conducted at NIH, but did not result in ei-
ther increased response (62% at 6 months) or
decreased relapse (37%, despite maintenance
therapy with MMF) in comparison to historical
data.36 The mammalian target of rapamycin
(mTOR) inhibitor rapamycin/sirolimus (RAPA)37
was also tested in a randomized trial con-
ducted at NIH; the addition of RAPA to the
standard ATG + CyA resulted in a response rate
of 51%, which was comparable to that of the
control arm (ATG + CyA, 62%), with similar re-
lapse and survival rates.38
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Some investigators developed different
strategies of IST, with the aim of retaining (or
possibly increasing) a marked IS activity, ide-
ally with a better toxicity profile. They used
lymphocyte depleting agents other than ATG,
such as cyclophosphamide (CTX) or alem-
tuzumab. High-dose CTX (50 mg/kg intra-
venously on 4 consecutive days) was mainly
tested at the Johns Hopkins University; the
initial results were excellent, with a response
rate of about 70% (even if the time-to-response
appeared delayed in comparison to that ex-
pected with ATG).39 This single-center experi-
ence continues to show interesting results,
with the most recent follow up reporting 44
naïve AA patients showing response rate,
overall survival and event free survival of 88%,
71% (the majority complete) and 58%, respec-
tively.40 However, most investigators do not
consider CTX as a feasible treatment option for
AA patients, based on the results of the ran-
domized study versus ATG + CyA conducted at
NIH. This study was early stopped due to in-
creased fatal infectious complications in the
experimental arm (CTX + CyA), related to the
prolonged neutropenia resulting from CTX
myelotoxicity;41 in addition, the latest follow up
did not confirm Johns Hopkins’ data sug-
gesting that CTX may reduce the risk of
MDS/AML development.42
Another candidate agent for inducing lym-
phocyte depletion in AA patients is the anti-
CD52 monoclonal antibody alemtuzumab,
which specifically kills CD52-bearing cells via
both antibody-dependent cellular cytotoxicity
and complement-mediated lysis. We have re-
cently reported, in collaboration with the
EBMT Working Party for Severe Aplastic
Anemia (WPSAA), that an alemtuzumab-based
IS regimen (also including low-dose CyA) was
feasible, safe and effective for the treatment of
AA patients.43 Alemtuzumab was given subcu-
taneously with negligible injection-related side
effects, and the low rate of infectious compli-
cations ruled out most safety concerns; prelim-
inary efficacy data suggested response rates
not below standard IS regimen (58%), with
easy re-treatment in case of relapse. These
data confirms observations from smaller se-
ries.44,45 However, recent data from NIH seem
only partially confirm these positive results;46
in fact, alemtuzumab resulted in a 56% re-
sponse rate in relapsed AA (n=23) and 36% in
refractory AA (n=25). However, quite surpris-
ingly, as front line treatment alemtuzumab re-
sulted in a response rate as low as 19% (on 16
patients only); it has to be remarked that in the
NIH experience alemtuzumab was used as
single agent, without CyA.
Other IS agents may be also hypothesized
for the treatment of AA; in the past years, the
anti-CD25 monoclonal antibody daclizumab
was used for moderate forms of AA, with a re-
sponse rate of about 40%.47,48 Given the proven
role of cytokines in suppressing the hemato -
poiesis in AA,7 some cytokine inhibitors have
been hypothesized for the treatment of AA, es-
pecially the already available TNF-α inhibitors
etanercept (a TNF-receptor/Ig fusion pro-
tein),49 infliximab (a chimeric anti-TNF-α
mAb) and adalimumab (a fully humanized
anti-TNF-α mAb). One could also hypothesize
that in the future additional IS agents will be
investigated in AA, such as alefacept,50 efal-
izumab,51 anti-IFN agents52 or even immuno -
modulation by mesenchymal stem cells.53Current immunosuppression: the matter of different ATG preparations
ATG is a heterologous anti-serum obtained
by injecting human lymphocytes in animals;
various ATG preparations exist, which differ in
stimulating antigens (peripheral lymphocytes,
thymocytes or even T cell lines), and/or in the
host animal (either horse or rabbit). Thus,
even if comprehensive descriptions of the
composition of each anti-serum are limited,
they are obviously different;54-56 in addition, at
least in the past, inter-lot variation due to man-
ufacturing processes cannot be excluded.57
The majority of available data coming from
large randomized clinical trials refer to poly-
clonal ATGs obtained from horse (h), which
have to be considered the gold standard for AA
treatment. Of note, US and Japanese investi-
gators utilized hATG (ATGAM®, Upjohn; 40
mg/kg/day for 4 days),24,25 which is different
from the hATG preparation used in Europe
(Lymphoglobuline®, Genzyme; 15 mg/kg/day
for 5 days).20,26 Even if a formal head-to-head
comparison has been never conducted, both h-
ATG preparations resulted in response rates
ranging between 50% and 70%;20,24-26 thus,
they are considered equivalent as standard IST
for AA. However, since 2008 Lymphoglobuline
is no longer available in Europe, and physi-
cians were forced to utilize other ATG prepara-
tions. Alternative polyclonal ATGs may be ob-
tained from rabbits (r); two rATGs are cur-
rently available (Thymoglobuline®, Genzyme;
ATG-Fresenius®) but to date the clinical re-
sults with these agents are less robust for the
lack of large randomized trials. Thymoglobu-
line has been utilized in AA patients, and both
retrospective data and prospective series have
demonstrated a substantial efficacy. In most
cases, rATG was used as second-line IST (after
initial hATG) to prevent side effects due to pos-
sible sensitization to horse proteins, resulting
in response rates up to 68% (in relapsed pa-
tients).33,34 As a front-line therapy, the experi-
ence with Thymoglobuline is quite limited; the
only prospective trial is currently ongoing at
NIH, where investigators are comparing head-
to-head h-ATG (ATGAM) and r-ATG (Thy-
moglobuline), both arms with CyA, as first line
treatment for AA patients (NCT00260689). The
recruitment is now closed (60 patients per
arm), and preliminary data were just pre-
sented at the 2010 ASH meeting;58 very sur-
prisingly, r-ATG was markedly inferior to h-ATG
in terms of response rate (33% vs 62% and 35%
vs 68% at 3 and 6 months, respectively). Of
note, lymphocyte depletion after r-ATG was
markedly longer-lasting in comparison to h-
ATG, raising the question that lymphocyte de-
pletion may be not sufficient to achieve hema-
tological remission in AA patients. Based on
this data, one could hypothesize that addi-
tional immune or non-immune mechanisms
may be involved in the pathophysiology of AA,
and that h-ATG may target them more effi-
ciently than r-ATG. For instance, regardless the
antibodies resulting in T cell depletion, h-ATG
might contain antibodies targeting immune
cytokines involved in the inhibition or in the
damage of hematopoietic stem cells. The NIH
data were in agreement with a retrospective
study from Brazil,59 which showed a 34.5% re-
sponse rate with Thymoglobuline in compar-
ison to the 59.5% achieved with Lymphoglobu-
line (patients were 42 and 29, respectively).
However, other retrospective experiences are
in contrast with the results of this randomized
study: investigators at the Cleveland Clinic
treated 22 naïve AA patient with Thymoglobu-
line, showing a response rate of 50% and 54%
at 6 and 12 months, respectively; these results
were comparable to the historical control of 67
AA patients who have received initial treat-
ment with ATGAM (59% response rate at 6 and
12 months).60 A similar retrospective study
was conducted by the Spanish group,61 which
showed that 75 AA patients receiving front-line
treatment with Thymoglobuline (2.5 mg/kg for
5 days) had a response rate of 45%, which was
comparable to the 49% of the 35 patients who
have received Lymphoglobuline. Additional
studies are currently ongoing to investigate
the efficacy of Thymoglobuline: the EBMT is
retrieving its retrospective registry to assess
the actual response rate. In addition, the
EBMT is running a pilot study (NCT00471848)
to investigate whether 2.5 mg/kg/day of Thy-
moglobuline (for 5 days) may be equivalent to
the most utilized dose (3.75 mg/kg/day). In-
deed, based on these data, at the moment h-
ATG + CyA seems the safest treatment for AA
patients; Thymoglobuline, which have in any
case a substantial efficacy, should be recom-
mended only if h-ATGs are not available, or
within prospective trials. Finally, ATG-Frese-
nius should not be used as IST for AA patients,
given that its use is limited to anecdotic and
disappointing experiences.62
Conclusions
To date, ATG + CyA remains the standard
IST for AA patients. All the attempts to improve
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the results obtained with this regimen have
been unfruitful. Unexpectedly, recent observa-
tion have confounded rather than clarified our
knowledge of IST in AA; in fact, the dogma that
different ATG preparations may be equally ef-
fective has been unexpectedly debunked. The
fact that hematological response does not cor-
relate with lymphocyte depletion also suggest
that h-ATG may work through unknown mech-
anisms of actions, even other than immune,
leading to a possible dispute of AA pathophysi-
ology itself. Even if these data have to be con-
firmed, at the moment h-ATG seems the best
standard of care for AA patients; this repre-
sents a urgent challenge for those Countries
(i.e., Europe) where h-ATG is no longer avail-
able. At the moment, it is not clear whether
novel IS agents or strategies may be useful to
improve the results of current IST; the design
of large, co-operative prospective studies
seems the only way to unravel the open issues
in IS for the treatment of AA.
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Objective: To assess the influence of hepatitis C virus
(HCV) infection on disease appearance and outcome of
ocular adnexal non-Hodgkin lymphoma (ONHL).
Design: Retrospective comparative study (from Janu-
ary 1, 1992, through December 31, 2006).
Methods: The medical records of 129 patients with
ONHLwere retrospectively reviewed.All the patientswere
tested serologically for the presence of HCV infection.
Patients were divided into 2 groups according to the pres-
ence or absence of HCV infection.
Main Outcome Measures: Prevalence of HCV infec-
tion, staging to evaluate the extent of disease at the on-
set, and clinical outcome data on overall and disease-
free survival.
Results:The prevalence of HCV infection among the pa-
tients with ONHLwas 17.8%. Seropositivity for HCV in-
fectionwas significantly associatedwith extraorbital lym-
phoma at the onset (P=.006). High prevalence ofmucosa-
associated lymphoid tissue disease (79.8%)was registered.
Protocol therapy included radiotherapy and chemo-
therapy, depending on the stage of the disease. Com-
plete remission was achieved in 99 patients (76.7%). A
total of 23.6% of patients with HCV-seronegative status
and 21.7% of those with HCV-seropositive status expe-
rienced relapse of the lymphomatous disease. No signifi-
cant differences in the 5-year overall survival and disease-
free survival between the 2 groups were observed.
Conclusions: Prevalence of HCV infection in patients
with ONHL is a relevant issue, accounting for 17.8% of
the examined patients. Infection with HCV may influ-
ence the initial appearance of ONHL because it is asso-
ciated with more widespread disease at the onset. How-
ever, the overall and disease-free survival of the infected
patients are not statistically different than that of pa-
tients who are not infected.
Arch Ophthalmol. 2010;128(10):1295-1299
H EPATITIS C VIRUS (HCV)represents a viral pan-demic and is well knownas the causative agent ofchronic viral hepatitis,
which has been linked to the develop-
ment of hepatocellular carcinoma.1 Hepa-
titis C virus is a hepatotropic virus that can
also replicate in lymphoid cells. The vi-
rus has been shown to sustain clonal ex-
pansion of B lymphocytes in patients with
HCV infection.2 This observation raised the
question of whether HCV is a lymphoma-
genic virus and has led to evaluation of the
potential role of HCV infection within
B-cell non-Hodgkin lymphoma, as well as
other hematologic malignant neo-
plasms.3-6 A pathogenic link betweenHCV
and non-Hodgkin lymphoma (NHL),
mostly marginal zone lymphoma of mu-
cosa-associated lymphoid tissue (MALT),
has been suggested.3-10 In contrast, other
authors11-13 have not confirmed such an
association.
Ocular adnexal non-Hodgkin lym-
phoma (ONHL) (eg, conjunctiva, lachry-
mal gland, and orbital soft tissue) is one
of the most common forms of extranodal
lymphomas and usually displays limited
stages of disease, an indolent clinical
course, and a tendency to remain local-
ized for several years.14 Only 1 study10
shows a positive association between
HCV infection and the development of
ONHL. The authors of this previous
article state that HCV infection con-
comitant to ONHL is associated with
more disseminated disease at the diag-
nosis and with poor prognosis. The cur-
rent study aims to assess whether HCV
infection plays a role in determining the
clinical features of HCV-seropositive
orbital lymphomas, especially regarding
the prognosis.
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METHODS
STUDY GROUP
A retrospective study of a series of 129 patients with orbital
ONHL, who had been referred from January 1, 1992, through
December 31, 2006, to theOrbitalUnit of theUniversity ofNaples
Federico II, was performed. The patients included in this study
had the onset symptom of orbital localization of ONHL. Data
concerning age, sex,mass localization, and follow-upwere avail-
able for all the examined patients. All the patients had a diag-
nosis of orbital lymphoma based on pathologic examination of
an incisional biopsy specimen. The patients with ONHL diag-
nosed according to the previous classification for NHL (Work-
ing Formulation classification) were reclassified according to
the latest criteria of the World Health Organization classifica-
tion15 by pathologic reevaluationwith additional immunochemi-
cal examinations.
The staging workup consisted of physical examination, bio-
chemical blood profile, total-body computed tomography, and
bonemarrow biopsy. In patients with conditions diagnosed af-
ter 2002, positron emission tomography was also performed.
Each patient underwent tests for antibodies to HCV as-
sayed by a second-generation enzyme-linked immunoassay
(HCV RNA qualitative reverse-transcriptase polymerase chain
reaction standardizedmethod) and determination ofHCVgeno-
type. Furthermore, we analyzed the presence of chronic he-
patic disease. The patients who hadHCV-seropositive status un-
derwent liver biopsywith the aimof evaluating thehepatic disease
associatedwith the viral infection. The chronic liver disease was
classified according to criteria developed by Ishak et al.16
First-line treatment consisted of radiotherapy, in propor-
tions of 1.8 or 2.0 Gy, 5 times per week, with total doses rang-
ing from 34.2 to 50.0 Gy, when the disease was localized at the
only orbit.When the lymphomatous disease appeared to be dis-
seminated, according to the staging, a conventional protocol
therapy based on cyclophosphamide, doxorubicin hydrochlo-
ride, vincristine sulfate, and prednisone (CHOP) chemo-
therapy or a CHOP-like schemewas administrated. In selected
patients whose conditions were diagnosed after 2002, ritux-
imab was added.
After antineoplastic treatment, 6 patients with HCV-sero-
positive status who hadONHLwere treatedwith interferon alfa
(3 000 000 units 3 times a week for 12 months) subcutane-
ously. They were also given ribavirin, 1000 mg/d, orally.
All patients were followed up every 3 months with clinical
evaluation and laboratory tests. They were also followed up ev-
ery 6 months with ultrasonography and computed tomogra-
phy (with positron emission tomography and computed to-
mography after 2002).
STATISTICAL ANALYSIS
Clinical characteristics and disease extent at onset of the HCV-
seropositive and HCV-seronegative groups were verified with
the 2 test and t test for nominal and continuous clinical vari-
ables, respectively. Cumulative risk for relapse of ONHL (ie,
disease-free survival) or death (ie, overall survival) during the
follow-up was assessed by Kaplan-Meier curves, and a com-
parison between HCV-seropositive and HCV-seronegative pa-
tients with NHL was performed with the log-rank test.
Overall survival was calculated starting from the date of
pathologic diagnosis to death or to the latest date of follow-up
visit, whereas time to progression and disease-free survival were
calculated from first day of treatment to relapse, time to pro-
gression and time of death, or the latest date of follow-up visit.
RESULTS
The follow-up varied from a minimum of 12 months to a
maximum of 185 months, with an average of 75 months.
The frequency of the different histologic types of ONHL
is shown in Figure 1. The clinical characteristics of the
129 patients included in this study are summarized in
Table 1. The median age of the patients was 62.88 years
(range, 26-93 years), and themale to female ratiowas 0.61.
Twenty-three patients (17.8%) were infected with
HCV. In all patients, the diagnosis of HCV infection pre-
ceded the diagnosis of lymphoma. All patients had HCV
RNA detectable by polymerase chain reaction.
Mucosa-associated lymphoid tissue is the most fre-
quent type of lymphoma, resulting in 79.8% of cases. A
similar percentage was found among patients with HCV-
seropositive status. No significant differences were found
between the 2 groups in terms of distribution of the dif-
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Figure 1. Comparison of the overall survival between the 2 groups of
patients (hepatitis C virus [HCV] seropositive and seronegative) assessed by
Kaplan-Meier curves (P=.79).
Table 1. Clinical Characteristics at Disease Onset
Characteristic
No. (%) of Patients
by HCV Status (N=129)a
P
ValueSeropositive Seronegative
No. of patients 23 (17.8) 106 (82.2) . . .
Age, median (range), y 64.34 (43-84) 62.88 (26-93) . . .
Sex, M/F 4/19 45/61 . . .
Orbital lymphoma 10 (43.5) 86 (81.1) .001
Conjunctival
lymphoma
2 (8.7) 10 (9.4) .99
Eyelid lymphoma 1 (4.3) 8 (7.5) .99
Lacrimal gland 9 (39.1) 22 (20.8) .10
Extraocular muscles 1 (4.3) 1 (0.9) .32
Stage
1 15 (65.2) 96 (90.6) .004
2 0 0 . . .
3 0 0 . . .
4 8 (34.8) 11 (10.4) .006
Positive BMB 8 (34.8) 10 (9.4) .004
Abbreviations: BMB, bone marrow biopsy; ellipses, not applicable;
HCV, hepatitis C virus; M, male; F, female.
aData are number (percentage) of patients unless otherwise indicated.
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ferent histopathologic subtypes (Table 2). The histo-
logic analysis of the hepatic tissue in the HCV-sero-
positive patients showed chronic active hepatitis in 6
patients (26.1%) and no signs of liver disease in the re-
maining 17 patients (73.9%). The apparent disease dura-
tion was calculated as the time passed by the first known
risk of infection (eg, major orminor surgery, transfusion,
tattooing, or intravenous drug abuse) to the time of the
diagnosis of the orbital lymphoma. The average time was
22.6 years (SD, 13.9 years).
As reported in Table 1, the extent of the disease was
significantly different between the 2 groups: 8 (34.8%) pa-
tients with HCV-seropositive status had stage IV disease
at the diagnosis vs 11 (10.4%) patients with HCV-
seronegative status. Infection with HCVwas significantly
associatedwith extraorbital disease at the onset (P=.006).
Radiotherapy treatment was administered in 108 pa-
tients (83.7%) as single-line therapy, whereas 21 pa-
tients (16.3%) were treated with a combination of radio-
therapy and chemotherapy. The therapeutic outcome is
summarized in Table 3. Ninety-nine patients (76.7%)
achieved complete remission of the NHL. Thirty pa-
tients experienced relapse of the disease with extra-
nodal localization: 25 (23.6%) of these patients had
HCV-seronegative status and5patients (21.7%)hadHCV-
seropositive status (P=.99). The median time to disease
progression was 57.6 and 55.0 months for the HCV-
seronegative and HCV-seropositive groups, respec-
tively. The 5-year overall survival and disease-free sur-
vival were not significantly different in the 2 groups
(P=NS) (Figure 1 and Figure 2).
COMMENT
The association betweenHCV infection andNHLhas been
postulated in several studies.1-10 This correlation has been
mostly observed in countries such as Italy, the United
States, and Japan.6,8-10 However, this issue remains con-
troversial based on additional studies.12,17 In Italy a preva-
lence of HCV infection in NHL ranging from 15% to 30%
has been reported.4,6
In the literature there are few studies10,12,13,18 that ex-
plore the association of HCV infection and ocular ad-
nexal lymphomas (eg, conjunctiva, lachrymal gland, and
orbital soft tissue), even though the ocular region is one
of themost common sites of extranodal lymphomas. Fer-
reri and coworkers10 have shown clinical implications of
HCV infection inMALT-type lymphoma of the ocular ad-
nexa. Of 55 patients, 13% tested seropositive for HCV.
The concomitantHCV infectionwas associatedwithmore
disseminated disease and aggressive behavior in ocular
adnexal lymphoma. By contrast, in an Austrian study,12
only 2 of 45 patients (4%) had a concomitant HCV in-
fection, and neither influence of HCV on clinical course
nor risk of relapse was found. In a short report,13 per-
formed in France, of 40 analyzed patients with ONHL,
only 1 patient had HCV-seropositive status.
In the present study, the prevalence of HCV infection
in the examined populationwithONHLwas 17.8%, simi-
lar to what has been reported in other Italian studies on
patients from other districts with NHL localized in differ-
ent sites.3,12 The variable worldwide prevalence of HCV
together with different environmental and genetic fac-
tors could explain these contrasting results. In fact, the
prevalence ofHCV infection in Italy is high (3%-5%).5 For
comparison, the role of Chlamydia psittaci in ocular ad-
nexal lymphoma appears to be especially pronounced in
Italy,19 whereas widely varying rates of infection could be
found in different geographic regions.20
Recently, an increasing amount of biologic data have
been found that support the role of HCV in lymphoma-
genesis.21-23 It seems that the long-term antigenic stimu-
lation provided by these agents may elicit host immune
Table 2. Distribution of Different Disease Subtypes Between
the 2 Groups of Patients
Subtype
HCV Seropositive,
No.
HCV Seronegative,
No. P Value
MALT 18 85 .78
Diffuse 2 9 .99
Follicular 0 9 .36
Mantle 3 3 .69
Abbreviations: HCV, hepatitis C virus; MALT, mucosa-associated lymphoid
tissue.
Table 3. Study Outcome Data
Outcome
No. (%) of Patients by HCV
Status (N=129)a
P
Value
Seropositive
(n=23)
Seronegative
(n=106)
Relapse rate 5 (21.7) 25 (23.6) .99
Local relapse 0 12 (11.3) .12
Systemic relapse 4 (17.4) 12 (11.3) .48
Systemic and local
relapse
1 (4.3) 1 (0.9) .32
Follow-up, median, mo 71.7 77.4 . . .
TTP, median, mo 55.0 57.6 . . .
Abbreviations: ellipses, not applicable; HCV, hepatitis C virus; TTP, time to
progression.
aData are number (percentage) of patients unless otherwise indicated.
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Figure 2. Comparison of the progression-free survival between the 2 groups
of patients (hepatitis C virus [HCV] seropositive and seronegative) assessed
by Kaplan-Meier curves (P=.53).
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responses able to promote and sustain clonal B-cell ex-
pansion.3 A significant increase of NHL in patients with
more than 15 years of HCV infection has been reported.6
In our study the median duration of HCV infection was
22 years, with 34.8% of patients with HCV-seropositive
status having disseminated disease at onset and only 9.4%
of patientswith seronegative status havingwidespread dis-
ease at onset (P=.004) (Table 1). This finding supports
the hypothesis that HCV infection allows spreading of the
lymphoma, sustaining its clonal expansion. Although the
HCV genome and its replicative intermediates have been
detected inperipheral bloodmononuclear cells and in lym-
phoid tissues of chronically infected patients,21 its role as
a trigger agent of a frank B-cell neoplastic disorder is not
clear yet.21-23 In fact, because the virus lacks reverse tran-
scriptase, it is unable to integrate into the host genome and
to encode for any known oncogenesis. Considering this
possible pathogenic mechanism, the need for analysis of
the biopsied tissue for the presence of HCV is unevent-
ful, as advocated by some authors.18
A history of liver disease may be considered a pos-
sible pathogenic factor on the progression of lymphoma
staging in patients with HCV-seropositive status.4 How-
ever, only 6 of 23 patients in our cohort had an active
viral liver disease. Considering these data, we were not
able to state that liver disease gravity may have condi-
tioned lymphoma staging in our group of patients.
Patients included in this study received radiotherapy
alone or with adjuvant chemotherapy, depending on the
stage of the disease. As we previously reported in primary
NHL with different site distribution, the use of an appro-
priate therapeutic option also resulted in a favorable out-
come for this subset of patients with extranodal lympho-
mas.5 Theoverall outcome resulted in a complete remission
of NHL in 99 patients (76.7%). A total of 25 (23.6%) of
the patients with HCV-seronegative status and 5 (21.7%)
of those with HCV-seropositive status experienced re-
lapse of the disease; however, we did not observe a statis-
tically significant difference in the 5-year overall survival
and disease free survival between the 2 groups (Tables 1
and 3 and Figures 1 and 2). It can be argued that the ap-
propriate use of the protocol therapy based on a careful
evaluation of the stage or extent of the disease can mini-
mize the negative effect of HCV infection.
The results of this study were compared with those
of the only previously published large Italian study10 in
the PubMed database, to our knowledge, which con-
cerned the positive link betweenHCV infection and ocu-
lar adnexal lymphoma. The authors of the other study
similarly found that HCV infection is associated with a
more aggressive clinical stage at the onset, but they con-
versely reported that patients with HCV-seropositive sta-
tus had a poor prognosis over time compared with those
with HCV-seronegative status. Possible explanations of
the difference regarding the outcome between these re-
ported data and our own data may be ascribed to differ-
ences in the first-line therapy choices.
In a study24 performed with a French population that
demonstrated the link between HCV infection and the
diffuse large cell lymphoma, the authors suggested that
specific protocols, including antiviral therapy, should be
designed for patients affected by lymphoma. Recent re-
ports, attesting to the efficacy of antiviral treatment on
the course of HCV-related B-cell NHL, strengthen the hy-
pothesis of a link between HCV infection and B-cell lym-
phoma.25,26 The value of the antiviral therapy was ruled
out by the statistical analysis of this study because of the
paucity of patients with HCV-seropositive status treated.
Nevertheless, the use of antiviral therapy may improve
the outcome of patients infected with NHL, as we re-
ported in a previous study.25
To summarize, HCV infection has a potential nega-
tive effect on patients infected with ocular lymphoma be-
cause it is associated with a more diffuse dissemination
at the onset. Discrepancy with previous studies in terms
of the incidence of HCV-seropositive cases among pa-
tients infected with ONHLmay be explained by the geo-
graphic variations of this infection. Therefore, although
an influence of HCV infection on lymphoma exists, the
different prevalence can modify its role as a prognostic
factor. Outcome seems to be slightlymodified by the pres-
ence of this infection, probably because the effective-
ness of the recent first-line treatment couldminimize the
influence of this risk factor. However, future studies will
be necessary to better assess the influence of infectious
agents andmalignant neoplasms and the possible role of
antiviral therapy. It must be considered that the data re-
ported herein were collected in a single referral center.
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 Purpose: To prospectively compare the assessment of metabolic re-
sponse to yttrium 90 ( 90 Y)–ibritumomab tiuxetan radioimmu-
notherapy (RIT) by using fl uorine 18 ( 18 F) fl uorodeoxyglucose 
(FDG) combined positron emission tomographic– computed 
tomographic (PET/CT) imaging at 2 and 6 months to 
determine the most appropriate time to detect therapeutic 
response in refractory non–Hodgkin lymphoma (NHL) pa-
tients treated with RIT.
 Materials and 
Methods: 
The ethical committee of the university approved the 
protocol and all patients signed informed consent. Twenty-
three consecutive patients (10 women, 13 men; mean 
age, 51.8 years  6  7.3 [standard deviation ]) treated by 
using RIT for relapsed or refractory follicular NHL were 
enrolled. For all patients,  18 F FDG PET/CT scanning was 
performed at baseline and at 2 and 6 months after RIT. 
Response was assessed by using the International Workshop 
Criteria (IWC) and revised criteria (IWC + PET) as well 
as the criteria of the European Organization for Research 
and Treatment of Cancer. One-way analysis of variance for 
repeated measures, receiver operator curve analysis, and 
Kaplan-Meier curves were used for statistical analysis.
 Results: PET/CT performed at 2 months revealed complete ( n = 12) 
or partial ( n = 4) metabolic response in 16 of 23 patients 
with complete or partial clinical response. These fi ndings 
were all confi rmed at 6-month scanning. PET/CT indicated 
refractory or persistent disease at 2 and 6 months in 
the remaining seven patients. Better overall survival was 
observed for patients with a reduction in the maximum 
standard uptake value of 49% or higher (both at 2 and 
6 months after RIT) when compared with those with a 
decrease of less than 49% ( P  , .05).
 Conclusion: Early assessment of response to RIT by using PET/CT 
might be useful in the identifi cation of patients needing 
additional therapeutic strategies.
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between November 2005 and April 
2008. Refractory/relapsed disease was 
confi rmed in all patients before RIT by 
using clinical, laboratory, and/or imag-
ing or histologic fi ndings obtained from 
biopsy results. Before RIT, 17 patients 
received combined cyclophosphamide-
doxorubicin-vincristine-prednisone and 
six received a fl udarabine-mitoxantrone 
(Fludara, Schering, Berlin, Germany; 
Onkotrone, Baxter, Rome, Italy) regi-
men. One patient had undergone bone 
marrow autologous transplantation and 
two had undergone local external-beam 
radiation therapy. Nine had multiple re-
missions and subsequent relapses. All 
patients received at least one course of 
rituximab therapy. All patients strictly 
fulfi lled recommended inclusion crite-
ria, which were as follows: relapsed or 
refractory low-grade or follicular B-cell 
NHL, having less than 25% lymphoma 
marrow involvement and/or impaired 
bone marrow reserve, and absence of 
severe thrombocytopenia (ie, a platelet 
count of  . 100 000 per mm 3 ). 
 All patients underwent comprehen-
sive evaluation, including clinical and 
hematologic data, as well as neck ultra-
sonography and chest, abdominal, and 
phocytes by coating them beforehand 
with rituximab. 
 Recently, fl uorine 18 ( 18 F) fl uorode-
oxyglucose (FDG) combined positron 
emission tomographic–computed to-
mographic (PET/CT) imaging has been 
recognized as a suitable tool for stag-
ing, follow-up, and tumor response as-
sessment of NHL patients ( 7–9 ). It of-
fers the advantage of functional tissue 
characterization by measuring glucose 
uptake, which is independent of mor-
phologic or size criteria. However, no 
consensus has been reached regarding 
the optimal timing for performing  18 F 
FDG PET/CT after RIT in lymphoma 
patients. Therefore, the aim of the our 
study was to prospectively compare the 
assessment of metabolic response to 
RIT by performing  18 F FDG PET/CT at 
2 and 6 months after treatment to de-
termine the most appropriate time to 
detect therapeutic response in refrac-
tory NHL patients treated with  90 Y–
ibritumomab tiuxetan RIT. 
 Materials and Methods 
 Patients 
 The ethical committee of our univer-
sity approved the study protocol. All 
patients undergoing RIT and imaging 
studies signed informed consent in 
accordance with the Declaration of 
Helsinki. 
 Twenty-three consecutive patients 
(mean age, 51.8 years  6 7.3 [standard 
deviation]; range, 43–76 years) con-
sisting of 10 women (mean age, 53.5 
years  6 8; range, 43–65 years) and 
13 men (mean age, 54.4 years  6 9; range, 
49–76 years) were referred for  90 Y–
ibritumomab tiuxetan treatment of low-
grade follicular NHL that was relapsed 
after or refractory to chemotherapy 
and immunotherapy ( Table E1 [online]) 
 Follicular lymphoma is one of the most frequently occurring types of non–Hodgkin lymphoma (NHL), 
accounting for 70% of all indolent 
cases. The overall prevalence of NHL in 
the European Union is approximately 
230 000, with an annual incidence of 
about 70 000. Approximately 18 500 
new cases of follicular lymphoma are 
diagnosed annually in the United States 
( 1,2 ). Although the therapeutic options 
for patients with NHL have improved 
over the past 20 years, most patients 
with low-grade lymphoma ultimately 
die of their disease, regardless of the 
treatment used ( 3 ). 
 Targeted radioimmunotherapy (RIT) 
is attractive as an approach toward 
treatment because follicular lymphoma 
cells are intrinsically extremely sensitive 
to radiation. Yttrium 90 ( 90 Y)–ibritu-
momab tiuxetan (Zevalin; Schering AG, 
Berlin, Germany) for RIT is currently ap-
proved for adult patients with relapsed 
or refractory CD20+ follicular B-cell 
NHL in Europe and the United States 
( 4–6 ). It combines the tumor-targeting 
ability of an anti-CD20 monoclonal an-
tibody and the tumor-destroying power 
of  90 Y radiation confi ned to a small area. 
This treatment ensures a high bioavail-
ability at tumor sites and prevents the 
radioactivity from being distributed 
through the body by circulating lym-
 Implication for Patient Care 
 Early assessment of response to  n
RIT by using PET/CT might be 
useful in the identifi cation of 
patients needing additional thera-
peutic strategies or to avoid inef-
fective therapies and diagnostic 
procedures. 
 Advances in Knowledge 
 Fluorine 18 (  n 18 F) fl uorodeoxyglu-
cose (FDG) PET/CT assessment 
of metabolic response to radio-
immunotherapy (RIT) in non–
Hodgkin lymphoma (NHL) 
patients performs equally well at 
both 2 and 6 months, with an 
accuracy of 91% in predicting 
clinical outcome at 12-month 
follow-up. 
  n  18 F FDG metabolic data after 
RIT showed signifi cant difference 
in maximum standard uptake 
value (SUV max ) between respond-
ers and nonresponders with a 
better overall survival in NHL 
patients with a 49% or higher 
reduction in SUV max . 
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ers fi rst evaluated the CT images alone. 
Mass sizes were visually estimated and 
those considered as potentially clinically 
important were measured by using 
electronic calipers for at least two max-
imum diameters. A lesion in the base-
line study was defi ned as an identifi able 
mass or lymph node larger than 1 cm 
in minimum diameter with soft- tissue 
mediastinal window settings. Then, 
maximum standardized uptake values 
(SUV max ) were determined and corrected 
for body weight. 
 Response Assessment 
 Response assessment was performed for 
PET/CT scans by using three methods: 
International Workshop Response Crite-
ria (IWC) ( 10 ); revised IWC + PET crite-
ria ( 11,12 ), and PET response criteria of 
the European Organization for Research 
and Treatment of Cancer (EORTC) ( 13 ) 
( Table E2 ). The IWC evaluation per-
formed at mid-term  follow-up was con-
sidered as a reference standard together 
with clinical and hematologic evaluation. 
The accuracy of each method in predict-
ing the results of the comprehensive as-
sessment (ie, clinical and hematologic 
and imaging), carried out at mid-term 
follow-up, was tested. 
 At baseline PET/CT scanning, all 
lymph nodes and extranodal masses 
were systematically evaluated according 
to topographic criteria and up to eight 
of the hottest (those with the highest 
levels of uptake ) representative lesions 
( . 1 cm in size) per patient were identi-
fi ed as target lesions. SUV max and bidi-
mensional tumor size measurements 
were obtained for each target lesion 
and in the location of the treated le-
sion (background) when tumor uptake 
was no longer visually detectable. The 
presence and metabolic activity of new 
 lesions were also recorded. The per-
centage change in SUV max and in tumor 
size (sum of the product of the diame-
ters [SPD]) between baseline and both 
2 and 6 months post-RIT scans were 
calculated for each target lesion. 
 Response to RIT was classifi ed ac-
cording to IWC criteria ( 10 ) and fur-
ther categorized according to revised 
IWC + PET criteria ( 11,12 ) and EORTC 
PET response criteria ( 13 ) at both 2 
vance NXi; GE Healthcare) and a four 
detector–row CT system (LightSpeed 
Plus; GE Healthcare ). In all studies, 
PET/CT imaging was performed 75–90 
minutes after intravenous administra-
tion of 12–15 mCi (444–555 MBq) of 
 18 F FDG. Multidetector CT (pitch, 1.5; 
tube charge, 120 mAs; and tube voltage, 
120 kVp) was performed without intra-
venous and/or oral contrast medium as 
part of the PET/CT examination. PET 
scanning was subsequently performed 
with 4 minutes per bed position and six 
to eight bed positions per patient, de-
pending on patient height. Raw CT data 
were reconstructed in transverse im-
ages with a 4.25-mm section thickness. 
Sagittal and coronal CT images were 
generated by means of reconstruction 
of the transverse data. Raw PET data 
were reconstructed both with and with-
out attenuation correction in trans-
verse, sagittal, and coronal images. At-
tenuation correction was performed on 
the basis of the attenuation coeffi cients, 
which were determined by using itera-
tive reconstruction. Patients fasted for 
4–6 hours prior to imaging and blood 
glucose level was determined in all pa-
tients before  18 F FDG administration. 
A cutoff value of less than 160 mg/dL 
(8.8816 mmol/L ) was considered ap-
propriate to perform the examination. 
 At the mid-term evaluation, unen-
hanced CT scans of the neck, chest, ab-
domen, and pelvis were performed with 
a multidetector scanner (Toshiba Aquil-
ion; Toshiba Medical Systems, Otawara, 
Tochigi, Japan) by using the following 
parameters: pitch, 1.0; tube charge, 240 
mAs; and tube voltage, 120 kVp. 
 Imaging Evaluation 
 All images were reviewed at a worksta-
tion by using PET/CT fusion software 
(Volumetrix for PET-CT; GE Healthcare, 
Waukesha, Wis). Each set of baseline 
and follow-up PET/CT studies, as well 
as the fi nal CT scans, were interpreted 
by two experienced nuclear physicians 
(G.S. and L.P, each with 15 years ex-
perience) in consensus, one of whom 
(L.P.) is a radiologist . Images were in-
terpreted promptly after acquisition. At 
that moment, readers were aware only 
of the timing of follow-up. The examin-
pelvic CT at baseline, at 6 months 
after RIT, as well as mid-term follow-up 
(mean, 12.8 months  6 5.9; range, 7–20 
months). In particular, clinical fi ndings, 
including signs and symptoms such as 
painless swelling in the lymph nodes of 
the neck, axilla, or groin, unexplained 
fevers, drenching night sweats, fatigue, 
unexplained weight loss, itching, red-
dened patches on the skin, nausea, 
vomiting, or abdominal pain, correlated 
with the results of complete blood 
counts, serum electrolytes, liver and 
kidney function tests, and serum lac-
tate dehydrogenase levels. No patients 
showed bone marrow involvement 
before RIT. A majority of relapses or 
evidence of refractory disease was seen 
following physical examination during 
scheduled or unscheduled visits. 
 A baseline  18 F FDG PET/CT scan 
at restaging was performed 10–14 
days (mean, 12 days  6 1) before RIT. 
 18 F FDG PET/CT examinations to help 
evaluate responses were performed 2 
(mean, 2.1 months  6 0.3; range, 1.7–
2.4 months) and 6 (mean, 5.6 months 
 6 0.2; range, 5.4–6.3 months) months 
after RIT and their results were com-
pared with those of the baseline imag-
ing examination, as well as with the 
clinical and hematologic data. 
 Treatment Procedures 
 Patients underwent  90 Y–ibritumomab 
tiuxetan treatment according to a stan-
dardized regimen: an initial dose of 
rituximab (250 mg per square meter of 
body surface area) was administered in-
travenously on day 1; on day 8, a second 
identical dose of intravenous rituximab 
was followed by a single intravenous 
injection of  90 Y–ibritumomab tiuxetan 
(14.8 MBq/kg), for a maximum of 1169 
MBq. No treatment other than RIT was 
administered between the baseline and 
follow-up  18 F FDG PET/CT examina-
tions; moreover, no changes in therapy 
resulted from the early (2-month) pa-
tient evaluation. 
 Imaging Technique 
 18 F FDG PET/CT was performed with 
a commercial PET/CT scanner (Dis-
covery LS; GE Healthcare, Milwaukee, 
Wis) that combines a PET scanner (Ad-
248 radiology.rsna.org n Radiology: Volume 254: Number 1— January  2010  
 NUCLEAR MEDICINE: Metabolic Response of Non–Hodgkin Lymphoma to Radioimmunotherapy  Storto et al
in one site with involvement of a single 
extranodal site and lymphoma-related 
symptoms), and one as stage 4BX (ie, 
extensive disease in one site with bulky 
disease and lymphoma-related symp-
toms) at reevaluation before RIT. 
 FDG PET/CT Response Assessment 
after RIT 
 The 2-month CT scan (IWC) resulted 
in six complete response, 10 partial 
response and seven nonresponse out-
comes, while the 6-month scan showed 
10 complete response, six partial re-
sponse and seven nonresponse ( Table 1 ) 
outcomes. Assessment of response by 
using IWC + PET and  18 F FDG PET/CT 
scanning (EORTC) at both 2 and 6 months 
helped identify 12 complete response, 
four partial response and seven non-
response outcomes. 
 Two patients showing complete 
response at 12-month follow-up were 
classifi ed as metabolic partial response 
by using IWC + PET criteria ( Fig 1 ). 
Both showed at least a 50% decrease in 
SPD of their  18 F FDG PET/CT results at 2 
( 2 51% and  2 52%, respectively ;  P  , .05) 
and 6 ( 2 51% and  2 55%, respectively; 
 P  , .05) months, and continued to 
show FDG uptake in the previously 
involved sites. 
 The overall accuracy at the 2- month 
assessment was 65% (15 of 23) for 
IWC and 91% (21 of 23) for both IWC + 
PET and EORTC ( P  , .05 vs IWC), 
while at the 6-month evaluation, accu-
racy was 83 % (19 of 23) and 91% (21 
of 23), respectively ( P = .39). 
 Of the 14 patients with persistent 
complete response at mid-term follow-up, 
 Blood glucose level was stable in 
each patient (91 mg/dL  6 28 vs 93 mg/
dL  6 21 vs 89 mg/dL  6 23;  P = .82 
over time) and none of the patients ex-
perienced signifi cant weight loss during 
the study (67 kg  6 6 vs 66 kg  6 6 vs 
67 kg  6 6;  P = .95 over time ). 
 Statistical Analysis 
 Differences between mean values were 
assessed by using the Student  t test 
(two-tailed probability) for paired data. 
The McNemar test was used to com-
pare proportions. The one-way analysis 
of variance for repeated measures was 
also used. The post hoc analysis was 
performed with a Bonferroni correc-
tion. Receiver operator curve analysis 
was performed to estimate the optimal 
cutoff of percentage of SUV max decline 
for differentiating metabolic respond-
ers from nonresponders. Both 2- and 
6-month responses to RIT were corre-
lated with overall survival, which was 
defi ned as time from RIT until death 
from any cause or time of last censor. 
Overall survival was computed by using 
Kaplan-Meier curves. A  P  value of less 
than .05 was considered to indicate a 
signifi cant difference. 
 Results 
 Seven patients were classifi ed as Ann 
Arbor stage 2B, one as stage 2BE (ie, 
involvement of two lymph node groups 
on the same side of the diaphragm and 
of a single extranodal site next to the nodal 
groups with presence of lymphoma-
 related symptoms), 12 as stage 4B, 
two as stage 4BE (ie, extensive disease 
and 6 months after RIT. In particular, 
 metabolic tumor response was assessed 
visually (IWC + PET) and semiquantita-
tively (EORTC). Briefl y, EORTC criteria for 
PET responses defi ne progressive meta-
bolic disease as an increase in  18 F FDG 
tumor SUV max of greater than 25% in a 
target lesion defi ned on a baseline scan, 
a visible increase in the extent of  18 F 
FDG tumor uptake ( . 20% in the longest 
dimension), or the appearance of new 
tracer uptake; stable metabolic disease 
as an increase in SUV max of less than 
25% or a decrease of less than 15%; 
and a partial response as a reduction in 
SUV max of 25% or more. Complete meta-
bolic response would be a complete reso-
lution of  18 F FDG uptake in the tumor 
mass so that it was indistinguishable 
from surrounding normal tissues. 
 Clinical Follow-up 
 Performance status and status of dis-
ease (assessed by means of clinical pa-
rameters and on the basis of imaging 
results) were monitored during follow-up. 
The fi nal assessment at mid-term follow-
up was performed according to clinical 
and dimensional criteria obtained at 
the last CT examination (IWC) ( 9–11 ). 
In particular, this system defi nes cat-
egories of complete response, partial 
response, stable disease, and progres-
sive disease. For the statistical evalua-
tion, responder patients were defi ned 
as those with complete or partial re-
sponse. Nonresponder patients were 
those with no response or progressive 
disease. RIT side effects were also re-
corded, if any, by using laboratory data 
and medical records. 
 Table 1 
 Overall Response Assessed at Mid-term Follow-up 
2-month Follow-up 6-month Follow-up Mid-term Follow-up
Response IWC IWC + PET EORTC IWC IWC + PET EORTC Comprehensive Assessment
Complete 6/23 (26) 12/23 (53) * 12/23 (53) * 10/23 (44) 12/23 (53) 12/23 (53) 14/23 (61)
Partial 10/23 (44) 4/23 (17)† 4/23 (17) † 6/23 (26) 4/23 (17) 4/23 (17) 2/23 (9)
Nonresponders (progressive + 
 stable disease)
7/23 (30) 7/23 (30) 7/23 (30) 7/23 (30) 7/23 (30) 7/23 (30) 7/23 (30)
Note.—Numbers are raw data; percentages are in parentheses.
*  P  , .05 vs IWC.
 †  P  , .01 vs IWC.
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 Clinical Follow-up and Survival 
 The median follow-up period was 12 
months (range, 7–19 months). At the 
6-month clinical evaluation, 10 (43%) 
of 23 patients had continued com-
plaint of disease-related symptoms (no 
further therapies were implemented 
at that time), whereas the remaining 
patients experienced a substantial re-
lief of symptoms, as well as recovery 
of hematologic parameters. In the lat-
ter group, clinical responses remained 
substantially unmodifi ed thereafter. 
At mid-term follow-up, 14 (61%) of 
23 patients had persistent complete 
response, two (9%) patients had partial 
response, three (13%) were considered 
stable and four (17%) showed progres-
sive disease. None of the responders 
died or relapsed; in particular, those 
who achieved partial response showed 
clinical and hematologic improvement 
during the study. 
 In the nonresponders group, two 
(28%) of seven patients died because of 
late hematologic complications (severe 
neutropenia with lethal sepsis), three 
required red blood cell transfusion, and 
four patients underwent rescue che-
motherapy with the combined regimen 
of rituximab and cyclophosphamide-
doxorubicin-vincristine-prednisone at 
12-month follow-up. One patient had 
evidence of a new location (soft tissue), 
two presented with a paravertebral re-
lapse and histotype shift to large-cell 
NHL at biopsy; these fi ndings were 
evident by 13-months (range, 10–17 
months) of follow-up. 
 Receiver operator curve analysis 
showed that a reduction in SUV max of 
49% at both 2 and 6 months after RIT 
was optimal for differentiating meta-
bolic responders from nonresponders. 
Better overall survival ( Fig 2 ) was ob-
served in patients with a reduction in 
SUV max of 49% or higher (at both 2 and 
6 months after RIT) as compared with 
those with a decrease of less than 49% 
(median survival, 15 vs 10 months; 
 P  , .05). 
 Discussion 
 Although results of several studies ( 14–
16 ) have suggested the advantages of 
 At both 2- and 6-month  18 F FDG 
PET/CT, the SUV max of target lesions 
was signifi cantly lower in responder pa-
tients as compared with nonresponders 
( P  , .05) ( Table 3 ). At 2-month  18 F 
FDG PET/CT, the mean change in 
SUV max of the target lesions was 22%  6 
67 in nonresponders and  2 78%  6 17 in 
responders ( P  , .001); at the 6-month 
scan, the mean change in SUV max was 
28%  6 73 in nonresponders and  2 79% 
 6 15 in responders ( P  , .001). In par-
ticular, no signifi cant differences were 
found in SUV max changes after RIT be-
tween patients with complete response 
and those with partial response at both 
2- ( 2 76%  6 16 vs  2 75%  6 16;  P = 
.68) and 6- ( 2 77%  6 15 vs  2 82%  6 8; 
 P = .18) month scans. In patients with 
stable disease, SUV max remained un-
changed over time, whereas it increased 
in those with disease progression. 
12 were correctly identifi ed by using 
2- and 6-month IWC + PET, while IWC 
detected only six of them at 2 months 
and 10 at 6 months ( Table 2 ). 
 Of seven patients who progressed 
at 2- and 6-month  18 F FDG PET/CT, 
one had both a new lesion and showed 
changes in target lesions, while the 
others presented changes in target le-
sions only. 
 There was no difference in the num-
ber of locations at baseline between 
responders and nonresponders (3.9  6 
2.0 vs 4.3  6 1.8;  P = .69). At 2-month 
 18 F FDG PET/CT, the mean change in 
the SPD of the target lesions was 
83%  6 163 in nonresponders and 
 2 71%  6 23 in responders ( P  , .001); at 
the 6-month scan, the mean change in 
SPD was 146%  6 207 in nonrespon-
ders and  2 83%  6 22 in responders 
( P  , .0001). 
 Figure 1 
  
 Figure 1: Overall responses assessed by using PET (IWC + PET) related to comprehensive 
assessment at mid-term follow-up. 
 Table 2 
 Accuracy of Predicting Results of Comprehensive Assessment at Mid-term Follow-up 
Complete Response (14/23)
Follow-up Accuracy of IWC + PET (%) Accuracy of IWC (%)  P  Value
2 months 86 (12/14) 43 (6/14)  , .01
6 months 86 (12/14) 71 (10/14) .40
Agreement for 2 versus 6 months 100 59
Note.—Numbers in parentheses are raw data used to calculate percentages.
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They concluded that the best meta-
bolic response could be determined as 
early as six weeks after RIT in more 
than 90% of cases and that the effect of 
radiation-induced infl ammation at  18 F 
FDG PET/CT is probably not an impor-
tant consideration after the low-dose 
irradiation caused by RIT. 
 Nevertheless, there is a limited 
amount of data available concerning the 
optimal time to perform PET/CT stud-
ies after RIT ( 18,20 ). This is crucial, 
as early assessment of lesion metabolic 
response in NHL may be useful in sug-
gesting the need for alternate therapeu-
tic strategies earlier. In our study, re-
sults from  18 F FDG PET/CT performed 
2 months after RIT were equivalent to 
those from scans performed at 6 months 
(91% accuracy; 21 of 23) in evaluating 
outcome at mid-term follow-up, thus 
leading to a possible early change in 
patient management. Our results are 
consistent with those reported by other 
authors ( 25–28 ) on the response rate 
to RIT and with previous data on the 
important value of  18 F FDG PET/CT in 
the assessment of metabolic response 
in these patients ( 11–14,20,29–31 ). 
 Morphologic data derived from CT 
(IWC) by using an independent assess-
ment of images in responding patients 
showed lower complete response and 
higher partial response rates when com-
pared with PET/CT results (EORTC or 
IWC + PET) at both 2 and 6 months. 
Although morphologic assessment has 
been considered the standard for help-
ing detect therapy response, the limita-
tions of conventional CT-based disease 
evaluation for NHL are well-known. The 
use of anatomic size criteria for lymph 
nodes is unreliable, since subcentimeter 
lymph nodes may be malignant and large 
nodes may be nonmalignant. Moreover, 
size reduction generally occurs slowly 
and over time, and posttreatment fi bro-
sis is often diffi cult to differentiate from 
residual disease ( 18,20 ). 
 The accuracy of  18 F FDG PET/CT 
in helping detect complete response in 
our study was higher than that of CT 
data alone. The fi ndings of our study 
confi rm those of earlier studies ( 17,18 ) 
that an early (at 2 months) metabolic 
assessment after RIT by using  18 F FDG 
 Our fi ndings further support the 
fact that  18 F FDG PET/CT performed 
8 weeks after RIT may provide use-
ful information to correctly stratify 
treatment response in these patients 
( 17,18,20 ). At this point, therapy-
 induced infl ammation, which had been 
previously thought to affect imaging 
fi ndings ( 21–24 ), does not appear to be 
a problem. Furthermore, Bodet-Milin 
et al ( 18 ) have recently reported that 
 18 F FDG-PET imaging performed six 
weeks after fractionated RIT with 
humanized anti-CD22  90 Y-epratuzumab 
is reliable for early disease assessment. 
 18 F FDG PET for early chemotherapy 
result assessment, few trials have sup-
ported the benefi ts of such methods in 
the early assessment of RIT ( 17,18 ). 
Our study results suggest that metabolic 
fi ndings obtained by using  18 F FDG 
PET/CT at 2 months are not different 
from those at 6 months after RIT, and 
that both are predictive of clinical re-
sponse assessment at 12-month follow-up. 
At present, standard guidelines rec-
ommend reassessing patient status 
after the completion of treatment every 
3 months for 2 years, every 6 months 
for 3 years, and then annually ( 19 ). 
 Table 3 
 Assessment of Metabolic Tumor Response in Target Lesions 
Comprehensive Assessment at 
Mid-term Follow-up
SUV 
max
 
Baseline Two Months after RIT Six Months after RIT  P  Value
Responders 5.7  6 5.1 * 1.3  6 2.2 * 1.2  6 2.3 *  , .0001
 Complete response 5.7  6 5.3 † 1.3  6 2.2 ‡ 1.3  6 2.4 ‡  , .0001
 Partial response 5.1  6 2.6 † 1.2  6 1.8 ‡ 0.9  6 1.0 ‡  , .01
Nonresponders 8.0  6 4.9 9.9  6 7.3 10.5  6 7.7  , .05
 Stable disease 5.6  6 2.4 5.4  6 3.5 5.9  6 1.7 .95
 Progressive disease 9.6  6 5.5 12.9  6 7.7 13.5  6 7.9  , .05
Note.—Data are the mean  6 standard deviation.
 * P  , .05 vs nonresponders.
 †  P  , .05 vs progressive disease.
 ‡ P  , .01 vs nonresponders.
 Figure 2 
  
 Figure 2: Overall survival versus percentage variations in SUV 
max
 . Overall 
survival is longer for patients with decline in SUV 
max
 of 49% or higher than in 
those with decline in SUV 
max
 of less than 49%. 
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